 
 
Clinical  Development  & Medical  Affairs  
 
 
LGX818/MEK162  
 
Protocol  CMEK162X2110  / C4221005  
 
 
A Phase  Ib/II, multicenter,  open -label,  dose  escalation 
study  of LGX818  in combination  with MEK162  in adult 
patients with BRAF V600 - dependent advanced solid 
tumors  
 
 
 
 
Document type  Amended  Protocol  Version 
EUDRACT number  2011 -005875 -17 
Version number  10 
Development phase  Ib/II 
Document status  Final  
Release date 15-March -2021  
 
 
 
 
Property  of Array  BioPharma  
(a wholly  owned  subsidiary  of Pfizer  Inc.) 
Confidential  
May not be used,  divulged,  published,  or otherwise  disclosed 
without the consent of Array BioPharma  
Array  BioPharma  
Amended  Protocol  Version  10 Confidential  Page  2 
Protocol  No. CMEK162X2110  / C4221005  
PFIZER  CONFIDENTIAL   
 Table  of Contents  
Table  of Contents  ................................ ................................ ................................ .................  2 
List of Tables  ................................ ................................ ................................ .......................  8 
List of Figures  ................................ ................................ ................................ ......................  9 
List of abbreviations  ................................ ................................ ................................ ...........  10 
Glossary  of terms  ................................ ................................ ................................ ...............  14 
Amendment  10 ................................ ................................ ................................ ...................  15 
Amendment  9 ................................ ................................ ................................ .....................  19 
Amendment  8 ................................ ................................ ................................ .....................  25 
Amendment  7 ................................ ................................ ................................ .....................  27 
Amendment  6 ................................ ................................ ................................ .....................  28 
Amendment  5 ................................ ................................ ................................ .....................  31 
Amendment  4 ................................ ................................ ................................ .....................  33 
Amendment  3 ................................ ................................ ................................ .....................  36 
Amendment  2 ................................ ................................ ................................ .....................  38 
Amendment  1 ................................ ................................ ................................ .....................  42 
Protocol Summary  ................................ ................................ ................................ .............  44 
1 Background  ................................ ................................ ................................ ........................  47 
1.1 Overview  of disease  pathogenesis,  epidemiology  and current  treatments  .............  47 
1.1.1 The RAF/MEK/ERK  pathway,  BRAF -mutations  and cyclin - 
dependent kinases 4 and 6 in solid tumors  ................................ ............  47 
1.1.2 Malignant  Melanoma ................................ ................................ .............  48 
1.1.3 Metastatic  Colorectal  Cancer  (mCRC)  ................................ ..................  50 
1.2 Introduction to investigational treatment(s) and other study  treatment(s)  .............  50 
1.2.1 Overview  of LGX818  ................................ ................................ ............  50 
1.2.2 Overview  of MEK162  ................................ ................................ ...........  54 
1.2.3 Overview  of LEE011  ................................ ................................ .............  59 
1.2.4 Overview  of combination  treatment  ................................ ......................  62 
1.3 Anticipated  risks  and safety  considerations of  the study  drug combinations  .........  64 
1.3.1 Dual  combination  LGX818  and MEK162  ................................ .............  64 
1.3.2 Triple combination LGX818 and MEK162 and LEE011  .....................  65 
2 Rationale  ................................ ................................ ................................ ............................  66 
2.1 Study  rationale and purpose  ................................ ................................ ...................  67 
2.2 Rationale  for the study  design  ................................ ................................ ................  68 
2.3 Rationale  for dose and regimen  selection  ................................ ..............................  69 
2.4 Rationale for choice of combination drugs  ................................ ............................  69 
3 Objectives  and endpoints  ................................ ................................ ................................ ... 69 
Array  BioPharma  
Amended  Protocol  Version  10 Confidential  Page  3 
Protocol  No. CMEK162X2110  / C4221005  
PFIZER  CONFIDENTIAL   
 4 Study  design  ................................ ................................ ................................ .......................  71 
4.1 Description  of study  design  ................................ ................................ ....................  72 
4.2 Timing  of interim  analyses  and design  adaptations  ................................ ................  74 
4.3 Definition of end of the study  ................................ ................................ ................  75 
4.4 Early  study  termination  ................................ ................................ ..........................  75 
5 Population  ................................ ................................ ................................ ..........................  75 
5.1 Patient population  ................................ ................................ ................................ .. 75 
5.2 Inclusion  criteria  ................................ ................................ ................................ ..... 76 
5.3 Exclusion criteria  ................................ ................................ ................................ ... 76 
6 Treatment  ................................ ................................ ................................ ...........................  79 
6.1 Investigational treatment, other study  treatment, supportive treatment  .................  79 
6.1.1 Dosing  regimen  ................................ ................................ .....................  79 
6.1.2 Supportive treatment/precautions  ................................ ..........................  81 
6.1.3 Ancillary  treatments  ................................ ................................ ..............  82 
6.1.4 Guidelines  for continuation  of treatment  ................................ ...............  82 
6.1.5 Treatment duration  ................................ ................................ ................  82 
6.2 Dose  escalation  guidelines  ................................ ................................ .....................  82 
6.2.1 Definition  of treatment  cycle  ................................ ................................ . 82 
6.2.2 Starting  dose rationale  ................................ ................................ ...........  83 
6.2.3 Provisional dose levels  ................................ ................................ ..........  84 
6.2.4 Criteria for dose escalation and determination of MTD  ........................  86 
6.2.5 Definitions  of dose limiting  toxicities  (DLTs)  ................................ ...... 88 
6.2.6 Follow -up for toxicities  ................................ ................................ .........  90 
6.3 Dose  modifications  ................................ ................................ ................................ . 91 
6.3.1 Dose  modification  and dose delay  ................................ .........................  91 
6.3.2 Treatment  interruption  and treatment  discontinuation  ...........................  91 
6.3.3 Additional  follow -up for hepatic  toxicities  in patients  receiving  
LEE011  ................................ ................................ ................................  108 
6.4 Concomitant medications  ................................ ................................ .....................  108 
6.4.1 Permitted  concomitant  therapy  ................................ ............................  108 
6.4.2 Permitted concomitant therapy requiring caution and/or action for 
LGX818  and MEK162  ................................ ................................ ........  109 
6.4.3 Prohibited  concomitant  therapy  dual and triple  combination  ..............  111 
6.5 Patient numbering, treatment assignment and randomization  .............................  111 
6.5.1 Patient numbering  ................................ ................................ ................  111 
6.5.2 Treatment assignment and randomization  ................................ ...........  112 
6.6 Study  drug supply  ................................ ................................ ................................  112 
Array  BioPharma  
Amended  Protocol  Version  10 Confidential  Page  4 
Protocol  No. CMEK162X2110  / C4221005  
PFIZER  CONFIDENTIAL   
 6.6.1 Study  drug preparation and dispensation  ................................ .............  112 
6.6.2 Study  drug packaging and labeling  ................................ .....................  112 
6.6.3 Drug supply  and storage  ................................ ................................ ...... 112 
6.6.4 Study  drug compliance and accountability  ................................ ..........  113 
6.6.5 Disposal  and destruction  ................................ ................................ ...... 113 
7 Visit schedule and assessments  ................................ ................................ ........................  113 
7.1 Study  flow and visit schedule  ................................ ................................ ..............  113 
7.1.1 Molecular  Pre-screening  assessments  ................................ ..................  123 
7.1.2 Screening  ................................ ................................ .............................  123 
7.1.3 Treatment  period  ................................ ................................ .................  124 
7.1.4 End of treatment visit, including premature withdrawal and study 
completion visit ................................ ................................ ...................  124 
7.1.5 Follow -up period  ................................ ................................ .................  126 
7.2 Assessment types  ................................ ................................ ................................ . 126 
7.2.1 Efficacy  assessments  ................................ ................................ ...........  126 
7.2.2 Safety  and tolerability  assessments  ................................ .....................  128 
7.2.3 Pharmacokinetics  ................................ ................................ .................  135 
7.2.4 Biomarkers  ................................ ................................ ..........................  139 
7.2.5 Other  assessments  ................................ ................................ ................  144 
8 Safety  monitoring and reporting  ................................ ................................ ......................  144 
8.1 Adverse  events  and Serious  Adverse  Events  ................................ .......................  144 
8.1.1 Time  Period  and Frequency  for Collecting  AE and SAE  
Information  ................................ ................................ ..........................  144 
8.1.2 Methods  of Detecting  AEs and SAEs  ................................ ..................  146 
8.1.3 Follow -up of AEs and SAEs  ................................ ...............................  146 
8.1.4 Regulatory  Reporting  Requirements  for SAEs  ................................ .... 147 
8.1.5 Exposure During Pregnancy or Breastfeeding and Occupational 
Exposure  ................................ ................................ ..............................  147 
8.1.6 Cardiovascular  and Death  Events  ................................ ........................  149 
8.1.7 Disease -Related Events and/or Disease Related Outcomes Not 
Qualifying  as AEs or SAEs  ................................ ................................ . 149 
8.1.8 Adverse Events of Special Interest  ................................ ......................  149 
8.1.9 Medical  Device  Deficiencies  ................................ ...............................  150 
8.1.10  Medication  Errors  ................................ ................................ ................  150 
8.2 Treatment  Overdose  ................................ ................................ .............................  150 
8.3 Warnings  and precautions  ................................ ................................ ....................  151 
8.4 Data  Monitoring  Committee  ................................ ................................ ................  151 
Array  BioPharma  
Amended  Protocol  Version  10 Confidential  Page  5 
Protocol  No. CMEK162X2110  / C4221005  
PFIZER  CONFIDENTIAL   
 9 Data  collection  and management  ................................ ................................ .....................  151 
9.1 Data confidentiality  ................................ ................................ ..............................  151 
9.2 Site monitoring  ................................ ................................ ................................ ..... 152 
9.3 Data collection  ................................ ................................ ................................ ..... 152 
9.4 Database management and quality  control  ................................ ..........................  153 
10 Statistical  methods  and data analysis  ................................ ................................ ...............  153 
10.1 Analysis  sets ................................ ................................ ................................ .........  154 
10.1.1  Full Analysis  Set ................................ ................................ ..................  154 
10.1.2  Safety  Set ................................ ................................ .............................  154 
10.1.3  Dose -Determining  Set ................................ ................................ .........  154 
10.2 Patient  demographics/other  baseline  characteristics  ................................ ............  155 
10.3 Treatments  (study  treatment,  concomitant  therapies,  compliance)  ......................  155 
10.3.1  Study  treatment  ................................ ................................ ....................  155 
10.3.2  Concomitant  therapies  ................................ ................................ .........  155 
10.3.3  Compliance  ................................ ................................ ..........................  155 
10.4 Primary  objective  ................................ ................................ ................................ . 155 
10.4.1  Variable  ................................ ................................ ...............................  156 
10.4.2  Statistical  hypothesis,  model,  and method  of analysis  ........................  157 
10.4.3  Handling of missing values/censoring/discontinuations  ......................  162 
10.4.4  Supportive analyses  ................................ ................................ .............  162 
10.5 Secondary  objectives  ................................ ................................ ............................  163 
10.5.1  Efficacy  ................................ ................................ ...............................  163 
10.5.2  Safety  ................................ ................................ ................................ ... 164 
10.5.3  Pharmacokinetics  ................................ ................................ .................  165 
10.5.4  Biomarkers  ................................ ................................ ..........................  167 
10.5.5  Resource utilization  ................................ ................................ .............  168 
10.5.6  Patient -reported  outcomes  ................................ ................................ ... 168 
10.6 Exploratory  objectives  ................................ ................................ .........................  168 
10.7 Interim  analysis  ................................ ................................ ................................ .... 168 
10.8 Sample size calculation  ................................ ................................ ........................  168 
11 Ethical  considerations  and administrative  procedures  ................................ .....................  170 
11.1 Regulatory  and ethical compliance  ................................ ................................ ...... 170 
11.2 Responsibilities  of the investigator  and IRB/IEC/REB  ................................ ........  170 
11.3 Informed  consent  procedures  ................................ ................................ ...............  170 
11.4 Discontinuation of the study  ................................ ................................ ................  171 
11.5 Publication of study  protocol and results  ................................ .............................  171 
Array  BioPharma  
Amended  Protocol  Version  10 Confidential  Page  6 
Protocol  No. CMEK162X2110  / C4221005  
PFIZER  CONFIDENTIAL   
 11.6 Data Sharing  ................................ ................................ ................................ .........  171 
11.7 Study  documentation, record keeping and retention of documents  .....................  171 
11.8 Confidentiality  of study  documents  and patient records  ................................ ...... 172 
11.9 Audits  and inspections  ................................ ................................ .........................  172 
11.10  Financial  disclosures  ................................ ................................ ............................  172 
12 Protocol  adherence  ................................ ................................ ................................ ...........  172 
12.1 Amendments  to the protocol  ................................ ................................ ................  173 
13 References  (available  upon  request)  ................................ ................................ ................  174 
14 Appendices  ................................ ................................ ................................ .......................  178 
14.1 Appendix 1 - Response Evaluation Criteria in Solid Tumors (RECIST 1.1) 
Harmonization  of Efficacy  Analysis of Solid Tumor Studies  .............................  178 
14.1.1  Introduction  ................................ ................................ .........................  178 
14.1.2  Efficacy  assessments  ................................ ................................ ...........  179 
14.1.3  Definitions  ................................ ................................ ...........................  179 
14.1.4  Disease measurability  ................................ ................................ ..........  179 
14.1.5  Eligibility  based on measurable disease  ................................ ..............  180 
14.1.6  Methods  of tumor  measurement  - general  guidelines  ..........................  180 
14.1.7  Baseline  documentation  of target  and non-target  lesions  ....................  182 
14.1.8  Follow -up evaluation  of target  and non-target  lesions  ........................  183 
14.1.9  Follow -up & recording  of lesions  ................................ ........................  183 
14.1.10  Non-nodal  lesions  ................................ ................................ ................  183 
14.1.11  Nodal  lesions  ................................ ................................ .......................  183 
14.1.12  Determination  of target  lesion  response  ................................ ..............  184 
14.1.13  Determination  of non-target  lesion  response  ................................ ....... 186 
14.1.14  New  lesions  ................................ ................................ .........................  187 
14.1.15  Evaluation  of overall  lesion  response  ................................ ..................  187 
14.1.16  Efficacy  definitions  ................................ ................................ ..............  188 
14.1.17  Best overall  response  ................................ ................................ ...........  188 
14.1.18  Time  to event  variables  ................................ ................................ ........  191 
14.1.19  Progression -free survival  ................................ ................................ ..... 191 
14.1.20  Overall  survival  ................................ ................................ ...................  191 
14.1.21  Time  to progression  ................................ ................................ .............  191 
14.1.22  Time  to treatment  failure  ................................ ................................ ..... 191 
14.1.23  Duration  of response  ................................ ................................ ............  192 
14.1.24  Time  to response  ................................ ................................ ..................  192 
14.1.25  Definition  of start and end dates  for time to event  variables  ...............  193 
14.1.26  Handling  of patients  with non-measurable  disease  only at baseline...195  
Array  BioPharma  
Amended  Protocol  Version  10 Confidential  Page  7 
Protocol  No. CMEK162X2110  / C4221005  
PFIZER  CONFIDENTIAL   
 14.1.27  Sensitivity  analyses  ................................ ................................ .............  196 
14.1.28  Data  handling  and programming  rules  ................................ ................  198 
14.1.29  Study/project  specific  decisions  ................................ ..........................  198 
14.1.30  Treatment  and study  completion  CRFs  ................................ ...............  198 
14.1.31  Study  evaluation completion  ................................ ...............................  199 
14.1.32  Medical validation of programmed overall lesion response ................  200 
14.1.33  Programming  rules  ................................ ................................ ..............  200 
14.1.34  Calculation of ‘time to event’ variables  ................................ ..............  200 
14.1.35  Incomplete  assessment  dates  ................................ ...............................  200 
14.1.36  Incomplete  dates  for last contact  or death  ................................ ...........  201 
14.1.37  Non target  lesion  response  ................................ ................................ ... 201 
14.1.38  Study/project  specific  programming  ................................ ....................  201 
14.1.39  Censoring  reason  ................................ ................................ .................  201 
14.1.40  References  (available  upon  request)  ................................ ....................  202 
14.2 Appendix  2 - The 2009  American  Joint  Committee  on Cancer  (AJCC)  
staging  system  ................................ ................................ ................................ ...... 203 
14.3 Appendix  3 - Guidelines  for the treatment  of study  drug combination  induced  
skin toxicity  ................................ ................................ ................................ ..........  204 
14.3.1  Rash  ................................ ................................ ................................ ..... 204 
14.3.2  Hand  Foot Skin Reaction  ................................ ................................ ..... 205 
14.3.3  References  (available  upon  request)  ................................ ....................  206 
14.4 Appendix 4 - List of concomitant medications prohibited or to be used with 
caution for dual and triple combination  ................................ ...............................  207 
14.5 Appendix  5 – Statistical methodology  LGX818  and MEK162 dual 
combination  ................................ ................................ ................................ ..........  212 
14.5.1  Prior  Distributions  of 5 parameter  dual combo  
(LGX818+MEK162) model  ................................ ................................  212 
14.5.2  Data from the ongoing study  LGX818X2101  ................................ ..... 215 
14.5.3  LGX818 change in regimen  ................................ ................................  215 
14.5.4  Operating  characteristics  of the  Bayesian  Logistic Regression  
Model  and hypothetical  dose escalation  scenarios  ..............................  216 
14.5.5  Simulated  operating  characteristics  ................................ .....................  216 
14.5.6  Hypothetical  dose escalation  scenarios  ................................ ...............  221 
14.5.7  Power  for analysis  of key secondary  variables  ................................ .... 223 
14.5.8  References  (available  upon  request)  ................................ ....................  223 
14.6 Appendix 6 - Operating characteristics of the combination Bayesian logistic 
regression model and hypothetical dose escalation scenarios LGX818 and 
MEK162  and LEE011  triple  combination  ................................ ...........................  224 
Array  BioPharma  
Amended  Protocol  Version  10 Confidential  Page  8 
Protocol  No. CMEK162X2110  / C4221005  
PFIZER  CONFIDENTIAL   
 14.6.1  Statistical Model  ................................ ................................ ..................  224 
14.6.2  Prior  Specification  ................................ ................................ ...............  224 
14.6.3  References  (available  upon  request)  ................................ ....................  227 
14.7 Appendix 7: Adverse Events: Definitions and Procedures for Recording, 
Evaluating,  Follow -up, and Reporting  ................................ ................................ . 228 
14.7.1  Definition  of AE ................................ ................................ ..................  228 
14.7.2  Definition  of an SAE ................................ ................................ ...........  229 
14.7.3  Recording/Reporting  and Follow -up of AEs and/or  SAEs  .................  231 
14.7.4  Reporting  of SAEs  ................................ ................................ ...............  234 
14.8 Appendix  8: Liver  Safety:  Suggested  Actions  and Follow -up Assessments  ........  234 
14.9 Appendix  9: ECG  Findings  of Potential  Clinical  Concern  ................................ ... 236 
14.10  Appendix  10: Alternative  Measures  During  Public  Emergencies  ........................  237 
14.10.5  Adverse  Events  and Serious  Adverse  Events  ................................ ...... 240 
 
List of Tables  
Table  1-1 Incidence  of BRAF - mutations  in human  cancers  ................................ . 48 
Table  3-1 Objectives  and related endpoints  ................................ ...........................  69 
Table  6-1 Provisional  dose levels  dual combination  ................................ .............  84 
Table  6-2 Provisional  dose levels  triple  combination  ................................ ............  84 
Table 6 -3      Criteria for defining dose -limiting toxicities for dual and triple 
combination  ................................ ................................ ................................ ...............................  89 
Table 6 -4 Criteria for interruption and re -initiation of LGX818/MEK162/LEE011 
triple -combination  treatment  ................................ ................................ ................................ ..... 93 
Table  7-1 Visit  evaluation  schedule  ................................ ................................ ..... 115 
Table  7-2 Visit  evaluation  schedule  for patients  as of Amendment  10 ...............  121 
Table  7-3 WHO  performance  status  scale  ................................ ...........................  130 
Table  7-4 Schedule  of blood  sample  collections  for PK in dose escalation  ........  136 
Table 7 -5 Schedule  of blood  sample  collections  for PK in dual-combination  Phase 
II arms  2 and 3, (and arm 1 if requireda) / triple -combination  Phase  II arm A .......................  137 
Table  7-6 Biomarker sample collection schedule  ................................ ................  140 
Table  7-7 Processing  requirements  for fresh  tumor  biopsy  samples  ...................  142 
Table  10-1 PK parameters  ................................ ................................ .....................  166 
Table  14-1 Response criteria for target lesions  ................................ .....................  184 
Table  14-2 Response  criteria  for non-target  lesions  ................................ ...............  186 
Table  14-3 Overall  lesion  response  at each assessment  ................................ .........  187 
Array  BioPharma  
Amended  Protocol  Version  10 Confidential  Page  9 
Protocol  No. CMEK162X2110  / C4221005  
PFIZER  CONFIDENTIAL   
 Table 14 -4      Overall lesion response at each assessment: patients with non -target 
disease  only ................................ ................................ ................................ .............................  195 
Table  14-5 Options  for event  dates  used in PFS,  TTP,  duration  of response  .........  196 
Table 14 -6 The 2009 American Joint Committee on Cancer (AJCC) staging system 
for malignant  melanoma  ................................ ................................ ................................ .........  203 
Table  14-7 Treatment  of skin toxicity ................................ ................................ .... 205 
Table  14-8 Supportive  care for the prevention  and management  of HFSR  ...........  206 
Table 14 -9 Narrow therapeutic index substrates of CYP3A4*, CYP2B6, CYP2C9 
prohibited or to be administered with caution  ................................ ................................ ........  207 
Table 14 -10      List of CYP inhibitors and inducers prohibited or to be used with 
caution  ................................ ................................ ................................ ................................ ..... 208 
Table  14-11     List of BCRP substrates, BSEP inhibitors, P -gp inhibitors/inducers,  and 
MATE1/2, P -gp, OAT1, OAT3, OCT1, OCT2, OATP1B1 and OATP1B3 substrates to be 
used with caution  ................................ ................................ ................................ ....................  209 
Table  14-12 List of QT prolonging  drugs  ................................ ................................  211 
Table  14-13 Data  from  ARRAY -162-111 ................................ ...............................  212 
Table  14-14 Predictive  distribution  of model  parameters  ................................ ........  213 
Table  14-15 Summary  of prior  probabilities  of DLT rates ................................ ...... 214 
Table  14-16 Data  from LGX818X2101 - as of 23/Nov/2011  ................................ ... 215 
Table  14-17 True  underlying  probabilities  of DLT  for Scenario  1 ..........................  218 
Table  14-18 True  underlying  probabilities  of DLT  for Scenario  2 ..........................  218 
Table  14-19 True  underlying  probabilities  of DLT  for Scenario  3 ..........................  218 
Table  14-20 True  underlying  probabilities  of DLT  for Scenario  4 ..........................  219 
Table  14-21 True  underlying  probabilities  of DLT  for Scenario  5 ..........................  219 
Table  14-22 Preference  matrix  ................................ ................................ .................  220 
Table  14-23 Results  ................................ ................................ ................................ . 221 
Table  14-24 Hypothetical  dose escalation  scenarios  ................................ ...............  222 
Table  14-25 Data  from  CLEE11X2101  ................................ ................................ ... 225 
Table  14-26 Prior,  posterior  and predictive  distribution  of (log(alpha 4),log(beta 4))..... 
225 
Table  14-27 Prior  distribution  of model  parameters  ................................ ................  226 
Table 14 -28 Summary of prior distribution of DLT rates for triple combo 
(LGX818+MEK162+LEE011) including current DLT data (up to Apr 16, 2013) from dual 
combo (LGX818+MEK162)  ................................ ................................ ................................ ... 226 
Table  14-29 Dose decisions recommended by  BLRM  ................................ ............  227 
List of Figures  
Figure  1-1 Overview  of Ras-Raf-ERK -MEK  pathway  (adopted  from  Cho 2009 ) .............  47 
Figure  4-1 Study  Design  ................................ ................................ ................................ ..... 72 
Array  BioPharma  
Amended  Protocol  Version  10 Confidential  Page  10 
Protocol  No. CMEK162X2110  / C4221005  
PFIZER  CONFIDENTIAL   
 List of abbreviations   
AE Adverse  event  
AKT/PKB  See PKB 
ALT/SGPT  Alanine  aminotransferase/glutamic  pyruvic  transaminase 
ANC Absolute neutrophil count  
aPTT  Activated partial thromboplastin time 
AST/SGOT  Aspartate  aminotransferase/glutamic  oxaloacetic  transaminase 
ATP Adenosine triphosphate  
AUC Area  under the curve  
AV Atrioventricular  
BCRP  Breast  cancer  resistance  protein  
BID Bis in diem/twice daily 
BLRM  Bayesian logistic regression model  
BOR  Best overall response  
BRAF  V-raf murine sarcoma viral oncogene homolog B1 
BRAFi  BRAF inhibitor  
BUN Blood urea nitrogen  
CHF Congestive heart failure  
CK/CPK  Creatine  kinase  / Creatine  phosphokinase 
CL Clearance  
Cmax  Maximum  plasma  concentration  
CNS Central  nervous system  
COVID -19 Coronavirus  disease 2019  
CR Complete response  
CRC / mCRC  Colorectal  cancer  / metastatic  CRC 
CrCl Creatinine clearance  
CRF Case  report form 
CRO  Contract  research  organization  
CSF Clinical  service form 
CSR Central  serous retinopathy / Clinical study report  
CT Computed  tomography  
CTCAE  Common  terminology  criteria  for adverse  events 
CV Coefficient of variation  
CYP Cytochrome  P450  
DCR Disease  control rate 
DDS Dose  determining set 
DILI Drug -induced  liver injury  
DLT Dose  limiting toxicity  
DMC  Data  monitoring committee  
DNA Deoxyribonucleic  acid 
DOR  Duration  of response  
DS&E  Drug  safety and epidemiology  
DTIC  Dacarbazine  
EC Ethics committee  
ECG  Electrocardiogram  
ECHO  Echocardiogram  
ECOG  Eastern cooperative oncology group  
Array  BioPharma  
Amended  Protocol  Version  10 Confidential  Page  11 
Protocol  No. CMEK162X2110  / C4221005  
PFIZER  CONFIDENTIAL   
  
 
eCRF  Electronic  case  report/record  form 
EDC Electronic data capture  
EDP Exposure  during  pregnancy  
EGF Epidermal  growth factor  
EGFR  Epidermal  growth  factor  receptor  
EMEA  European  Medicines Evaluation Agency  
EOT End of treatment  
ErbB  Erythroblastic leukemia viral oncogene  
ERG  Electroretinogram  
ERK Extracellular  signal  regulated kinase  
EUA Emergency  use authorization  
EWOC  Escalation  with overdose  control  
FAS Full analysis set 
FDA Food  and Drug Administration  
FDG-PET Fluorodeoxyglucose  positron  emission  tomography 
FFPE  Formalin -fixed paraffin embedded  
FMI Final  market image  
FU Follow -up 
GCP  Good  clinical practice  
GGT Gamma -glutamyl  transferase  
GI Gastrointestinal  
GLP Good  laboratory practice  
GTPase  Guanosine -5'-triphosphatase  
hCG Human  chorionic gonadotropin  
HDL High-density  lipoprotein  
HDPE  High-density  polyethylene  
hERG  Human  ether -à-go-go related  gene  
HFSR  Hand  foot skin reaction  
Hgb Hemoglobin  
HIV Human  immunodeficiency virus 
HR Heart  rate 
hr(s) Hour(s)  
i.v. Intravenous  
IB Investigator  brochure  
IC50 Inhibition  concentration 50% 
ICF Informed  consent  form 
ICH International Conference on Harmonization  
IEC Institutional  ethics committee  
IHC Immunohistochemistry  
ILD Interstitial lung disease  
IN Investigator  notification  
INR International  normalized ratio 
IOP Intra ocular pressure  
IRB Institutional  review  board  
IUD Intra-uterine  device  
IUS Intra-uterine  system  
KA Keratoacanthomas  
Array  BioPharma  
Amended  Protocol  Version  10 Confidential  Page  12 
Protocol  No. CMEK162X2110  / C4221005  
PFIZER  CONFIDENTIAL   
  
 
KRAS  V-Ki-ras2 Kirsten  rat sarcoma  viral oncogene  homolog 
LC/MS/MS  Liquid chromatography tandem mass spectrometry 
LDH Lactate dehydrogenase  
LDL Low-density  lipoprotein  
LFT Liver  function test 
LIMS  Laboratory information management system  
LLN Lower  limit of normal  
LLOQ  Lower  limit of quantitation  
LPLT  Last patient last treatment  
LPLV  Last patient last visit 
LVEF  Left ventricular  ejection  fraction  
MAPK  Mitogen -activated protein kinase 
MedDRA  Medical  dictionary  for regulatory  activities 
MEK  Mitogen -activated protein kinase kinase  
MIA Melanoma  inhibitory activity  
MRI Magnetic resonance imaging  
MTD Maximum  tolerated dose  
MUGA  Multi -gated  acquisition  scan 
NaF PET  Sodium  fluoride  positron  emission  tomography 
NCI National Cancer Institute  
NRAS  Neuroblastoma RAS viral oncogene homolog  
NSCLC  Non-small  cell lung cancer  
NYHA  New York Heart Association  
OAT Organic  anion transporter  
OCT Optical  coherence  tomography  / organic  cation  transporter  
ORR  Overall  response rate 
OS Overall survival  
PD Pharmacodynamic  / Progression  of disease  
PFS Progression  free survival  
P-gp Permeability  glycoprotein  
PHI Protected  health information  
Pi Inorganic phosphorus/phosphate  
PI3K Phosphatidylinositol  3' kinase  
PIK3CA  Phosphatidylinositol  3' kinase  catalytic  alphapolypeptide 
PK Pharmacokinetic  
PKB Protein  kinase  B (also  known  as AKT)  
PLT Platelets  
po Per os/by mouth/orally  
PPS Per protocol set 
PR Partial response  
PS Performance  status  
PT Prothrombin  time 
PTEN  Phosphatase and tensin homolog  
PVC Premature  ventricular  contraction  
QD Quaque  die/once daily 
QOD  Every  other day 
QTcB  QT interval adjusted according to Bazett  
Array BioPharma 
Amend ed Protoco l Version 10 Confid ential Page 13 
Protoco l No. CMEK162X2 110 / C422 1005 
PFIZER  CONFIDENTIAL   
  
 
QTcF  QT interval  adjusted  according  to Fredericia  
RAF V-raf murine sarcoma viral oncogene  
RAP Report  and Analysis  Plan (RAP)  (i.e. regulatory  document  which  provides  evidence  of 
preplanned analyses)  
RAS Rat sarcoma  viral oncogene  homologue  
Rb Retinoblastoma protein  
RBC Red blood cells 
REB Research  ethics board  
RECIST  Response  evaluation  criteria  in solid tumors 
RP2D  Recommended Phase II dose  
RT-PCR  Reverse -transcriptase  polymerase  chain  reaction 
RVO  Retinal vein occlusion  
SAE Serious  adverse event  
SARS -CoV2  Severe  acute  respiratory  syndrome  coronavirus  2 
SCC Squamous cell carcinoma  
SD Stable disease  
SEC Study  evaluation completion  
SUSAR  Suspected  unexpected  serious  adverse  reactions 
T/C Tumor volume over control volume  
T1/2 Terminal  elimination  half-life 
TBili Total  bilirubin  
tCa Total calcium  
TEN Toxic  Epidermal  Necrolysis  
TGI Tumor  growth inhibition  
TKIs Tyrosine  kinase inhibitors  
tmax Time to reach maximum plasma concentration  
TSH Thyroid -stimulating  hormone  
TTP Time to progression  
ULN Upper  limit of normal  
US United  States  
Vss Volume of distribution at steady state  
WBC  White  blood  cells 
WHO  World  Health  Organization  
Array BioPharma 
Amend ed Protoco l Version 10 Confid ential Page 14 
Protoco l No. CMEK162X2 110 / C422 1005 
PFIZER  CONFIDENTIAL   
 Glossary  of terms  
Assessment  A procedure used to generate data required by the study.  
Baseline  Baseline  (i.e. Screening/baseline)  assessments  are the most  recent 
assessments  which  are performed  prior to the first administration  of 
study treatment.  
Cycle  Number  and timing  or recommended  repetitions  of therapy  are usually 
expressed as number of days (i.e. every 28 days)  
Dose cohort  A group  of newly  enrolled  patients  treated  at a specific  dose  and regimen 
at the same time.  
Dose level The dose of drugs given to the patient.  
Enrollment  Point/time  of patient  entry  into the study;  the point  at which  informed 
consent is obtained and patient meets all inclusion and none of the  
exclusion criteria.  
Patient number  A unique  identifier  number  (consisting  of the center  number  and patient 
number) assigned to each patient who enrolls in the study.  
Period  A subdivision  of the study  timeline;  divides  stages  into smaller  functional 
segments such as screening/baseline, treatment, washout, etc.  
Phase II Selected group of patients enrolled during the Phase II part of the study.  
Stage in cancer  The extent  of a cancer  in the body.  Staging  is usually  based  on the size 
of the tumor, whether lymph nodes contain cancer, and whether the 
cancer has spread from the original site to other parts of the body  
Stage related to study timeline  A major  subdivision  of the study  timeline;  begins  and ends  with major 
study milestones such as enrollment, completion of treatment, etc.  
Study  evaluation  completion 
(SEC)  Point/time  which  marks  the end of study  for an individual  patient.  Survival 
continues beyond SEC.  
Study treatment  Drugs  whose  properties  are being  tested  in combination  in the study  (i.e. 
study drugs or study drugs combination).  
Study treatment discontinuation  Point/time  when  patient  permanently  stops  taking  study  treatment  for any 
reason (i.e. end of treatment).  
Variable  Identifier  used  in the data analysis;  derived  directly  or indirectly  from data 
collected using specified assessments at specified timepoints  
Array BioPharma 
Amend ed Protoco l Version 10 Confid ential Page 15 
Protoco l No. CMEK162X2 110 / C422 1005 
PFIZER  CONFIDENTIAL   
 Amendment  10 
Amendment  rationale  
In 2018,  LGX818  (encorafenib)  450 mg orally  QD, in combination  with MEK162  (binimetinib) 
45 mg orally BID, received marketing approval in several jurisdictions, including the United 
States and the European Union, for the treatment of patients with unresectable or metastatic 
BRAF  V600 -mutant  melanoma.  This approval  was based  on the ongoing  randomized  Phase  III 
COLUMBUS Study (CMEK162B2301).  
At this stage  of the trial, the safety  and efficacy  of the dual combination  of LGX818/MEK162 
and the triple combination of LGX818/MEK162/LEE011 have been thoroughly assessed.  
Therefore,  Amendment  10 allows  for patients  still on treatment  to be monitored  in a manner 
that is consistent with local standard -of-care practice. In addition, post -treatment disease 
progression  follow -up (if applicable)  and/or  survival  follow -up (including  documentation  of 
subsequent  antineoplastic  therapies)  will no longer  be performed for patients in the Phase II 
part of the study.  
As of the date of this amendment, 10 patients are still on study treatment, with 5  patients 
receiving the dual combination (LGX818/MEK162) and 5 patients receiving the triple 
combination  (LGX818/MEK162/LEE011).  In addition,  20 patients  enrolled  in the Phase  II part 
of the study  who have  discontinued  study  treatment  are still in the disease  progression/survival 
follow -up period,  with 12 patients  who had received  the dual combination  (LGX818/MEK162) 
and 8 patients who had received the triple combination (LGX818/MEK162/LEE011).  
The purpose  of this amendment  is to: 
1. To modify the frequency of assessments to allow for patients still on treatment to be 
monitored in a manner that is consistent with local standard -of-care practice.  
2. To discontinue post -treatment disease progression follow -up (if applicable) and/or 
survival  follow -up (including  documentation  of subsequent  antineoplastic  therapies)  for 
patients in the Phase II part of the study.  
3. To revise the Adverse Event and Serious Adverse Events sections to align with Pfizer 
standard operating procedures, with SAE reporting directly to Pfizer Safety;  
4. To reflect the dose modification and management related to MEK162 - and LEE011 - 
emerging  ILD/pneumonitis  and LEE011 -emerging  Toxic  Epidermal  Necrolysis  (TEN);  
Changes  to the Protocol  
Changes  to specific  sections  of the protocol  are shown  in the track  changes  version  of the 
protocol.  
Section  1.2 
• Section  1.2.1 : addition  of nomenclatures  used for LGX818;  
• Section  1.2.2 : addition  of nomenclatures  used for MEK162;  
Array BioPharma 
Amend ed Protoco l Version 10 Confid ential Page 16 
Protoco l No. CMEK162X2 110 / C422 1005 
PFIZER  CONFIDENTIAL   
  
• Section  1.2.3: addition of nomenclat ures used for LEE0l 1 and references  to the cmTe nt 
LEE0l 1 Investigato r's Brochure. 
Section  4 
•  Section  4.1 Descriptio n of study design:  Section  was updated to add text regarding study 
evaluat ion completio n and disco ntinu ation of pos t-treatment disease  progressio n 
follow-up (if app licable) a nd/or smvival follow-up (incl uding doc umentation of 
subsequent antineoplastic t herapies). 
• Sectio n 4.3 Definiti on of end of study: The definition for the end of study  was updated . 
Section  6 
•  Sectio n 6.3 Dose modificat ions: Table 6-4: Added dose modificatio ns related to 
ILD/pneumonitis based upon MEK162 a nd LEE0ll  prescribing info1mation and for 
TEN based upo n LEE011 prescribing info1mation. In addition, clarificat ions we re added 
to dose  modificatio ns related to ECG Q TcF inte1val prolonged. 
• Section  6.4.1: Pennitted concomitant therapy: Clarificatio n that COVI D-19 vacc ination 
may be ad mini stered.  
Section  7 
•  Section 7.1 Study  flow  and visit schedule: added new table outlinin g the visit 
evaluation sched ule for  patie nts (Table 7-2) along wit h references to Table 7 -2 
(multiple locatio ns). This sectio n was updated  to allow for patients to be monitored in 
a mann er that is consistent with local standard-of-care practice fo r patients wit h 
adva nced or metastatic melanoma or advanced CRC . 
• Section  7.1.3  Treatment  period: This sectio n was updated to indicate  patie nts are to be 
monitored in a ma nner that is consistent w ith local  standa rd-of-care practice.  
•  Sectio n 7.1.4  End of treatment visit , inclu ding prematme withdrawa l and study 
completion  visit: This section was updated  to define  study  completion for individual 
patie nts and to discontinue post -treatme nt disease prog ressio n follow-up (if 
applicable) a nd/or s mvival fo llow-up (including doc umentation of subseq uent 
antineo plastic therapies) for patie nts in the Phase II paiis of t he study. 
•  Section 7.1.5.2 Disease progressio n follow-up period: This section was update d to 
discontinue  post-treatment disease  progressio n follow -up (if applicable) for patie nts in 
the Phase II paiis of t he study. 
•  Sectio n 7.1.5.3 Smvival fo llow-up pe riod: This sectio n was updated to disco ntinue 
smvival  follow-up (inclu ding doc umentation of subsequent antineoplastic  therapies) 
for patie nts in the Phase II paiis of t he study. 
• Sectio n 7.2.2  Safety  and tolerabi lity assess ments and subsectio ns: These sectio ns were 
updated to indicate assess ments will be perfonned as o utlined in  Table  7-2. 
•  

Array BioPharma 
Amend ed Protoco l Version 10 Confid ential Page 17 
Protoco l No. CMEK162X2 110 / C422 1005 
PFIZER  CONFIDENTIAL   
 Section  8 
The following  sections  were  revised  or added  to align  with Pfizer  standard  operating 
procedures:  
• Section  8.1 Adverse  Events  and Serious  Adverse  Events.  
• Section 8.1.1 Time Period and Frequency for Collecting AE and SAE Information: 
Previous  Section  Definitions  and Reporting  was deleted.  Definitions  of AE and SAEs 
can be found in Section 14.7 Appendix 7.  
• Section  8.1.1.1  Reporting  SAEs  to Pfizer  Safety.  
• Section  8.1.1.2  Recording  Nonserious  AEs and SAEs  on the CRF.  
• Section  8.1.2  Methods  of Detecting  AEs and SAEs.  
• Section  8.1.3  Follow -up of AEs and SAEs  
• Section  8.1.4  Regulatory  Reporting  Requirements  for SAEs  
• Section  8.1.5  Exposure  During  Pregnancy  or Breastfeeding  and Occupational 
Exposure  
• Section 8.1.5.1 Exposure During Pregnancy  
• Section 8.1.5.2 Exposure During Breastfeeding  
• Section 8.1.5.3 Occupational Exposure  
• Section  8.1.6  Cardiovascular  and Death  Events  
• Section  8.1.7  Disease -Related  Events  and/or  Disease  Related  Outcomes  Not 
Qualifying as AEs or SAEs  
• Section  8.1.8  Adverse  Events  of Special  Interest  
• Section  8.1.8.1 Lack of  Efficacy  
• Section  8.1.9  Medical  Device  Deficiencies  
• Section  8.1.10  Medication  Errors  
• Section  8.2 Treatment  Overdose:  Section  added  to align  with Pfizer  standard  operating 
procedures.  Previous Section 8.2 Serious Adverse Events was revised and moved to 
Section 8.1 Adverse Events and Serious Adverse Events . 
Section  11 
• Section  11.6 Data  Sharing:  Added  section  to align  with Pfizer  standard  operating 
procedures.  
Array BioPharma 
Amend ed Protoco l Version 10 Confid ential Page 18 
Protoco l No. CMEK162X2 110 / C422 1005 
PFIZER  CONFIDENTIAL   
 Appendices  
The following  Sections  and Appendices  were  added  to align  with Pfizer  standard  operating 
procedures.  
• Section  14.7 Appendix  7: Adverse  Events:  Definitions  and Procedures  for Recording, 
Evaluating, Follow -up, and Reporting.  
• Section  14.8 Appendix  8: Liver  Safety:  Suggested  Actions  and Follow -up 
Assessments.  
• Section  14.9 Appendix  9 ECG  Findings  of Potential  Clinical  Concern.  
• Section  14.10  Appendix  10: Alternative  Measures  During  Public  Emergencies  
Array BioPharma 
Amend ed Protoco l Version 10 Confid ential Page 19 
Protoco l No. CMEK162X2 110 / C422 1005 
PFIZER  CONFIDENTIAL   
 Amendment 9 
Amendment  rationale  
As of the release  date of this amendment,  20 patients  in the CMEK162X2110  study  (11 in Phase  
Ib/II dual combination [LGX818 + MEK162] and 9 patients in the Phase  Ib/II triple 
combination [LGX818/MEK162/LEE011]) were continuing to derive benefit from study 
treatment.  In order  to minimize  the burden  on the patients  and to reduce  their radiation  exposure, 
this amendment allows the frequency of tumor assessments in all continuing patients to be 
reduced  to every  8-12 weeks  based  on Investigator  discretion.  Patients  (both  dual- and 
triple -combination patients) may be transitioned to this less frequent imaging schedule once 
they have  completed  ≥ 24 months  of study  treatment  (Cycle  25 Day 1 onward).  In order  to more 
fully  assess  the safety  and efficacy  in all patients  following  prolonged  treatment,  the definition 
of end of study  has been  revised  to be when  all patients  in Phase  II have  died or when  all patients 
have  completed  study  evaluation  completion  (SEC),  or have  been  lost to follow -up or withdrew 
consent, whichever occurs first.  
In addition, this protocol is also being amended to change the frequency and type of 
ophthalmologic examinations. In a separate Phase 3 study (CMEK162B2301; 
ClinicalTrials.gov identifier [STUDY_ID_REMOVED]) in patients with BRAF V600 -mutant melanoma 
treated  with the combination  of LGX818  (450 mg once  daily  [QD])  plus MEK162  (45 mg twice 
daily [BID]), the median time to onset of retinopathy (all grades) was 1.2 months, and there 
were no patients with a new onset event after 24 months. No patients treated with the 
combination LGX818 (450 mg once daily [QD]) plus MEK162 (45 mg BID) experienced a 
retinal vein occlusion (RVO) event. Based on these findings, and in order to minimize the 
burden  on both dual- and triple -combination  patients  who continue  to derive  benefit  from  study 
treatment,  this amendment  allows  patients  who have been receiving  study treatment  
≥ 24 months (Cycle 25 Day 1 onwards) who have not had a retinal adverse event (AE) to be 
evaluated  for visual  acuity  at each scheduled  patient  visit and at the End of Treatment.  Patients 
with changes  in visual  acuity  or other  ocular  complaints  at any time on study  should  be referred 
to an ophthalmologist for full ophthalmic examination.  
This protocol is also being amended to remove the collection of an unscheduled PK sample 
taken  in the event  of a QTcF  change  from  baseline  > 60 msec,  or a new absolute  QTcF  interval  
≥ 501 msec. This is being done to reduce burden on the patients and the sites and would not 
significantly contribute to the PK data already accumulated on this study. Additionally, 
collection  of the PK data upon  a specified  DLT  or QT prolongation  provides  minimal  actionable 
information to the investigator in the event these adverse events happen due to the processing 
time of PK samples.  
Additionally,  the protocol  is being  amended  to remove  the fasting  requirement  for both the dual- 
and triple -combination treatments. Based on results of two dedicated clinical pharmacology 
studies, both binimetinib (CMEK162A2103) and encorafenib (ARRAY -818-102) exposures 
were unaffected by food, suggesting patients can take the dual -combination treatment with or 
without  food.  Since  the package  insert  for LEE011  (ribociblib)  indicates  patients  can also take 
LEE011 with or without food, the fasting restriction was removed for the triple combination.  
Array BioPharma 
Amend ed Protoco l Version 10 Confid ential Page 20 
Protoco l No. CMEK162X2 110 / C422 1005 
PFIZER  CONFIDENTIAL   
 Furthermore, the protocol is being amended to remove the restriction of agents that elevate 
gastric pH, including antacids, proton pump inhibitors and H2 -antagonists. Based on the 
results of a dedicated clinical pharmacology study, both binimetinib and encorafenib 
(ARRAY -162-105) exposures were unaffected by rabeprazole, a proton pump inhibitor, 
suggesting  patients  can take the dual-combination  treatment  with agents  that elevate  gastric 
pH. 
Additional revisions have been made to sections of the protocol that are specific to the triple - 
combination arms with LEE011 in order to reflect recent clinical development changes 
pertaining to dose modification for LEE011.  
In Appendix 4 of the protocol, language was added to Table 14 -9 through Table 14 -11 stating 
that the substrates in the tables do not represent an exhaustive list of substrates, inducers or 
inhibitors.  
Changes  to the protocol  
Changes to specific sections of the protocol are shown in the track changes version of the 
protocol.  
• 4.3 Definition of end of study, 7.1.5.2 Disease progression follow -up period, and 7.1.5.3 
Survival follow -up period.  
The above section was  amended to  clearly  define the end of study.  
• 6.1.1.1  Dose  Administration  of dual combination  (LGX818  and MEK162)  and 6.1.1.2  Dose 
Administration of triple combination (LGX818 and MEK162 and LEE011)  
The above sections were modified to allow patients to take either the dual combination 
(LGX818 and MEK162) or the triple combination (LGX818 and MEK162 and LEE011) 
with or without food.  
• 6.2.5 Definitions of dose limiting toxicities; 6.3.1  Dose modification and dose delay  
The above sections were modified to reflect the change in the CTCAE version to be used 
for data analysis, from version 4.0 to version 4.03. The CTCAE version 4.03 was 
implemented before patients were enrolled to the study.  
• Table  6-4 Criteria  for interruption  and re-initiation  of LGX818  and MEK162  or LGX818 
and MEK162 and LEE011 treatment;  
 
Table 6 -4 was amended to provide detailed dose modification guidelines for patients 
undergoing treatment with the dual combination (LGX818 and MEK162) and the triple 
combination (LGX818 and MEK162 and LEE011).  
• 6.3.2  was Section  6.2.6.2  – Follow -up evaluations  for appearance  of central  serous 
retinopathy (CSR)  
The above section was amended to include information on the ophthalmic examination 
schedule for patients without a retinal AE.  
Array BioPharma 
Amend ed Protoco l Version 10 Confid ential Page 21 
Protoco l No. CMEK162X2 110 / C422 1005 
PFIZER  CONFIDENTIAL   
 • 6.3.3  Additional  follow -up for hepatic  toxicities  in patients  receiving  LEE011  
The above  section  was amended  to provide  the specifics  of hepatic  toxicity  monitoring,  and 
add additional guidance for the investigation of potential hepatic toxicity.  
• 6.4.1  Permitted  concomitant  therapy  
The above section was revised to add a subsection with guidance on the use of 
corticosteroids while on study.  
• 6.4.2  Permitted  concomitant  therapy  requiring  caution  and/or  action  for LGX818  and 
MEK162  
The above  section  was revised  to include  drug-drug interaction  risks  of clinical  relevance.  
• 6.4.2.1  Additional  permitted  concomitant  therapy  requiring  caution  and/or  action  for 
addition of LEE011 in the triple combination  
The above section was amended to add additional guidance on the use of concomitant 
therapy  requiring  caution  for patients  during  treatment  with the triple  combination  LGX818 
and MEK162 and LEE011.  
• 6.4.3.1  Additional  prohibited  concomitant  therapy  for addition  of LEE011  in the triple 
combination  
The above section was amended to add additional guidance on prohibited concomitant 
therapy for patients during treatment with the LGX818/MEK162/LEE011 triple 
combination.  
• Table  7-1 Visit evaluation  schedule;  7.1 Study  flow and visit schedule.  
The above  table  was amended  in the row for ophthalmologic  examination  to allow  patients 
who have been on the LGX818/MEK162 dual -combination and 
LGX818/MEK162/LEE011  triple -combination  treatment  for ≥ 24 months  (Cycle  25 Day 1 
onward)  without  a retinal  AE to be evaluated  only for visual  acuity  at each scheduled  patient 
visit and at the End of Treatment visit. These patients are also required to have a full 
ophthalmic examination if clinically indicated and at the End of Treatment visit.  
The above  table  was also amended  in the row for tumor  evaluation  per the Response  Criteria 
in Solid Tumors (RECIST) by computed tomography (CT)/magnetic resonance imaging 
(MRI) to allow patients who have been on the LGX818/MEK162 dual - combination and 
LGX818/MEK162/LEE011  triple -combination  treatment  for ≥ 24 months  to have  CT/MRI 
scans every 8 -12 weeks (± 7 days) instead of every 8 weeks. Also, this row was amended 
to allow  patients  who have  been  on either  combination  treatment  for ≥  24 months  and then 
discontinue  study  treatment for any  reason  other  than disease  progression  to have  CT/MRI 
scans every 8 -12 weeks (± 7 days) instead of every 8 weeks.  
Array BioPharma 
Amend ed Protoco l Version 10 Confid ential Page 22 
Protoco l No. CMEK162X2 110 / C422 1005 
PFIZER  CONFIDENTIAL   
 The above table was amended to add the recommendation following the 30 -day follow -up 
period and when clinically appropriate for patients to be monitored with physical 
examinations,  dermatological  examinations  and chest  CT scans  for cutaneous  and 
non-cutaneous  secondary  malignancies  for up to 6 months  after the last encorafenib  dose or 
until initiation of another antineoplastic therapy.  
The above section was amended to reflect the changes in the tumor evaluation schedule 
described as for Table 7 -1. 
• 7.1.5.2  Disease  progression  follow -up period  
The above section was amended for tumor evaluation per RECIST by CT/MRI to allow 
patients who have been on the LGX818/MEK162 dual -combination or 
LGX818/MEK162/LEE011 triple -combination treatment for ≥  24 months and then 
discontinue  study  treatment for any  reason  other  than disease  progression  to have  CT/MRI 
scans every 8 -12 weeks (± 7 days) instead of every 8 weeks.  
• 7.1.5.3  Survival  follow -up period  
The above  section  has been  modified  to remove  the 18-month  follow -up. 
• 7.2.1 Efficacy  assessments  
The above section was amended for tumor evaluation per RECIST by CT/MRI to allow 
patients who have been on the LGX818/MEK162 dual -combination treatment or 
LGX818/MEK162/LEE011 triple combination for ≥ 24 months to have CT/MRI scans 
every  8-12 weeks  (± 7 days)  instead  of every  8 weeks  until disease  progression.  The above 
section was also amended for tumor evaluation per RECIST by CT/MRI to allow patients 
who have been on the dual - or triple -combination treatment for ≥ 24 months and then 
discontinue study  treatment for any  reason other than disease progression to have CT/MRI 
scans every 8 -12 weeks (± 7 days) instead of every 8 weeks. The above section was also 
amended to remove the note that all radiological assessments are to be centrally collected 
by an imaging  CRO,  and to remove  the note that such assessments  may be assessed  centrally 
if deemed necessary.  
• 7.2.2.7 Ophthalmologic  evaluation  
The above  section  was amended  to allow  patients  who have  been  on the LGX818/MEK162 
dual-combination or LGX818/MEK162/LEE011 triple -combination treatment for ≥ 24 
months  without  a retinal  AE to be evaluated  only for visual  acuity  at each scheduled  patient 
visit and at the End of Treatment visit. These patients are also required to have a full 
ophthalmic examination if clinically indicated and at the End of Treatment visit.  
Array BioPharma 
Amend ed Protoco l Version 10 Confid ential Page 23 
Protoco l No. CMEK162X2 110 / C422 1005 
PFIZER  CONFIDENTIAL   
 • 7.2.2.8.2 Electrocardiogram (ECG) schedule for the triple combination  
The above section was amended to remove text around unscheduled PK sample collection 
when  an ECG  with a QTcF  change  from  baseline  > 60 msec  or a new absolute  QTcF  ≥ 501 
msec result is observed.  
• 7.2.3.1.1  Pharmacokinetic  blood  sample  collection  and handling  
The above section was amended stop collection of unscheduled PK samples and text was 
removed  where  this practice  was discussed.  This includes  addition  of footnotes  in 
Table 7 -4 and Table 7 -5 denoting collection should be stopped upon the effective date of 
this amendment.  
• 8.1.1  Definitions  and reporting  
The above  section  was modified  to reflect  the change  in the CTCAE  version  to be used for 
assessment of AEs, from version 4.0 to version 4.03.  
• 9.3 Data collection  
The above section was amended to remove the note that all imaging data to be centrally 
collected by an imaging CRO, and to remove the note that such imaging data may be 
assessed centrally if deemed necessary.  
• 9.4 Database management and quality  control  
The above  section  was amended  to remove  the note that all imaging  data are to be assessed 
centrally.  
• 10 Statistical  methods  and data analysis  
The above  section  was amended  to indicate  the final clinical  study  report  will be completed 
once all patients have completed or discontinued from the study.  
• 10.5.2.1  Adverse  events  and 10.5.2.2  Laboratory  abnormalities  
The above sections were amended to reflect that CTCAE version 4.03 was used in the 
grading of AEs and laboratory abnormalities.  
• Table  14-11 List  of P-gp Inhibitors  to be used with caution  and Table  14-12 List  of BCRP, 
OAT1,  OAT3,  OCT1,  OCT2,  OATP1B1  and OATP1B3  substrates  to be used with caution  
Table  14-11 was combined  with Table  14-12 and renamed  to List of BCRP  substrates,  BSEP 
inhibitors, P -gp inhibitors/inducers, and MATE1, P -gp, OAT1, OAT3, OCT1, OCT2, 
OATP1B1 and OATP1B3 substrates to be used with caution.  The List of BCRP OAT1, 
OAT3, OCT1, OCT2, OATP1B1 and OATP1B3 substrates to be used with caution was 
updated to add BSEP inhibitors, MATE1 and P -gp inhibitors/inducers ( Table 14 -11). 
Array BioPharma 
Amend ed Protoco l Version 10 Confid ential Page 24 
Protoco l No. CMEK162X2 110 / C422 1005 
PFIZER  CONFIDENTIAL   
 • Table  14-12 Drugs  with a conditional  risk of Torsades  de Pointes,  and a second  Table  
14-12 Drugs  with a possible  risk of Torsades  de Pointes;  Appendix  4 List of concomitant 
medications prohibited or to be used with caution for dual and triple combination  
Information regarding Torsades de Pointes and Drugs with a possible risk of Torsades de 
Pointes (in 2 tables labelled Table 14 -12) were combined and updated and a new table 
(Table  14-12, List of QT prolonging  drugs),  was added.  The new table  updates  and expands 
the list of QT prolonging  drugs  and matches  the changes  made  in Section  6.4 on concomitant 
medications.  
Other  minor  clarification  changes  and corrections  to typographical  errors  have  been  made.  
IRB/IEC  
A copy of this amended protocol will be sent to the Institutional Review Board 
(IRBs)/Independent Ethics Committee (IECs) and Health Authorities.  
The changes described in this amended protocol require IRB/IEC approval prior to 
implementation. The changes herein affect the Informed Consent. Sites are required to update 
and submit for approval a revised Informed Consent that takes into account the changes 
described in this protocol amendment.  
Array BioPharma 
Amend ed Protoco l Version 10 Confid ential Page 25 
Protoco l No. CMEK162X2 110 / C422 1005 
PFIZER  CONFIDENTIAL   
 Amendment  8 
Amendment  rationale  
The main  purpose  of this amendment  is to address  recently  observed  safety  findings  from 
patients treated with LEE011 (Ribociclib) in other clinical trials.  
1. Recent data suggests a potential risk of hepatic toxicity (drug induced liver injury [DILI] 
indicated by an increase of transaminases, in isolation or with bilirubin increase, in 
patients  treated  with LEE011.  Updates  to monitoring  for hepatobiliary  toxicities  including 
ALT, AST, and total bilirubin have been added.  
2. Updates  to monitoring  and dose adjustment  guidelines  for QTcF  prolongation  in order  to 
improve  patient  safety  based  on program  standard  language  recommendations  have  been 
implemented. Specific changes are as follows:  
a. Dose  modification  guidelines  have  been  changed  to more  strictly  manage  QTcF 
prolongation  
b. Additional  ECG  assessments  
c. Follow -up of electrolyte  abnormalities  until normalization  in the event  of QTcF 
prolongation  
d. Mandated  review  of concomitant  medications  in the event  of QTcF  prolongation,  also 
updated based on recent metabolism data for LEE011 or MEK162  
e. Mandated  review  of dosing  regimen  in the event  of QTcF  prolongation  
f. Addition  of continued  ECG  monitoring  for all cycles  in the event  of a patient  QTcF  
≥ 481 ms at any time before  Cycle 7 Day  1 
This amendment  also documents  a change  in study  sponsorship  from  Novartis  to Array 
BioPharma. Study design and procedures are not affected by the sponsorship change.  
Changes to the protocol  
Changes  to specific  sections  of the protocol  are shown  in the track  changes  version  of the 
protocol using strike through red font for deletions and red underlined for insertions.  
• The Protocol  Summary  is updated  to reflect  the changes  to the inclusion  and exclusion 
criteria  
• Section  5.3 Exclusion  criteria  has been  updated  with the following:  
• Addition of criteria for the following laboratory values within normal limits or 
corrected to within normal limits with supplements before the first dose of study 
medication:  sodium,  inorganic  phosphate,  calcium  (corrected  for serum  albumin)  
• Clarification  of QTcF  interval  criteria  on the ECG  (ie: unreadable  or not interpretable) 
or QTcF >450 ms. All as determined by screening ECG (mean of triplicate ECGs)  
• Addition  of symptomatic  pericarditis within  12 months  prior to  starting study  drug 
• Addition  of any other  clinically  significant  heart  disease  (e.g. documented  congestive 
heart failure, documented cardiomyopathy)  
• Increase  in exclusion  window  from  3 months  to 12 months  prior  to starting  study  drug 
for unstable angina pectoris and acute myocardial infarction  
Array BioPharma 
Amend ed Protoco l Version 10 Confid ential Page 26 
Protoco l No. CMEK162X2 110 / C422 1005 
PFIZER  CONFIDENTIAL   
 • Addition exclusion window of 12 months prior to starting study drug for clinically 
significant resting bradycardia, history or presence of ventricular tachyarrhythmia, 
complete  left bundle  branch  block,  right  bundle  branch  block  and left anterior  hemi 
block (bifasicular block)  
• Clarification that patients who are currently receiving agents known to cause QT 
prolongation, induce Torsades de Pointes, or that are metabolized predominantly 
through  CYP3A4  and have  a narrow  therapeutic  index,  and cannot  be discontinued  7 
days prior to Cycle 1 Day 1, are excluded  
• Section  6.1.1,  added  grapefruit  hybrids,  pummelos,  starfruit  and Seville  (sour)  oranges  to 
list of items to be avoided due to CYP3A4 mediated interaction  
• Table  6-4 - Dose  modification  guidelines, has  been  updated to: 
• Include  new guidelines  for the management  of QTcF  prolongation.  Dose  reduction  is 
recommended in case of grade 2 QTc prolongation (QTcF 481 -500 ms). For patients 
who experience grade 3 QTc prolongation (QTcF ≥ 501 ms) on at least two separate 
ECGs, local cardiologist consultation is also recommended in addition to dose 
reduction.  Patients  who experience  grade  4 QTc prolongation  must  discontinue  study 
treatment.  
• Section  6.3.3  added  to outline Additional  follow -up for hepatic toxicities  
• Section  6.4.3.1  updated  to reference  medications  that are known  to induce  Torsades 
de Pointes  
• Section  7.2.2.8.2  was updated  to clarify  follow -up guidelines  in the event  a QTcF  value 
of ≥ 481 ms is observed prior to cycle 7  
• Appendix  4 includes  new tables  listing  medications  with a risk of Torsades  de Pointes  
In addition  to these  changes,  inconsistencies  and typographical  errors  have  been  corrected 
as needed.  
IRB/IEC  
A copy of this amended protocol will be sent to the Institutional Review Board 
(IRBs)/Independent Ethics Committee (IECs) and Health Authorities.  
The changes  described  in this amended  protocol  require   IRB/IEC  approval  prior  
to implementation.  
The changes herein affect the Informed Consent. Sites are required to update and submit for 
approval a revised Informed Consent that takes into account the changes described in this 
protocol amendment.  
Array BioPharma 
Amend ed Protoco l Version 10 Confid ential Page 27 
Protoco l No. CMEK162X2 110 / C422 1005 
PFIZER  CONFIDENTIAL   
 Amendment  7 
Amendment  rationale  
• This protocol  amendment  is based  on Urgent  Safety  Measures  (re: Investigator 
Notification letter dated 07Feb2014):  
• A fatal event of intracranial hemorrhage occurred in a 21 -year-old patient in a phase Ib 
study of LEE011 in combination with MEK162 [MEK162X2114]. Based on the normal 
laboratory assessments, absence of other known risk factors for intracerebral bleeding 
together with early signs of clinical response to treatment, the investigator suspected 
undetected  intracranial  metastases  as the source  of the bleeding.  The relationship  to study 
drugs cannot be ruled out.  While the protocol excludes patients with symptomatic brain 
metastases, brain imaging prior to study entry had not been required and was not 
performed for this patient.  As a precautionary measure, this amendment will mandate 
brain  imaging  for all patients  at screening  and will exclude  patients  with brain  metastases 
from the triple -combination part of the study.  Furthermore, patients with abnormal 
coagulation evaluations at Screening/baseline will be excluded from the triple - 
combination part of the study.  
Changes to the protocol  
Changes  to specific  sections  of the protocol  are shown  in the track  changes  version  of the 
protocol using strike through red font for deletions and red underlined for insertions.  
• Section  5.3, Exclusion  criteria  has been  updated  for the triple -combination  part of the 
study to include the following:  
1. Exclusion  criterion  no. 3 has  been  updated  to exclude  patients  with brain metastases.  
2. Exclusion  criterion  no. 7 has been  updated  to exclude  patients  with abnormal 
coagulation evaluations: PT/INR >1.5 x ULN or aPTT >1.5 x ULN.  
• Section 6.1.5, Treatment duration has been updated to exclude from treatment beyond 
progression  patients  in the triple -combination  part of the study  that appear  with new brain 
metastases.  
• Table 7 -1, Visit evaluation schedule has been updated to include mandatory brain 
MRI/CT  at Screening/baseline  for patients  in the triple -combination  part of the study.  
• Section 7.2.1, Efficacy  assessment has been updated to include mandatory  baseline brain 
imaging  to access  CNS  disease  for the patients  in the triple -combination  part of the study.  
IRB/IEC  
A copy of this amended protocol will be sent to the Institutional Review Board 
(IRBs)/Independent Ethics Committee (IECs) and Health Authorities.  
1. Urgent  Safety  Measures  (re: Investigator  Notification  letter  dated  07 Feb 2014):  
This amendment  is required  for patient  safety  (i.e. necessary  to eliminate  immediate  hazards  to 
the trial subjects ICH GCP 3.3.8). Therefore updated exclusion criteria and baseline imaging 
assessments will be implemented prior to IRB/IEC approval, but will be sent for approval as 
well.  
Array BioPharma 
Amend ed Protoco l Version 10 Confid ential Page 28 
Protoco l No. CMEK162X2 110 / C422 1005 
PFIZER  CONFIDENTIAL   
 Amendment  6 
Amendment  rationale  
1. Urgent  Safety  Measures  (re: Investigator  Notification  letter  dated  08 Nov 2013):  
• The main objective of this amendment is to modify existing safety monitoring for 
visual toxicities. This is based on a new unexpected non -clinical finding from the 
13-week monkey toxicology study with LGX818. In this study, two monkeys 
treated at a dose of 60mg/kg/day presented retinal changes at the assessment on 
week  12 (please  refer  to the Investigator  Notification  letter  dated  08 Nov 2013).  As 
for this protocol  sufficient  ophthalmic  examinations  are already  in place  to monitor 
for the potential risk of retinal/ocular changes, these examinations and frequency  
of the examinations will not change. However this amendment includes modified 
recommendations for LGX818 dose modifications for visual toxicity and in 
addition, modified definitions of ophthalmologic DLT’s are provided.  
2. Other  Changes  Implemented  under  Protocol  Amendment  6: 
• In addition, prohibited medications are updated. Since LGX818 is mainly 
metabolized  by CYP3A4  (>80%), concomitant  use of strong  CYP3A4  inhibitors 
would likely significantly increase the exposure of LGX818. Therefore 
concomitant use of strong systemic CYP3A4 inhibitors is prohibited during this 
study. Language in Section 6.4.2 and Section 6.4.3 , and Appendix 4 (Section 
14.4)  is amended  accordingly  and a corresponding  exclusion  criterion  was added 
in Section 5.3 . 
• Also,  this amendment  clarifies  that any language  regarding  the triple  combination 
of LGX818/MEK162/LEE011 in this protocol (introduced under protocol 
amendment 5) is not applicable to the USA and Singapore, as indicated in the 
applicable Protocol Sections. Any other changes introduced under protocol 
amendment 5, are by this amendment now made applicable to the USA and 
Singapore. Which are as follows:  
a. Table  6-4 under  ‘Creatine  phosphokinase  (CPK)’  clarifying  text added:  If the 
LGX818 dose administered is > 450mg QD, then the LGX818 dose must be 
reduced to 450mg QD during the MEK162 dosing interruption. If the 
LGX818 dose was reduced to 450mg QD during MEK162 dosing 
interruption, the LGX818 dose must be re -escalated to the previous 
administered dose once MEK162 dosing is restarted. Section 6.3.2 was 
amended accordingly.  
b. Section 1.2.1.2 and Section 1.2.2.2 (and subsections) have been updated with 
data from  the most  recent  Investigator  Brochure  for LGX818  and Investigator 
Brochure for MEK162, respectively.  
c. Section 6.4.2 was updated for new available data: 1) MEK162 is also an 
inhibitor  of CYP2B6.  2) There  is a potential  for MEK162  to induce  CYP3A4.  
3) The solubility of LGX818 and MEK162 is pH dependent. Patients 
receiving  concomitant  treatments  that could  potentially  modify  the gastric  pH 
(i.e. PPI) should be instructed to take them at least two hours after the 
administration of LGX818 and/or MEK162.  
Array BioPharma 
Amend ed Protoco l Version 10 Confid ential Page 29 
Protoco l No. CMEK162X2 110 / C422 1005 
PFIZER  CONFIDENTIAL   
 d. Section  7.2.2.2  was corrected  for the collection  of vital signs  at Cycle  2 Day 
15 also for patients enrolled in the Phase II part of the study.  
e. For clarity  of presentation,  the description  in Section  10.4.2.1  of the prior 
distributions for the 5 parameter BLRM has been moved to Appendix 5 
(statistical methodology LGX818 and MEK162 dual combination).  
This amendment occurs while the study drug dual combination of LGX818 and MEK162 is 
enrolling in the Phase II part of the study. In this ongoing study two RP2Ds were declared: 
600mg/45mg  and 450mg/45mg  (LGX818  QD/ MEK162  BID).  The dose escalation  part for the 
triple  combination  LGX818,  MEK162  and LEE011  is open  for enrollment  at participating  sites.  
Changes to the protocol  
Changes  to specific  sections  of the protocol  are shown  in the track  changes  version  of the 
protocol using strike through red font for deletions and red underlined for insertions.  
• Section  1.2.1.1.2  and Section  1.2.1.2  were  updated  with the new data of the 13-week 
monkey toxicology study.  
• Table 6 -3 and Table 6 -4 have been amended to include the modified definitions of the 
ophthalmologic  DLT  and the modified  recommendations  for LGX818  dose modifications 
for visual toxicity, respectively. Section 6.2.6.2 and Section 6.3.2 have been updated 
accordingly.  
• Section 6.4.2 and Section 6.4.3, have been updated to include the new data on 
concomitant use of strong systemic inhibitors of CYP3A4, which are as per this 
amendment  prohibited.  Section  6.4.3.1,  Table  14-10 and exclusion  criterion  17 (Section 
5.3) were updated accordingly, as well was exclusion criterion 18 (Section 5.3) added.  
• For the clarification that any language regarding the triple combination with LEE011 in 
this protocol is not applicable to the USA and Singapore, a statement was added to the 
Protocol  Summary  and to Section  1, Section  2, Section  3, Section  4, Section  5, Section  6, 
Section 7, Section 10, Section 11.3, Section 14.3, Section 14.4 and Section 14.6.  
• Section  7.2.4.1.3  was updated  to clarify  that the collection  of a fresh  tumor  biopsy  at the 
time of relapse is strongly  encouraged if feasible according to the investigator . Section  
7.2.4.1.4  and Section  7.2.4.2.1  were  updated  to align  the collection  of the tissue  with the 
requirements of the analysis lab. Table 7 -5 was updated accordingly.  
IRB/IEC  
A copy of this amended protocol will be sent to the Institutional Review Board 
(IRBs)/Independent Ethics Committee (IECs) and Health Authorities.  
1. Urgent  Safety  Measures  (re: Investigator  Notification  letter  dated  08 Nov 2013):  
This amendment  is required  for patient  safety  (i.e. necessary  to eliminate  immediate  hazards  to 
the trial subjects ICH GCP 3.3.8). Therefore dose modifications for ocular adverse events and 
updated DLT criteria will be implemented prior to IRB/IEC approval, but will be sent for 
approval as well.  
2. Other  Changes  Implemented  under  Protocol  Amendment  6: 
Array BioPharma 
Amend ed Protoco l Version 10 Confid ential Page 30 
Protoco l No. CMEK162X2 110 / C422 1005 
PFIZER  CONFIDENTIAL   
 All other changes described in this amendment require IRB/IEC approval prior to 
implementation. In addition, if the changes herein affect the Informed Consent, sites are 
required to update and submit for approval a revised Informed Consent that takes  into account 
the changes described in this amended protocol.  
Array BioPharma 
Amend ed Protoco l Version 10 Confid ential Page 31 
Protoco l No. CMEK162X2 110 / C422 1005 
PFIZER  CONFIDENTIAL   
 Amendment  5 
Amendment  rationale  
1. The main  rationale  for this amendment  is to add LEE011  to the LGX818  and MEK162 
combination treatment in order to explore safety  and preliminary  efficacy  of this triple 
combination in patients with BRAF V600 -dependent advanced solid tumors.  
Pre-clinical evidence suggests that the addition of LEE011 to the dual combination of 
MEK162 and LGX818, could potentially improve the clinical response in patients  
with BRAF V600 -dependent melanoma (see Section 1.2.4.3). Although clinical trials 
with selective BRAF and MEK inhibitors have shown significant activity in patients 
with BRAF mutant melanoma, these patients ultimately  relapse and fail to continue to 
respond  to these  therapies.  Therefore,  targeting  both the RAS/RAF/MEK/ERK  and the 
Cyclin D -CDK4/6 pathways downstream may improve and prolong response and be 
an effective strategy to expand therapeutic options for these patients with advanced 
melanoma that have very poor prognosis and constitute a high unmet medical need.  
Therefore the triple combination of LGX818 and MEK162 and LEE011 will be 
evaluated in a dose escalation to determine the MTD and/or RP2D in patients with 
BRAF V600 -dependent advanced solid tumors. Once the MTD and/or RP2D is 
declared,  the preliminary  efficacy  of the triple  combination  will be assessed  in patients 
with BRAF V600 mutant advanced melanoma naïve to prior treatment with a BRAF 
inhibitor (arm A).  
The triple  combination  will be evaluated  in parallel  and separately  from  the evaluation 
of the dual combination.  
2. In addition, this amendment was used to clarify that in those patients dosed with a 
LGX818 dose > 450mg QD, the LGX818 dose is recommended to be reduced to 
450mg QD during a MEK162 dosing interruption while maintaining LGX818 dosing 
(as per Table  6-4 for grade  3 CPK,  eye disorders  - retinopathy  and eye disorders  – any 
other), to reduce any potential risk of developing adverse events to the patient. This is 
recommended since a dose of 450mg QD LGX818 is the maximum tolerated dose for 
LGX818 as a single agent, and there is an improved tolerability of LGX818 in the 
combination with MEK162 compared to LGX818 as a single agent. Once MEK162 
dosing is  restarted, the LGX818 dose can be re -escalated to the previous administered 
dose.  
This amendment occurs while the study drug dual combination of LGX818 and MEK162 is 
enrolling in the Phase II part of the study at the RP2D of 600mg LGX818 QD and 45mg 
MEK162  BID.  In this ongoing  study  two RP2Ds  were  declared:  600mg/45mg  and 450mg/45mg 
(LGX818 QD/ MEK162 BID).  
Changes to the protocol  
Changes to specific sections of the protocol are shown in the track changes version of the 
protocol using strike through red font for deletions and red underlined for insertions.  
• All relevant  Sections,  Tables  and Figures  throughout  the protocol  were  updated  to include 
the evaluation of the triple combination of LGX818 and MEK162 and LEE011.  
Array BioPharma 
Amend ed Protoco l Version 10 Confid ential Page 32 
Protoco l No. CMEK162X2 110 / C422 1005 
PFIZER  CONFIDENTIAL   
 • Sections  1.2.1.2  and 1.2.2.2  (and subsections)  have  been  updated  with data from  the most 
recent Investigator Brochures for LGX818 and MEK162, respectively.  
• Sections  1.2.3  (and subsections), 1.2.4.3,  1.2.4.4,  1.3.2, 6.1.1.2,  6.4.2.1,  6.4.3.1, 7.2.2.8.2,  
and Tables  6-2, 6-4, 6-6 were  added  for the triple combination.  
• Table  6-4 and Section  6.3.2  were  amended  to include  the guidance  on the LGX818  dose 
reduction/re -escalation during MEK162 dosing interruption for certain toxicities.  
• Section  6.4.2  was updated  for new  available data 
• Section  7.2.2.2  was corrected  for the collection  of vital signs  at Cycle  2 Day 15 also for 
patients enrolled in the Phase II part of the study.  
• For clarity  of presentation,  the description  in Section  10.4.2.1  of the prior  distributions  for 
the 5 parameter BLRM has been moved to Appendix 5.  
• Section  14.6 (Appendix  6) was added  to describe  the operating  characteristics  of the 
BLRM and hypothetical dose escalation scenarios of the triple combination.  
• Other minor changes in the protocol text were made for consistency/clarification.  
• The protocol  summary  has been  updated  according  to the changes  in the amended 
protocol.  
IRB/IEC  
A copy of this amended protocol will be sent to the Institutional Review Board 
(IRBs)/Independent Ethics Committee (IECs) and Health Authorities.  
The changes described in this amended protocol require IRB/IEC approval prior to 
implementation. In addition, if the changes herein affect the Informed Consent, sites are 
required to update and submit for approval a revised Informed Consent that takes  into account 
the changes described in this amended protocol.  
Array BioPharma 
Amend ed Protoco l Version 10 Confid ential Page 33 
Protoco l No. CMEK162X2 110 / C422 1005 
PFIZER  CONFIDENTIAL   
 Amendment  4 
Amendment  rationale  
The rationale  for this amendment  is to allow  reduction  of the MEK162  dose in case of MEK162 
related toxicities. The current language in this protocol recommends a reduction to the next 
lower,  previously  tested  (i.e. in this study)  dose level  of the respective  study  drug.  This applied 
only to LGX818 and not to MEK162, since only the LGX818 dose has been escalated and no 
lower dose levels than 45mg MEK162 have been tested in this study.  
Therefore  this amendment  introduces  the modified  recommendation:  treatment  at the next lower, 
previously  tested dose level of LGX818 and the next lower dose level of MEK162 (please see 
Table 6 -1). Treatment with LGX818 should be maintained at the same dose level if, in the 
judgment of the investigator, the adverse event is considered to be unrelated to LGX818.  
In addition,  this amendment  introduces  a number  of further  changes  and clarifications:  
• For patients considered for enrollment in this study for whom molecular status is not 
known and who have a tumor which is not routinely screened for a BRAF mutation at a 
local  laboratory,  both fresh  and archival  tumor  tissue  can be used for the local  assessment 
of the mutational status. As the BRAF mutational status assessment for these cases is 
specifically performed for this study at the local laboratory, both patients giving fresh 
tumor sample and allowing use of archival tumor tissue must sign Molecular pre - 
screening Informed consent prior to this assessment. Therefore the language in the 
protocol was amended to require Molecular pre -screening Informed consent to be signed 
for allowing both collection of fresh tumor sample and use of archival tumor tissue. 
Previously this was required only for patients from whom fresh tumor sample was 
collected.  
• Minimal criteria to allow dosing beyond progression were added: it was clarified that 
dosing beyond progression of disease is not allowed in situations where the patient has a 
rapid  progression  of disease  and needs  urgent  alternative  medical  intervention,  if patients 
have worsening of clinically relevant laboratory values or if patients have a clinically 
relevant decline in performance status at time of progression.  
• The early  tumor assessment on C1D28 has been removed from the Phase II part of the 
protocol  in order  to reduce  the amount  of irradiation  patients  enrolled  in this part of the 
study would receive and for consistency with the tumor assessment schedule of future 
studies involving MEK162 and LGX818.  
• As supported by additional data now available, the new MEK162 tablet variants as 
described in this protocol, no longer need to be administered to the patients under 1 -hour 
fasting  periods  prior,  and after dosing  of the evening  MEK162  doses.  Therefore  language 
referring to this fasting has been removed from the protocol.  
• The frequency  of physical examinations, vital signs and performance status assessments 
was reduced and the collection of several clinical chemistry laboratory parameters was 
removed  for the Phase  II part  of the study,  as sufficient  safety  data were  collected  during 
the Phase Ib part of the study.  
• In order to assess the potential impact of demographic differences (e.g. Japanese vs 
Caucasian)  on the PK of the LGX818  and MEK162  combination,  the protocol  has been  
Array BioPharma 
Amend ed Protoco l Version 10 Confid ential Page 34 
Protoco l No. CMEK162X2 110 / C422 1005 
PFIZER  CONFIDENTIAL   
 modified  to allow  PK samples  to be collected  from  additional  patients  enrolled  in the 
Phase II part.  
• The time points  and requirements  for the fresh  tumor  biopsy  and skin biopsy  collection 
were clarified and further specified.  
The current study began recruitment on 28 -May-2012. As of 16 -April -2013, 35 patients with 
advanced  solid  tumors  with BRAF  mutations  have  been  enrolled  and treated  for at least 28 days. 
This amendment  occurs  while  the study  drug combination  is being  evaluated  at the seventh  dose 
cohort (800mg LGX818 QD and 45mg MEK162 BID) and expanded dose level cohort six of 
450mg LGX818 QD and 45mg MEK162 BID. In parallel, recruitment to the Phase II part of 
the study started on 18 -Apr-2013 with the RP2D of 600mg LGX818 QD and 45mg MEK162 
BID.  
Changes to the protocol  
Changes  to specific  sections  of the protocol  are shown  in the track  changes  version  of the 
protocol using strike through red font for deletions and red underlined for insertions.  
• Sections  1.2.1.1.1  and 6.4.2  were  updated  with newly  available  data.  Table  14-12 was 
updated accordingly.  
• Sections  4.1 and 7.1.1  were  amended  with the new requirements  for signing  of Molecular 
pre-screening ICF. The Molecular pre -screening ICF was corrected accordingly.  
• Language  referring  to fasting  for the new MEK162  tablet  variants  has been  removed  from 
Section 6.1.1.  
• Section  6.1.5  was amended  to included  cases  in which  treatment  beyond  progression  is not 
allowed.  
• Section  6.3.2  and Table  6-3 have  been  amended  to revise  the wording  on dose level 
reduction.  
• The Visit  Names/Numbers  for the D28 visits  were  removed  from  Table  7-1 to be 
consistent with the clinical data base visit numbering.  
• Section 7.2.1 was amended to indicate that the C1D28 tumor imaging assessment is not 
required  for the patients  enrolled  in the Phase  II part of the study.  Section  7.1 and Table  7- 
1 were updated accordingly.  
• Sections 7.2.2.1, 7.2.2.2, 7.2.2.3 and 7.2.2.5.2 were amended to reduce the frequency of 
physical examination, vital signs and performance status assessments, and to remove the 
collection of chloride, urea or BUN, uric acid, total  cholesterol,  triglycerides,  HDL,  LDL, 
TSH,  T3 and T4 from  the clinical  chemistry  laboratory  assessment  for patients  enrolled  in 
the Phase II part of the protocol. Table 7 -1 was revised accordingly.  
• Sections 7.2.3 and 7.2.3.1.1 were amended to include language that collection of PK 
samples  from  additional  patients  than previously  specified,  is allowed  if required  as per 
instruction from the Sponsor. Tables 3 -1, 7-1, 7-4 and 7 -5 were updated accordingly.  
• Sections  7.2.4.1.2,  7.2.4.1.3  and 7.2.4.2  were  amended  to clarify  and further  specify  the 
time points and requirements under which fresh tumor and skin biopsies should be 
collected. Tables 7 -1 and 7 -5 were revised accordingly.  
Array BioPharma 
Amend ed Protoco l Version 10 Confid ential Page 35 
Protoco l No. CMEK162X2 110 / C422 1005 
PFIZER  CONFIDENTIAL   
 • Sections  7.2.4.4  and 7.2.4.5  were  updated  to clarify  which  samples  collected  during  the 
study,  are meant  to be stored  for 15 years  for optional  additional  exploratory  biomarker 
assessments and to include further potential use of all remaining study samples.  
IRB/IEC  
A copy of this amended protocol will be sent to the Institutional Review Board 
(IRBs)/Independent Ethics Committee (IECs) and Health Authorities.  
The changes described in this amended protocol require IRB/IEC approval prior to 
implementation. In addition, if the changes herein affect the Informed Consent, sites are 
required to update and submit for approval a revised Informed Consent that takes into account 
the changes described in this amended protocol.  
Array BioPharma 
Amend ed Protoco l Version 10 Confid ential Page 36 
Protoco l No. CMEK162X2 110 / C422 1005 
PFIZER  CONFIDENTIAL   
 Amendment  3 
Amendment  rationale  
The production of the original MEK162 tablet that is currently used in this study will cease. 
Two new MEK162  tablet  variants  have  been  developed.  One variant  is a modified  formulation 
of the MEK162  drug product  (hence  forth  referred  to as “MEK162  smaller  tablet”)  and the other 
variant  has the same  formulation  but contains  drug substance  from  a new  manufacturer  (hence 
forth referred to as “new MEK162 tablet variant”).  
Two relative  bioavailability  studies  in humans  are currently  ongoing  in order  to compare  
a) the MEK162  smaller  tablet  with the original  MEK162  tablet  (CMEK162X2108  study)  and 
b) the new MEK162 tablet variant with the original MEK162 tablet (CMEK162A2101 study).  
Based on the results of these two relative bioavailability studies, the MTD/RP2D of the 
LGX818 and MEK162 combination may need to be established with one or both of the two 
new MEK162  tablet  variants  (for further  details  please  see Section  6.2.3).  This amendment  will 
introduce this possibility.  
If it is decided based on the results of the two relative bioavailability studies, that the 
MTD/RP2D can be determined using the original MEK162 tablet, then enrollment in the 
CMEK162X2110 study will continue in the dose escalation or the Phase II part will start with 
one or both of the two new MEK162 tablet variants, as applicable at that time.  
• Since  food interaction  studies  with the two new MEK162  tablet  variants  have  not yet been 
performed at the time of this amendment, these new tablet variants would need to be 
administered to the patients under 1 -hour fasting periods prior, and after dosing of the 
evening MEK162 doses.  
In addition,  this amendment  was used to make  a few changes  for clarification  (please  see below 
Changes to the protocol for details).  
The current study began recruitment on 28 -May-2012. As of 05 -Nov-2012, 20 patients with 
advanced  solid  tumors  with BRAF  mutations  have  been  enrolled.  This amendment  occurs  while 
the study drug combination is being evaluated in the fourth dose cohort.  
Changes to the protocol  
Changes to specific sections of the protocol are shown in the track changes version of the 
protocol using strike through red font for deletions and red underlined for insertions.  
• Section 5.2 has been updated to clarify  the collection of mandatory fresh tumor biopsies at 
Screening/baseline for patients to be enrolled in the Phase II part. Section 7.2.4.1.1 and 
Table 7 -1 were amended accordingly.  
• Section 6.2.3 has been updated to include the possibility  to establish the MTD/RP2D with 
the MEK162 smaller tablet and/or new MEK162 tablet variant if needed. Sections 10.1.1,  
10.3.1  and 10.4.2.1  have  been  updated  accordingly.  
• Section  6.1.1,  Section  6.6.1  and Section  6.6.2  have  been  updated  to include  instructions  on 
dose administration of, and (label) information on the two new MEK162 tablet variants.  
Array BioPharma 
Amend ed Protoco l Version 10 Confid ential Page 37 
Protoco l No. CMEK162X2 110 / C422 1005 
PFIZER  CONFIDENTIAL   
 • Sections 7.1, Section 7.2.1 and Table 7 -1 have been updated to clarify the wording on 
imaging assessments. Sections 9.3 and 9.4 have been updated to accurately describe the 
process  of central  reviewing  of the imaging  assessments.  Section  10.4.4  and Section  10.5.1 
have been amended accordingly.  
IRB/IEC  
A copy of this amended protocol will be sent to the Institutional Review Board 
(IRBs)/Independent Ethics Committee (IECs) and Health Authorities.  
The changes described in this amended protocol require IRB/IEC approval prior to 
implementation. In addition, if the changes herein affect the Informed Consent, sites are 
required to update and submit for approval a revised Informed Consent that takes  into account 
the changes described in this amended protocol.  
Array BioPharma 
Amend ed Protoco l Version 10 Confid ential Page 38 
Protoco l No. CMEK162X2 110 / C422 1005 
PFIZER  CONFIDENTIAL   
 Amendment  2 
Amendment  rationale  
The main  rationale  of the amendment  is to introduce  a third  arm in the Phase  II part of the study 
to enroll 40 patients with locally advanced or metastatic BRAF V600 mutant melanoma who 
are naïve  to previous  treatment  with a selective  BRAF  inhibitor.  LGX818  has shown  in the first 
in human Phase I single agent CLGX818X2101 study, clinical antitumor activity at all dose 
levels tested (50 mg/day to 300 mg/day) in patients with metastatic BRAF V600 mutant 
melanoma who did not receive prior treatment with a selective BRAF inhibitor. As of 03 July 
2012, signs of clinical activity have been observed in 20 out of the 21 enrolled patients naïve 
for prior  selective  BRAF  inhibitor  treatment,  with reductions  in tumor  volume  of 8.3%  to 100% 
(including 11 PR (of which 8 confirmed)), observed after initiation of LGX818 single agent 
treatment.  In addition,  MEK162  has demonstrated  clinical  activity  in the human  phase  II single 
agent CMEK162X2201 study in patients with BRAF mutant metastatic melanoma (Ascierto 
2012). Recent data from the phase Ib/II combination study of the BRAF inhibitor Dabrafenib 
and MEK  inhibitor  Trametinib  also show  that patients  with BRAF  mutated  melanoma  clinically 
benefit  from  a BRAF/MEK  inhibitor  combination  with an improved  durability  of response  over 
single agent therapy (Weber 2012). The anticipated sample size of n = 40 patients was chosen 
in order  to ensure  desirable  statistical  properties  (correct  declaration  of activity/  inactivity)  with 
respect to the primary analysis.  
Additionally,  this amendment  will introduce  the possibility  to continue  to treat patients  beyond 
progression of disease. The recent overall survival data from the BRIM2 and BRIM3 clinical 
trials of the selective BRAF inhibitor Vemurafenib show that patients with BRAF mutated 
melanoma  may clinically  benefit  from  continued  treatment  beyond  progression  (Sosman  2012, 
Chapman 2011). This amendment will therefore allow that in special circumstances, such as 
cystic  lesions,  mixed  responses,  or new brain  metastases  treatable  with stereotactic  radiotherapy 
or surgery, patients to continue dosing with LGX818 and MEK162, if it is considered to be of 
benefit for the patient by the investigator, and in agreement with the Sponsor.  
Moreover, collection of fresh tumor biopsies at Screening/baseline for all patients enrolled in 
the Phase  II part, will be mandatory  as per this amendment  (unless  sufficient  fresh  tumor  tissue 
was collected during local molecular pre -screening which can be submitted to the Sponsor - 
designated laboratory at Screening (see Section 7.2.4). Clinical activity  of BRAF inhibitors is 
substantial  in terms  of response  rate. However,  not all patients  respond  and some  patients  show 
progression of disease after relatively short time periods (Flaherty 2010, Chapman 2011, 
Sosman 2012). In order to fully characterize the tumor, a comprehensive genomic analysis of 
the tumor  will be performed  at baseline  to better  understand  the genomic  profile  of the patient's 
tumors and potentially identify predictive markers of efficacy. As a result, characterization of 
select baseline gene mutation status in tumor tissue for the Phase II part will now be assessed 
as a secondary endpoint.  
A number  of additional  changes  and clarifications  are introduced  in this amendment:  
• All patients  enrolled  in the Phase  II part of the study  will be followed  for survival  more 
frequently: every three months instead of every four months.  
Array BioPharma 
Amend ed Protoco l Version 10 Confid ential Page 39 
Protoco l No. CMEK162X2 110 / C422 1005 
PFIZER  CONFIDENTIAL   
 • The recommended  dose modifications  for Grade  2 and 3 eye disorders  have  been  revised. 
The ocular toxicity profile of MEK162 is becoming better understood and investigators 
are gaining experience in assessing and managing these toxicities. Emerging data from 
several ongoing trials with MEK162 demonstrate that the events were low grade and 
appear to be reversible and manageable in all patients. In most cases, the events are 
transient in nature and resolve either without stopping treatment, upon dose reduction, or 
upon  interruption  of treatment  and subsequent  continuation  at the same  dose of MEK162. 
Based on these growing safety data from the clinical studies with MEK162, it is 
reasonable to consider maintaining the treatment of LGX818 and MEK162 for Grade 2 
CSR (central serous retinopathy)/CSR -like events, and also to allow dose reduction of 
MEK162 for Grade 3 CSR/CSR -like events. As result the DLT criteria for Grade 2 and 3 
Eye disorders have been revised accordingly.  
• The recommended dose modifications for CTCAE Grade 3 and 4 CPK have been revised. 
Blood creatine phosphokinase (CPK) elevations are mostly asymptomatic and not 
clinically significant. Therefore and based on the growing safety data from the ongoing 
clinical studies with MEK162, it is reasonable to review and consider to not dose modify 
LGX818  and MEK162  treatment  in asymptomatic  cases  of Grade  3 CPK  elevations  and to 
recommend  dose reduction  for symptomatic  Grade  3 blood  CPK  and for all Grade  4 blood 
CPK. As result the DLT criteria for CTCAE Grade 3 and 4 CPK have been revised 
accordingly.  
• The CYP inhibitors/inducers/substrates lists were updated according to the new lists 
published by FDA. Caution for co -medications that are UGT1A1 substrates was added 
since LGX818 was found to be an inhibitor of UGT1A1 in vitro. In addition, caution for 
co-medications that are substrates of renal transporters OAT1, OAT3 and OCT2 and 
hepatic  transporters  OATP1B1  and OATP1B3  was added  because  LGX818  was found  to 
inhibit OAT1, OAT3, OCT2, OATP1B1 and OATP1B3.  
• PK samples will be collected for the first 10 patients treated in each arm 2 and 3 in the 
Phase II part of the study. Previously, PK samples were collected in Phase II arm 2 from 
those patients from whom a fresh tumor biopsy could be collected (i.e. at least 15 
patients).  As per this amendment  a fresh  tumor  biopsy  at Screening/baseline  is mandatory 
for all patients in the Phase II part, it was redefined which patients treated in the Phase II 
arms 2 and 3, will be selected to provide PK samples.  
• To redefine the time of end of study (LPLV), the period of survival follow -up was 
amended to follow all patients enrolled in the Phase II part of the study for survival until 
death, or until all patients have completed SEC and have been followed for at least 18 
months  after their first dose of study  treatment,  or have  been  lost to follow -up or withdrew 
consent, whichever occurs first. Previously  patients were followed for survival until death 
or up to 18 months after LPLT, whichever occurs first.  
• Clarifications  throughout  the protocol.  
The current study began recruitment on 28May2012. As of 12July2012, six patients with 
advanced solid tumors with BRAF mutations have been enrolled and have completed the first 
dose cohort.  This amendment  occurs  while  the study  drug combination  is being  evaluated  in the 
second dose cohort.  
Array BioPharma 
Amend ed Protoco l Version 10 Confid ential Page 40 
Protoco l No. CMEK162X2 110 / C422 1005 
PFIZER  CONFIDENTIAL   
 Changes to the protocol  
Changes to specific sections of the protocol are shown in the track changes version of the 
protocol using strike through red font for deletions and red underlined for insertions.  
• Section  1.2.1.1.1  and 1.2.2.1.2  has been  updated  to include  more  recent  data on non-clinical 
pharmacokinetics of LGX818 and MEK162.  
• Section  1.2.1.2 has been updated to include more recent clinical experience with LGX818.  
• Sections 2.1, 3, 4.1 (including Figure 4 -1), 5.1 and 5.2 Inclusion Criterion 2 have been 
amended  to include  the additional  arm 3 in the Phase  II part of the study  and the objectives 
and endpoints  associated  with this population.  Sections  10.4,  10.4.1,  10.4.2.2  and 10.8 have 
been updated accordingly.  
• Sections  4.1, 6.1.5  and 7.1.3  were  amended  to include  the possibility  to continue  treatment 
with LGX818 and MEK162 beyond progression of disease under certain circumstances.  
• Section  5.2 Inclusion Criterion 8 was added to only allow patients to enroll in the Phase II 
part of the study that can provide a fresh tumor biopsy at Screening/Baseline. As 
consequence  a secondary  objective  has been  added  in Table  3-1 to include  the data analysis 
on these tumor samples. Sections 7.2.4 and 10.5.4.3.2, and Table 7 -1 have been updated 
accordingly.  
• Section  6.3.2  Table  6-3: recommended  dose modifications  for ‘creatine  phosphokinase’  and 
‘eye disorders’  have  been  amended.  Table  6-2 Criteria  for defining  DLTs  and Section  
6.2.6.2  have  been  updated  accordingly.  
• Section 6.4.2 and Appendix 4 Tables 14 -9 and 14 -12, were updated with newest data on 
permitted drugs to be used with caution.  
• Section 7.1.5.3 was revised to introduce survival follow -up phone calls every 3 instead of 
every 4 months. Table 7 -1 was updated accordingly.  
• Section 7.1.5.3 was revised to redefine the period of survival follow -up. Sections 7.1.5.2 
and 4.3 were updated accordingly.  
• Section 7.2.2.5.2 was updated to clarify that if total CPK is elevated ≥ CTCAE Grade 2, 
then isoenzymes in blood and myoglobin in blood and urine, should be weekly measured 
until resolved to ≤ CTCAE Grade 1.  
• Section  7.2.3.1.1  was updated  to add PK sample  collection  in Phase  II arm 3 and was revised 
to collect  PK samples  in Phase  II arms  2 and 3 from  the first 10 patients  treated  in each arm, 
instead of from those patients who can provide fresh tumor biopsies.  
• Sections 7.2.4.1.1, 7.2.4.1.2, 7.2.4.1.3 and 7.2.4.3, and Table 7 -5 have been updated to 
clarify the tumor tissue analysis, the collection time point for the fresh tumor biopsy at 
C1D16 and relapse, and the collection time point for the whole blood sample.  
• Section  13 was updated  with new references  added.  
• Other  minor  changes/corrections  in the protocol  text were  made  for consistency  and/or 
clarifications.  
• The protocol  summary  has been  updated  according  to the changes  in the amended  protocol.  
A copy of this amended  protocol  will be sent to the Institutional  Review  Board 
(IRBs)/Independent Ethics Committee (IECs) and Health Authorities.  
Array BioPharma 
Amend ed Protoco l Version 10 Confid ential Page 41 
Protoco l No. CMEK162X2 110 / C422 1005 
PFIZER  CONFIDENTIAL   
 The changes described in this amended protocol require IRB/IEC approval prior to 
implementation. In addition, if the changes herein affect the Informed Consent, sites are 
required to update and submit for approval a revised Informed Consent that takes  into account 
the changes described in this amended protocol.  
Array BioPharma 
Amend ed Protoco l Version 10 Confid ential Page 42 
Protoco l No. CMEK162X2 110 / C422 1005 
PFIZER  CONFIDENTIAL   
 Amendment  1 
Amendment  rationale  
This amendment addresses the enhanced safety measures to be implemented in order to 
minimize risks to patients to be treated in this study, as result of two Investigator Notification 
letters (Case PHHO2012DE003954 - acute liver failure with a fatal outcome, Case 
PHHO2012CH005184  - decreased  ejection  fraction,  heart  failure,  myocarditis,  and tachycardia) 
issued  by the Sponsor  for patients  treated  with MEK162  at a 60mg  BID dosing  schedule  in the 
CMEK162X2201 study.  
PHHO2012DE003954  is describing  a case of liver failure  with fatal outcome.  The investigator 
considered that the liver failure was related to the study drug. However other differential 
diagnoses such as muscular toxicity and /or thrombotic/vascular/ hepatic events may be 
considered in this case. This is the only  fatal liver failure case reported in a total of more than 
450 subjects/patients that have received at least 1 dose of MEK162 up to date.  
PHHO2012CH005184 is describing a case of reduced ejection fraction, symptoms of 
congestive  heart  failure,  myocarditis  and tachycardia.  The events  were  considered  suspected  to 
the study  drug by the investigator.  However  also other  differential  diagnoses  may be considered 
in this case.  The toxicities  stabilized  after study  treatment  discontinuation.  This is the only case 
of cardiac failure/myocarditis reported so far suspected to be related to MEK162.  
The following  will be implemented:  
• Increase  of the frequency of liver  transaminase and function test monitoring.  
• Revision of dose modification guidelines for patients with elevated transaminase levels,  
bilirubin levels and/or other liver function tests.  
• Increase  of the frequency  of cardiac  monitoring.  
In addition, this amendment was used to correct a typo in Exclusion Criterion 7 and to make a 
few other minor corrections for consistency. This amendment occurs while several sites have 
received HA and IRB approval for the original protocol.  
Changes to the protocol  
Changes to specific sections of the protocol are shown in the track changes version of the 
protocol using strike through red font for deletions and red underlined for insertions.  
• Section 5.3: in Exclusion Criterion 7 ‘directly measured CrCl ≥ 50% LLN’ was corrected 
to ‘directly measured CrCl < 50% LLN’.  
• Section 6.3.2 Table 6 -3: recommended dose modifications for ‘Bilirubin’, ‘AST or ALT’ 
and ‘AST or ALT and Bilirubin’ have been amended.  
• Section 7.2.2.5.2: CPK was added to the clinical chemistry panel as a parameter to be 
measured.  
• Section 7.2.2.5.2: Additional liver function test (LFT = AST, ALT, alkaline phosphatase 
and bilirubin (total, indirect and direct)) measurements have been added at Days 8 and 22 
of Cycle 2 and Day 15 of Cycle 4. Table 7 -1 has been amended accordingly.  
Array BioPharma 
Amend ed Protoco l Version 10 Confid ential Page 43 
Protoco l No. CMEK162X2 110 / C422 1005 
PFIZER  CONFIDENTIAL   
 • Section 7.2.2.8.2: Additional ECHO or MUGA evaluations have been added at Day 1 of 
Cycle  2, Day 1 of every  third  cycle  until Cycle  11 and Day 1 of every  fourth  Cycle  thereafter. 
Table 7 -1 has been amended accordingly.  
The changes  in this protocol  amendment  should  be considered  as substantial,  in Member  States 
of the European Union and European Economic Area (Directive 2010/C80/01/EC).  
A copy of this amended protocol will be sent to the Institutional Review Board 
(IRBs)/Independent Ethics Committee (IECs) and Health Authorities.  
The changes described in this amended protocol require IRB/IEC approval prior to 
implementation. In addition, if the changes herein affect the Informed Consent, sites are 
required to update and submit for approval a revised Informed Consent that takes  into account 
the changes described in this amended protocol.  
Array BioPharma 
Amend ed Protoco l Version 10 Confid ential Page 44 
Protoco l No. CMEK162X2 110 / C422 1005 
PFIZER  CONFIDENTIAL   
 Protocol  Summary  
[Any language regarding the triple combination of LGX818/MEK162/LEE011 in this 
Section is not applicable to the USA and Singapore]  
Study title : A Phase Ib/II, multicenter, open -label, dose -escalation study of LGX818 in 
combination with MEK162 in adult patients with BRAF V600 - dependent advanced solid 
tumors  
Study  phase : Ib/II 
Study  objectives : 
Primary  objectives : 
Phase  Ib: 1) To estimate  the MTD(s)  and/or  RP2D(s)  of oral LGX818  in combination  with oral 
MEK162 in patients with BRAF V600 -dependent advanced solid tumors. 2) To estimate the 
MTD(s) and/or RP2D(s) of oral LGX818 and MEK162 in combination with oral LEE011 in 
patients with BRAF V600 -dependent advanced solid tumors.  
Phase II: 1) To assess clinical efficacy of the LGX818 and MEK162 dual combination in the 
Phase II populations: BRAF V600 mutant metastatic colorectal cancer (mCRC) patients (arm 
1), BRAF  V600  mutant  metastatic  melanoma  patients  who have  progressed  after prior  selective 
BRAF inhibitor treatment (arm 2) and BRAF V600 mutant metastatic melanoma patients who 
are naïve to previous treatment with a selective BRAF inhibitor (arm 3). 2) To assess clinical 
efficacy  of the LGX818  and MEK162  and LEE011  triple  combination  in the Phase  II population: 
BRAF V600 mutant metastatic melanoma patients who are naïve to previous treatment with a 
selective BRAF inhibitor (arm A).  
Secondary  objectives : 
Phase Ib + II: To characterize the safety and tolerability of LGX818 and MEK162 in 
combination and LGX818 and MEK162 and LEE011 in combination.  
Phase  Ib: 
• To determine  the single  and multiple  dose PK profile  of the LGX818  and MEK162 
dual combination and LGX818 and MEK162 and LEE011 triple combination.  
• To assess  preliminary  clinical  anti-tumor  activity  of the LGX818  and MEK162  dual 
combination and LGX818 and MEK162 and LEE011 triple combination.  
Phase  II: 
• To further  assess  clinical  efficacy  of the LGX818  and MEK162  dual combination  in 
the Phase II populations, and of the LGX818 and MEK162 and LEE011 triple 
combination in the Phase II population.  
• To characterize  baseline  molecular  status  of molecules  relevant  to RAF/MEK/ERK 
and EGFR/PI3K/AKT signaling in tumor tissue.  
Study population : The dose escalation for both the dual and triple combination, will be 
conducted  in adult  patients  with locally  advanced  or metastatic  melanoma,  mCRC  or any other 
solid tumor upon agreement with the Sponsor, harboring the BRAF V600E mutation, or any 
other  BRAF  V600  mutation,  whose  disease  has progressed  despite  previous  anti-neoplastic  
Array BioPharma 
Amend ed Protoco l Version 10 Confid ential Page 45 
Protoco l No. CMEK162X2 110 / C422 1005 
PFIZER  CONFIDENTIAL   
 therapy or for whom no further effective standard therapy is available. Once MTD/RP2D has 
been  determined  for the dual combination,  patients  with BRAF  V600  mutant  mCRC  for whom 
no further effective standard therapy  is available will be enrolled in arm 1 of the Phase II part 
of the study. Patients with locally advanced or metastatic BRAF V600 mutant melanoma who 
have  progressed  after previous  treatment  with a selective  BRAF  inhibitor  will be enrolled  in the 
Phase II arm 2. Patients with locally advanced or metastatic BRAF V600 mutant melanoma 
who are naïve to previous treatment with a selective BRAF inhibitor will be enrolled in the 
Phase  II arm 3. Once  MTD/RP2D  has been  determined  for the triple  combination,  patients  with 
locally advanced or metastatic BRAF V600 mutant melanoma who are naïve to previous 
treatment with a selective BRAF inhibitor will be enrolled in the Phase II arm A.  
Patients  must  be at least 18 year with a performance  status  ≤ 2 and have  adequate  hematologic, 
renal, and hepatic function.  
Number of patients : Dual combination: approx. 127 (at least 18 in the dose escalation and 
28+41+40 respectively  in arms 1, 2 and 3 of the Phase II). Triple combination: approx. 52 (at 
least 12 in the dose escalation and 40 in arm A of the Phase II part).  
Overview of study design : This is a multi -center, open -label, dose finding, Phase Ib dose - 
escalation study to estimate the MTD(s) and/or RP2D(s) for the combinations of LGX818/ 
MEK162 and LGX818/ MEK162/ LEE011, followed by a Phase II part to assess the clinical 
efficacy  and to further  assess  the safety  of the combination  in selected  patient  populations.  Oral 
LGX818 and MEK162 will be administered on a continuous schedule, oral LEE011 will be 
administered continuously on a 3 weeks on, 1 week off schedule. Patients will be treated until 
progression of disease, unacceptable toxicity develops, or withdrawal of informed consent, 
whichever occurs first. Continued treatment beyond progression of disease will be allowed 
under certain circumstances. A cycle is defined as 28 days.  
The dose -escalation part of the trial will be conducted in adult patients with BRAF V600 - 
dependent advanced solid tumors and is expected to enroll at least 18 patients for the dual 
combination and at least 12 patients for the triple combination. The dose escalation will be 
guided by a Bayesian logistic regression model (BLRM). At each decision time point, the 
adaptive  BLRM  provides  the upper  boundary  for the combinations  that meet  the escalation  with 
overdose control (EWOC) criteria. Safety and tolerability data, PK, PD, and efficacy, as well 
as the recommendations from the Bayesian model  are used to determine  the dose combination 
for the next cohort(s) at a dose escalation teleconference. Provisional dose levels are given in 
Table 6 -1 and Table 6 -2. Various dose pairs will be explored until the MTD is determined 
and/or until a consensus between the Sponsor and Investigators is reached and it is considered 
that there is no benefit of further increasing the dose. At least 6 patients eligible for the dose 
determining set (DDS) must be treated at the dose(s) declared to be the MTD/RP2D.  
Following MTD/RP2D declaration of the dual combination, patients will be enrolled in three 
Phase II arms. Phase II arm 1 will consist of 28 patients with non -resectable advanced BRAF 
V600 mutant mCRC for whom no further effective standard therapy  is available. The Phase II 
arm 2 will consist of 41 patients with locally advanced or metastatic BRAF V600 mutant 
melanoma who have progressed after previous treatment with a selective BRAF inhibitor.  
The Phase  II arm 3 will consist  of 40 patients  with locally  advanced  or metastatic  BRAF  V600 
mutant  melanoma  who are naïve  to previous  treatment  with a selective  BRAF  inhibitor.  
Array BioPharma 
Amend ed Protoco l Version 10 Confid ential Page 46 
Protoco l No. CMEK162X2 110 / C422 1005 
PFIZER  CONFIDENTIAL   
 Following MTD/RP2D declaration of the triple combination, patients will be enrolled in one 
Phase II arm (arm A) which will consist of 40 patients with locally advanced or metastatic 
BRAF V600 mutant melanoma who are naïve to previous treatment with a selective BRAF 
inhibitor.  
All patients  will be followed  for 30 days for safety  assessments  after study  drugs  discontinuation. 
Patients enrolled in the Phase II parts of the study who discontinue study treatment for any 
reason  other  than disease  progression  will be followed  up for progression  of disease.  All patients 
enrolled in the Phase II parts of the study will be followed for survival.  
Note:  As of protocol  amendment  10, patients  who remain  on study  treatment  will have 
assessments performed as per local standard -of-care practice. In addition, post - 
treatment disease progression follow -up (if applicable) and/or survival follow -up 
(including documentation of subsequent antineoplastic therapies) will no longer be 
performed for any patient in the Phase II part of the study.  
Statistical considerations : A BLRM employing the EWOC principle will be used during the 
escalation  phase  for selection  of doses  to investigate  and for estimation  of the MTD.  Each  cohort 
will consist of newly enrolled patients. Estimation of the MTD during the escalation phase of 
the study will be based upon the estimation of the probability of DLT in cycle 1 in patients in 
the dose-determining  set (DDS).  The MTD  is defined  as the highest  drug dosage  not causing  in 
the first cycle of treatment medically  unacceptable, dose -limiting toxicity  (DLT) in more than 
35% of the treated patients. The corresponding statistical methodology is described in Section 
10.4.2 . 
The Sponsor and investigators will decide on next dose levels and dosing schedule(s) to be 
explored at the dose escalation teleconference. Dose escalation decisions will be based on a 
clinical  synthesis  of all relevant  available  data and not solely  on DLT  information.  The Sponsor 
will prepare minutes from these meetings.  
During the Phase II part of the dual combination, depending on the observed DLT rate, the 
BLRM will be re -run to confirm that the current dose combination still satisfies the overdose 
criteria. In the Phase II parts of the study, a Bayesian design will be used in order to estimate 
the true DCR  for the dual-combination  arm 1 and the true ORR  for the dual-combination  arms 
2 and 3 populations and for the triple -combination arm A, respectively.  
Array BioPharma 
Amend ed Protoco l Version 10 Confid ential Page 47 
Protoco l No. CMEK162X2 110 / C422 1005 
PFIZER  CONFIDENTIAL   
 
♦ 1 Background  
[Any language  regarding  LEE011 or CDK4 /6 signalin g in this Section  is not applicable  to 
the USA and Singapore]  
1.1  Overview of  disease  pathogenesis , epidemiology and  current 
treatments  
1.1.1  The RAF /MEK/ERK  pathway , BRAF -mutations  and cyclin -dependent 
kinases 4 and 6 in solid tumors  
Growt h factor -mediated proliferat ive signals  are trans mitted from  the extrace llular environment 
to the nucleus through several pathways , including the RASIRAF/M EK/ERK pat hway (Roberts 
2007 ). This pathway  comp rises an evolutio narily conserved signaling  cascade act ivated by the 
RAS small guanid ine ti·iphosphatase (GTPase), w hich in tum activates RAF , which in tum 
phosp ho1ylates and activate s MEK, which in tum activates  exti·acellu lar signal-regulated kinase 
(ERK).  ERK phospho1ylation of a variety of ti·anscriptio nal factors  regulates several key 
cellular activities including proliferatio n, diffe rentiation, Inigratio n, survival and angiogenesis. 
Abeffant signaling  through this pat hway has been shown to lead to unconsti·ained cell growth 
and cell transfo1mat ion (Yoon 2006 ; Scholl 2005 ) and is a character istic feature of many cancers. 
fuappropriate activatio n of the RAS pathway ca n occur through several dist inct mechanisms, 
including activat ing mutat ions in RAS  and BRAF  (Lea 2007 ), activate d growt h factor signaling 
(Nakazawa 2005 ), and cytokines and stress respo nse signals ( Mccubrey 2000 ; Chang 2003 ) 
(Figure 1-1). 
Figure  1-1 Overview of  Ras-Raf-ERK -MEK  pathway (adopted  from  Cho 2009 ) 
Growtch  factors  and  .... differentiation  factors  
 -,R-ec-eptor  I 
 
 -  . _J 
Raf 
ActiYating  , I 
1\1 utatious  
 
 
(MAPKK ) 
l 
(MAPK ) ERK  • 
 L  -------------------------------- --- Other substrat" es 
 
  
 

Array BioPharma 
Amend ed Protoco l Version 10 Confid ential Page 48 
Protoco l No. CMEK162X2 110 / C422 1005 
PFIZER  CONFIDENTIAL   
 Recently  activating  mutations  in the gene  encoding  the serine –threonine  protein  kinase  B-RAF 
(BRAF)  were  identified  in large -scale  screens  in human  cancers  (Davies  2002 ). Ninety  percent 
of reported BRAF mutations result in a substitution of glutamic acid for valine at amino acid 
600 (V600E mutation) which leads to a 500 -fold increase in its activity compared to the wild 
type protein kinase ( Wan 2004 ). Somatic mutations of BRAF occur in 60% of malignant 
melanomas and in 8 -15% in colorectal, ( Rajagopalan 2002 ), in 30% of serous borderline 
ovarian cancer ( Singer 2003 ), in 40 -70% of papillary thyroid carcinomas ( Brose  2002 ; Cohen 
2003 ; Nikiforova 2003 ; Fukushima 2003 ) and in 7 -8% of all solid tumors ( Brower 2010 ), 
implicating activating oncogenic mutations of BRAF as critical promoters of malignancy. 
Interestingly, BRAF and RAS mutations are restricted to the same tumor types usually in a 
mutually exclusive fashion, suggesting that these genes are on the same oncogenic signaling 
pathway  and that RAS  acts to activate  BRAF  in these  mutations  to these  tumors  (Davies  2002 ) 
(Table 1 -1). 
Table  1-1 Incidence  of BRAF - mutations  in human  cancers  
Cancer  Mutation incidence %  BRAF  
Melanoma  40-60 
CRC 8-15 
Pancreatic  5 
NSCLC  2-5 
BTC 25 
Ovarian (serous)  30 
PTC 40-70 
In the mammalian  cell cycle,  entry  into S phase is achieved by  cyclin -dependent  kinases  4 and 
6 (CDK4/6). D -cyclins are the positive regulators of these kinases, while the p16 protein 
encoded by the INK4a gene functions as their major inhibitor. Signal transduction pathways 
including  MAPK  and PI3K increase  cell proliferation upon  mitogen  stimulation by  upregulating 
the expression  of D-cyclins,  which  in turn activate  the kinases.  A wide  range  of human  tumors 
harbor genetic aberrations that increase the activity of CDK4/6. These genetic aberrations 
include  translocation,  amplification  and overexpression  of D-cyclins,  amplification  of CDK4/6 
kinases,  a mutation  of CDK4  resistant  to p16 binding  and inactivation  of p16 (Lundberg  1998 ). 
Agents  that inhibit  the activity  of CDK4/6  kinases  may be able to stop the proliferation  of these 
cancers and thereby function as effective anti -cancer drugs.  
1.1.2  Malignant Melanoma  
Malignant melanoma is one of the most aggressive human malignancies. Its incidence has 
rapidly increased throughout the world in the last few decades (in the order of 3 -7% per year 
for fair skin Caucasian population) ( Diepgen 2002 ), faster than that of all solid tumors, 
constituting  a significant  and growing  health  burden.  It is estimated  that 68,130  men and women 
will be diagnosed  with,  and 8,700  men and women  will die of, melanoma  of the skin in 2010  in 
the United  States  (Altekruse  2010 ). Although  the majority  of early  stage  patients  can be treated 
with surgical  resection,  and have  excellent  survival  rates  (approximately  90% at 5 years),  many 
will develop disseminated disease. The prognosis for patients with distant metastasis is, by 
contrast, very poor with survival rates ranging from 6.7% to 8% at 5 years, and a median 
survival of 6 to 9 months ( Jemal 2009 ). 
Array BioPharma 
Amend ed Protoco l Version 10 Confid ential Page 49 
Protoco l No. CMEK162X2 110 / C422 1005 
PFIZER  CONFIDENTIAL   
 Currently, the existing therapeutic options for patients with melanoma comprise 4 therapies 
approved  by the Food  and Drug  Administration  (FDA):  dacarbazine  (DTIC),  interleukin -2 (IL- 
2) ipilimumab (anti -CTLA -4) and vemurafenib (BRAF inhibitor). Single agent therapy with 
dacarbazine  (DTIC),  a cytotoxic  chemotherapy,  is generally  well tolerated,  but results  in overall 
response rate of 10% and no survival benefit for patients with metastatic disease (median PFS 
of 2-3 months and OS of 6 -10 months) ( Anderson 1995 ; Chapman 1999 ; Serrone 2000 ). 
Immunotherapy with high -dose IL -2 was approved based on its ability to produce durable 
response in a small subset of patients (5 to 10%) with metastatic melanoma ( Atkins 1999 ). 
Ipilumumab  (Yervoy® Bristol -Myers Squibb) was approved by  the FDA (25 March 2011) for 
the treatment of unresectable or metastatic melanoma based on a phase 3 randomized, double - 
blind  study  (MDX010 -20) of 676 patients  that demonstrated  longer  OS for patient  treated  with 
ipilimumab compared to tumor vaccine (median OS of 10 months vs 6 months, respectively). 
The best ORR was 10.9% in the ipilumumab arm compared to 1.5% in the tumor vaccine arm 
(Hodi 2010 ). The selective BRAF inhibitor PLX4032 (vemurafenib/Zelboraf® (Roche)), was 
approved by the FDA (17 August 2011) for the treatment of patients with unresectable or 
metastatic melanoma with the BRAF V600E mutation. In a phase 3, open -label, randomized 
study  (BRIM3  trial)  of 675 patients,  the patients  receiving  PLX4032  experienced  longer  mPFS 
and OS compared to those randomized to DTIC ( Chapman 2011 ). ORR was 48.4% vs 5.5% 
with a median PFS of 5.3 months vs 1.6 months, and an OS at 6 months of 84% vs 64% for 
PLX4032 and DTIC respectively.  
Preliminary results from a phase 1/2 study with the selective BRAF inhibitor GSK2118436 
(GlaxoSmithKline)  were  presented  at ASCO  2010  (Kefford  2010 ). The drug was well tolerated 
with main toxicities as follows: cutaneous events (including 15% of SCC), headache, 
nausea/vomiting,  and fatigue.  Responses  (PR)  were  observed  in 63% of the patients  with V600 
BRAF mutant melanoma receiving ≥ 150 mg bid. Clinical trials with the selective allosteric 
MEK1/2 inhibitor, GSK1120212 have also shown promising activity in patients with BRAF 
mutant melanoma ( Infante 2010 ; Kim 2011 ). In the phase 2 study, patients receiving 
GSK1120212 and previously treated with chemotherapy and/or immunotherapy had an ORR 
of 25% and a mPFS of 4 months. However, only minimal activity was observed in patients 
previously treated with a selective BRAF inhibitor (ORR 5%) ( Kim 2011 ). Main toxicities 
included rash, diarrhea and central serous retinopathy. Two phase 3 randomized studies are 
currently ongoing in patients with BRAF mutant melanoma: [STUDY_ID_REMOVED] comparing 
selective  BRAF  inhibitor  GSK2118436  to DTIC,  and [STUDY_ID_REMOVED]  comparing  MEK  inhibitor 
GSK1120212 to chemotherapy.  
Although clinical trials with selective BRAF inhibitors PLX4032 and GSK2118426, have 
shown significant activity in patients with BRAF mutant melanoma, these patients ultimately 
relapse with a median PFS of 6 to 7 months, and up to 50 % fail to respond to these therapies 
(Flaherty 2010 ; Kefford 2010 ; Chapman 2011 ; Ribas 2011 ). These results strengthen the 
importance of exploring new selective BRAF inhibitors, as single agent or in combination, to 
expand  therapeutic  options  for patients  with advanced  melanoma  that have  very poor prognosis 
and constitute a high unmet medical need.  
Array BioPharma 
Amend ed Protoco l Version 10 Confid ential Page 50 
Protoco l No. CMEK162X2 110 / C422 1005 
PFIZER  CONFIDENTIAL   
 1.1.3  Metastatic Colorectal Cancer (mCRC)  
Colorectal cancer (CRC) is the fourth most frequently diagnosed cancer and second leading 
cause of cancer death in the United States and in the European Union. In 2009, an estimated 
150,000  new cases  and 50,000  deaths  from  CRC  in the US have  occurred  (Engstrom  2009 ). In 
the last decade, substantial advances in the treatment of metastatic CRC have resulted in an 
improvement in overall survival from 10 -12 months to more than 20 months ( Grothey 2004 ). 
This improvement has occurred with the addition of irinotecan, oxaliplatin, bevacizumab, 
cetuximab and panitumumab to the standard treatment with 5 -fluorouracil (5 FU)/ leucovorin. 
However, because many patients eventually develop resistance to these agents, new agents to 
treat resistant tumors are an important area of investigation. The anti -EGFR monoclonal 
antibodies panitumumab and cetuximab were initially evaluated as monotherapy in patients 
with EGFR -expressing tumors after they became resistant to standard chemotherapy. 
Subsequent investigations discovered that oncogenic activation of signaling pathways 
downstream  of the EGFR,  such as mutations  of KRAS  and BRAF,  play an important  role in the 
progression  of colorectal  cancer.  There  is accumulating  evidence  that BRAF  mutations,  which 
may be present in up to 15% of patients with CRC have emerged as important predictive 
markers  of resistance  to the anti-EGFR  monoclonal  antibodies  (Karapetis  2008 ; Amado  2008 ). 
BRAF mutation is also a negative prognostic marker in patients with metastatic CRC and this 
effect, in contrast to KRAS mutations, seems not to be restricted to the outcome of cetuximab 
treatment ( Tol 2010 ). Therefore, patients with BRAF -mutation -related CRC have fewer 
treatment options. The highly selective BRAF inhibitor PLX4032 has shown some clinical 
activity in BRAF -mutant mCRC, albeit more modest than that observed in BRAF mutation - 
related  melanoma  (1/19  PR and 4 minor  responses,  mPFS  3.7 months);  however,  these  findings 
confirm that BRAF mutation is a therapeutic target in mCRC strengthening the importance of 
evaluating the clinical activity of new selective and potent BRAF inhibitors in this indication 
(Kopetz 2010 ). 
1.2 Introduction  to investigational  treatment(s)  and other  study 
treatment(s)  
1.2.1  Overview  of LGX818  
NVP -LGX818  is a ((S)-methyl  (1-((4-(3-(5-chloro -2-fluoro -3-(methylsulfonamido)  phenyl) -1- 
isopropyl -1H-pyrazol -4-yl)pyrimidin -2-yl)amino)propan -2-yl)carbamate. LGX818 (also 
known as encorafenib, PF -07263896, ONO -7702, and W0090) is a highly selective ATP - 
competitive small molecule RAF kinase inhibitor, which suppresses the RAF/MEK/ERK 
pathway  in tumor  cells expressing  BRAFV600E.  Similar  to other  selective  small  molecule  RAF 
kinase  inhibitors,  LGX818  inhibits  CRAF  (IC 50 = 0.30 nM),  BRAF  (IC 50 = 0.47 nM) as well as 
BRAFV600E (IC 50 = 0.35 nM) in cell -free assays, however, this class of inhibitor does not 
inhibit  RAF/MEK/ERK  signaling  in cells expressing  wild-type BRAF.  In the human  melanoma 
cell line A375 (BRAFV600E), LGX818 potently inhibits phospho -MEK (EC 50 = 2 nM) and 
phospho -ERK  (EC 50 = 3 nM) and proliferation  (EC 50 = 4 nM),  resulting  in cell cycle  arrest  and 
apoptosis. Given the high -degree of selectivity against other kinases, LGX818 has no 
antiproliferative  activity  in tumor  cell lines  that express  wild-type BRAF  and is highly  selective 
for BRAF V600E/D/K containing cell lines, with the greatest sensitivity observed in BRAF 
mutant melanoma and CRC lineages.  
Array BioPharma 
Amend ed Protoco l Version 10 Confid ential Page 51 
Protoco l No. CMEK162X2 110 / C422 1005 
PFIZER  CONFIDENTIAL   
 The narrow  kinase  profile  and potent  anti-proliferative  activity  of LGX818  translates  into a very 
wide  therapeutic  index  in vivo. LGX818  has been  evaluated  in multiple  human  tumor  xenograft 
models  grown  in nude  mice.  Similar  to the in vitro  profile,  the antitumor  activity  was restricted 
to tumors expressing BRAFV600E, while there was no anti -tumor effect in xenograft models 
expressing wild -type BRAF. Preclinical in vivo data suggest that LGX818 has a wide 
therapeutic index and that regression of BRAFV600E human melanoma tumor xenografts is 
associated with a strong and sustained inhibition of the RAF/MEK/ERK pathway.  
For further details on clinical and non -clinical experience, please refer to the current LGX818 
Investigator’s Brochure.  
1.2.1.1  Non-clinical  experience  
1.2.1.1.1  Non-clinical  pharmacokinetics  and metabolism  
Plasma pharmacokinetics of LGX818 has been investigated following single oral and IV dose 
in mouse,  rat, dog and monkeys.  LGX818  exhibited  a low plasma  clearance  (CL)  in the rat and 
mouse  and a moderate  to high plasma  clearance  in the monkey  and dog. Volume  of distribution 
at steady state (V ss) was low in the rodents and moderate in the non -rodent species examined 
(0.1 - 2.6 L/kg).  This was in agreement  with the observed  in vitro  plasma  protein  binding  where 
LGX818 showed high binding to plasma proteins in the mouse and rat and low to moderate 
binding to dog, monkey  and human  plasma  proteins.  Good  bioavailability  (F) was observed in 
the mouse, rat, and dog (~50%) and was low in the monkey at low doses (~5%). Moderate 
absorption  and bioavailability  (~ 40%)  was also observed  in the rat ADME  study  following  oral 
administration of a suspension of [14C] LGX818.  
The predominant route of excretion of [14C] LGX818 in rats was via fecal excretion while the 
urinary excretion was a minor route of elimination. LGX818 was eliminated in the rat mainly 
through  oxidative  metabolism  and to a much  smaller  extent,  through  parent  drug excretion.  The 
major circulating component in rat plasma was LGX818 with only a minor fraction of 
metabolites.  
LGX818  is a relatively  potent  reversible  inhibitor  of CYP2B6  (IC 50 ~ 1 µM),  CYP2C9  (IC 50 ~ 
5 µM), and CYP3A4/5 (IC 50 = 8 µM) and a weak (IC 50 ≥ 20 µM) reversible inhibitor of 
CYP1A2, CYP2C8, CYP2C19 and CYP2D6. LGX818 is also a time -dependent inhibitor of 
CYP3A4 (K I = 20.5 µM and K inact  = 0.0527 min -1). Furthermore, LGX818 was identified to 
potentially  induce  CYP3A4  based  on an in vitro  PXR  reporter  gene  assay  at high concentrations 
(≥ 10 -50 µM), likely achievable at doses greater than 800 mg in humans based on predicted 
human PK data. LGX818 is also a UGT1A1 inhibitor with in vitro IC50 ranging from 4 to 7 
uM. LGX818  is a substrate  of P-glycoprotein  with a high apparent  passive  permeability. It  is a 
weak inhibitor of BCRP (IC 50 = 10 -25 µM). LGX818 is a potent inhibitor of the renal 
transporters,  OCT1,  OAT1,  OAT3  and OCT2  (with  IC50s  at 4.2, 0.93 and 2.05 µM, respective) 
and hepatic transporters OATP1B1 and OATP1B3 (IC50 values of 5.35 µM and 6.16 µM, 
respectively).  It is therefore  advised  that substrates  for CYP2B6,  CYP2C9,  CYP3A4/5,  OAT1, 
OAT3,  and OCT2,  OCT1,  OATP1B1  and OATP1B3  with a narrow  therapeutic  index  be taken 
with caution with LGX818 (see Appendix 4 ). 
Array BioPharma 
Amend ed Protoco l Version 10 Confid ential Page 52 
Protoco l No. CMEK162X2 110 / C422 1005 
PFIZER  CONFIDENTIAL   
 LGX818 is metabolized by CYP3A4, CYP2D6 and CYP2C19. The primary  CYP responsible 
for this metabolism  is CYP3A4  (>50%);  it is therefore  advised  that strong  inhibitors  of CYP3A4 
(see Appendix 4 ), be taken with caution.  
1.2.1.1.2  Safety  pharmacology  and toxicology  
LGX818  was evaluated  in rats and Cynomolgus  monkeys  in toxicology  studies  ranging  from  1 
to 4 weeks  in duration.  Overall  LGX818  was well tolerated  at doses  at which  tumor  regression 
was observed.  Significant  toxicities  were  mainly  observed  in the female  rat at the highest  dosage 
of 400 mg/kg/day,  a dose well above  the maximum  dose level  to be evaluated  in this phase  Ib/II 
study.  
Preclinical cardiovascular safety pharmacology data did not indicate a clinical risk for QTc 
prolongation  based  on the findings  of the hERG  assay  and ECG  evaluation  in the GLP  4-week 
monkey  study. Also, there were no clinical signs in the 4 -wk GLP rat and monkey  studies that 
would indicate an effect on the CNS or respiratory system.  
In a 13 -week monkey toxicology study with LGX818, two monkeys treated at a dose of 
60mg/kg/day presented retinal changes at the assessment on week 12. These non -clinical 
findings suggest a potential risk of retinal changes with LGX818.  
Rat studies  
The 4-week  GLP  toxicology  study  in rats was performed  at daily  doses  of 20 mg/kg,  100mg/kg, 
and 400mg/kg. There were findings associated with the pharmacologic activity of a BRAF 
kinase inhibitor activation of the RAF/MEK/ERK pathway. These included hyperplasia and 
hyperkeratosis  in the skin (plantar  surface  of feet) and non-glandular  stomach  in rats which  was 
apparent  at all dose levels  in rats and presented  with recovery  4 weeks  after stopping  treatment. 
Additional  toxicity  was observed  in the 4-week  GLP  rat study  in the testes/seminiferous  tubules 
and epididymides that included an absence of the later stages of spermatid maturation. This 
finding  did not appear  to be reversible  in affected  tubules,  but there  were  normal  tubules  present 
in recovery  rats. There  was significant  mortality/morbidity  in the female  rats at the highest  dose 
(400 mg/kg/day).  In these  early  death  rats (around  Day 10), significant  lesions  were  seen in the 
kidneys, liver, stomach, esophagus, bone marrow, spleen, thymus, lymph nodes, pancreas, 
adrenal  glands,  and parathyroid  glands.  However,  in the 4 female  rats that survived  the recovery 
there were no histopathologic findings. Toxicity was more pronounced in females, where 
plasma exposure was noted to be approximately double that of males. One male rat at the 
highest dose of 400 mg/kg/day was also euthanized on Day 10, but the remaining male rats 
survived to their scheduled necropsy.  
The dose of 100 mg/kg/day was tolerated in the rat and considered the appropriate dose for 
calculation of the initial starting dose in the first -in-man clinical trial.  
Monkey  studies  
The studies  in monkeys  were  performed  at daily  doses  of 5, 20 and 100 mg/kg.  All doses  were 
well tolerated.  At the highest  dose of 100 mg/kg/day,  the only toxicity  observed  was an increase 
in diarrhea  and body  weight  loss, which  was believed  to be related  partially  to the vehicle.  There 
were no histopathologic findings in the monkeys at this highest dose.  
Array BioPharma 
Amend ed Protoco l Version 10 Confid ential Page 53 
Protoco l No. CMEK162X2 110 / C422 1005 
PFIZER  CONFIDENTIAL   
 1.2.1.1.3  Genotoxicity study  
The GLP AMES and Chromosomal Aberration assays indicate that LGX818 is not genotoxic. 
No in vivo genotoxicity studies have been conducted at this stage of development.  
1.2.1.2  Clinical  experience 
Clinical safety  
LGX818  is being  tested  in a first in human  Phase  I dose escalation  ([CLGX818X2101] ) study  
in patients with locally advanced or metastatic BRAF mutant melanoma as micro -emulsion 
(ME) and capsule formulation (CPS). As of 7 January  2013, 68 patients have been enrolled in 
the study.  54 Patients  were  treated  in the dose escalation  and 14 patients  in the dose expansion. 
Patients  were  treated  with LGX818 capsules  (CPS)  or micro -emulsion  (ME)  at 50 mg/day  and 
100 mg/day,  and with LGX818  (CPS)  at 150 mg/day,  200 mg/day,  300 mg/day,  450 mg/day,  
550 mg/day,  700 mg/day,  75 mg  BID, 100  mg BID  and 150  mg BID.  
In general LGX818 was well tolerated with mainly cutaneous adverse events reported. As per 
the cut -off date of 7 January 2013 seven dose limiting toxicities (DLTs) have been observed, 
all were grade 3 events and reversible: 5 DLTs occurred in the once daily dosing regimen 
(Palmar -plantar erythrodysaesthesia syndrome at 100 mg (with microemulsion)), pain in 
extremity at 300 mg, fatigue at 550 mg, diarrhea, headache and rash at 700 mg, and insomnia 
and asthenia at 700 mg) and 2 DLTs occurred in the twice daily regimen (facial paresis and 
confusional  state at 100 mg BID,  and neuralgia  and musculoskeletal  pain in shoulder  at 150 mg 
BID).  
The most  frequently  reported  LGX818 -related  AEs regardless  of CTCAE  Grade  occurring  in ≥ 
10% of patients overall (as per 7 January 2013) were: hyperkeratosis 25/54 (46%), 
Palmarplantar erythrodysaesthesia syndrome 25/54 (46%), keratosis pilaris 20/54 (37%), 
pruritus 20/54 (37%), alopecia 17/54 ( 32%), dry skin 17/54 ( 32%), arthralgia 16/54 (30%), 
fatigue  16/54  (30%),  pain in extremity  15/54  (28%),  nausea  13/54  (24%),  asthenia  12/54  (22%), 
decreased appetite 12/54 (22%), melanocytic naevus 12/54 (22%), myalgia 12/54 (22%), 
xerosis  12/54  (22%),  erythema  11/54  (20%),  hair texture  abnormal  10/54  (19%),  headache  9/54 
(17%), skin papilloma 9/54 (17%), dermal cyst 8/54 (15%), rash erythematous 8/54 (15%), 
insomnia 7/54 (13%), musculoskeletal pain 7/54 (13%), alanine aminotransferase increased 
6/54 (11%), and hypotrichosis 6/54 (11%).  
Different types of rash included erythema (20%), rash erythematous (15%), rash (9%), 
dermatitis acneiform (9%), eczema (9%) rash maculopapular (9%), rash follicular (6%), rash  
macular (6%), rash papular (4%), dermatitis exfoliative (2%), exfoliative rash (2%), livedo 
reticularis (2%), rash pruritic (2%), and rosacea (2%). At the cut -off date, 2 patients had a 
keratoacanthoma  and 2 patients  had a squamous  cell carcinoma  (SCC),  related  to the study  drug.  
The MTD for LGX818 has been declared at 450 mg QD. This dose is well tolerated and is the 
recommended phase II dose (RP2D).  
As of 7 January 2013, preliminary efficacy results are available for the 54 patients (26 BRAF 
inhibitor -naïve and 28 BRAF inhibitor -pretreated) enrolled in the dose escalation phase (all 
dose levels pooled). Among the 26 BRAF inhibitor -naïve patients, 16 (62%) had a partial 
response  (PR) [14 confirmed  PR (54%)],  and 7 (27%)  had stable  disease;  in the 24 naïve  patients  
Array BioPharma 
Amend ed Protoco l Version 10 Confid ential Page 54 
Protoco l No. CMEK162X2 110 / C422 1005 
PFIZER  CONFIDENTIAL   
 with at least 1 post -baseline tumor assessment all had a tumor reduction (decrease of 6% to 
100%). Out of the 28 BRAF inhibitor -pretreated patients, 3 (11%) had a PR [2 confirmed PRs 
(7%)], and 10 (36%) had stable disease, which includes the unconfirmed PRs.  
While retinal changes were observed in two monkeys treated at a dose of 60mg/kg/day at the 
assessment on week 12, no cases of retinal toxicity were reported in patients who received 
LGX818 monotherapy or in combination with any other compounds except for MEK162, a 
drug known  to be associated  with a risk of retinal  changes.  In addition,  as of November  2013  it 
is noteworthy that uveitis, a suspected class effect of BRAF inhibitors (according to the 
vemurafenib and dabrafenib prescribing information), has been reported in 2 patients treated 
with LGX818 monotherapy and in combination with MEK162, one each respectively.  
For further  details,  please  refer  to the current  LGX818  Investigator’s  Brochure.  
Clinical pharmacokinetics  
As of 7 January 2013, patients with locally advanced or metastatic BRAF mutant melanoma 
received escalating doses of LGX818. Oral doses of 50 mg, 100 mg (both capsule and 
microemulsion),  150 mg, 200 mg, 300 mg, 450 mg, 550 mg or 700 mg were  administered  once 
daily and oral doses of 75 mg, 100 mg and 150 mg were administered twice daily. The 
pharmacokinetics was investigated after a single dose (Day 1) and multiple doses (Day 15) in 
Cycle  1. Trough  samples  were  collected  on Day 1 of Cycle 2 to 10. In  the expansion  phase,  an 
additional C1D8 PK profile was collected from 0 to 8 hr. As this study is on -going, all data 
presented  are considered  preliminary.  The capsule  and microemulsion  formulations  of LGX818 
produced similar PK profiles. The median Tmax was around 2 hr for capsule formulation and 
0.5-2 hr for the microemulsion formulation. The half -life of LGX818 was approximately 3 
hours. From 50 mg to 700 mg QD Cmax and AUC increased in an approximately dose - 
proportional manner with increasing dose. The BID regimen resulted in a smaller 
Cmax/Ctrough  ratio as expected  compared  to QD regimen.  At the same  total daily  dose per day, 
the total AUC under BID regimen appears to be similar to the QD regimen. With QD or BID 
dosing, the Day 15 exposures were consistently lower (30 -60%) than the Day 1 exposures 
within subjects, probably due to induction of CYP enzymes. AUC and Cmax ratios at steady 
state (Day 15) relative to Day 1 did not appear to change with dose. The trough concentration 
on and after Cycle  2 Day 1 did not show  a trend  of further  decline,  suggesting  that C1D15  was 
close to or at steady state. So far limited data on C1D8 PK showed that Cmax and AUC were 
similar on C1D8 and C1D15 with a small decrease. At the above doses tested, the average 
concentrations  of LGX818  reached  or exceeded  the predicted  efficacious  concentrations  based 
on preclinical xenograft models (0.135 µg/mL).  
For further  details,  please  refer  to the current  LGX818  Investigator’s  Brochure.  
1.2.2  Overview  of MEK162  
MEK162  (also  known  as binimetinib,  PF-06811462,  ARRY -438162,  ONO -7703,  and W0074), 
is an oral, ATP non -competitive, highly selective inhibitor of MEK1/2 that has nanomolar 
activity against purified MEK enzyme (IC50 = 12 nM) and inhibits both basal and induced 
levels of ERK phosphorylation in numerous cancer cell lines with IC50s as low as 5 nM. 
MEK162  is especially  potent  at inhibiting  the cell proliferation  of mutant  BRAF  and RAS  
Array BioPharma 
Amend ed Protoco l Version 10 Confid ential Page 55 
Protoco l No. CMEK162X2 110 / C422 1005 
PFIZER  CONFIDENTIAL   
 human cancer cell lines in vitro . In vivo , MEK162 has demonstrated dose -dependent tumor 
growth inhibition in various subcutaneous tumor transplants harboring BRAFV600E or RAS 
mutations, including HT29, MIA PaCa2, A549, LoVo, Calu6, DU145 and COLO 205. These 
data suggest that MEK162 may provide a potential therapeutic benefit in cancer indications, 
harboring these mutations. MEK162 is currently being investigated in Phase I clinical testing 
and has been well tolerated up to a maximum tolerated dose (MTD) of 60mg BID in cancer 
patients.  
For further details on clinical and non -clinical experience, refer to the current MEK162 
Investigator’s Brochure.  
1.2.2.1  Non-clinical  experience  
1.2.2.1.1  Pharmacology studies  
The biological  activity  of MEK162  has been  evaluated  in vitro  (enzymatic  and cell culture)  and 
in vivo mouse  xenograft  studies.  
In vitro efficacy  studies  
In biochemical studies, MEK162 has been shown to be a potent and highly selective inhibitor 
of MEK. In  cellular assays, MEK162 has been shown to markedly  inhibit the phosphorylation 
of ERK in human cell lines as well as human whole blood. In human MALME -3M melanoma 
cells and in HT29 colorectal cancer cells, MEK162 significantly inhibited proliferation and 
viability, respectively. The ability of MEK162 to inhibit cancer cell growth in culture was 
evaluated using a standard 3 -(4,5-dimethylthiazol -2-yl)-5-(3-carboxymethoxyphenyl) -2-(4- 
sulfophenyl) -2H-tetrazolium  (MTS)  assay. In  the human  HT-29 colorectal  cell viability  assay, 
the IC 50 of cell growth was observed at a concentration of 163  nM MEK162. In the human 
melanoma Malme -3M cell proliferation assay, the IC 50 of cell growth was observed at a 
concentration of 30 nM MEK162.  
In vivo efficacy  studies  
In vivo studies were performed to evaluate the activity of MEK162 with respect to inhibiting 
tumor growth and tumor ERK phosphorylation. In the HT29 and in the COLO 205 colon 
carcinoma models, dose -dependent inhibition of tumor growth (up to 75% tumor growth 
inhibition TGI) was observed at doses ranging from 3 to 30 mg/kg, QD, by mouth (PO) for 21 
days. In the sensitive COLO 205 colon carcinoma model, MEK162 treatment resulted in 84% 
TGI with significant tumor regressions at a dose of 30 mg/kg. In the BxPC3 pancreatic 
carcinoma  model  (which  does not harbor  either  RAS  or RAF  mutations,  but harbors  MAP2K4 
mutation), significant tumor regressions (59%) were seen at doses of 30 mg/kg. In the BxPC3 
pancreatic  carcinoma  model  (which  does not harbor  either  RAS  or RAF  mutations,  but harbors 
MAP2K4mutation), ~70% TGI and 13% PRs were seen at doses of 30 mg/kg, QD, PO for 21 
days. Consistent with the mechanism of action for MEK162, TGI correlates with decreased 
phospho -ERK levels in tumor xenografts.  
Overall, MEK162 has demonstrated potent activity against MEK1/2 and broad anti - 
proliferative activity in vitro and in vivo.  
Array BioPharma 
Amend ed Protoco l Version 10 Confid ential Page 56 
Protoco l No. CMEK162X2 110 / C422 1005 
PFIZER  CONFIDENTIAL   
 1.2.2.1.2  Non-clinical  pharmacokinetics  and metabolism  
Pharmacokinetic  (PK)  studies  were  conducted  with MEK162  in rats, dogs  and monkeys.  After 
oral administration, the AUC and C max values for MEK162 increased in a nearly dose - 
proportional manner in rats and monkeys. The mean bioavailability was lowest in monkeys, 
higher in dogs, and highest in rats at equivalent doses (range across species: 13% to 72%). 
Following intravenous (IV) administration, the plasma clearance (CL) values were low -to- 
moderate  (range:  ~2 to 8 mL/min/kg)  and tended  to increase  across  species  such that monkey  > 
dog > rat. Mean  plasma  t1/2 values  showed  a similar  trend  where  monkey  > dog > rat 
(range:  ~2 to 9 hrs). The volume of distribution at steady state (V ss) values ranged from 0.189 
to 1.57 L/kg.  
In vitro experiments in Caco -2 and LLC -PK1 cells indicated that MEK162 had moderate 
membrane permeability and may be a substrate for active efflux. MEK162 was determined to 
be a substrate for both BCRP and P -gp transporters. MEK162 exhibited high plasma protein 
binding in vitro (>  95%) and is predicted to have good stability with respect to hepatic 
metabolism. Nonclinical in vitro and in vivo data indicate that main pathways of metabolism 
for MEK162  including  oxidation by  CYP2C19 and CYP1A2 and glucuronidation by  UGT1A. 
In human  plasma,  major  entities  include  glucuronides  of MEK162,  as well as the primary  active 
metabolite,  AR00426032,  which  is equipotent  to MEK162.  Formation  of AR00426032  that has 
been  monitored  in clinical  studies  was found  to be mediated  primarily  by CYP1A2  with minor 
contributions from other cytochrome P450 enzymes (CYPs). MEK162 did not significantly 
inhibit (IC50> 25µM) the major CYP isoforms. MEK162 was not a time -dependent inhibitor 
of CYP3A.  
Based  on results  from  the rat ADME  study,  the absorption  of MEK162  was approximately  50% 
of dose and bioavailability  was 47%.  Following  oral dosing  at 4 mg/kg  to rats, fecal  and urinary 
excretion accounted for 69.4% and 23.1% of total radioactivity, respectively. Unchanged 
MEK162  accounted  for approximately  5% of dose in urine  and 22% of dose in feces.  In addition, 
the glucoronide conjugate M10.9 accounted for 13% of dose in urine and metabolite M4 (loss 
of ethane diol) accounted for 34% of dose in feces. Overall, MEK162 is mainly excreted 
through urine and feces as unchanged parent drug, glucoronide conjugates and M4.  
Following  single - and repeat -dose administration  of MEK162  to Sprague -Dawley  rats for up to 
6 months, females were found to have approximately 2 -fold higher exposure than males at 
equivalent  doses.  The values  for Cmax and area under  the plasma  concentration -time curve  for a 
dosing  interval  from  time 0 extrapolated  to infinity  (AUC inf) increased  with dose,  although  the 
increase  in exposure  was less than dose proportional.  Cynomolgus  monkeys  receiving  MEK162 
for 28  days or 9  months showed no consistent differences in exposure between females and 
males. There were no significant changes in exposure versus day.  
1.2.2.1.3  Safety  pharmacology  and toxicology  
The toxicological evaluations of MEK162 include single -dose, and 28 -day and 6 -month 
repeat -dose studies in Sprague Dawley rats and 28 -day and 9 -month repeat -dose studies in 
cynomolgus  monkeys,  all of which  were  conducted  in accordance  with international  regulatory 
guidelines for nonclinical toxicity studies and in adherence to current GLP guidelines. These 
studies  were  supplemented  with local  tolerance,  9 safety  pharmacology  studies  (hERG  channel  
Array BioPharma 
Amend ed Protoco l Version 10 Confid ential Page 57 
Protoco l No. CMEK162X2 110 / C422 1005 
PFIZER  CONFIDENTIAL   
 assay and behavioral, cardiovascular, renal, pulmonary and 2  gastrointestinal 
function/tolerability studies as well as 2  non-GLP studies evaluating wound healing and 
immune function) and 3 developmental toxicity studies in the rat and the rabbit.  
In all of the GLP toxicology  studies conducted, there was no significant effect of MEK162 on 
vital signs, coagulation parameters, complement, organ weights or urinalysis parameters in 
doses  up to 100 mg/kg  in rats and 10 mg/kg  in monkeys.  Administration  of MEK162  to rats by 
oral gavage  was associated  with skin lesions  (inflammation/scabbing),  microscopic  findings  of 
soft tissue  mineralization  (which  did not occur  with the 26-week  dosing  regimen)  and reversible 
minimal to mild clinical pathology changes.  
Safety pharmacology studies were conducted to assess the effects of MEK162 on key organ 
systems  (cardiovascular,  respiratory,  neurobehavioral,  renal  and gastrointestinal  function).  Rats 
received  single  oral doses  of 10, 30 or 100 mg/kg  and monkeys  were  given  single  oral doses  of 
1, 3 and 10 mg/kg. There were no significant in vivo safety  findings at doses up to 100 mg/kg 
in rats and 10 mg/kg in monkeys in any of these studies.  
1.2.2.1.4  Genotoxicity study  
MEK162  is not genotoxic  in vitro and in vivo, based  on the results  of 3 genotoxicity  assays  (in 
vitro bacterial mutagenicity, mouse lymphoma assay and in vivo mouse micronucleus assay).  
1.2.2.2  Clinical experience  
As of the data -cut-off date of 07 Jan 2013, a total of 686 patients and healthy volunteers have 
received  at least one dose of MEK162,  either  as a single  agent  or in combination  with paclitaxel, 
PI3K, RAF l or IGF -1R inhibitors and have been evaluated for safety, including 90 healthy 
volunteers, 164 patients with rheumatoid arthritis and 432 patients with advanced cancer.  
MEK162  has been  evaluated  in 3 completed  studies  in healthy  subjects  (single  ascending  dose, 
multiple ascending dose, single -dose relative bioavailability  and food effect) and 2 completed 
studies in patients with rheumatoid arthritis (a Phase I multiple ascending dose study and a 
Phase II study, both in combination with methotrexate).  
The experience  with MEK162  as a single  agent  in oncology  patients  includes  3 ongoing  studies 
with a total of 216 patients  enrolled  as of the cut-off date.  These  are 2 Phase  I studies:  [ARRAY - 
162-111] in patients  with solid  tumors  with an expansion  phase  in biliary  and colorectal  cancer, 
(in this study  a dose range from 30 to 80  mg BID has been explored), and [CMEK162X1101] 
in Japanese patients with solid tumors and an expansion in patients with RAS or BRAF 
mutations, and one Phase II study: [CMEK162X2201] in patients with advanced melanoma, 
(45 mg and 60 mg BID dose levels have been explored).  
The experience with MEK162 in cancer patients in combination studies comprises 7 ongoing 
Phase I studies as of the cut -off date.  
For detailed information regarding clinical studies with MEK162, refer to the MEK162 
Investigator’s Brochure.  
Array BioPharma 
Amend ed Protoco l Version 10 Confid ential Page 58 
Protoco l No. CMEK162X2 110 / C422 1005 
PFIZER  CONFIDENTIAL   
 1.2.2.2.1  Clinical safety and efficacy  
Frequently reported AEs suspected to be related to study drug in single agent studies for 
advanced cancer are dermatitis acneiform, diarrhea, peripheral edema, increased blood CK, 
nausea, fatigue, rash and vomiting. Most of these AEs were Grade 1 or 2 with less than 5% of 
cases Grade 3 -4, with the exception of elevation of blood CK.  
Other less frequent but clinically relevant toxicities include left ventricular ejection fraction 
(LVEF)  decrease  and increase  of liver enzymes.  Four  patients  had Grade  2 LVEF  decrease,  and 
one patient  had Grade  3 LVEF  decrease.  Most  of the liver enzyme  increases  were  Grade  1 or 2. 
Grade  3 or 4 liver enzyme  elevations  were  reported  in 2/106  (1.8%)  patients  with AST  elevation 
and 1/106  (0.9%)  patient  with ALT  elevation.  No Grade  3-4 elevation  of bilirubin  was reported.  
In combination  studies,  the most  frequently  reported  AEs suspected  to be related  to study  drug 
were diarrhea, CK elevation, dermatitis acneiform/rash, nausea/vomiting and fatigue.  
CMEK162X2201  
[CMEK162X2201] is a phase II study  assessing  the safety and efficacy of MEK162 in patients 
with locally advanced and metastatic BRAF and NRAS mutated melanoma. As of the cut -off 
date, a total of 106 patients have received at least 1 dose of MEK162. Initially, the study 
explored the 60 mg BID dose, but due to the occurrence of 2 unexpected suspected severe 
adverse events (one case of fatal acute liver failure and another case of decreased ejection 
fraction), subsequent patients received 45 mg BID, which was the dose selected as the 
recommended Phase II dose. Thus, from the 106 patients who received at least 1 dose of 
MEK162,  25 patients  were  treated  with 60 mg BID MEK162  and 81 patients  were  treated  with 
45 mg BID MEK162. At the time of the cut -off, 93 (87.7%) patients have discontinued 
treatment  with 22 (21%)  having  discontinued  due to an AE; 13 (12.3%)  patients  are still ongoing.  
The most frequently treatment -related occurring events (≥ 20%) were dermatitis acneiform, 
diarrhea,  peripheral  edema,  increase  in CK levels,  nausea,  fatigue  and rash.  The most  common 
treatment -related  Grade  3-4 AEs were  CK increased  (20/106),  dermatitis  acneiform  (4/106)  and 
diarrhea (3/106). CSR -like events were reported by 40/106 (38%) patients regardless of 
relationship to MEK162 including Grade 3 -4 events in 3/106 (3%) patients. These events 
included  retinopathy,  blurred  vision,  retinal  edema,  generalized  eye disorder,  vitreous  floaters, 
retinal detachment, retinal pigment epitheliopathy, and visual impairment. Most CSR -like 
events  were  Grade  1, transient  in nature  and resolved  without  treatment  modification,  after dose 
reduction, or after interruption of treatment. Cardiac events regardless of relationship to 
MEK162 were reported by  4/106 (4%) patients. All were Grade 3 -4. Three reports of syncope 
(1 related to MEK162) were recorded. A serious and possibly drug related adverse event of 
ventricular  ejection  fraction  decreased,  heart  failure,  myocarditis  and tachycardia  was reported 
at a starting dose of 60 mg BID. No other case of decreased LVEF was reported.  
As of 7-Jan-2013,  in the [CMEK162X2201]  study,  among  the 35 patients  evaluable  for efficacy 
with mutant BRAF melanoma treated with MEK162 at 45mg BID, 2 confirmed and 6 
unconfirmed  partial  responses  (23%)  and 14 patients  with stable  disease  were  recorded.  In this 
group 63% of the patients achieved disease control. In the 35 patients evaluable for efficacy 
with NRAS  mutant  melanoma  treated  at 45 mg BID,  6 confirmed  and 2 unconfirmed  partial  
Array BioPharma 
Amend ed Protoco l Version 10 Confid ential Page 59 
Protoco l No. CMEK162X2 110 / C422 1005 
PFIZER  CONFIDENTIAL   
 responses (23%) and 15 patients with stable disease were recorded. Sixty  six % of the patients 
achieved disease control.  
1.2.2.2.2  Clinical  Pharmacokinetics  
In healthy subjects and patients with rheumatoid arthritis, the analysis of PK data was done 
using model independent (NCA) methods only. These analyses suggested that absorption was 
rapid, that there was extensive distribution and that the apparent terminal half -life was short. 
Contrary to expectation, given the short half -life, accumulation greater than that predicted by 
linear PK was observed. Overall when given BID, accumulation was around 1.5 to 1.7 fold. 
This apparent  non-linearity  in the PK of MEK162  may have  been  related  to a combination  of a 
relatively  high LLOQ  of the assay  used (5 ng/mL)  and the schedule  of blood  collection  for PK 
used. In order to overcome these limitations and to fully characterize the PK of MEK162 in 
cancer patients a model based analysis was conducted  using a population PK method. For this 
analysis, information from 130 subjects from two clinical studies, [CMEK162X2201] and 
[ARRAY -162-111], were used. Dose levels range from 30 mg BID to 80 mg BID.  
MEK162 PK was best described by a two compartment disposition model with first -order 
elimination  and first-order  absorption  with a lag time.  The estimated  between  subject  variability 
on apparent clearance (CL/F) was moderate (44%) and very high (~150%) for the apparent 
central volume of distribution (Vc/F) and apparent peripheral volume of distribution (Vp/F). 
The covariate effect of dose on relative bioavailability was identified as significant (at an α = 
0.001  significance  level).  Relative  to the 45 mg dose,  the bioavailability  of the 30 mg dose level 
was 120%; while the relative bioavailability of 60 mg and 80 mg doses were 88% and 77%. 
This dose dependence was not seen using model independent methods but most likely 
represents either solubility limited absorption of MEK162 or the impact of P -gp or a 
combination of the two. Based on the PK parameters estimated in this analysis when 
administered BID, MEK162 steady state is reached around Day 15 and the accumulation is 
around 1.7 fold, which is consistent with observation.  
For further  information  refer  to the current  MEK162  Investigator’s  Brochure.  
1.2.3  Overview  of LEE011  
LEE011 (also known as ribociclib) is an orally bioavailable, small molecule inhibitor of 
CDK4/6. LEE011 exhibits highly specific inhibitory activity against CDK4/cyclinD1 and 
CDK6/cyclinD3  complexes,  with concentration  resulting  in 50% inhibition  (IC50)  values  of 10 
nM and 39 nM, respectively, in isolated enzyme assays. It is inactive against the majority of 
other kinases. It is currently being tested in a clinical trial [CLEE011X2101] in adult cancer 
patients.  
For further details on clinical and non -clinical experience, please refer to the current LEE011 
Investigator’s Brochure.  
1.2.3.1  Pharmacology  of LEE011  
LEE011  inhibits  the growth  of many  tumor  cell types  in vitro  and in vivo, including  mantle  cell 
lymphoma, liposarcoma, rhabdoid tumors, neuroblastoma, and carcinomas of the esophagus, 
breast, lung  and pancreas.  Regardless of  the various  genetic aberrations  that may be present  in 
Array BioPharma 
Amend ed Protoco l Version 10 Confid ential Page 60 
Protoco l No. CMEK162X2 110 / C422 1005 
PFIZER  CONFIDENTIAL   
 the cancer cells, the anti -tumor activity of LEE011 requires the presence of functional 
retinoblastoma protein (Rb).  
LEE011 has demonstrated tumor growth suppression in multiple melanoma xenograft models 
including BRAF wild type and mutant ones as a single agent. Tumor regression was achieved 
in two models while tumor stasis was observed in five models. In primary V600E BRAF 
mutated  melanoma  models,  LEE011  in combination  with LGX818  (a potent  and selective  RAF 
inhibitor),  produced  significant  delay  in tumor  re-growth.  In mouse  models  resistant  to LGX818, 
LEE011 demonstrated tumor growth inhibition as single agent and in combination with 
LGX818, showed enhanced growth inhibition.  
1.2.3.1.1  Nonclinical  pharmacokinetics  (PK) and metabolism  of LEE011  
The PK of LEE011 was investigated in four different species: mouse, rat, dog and monkey. 
After oral administration to rats, LEE011 was moderately absorbed (48 to 84%), with 
bioavailability ranging between 10% and 65% across animal species. Maximum serum drug 
concentration  (Cmax)  was observed  between  2 and 4 hours  post-dose.  Terminal  half-life (T1/2) 
of LEE011  was moderate  in rodents  and monkeys  (2 to 7 h), and was comparatively  longer  (18 
h) in dogs.  
The binding of LEE011 to plasma proteins was moderate (unbound fraction in plasma for 
humans  is 30 ± 2%).  3H-LEE011  and its metabolites  were  extensively  distributed  into the organs 
and tissues  of rats including  choroid,  ciliary  body  and meninges  with the exception  of the brain. 
The highest radioactivity concentrations were found in tissues such as pituitary gland, pineal 
gland,  spleen,  kidney  and adrenal  medulla  with remarkably  high exposure  in the thyroid  gland. 
Distribution of LEE011 and/or its metabolites into melanin -containing structures was seen in 
pigmented rats.  
Oxidative metabolism of LEE011 is dominated by CYP3A4 with a minor contribution by 
flavin -containing monooxygenase 3 (FMO3). In vitro studies indicate LEE011 is a reversible 
inhibitor  of CYP1A2  (Ki = 16 μM),  CYP3A4  (Ki = 35 μM),  and CYP2E1  (IC50  = 62μM).  
LEE011 is also a time -dependent inhibitor of CYP3A4 (K I = 5.06 μM, k inact  = 0.0245 min-1). 
LEE011  was identified  as inhibitor  of the efflux  transporter  MDR1  (IC50  = 143μM)  and MXR 
(IC50 = 24μM). LEE011 could affect substrates of the MDR1 transporter, depending on the 
LEE011 dose and intestinal concentration. LEE011 inhibited the human bile salt export pump 
(BSEP) transporter (IC50 = 4.7 μM).  
PK data from the ongoing phase I study ( [CLEE011X2101] ) show that the plasma Cmax of 
LEE011 at steady state after 600 mg QD dosing in humans ranges from 943 -5860 ng/mL 
(arithmetic mean = 2940 ng/mL or 5.32 µM), which is well below the above mentioned Ki or 
IC50s for reversible inhibition of CYPs and transporters. The major DDI risk identified for 
LEE011  is its time-dependent  inhibition  of CYP3A4,  which  could  increase  exposures  of major 
CYP3A4 substrates.  
LEQ803 (N -demethylation) is a major metabolite in the rat and monkey, the main metabolite 
in humans and the only metabolite in dogs. This metabolite was found to interact with hERG 
channels in vitro . 
Array BioPharma 
Amend ed Protoco l Version 10 Confid ential Page 61 
Protoco l No. CMEK162X2 110 / C422 1005 
PFIZER  CONFIDENTIAL   
 In rat ADME studies, LEE011 was predominantly excreted with bile. The elimination of 
unchanged  drug was limited.  A minor  proportion  of the administered  dose is excreted  in urine. 
The bulk of the administered dose (87.3%) was excreted within 24 hours post -dose.  
Overall, the elimination of LEE011 may potentially be affected by co -administered drugs that 
inhibit  or induce  CYP3A4.  LEE011  may inhibit  the metabolism/transport  of sensitive  substrates 
of CYP3A4, CYP1A2, and BSEP.  
1.2.3.1.2  Safety  pharmacology and  toxicology of LEE011  
In vitro , LEE011  did not show  mutagenic  or phototoxic  potential.  
Safety  pharmacology  studies  did not reveal  any effects  on CNS  or respiratory  functions.  In the 
dog telemetry  study, prolongation of the average QT and QTc was observed with the potential 
to induce  PVCs  at higher  exposure  levels.  NVP -LEE011  and LEQ803  likely  contributed  to the 
QT prolonging effects seen in vivo . 
In rats and dogs, LEE011 induced bone marrow hypocellularity, lymphoid depletion, atrophy 
of the skin and intestinal mucosa, decreased bone formation and testicular atrophy. These are 
consistent  with the mechanism  of action  of LEE011.  In addition,  an increased  number  of ovarian 
corpora lutea was observed in a single female dog at the highest dose tested. The liver, bile 
system and gall bladder (proliferative changes, cholestasis, sand -like gallbladder calculi, and 
inspissated bile) were identified as additional target organs of toxicity which are not likely 
related to the primary pharmacology of LEE011. Correlating hematological and/or 
biochemistry  changes  were  seen for the effects  described  in the bone  marrow,  lymphoid  system 
and liver. All the described changes were fully reversible in rats and dogs.  
Based on its mechanism of action and preclinical toxicology studies, the major potential 
toxicities for LEE011 include myelosuppression, hepatic toxicity, and prolongation of the QT 
interval. The risk of these toxicities may  be amplified by  concomitant administration of strong 
inhibitors of CYP3A4.  
Please  refer  to the  current LEE011  Investigator’s  Brochure for  additional details.  
1.2.3.2  Clinical Study  with LEE011  
As of 4 February 2013, 56 patients have been treated with single agent LEE011 in the first -in 
human  phase  I study  [CLEE011X2101]  in which  LEE011  is administered  orally,  once  daily  for 
21 days followed by a 1 week rest (28 -day cycle). Doses tested include 50 mg (n=4), 70 mg 
(n=2),  140 mg (n=4),  260 mg (n=4),  280 mg (n=4),  350 mg (n=5),  400 mg (n=5),  600 mg (n=4),  
900 mg (n=13), 750 mg (n=8), and 1200 mg (n=3). In all, 8 DLTs have been observed. DLTs 
include  grade  3 mucositis  (n=1)  in the 50 mg cohort,  grade  3 pulmonary  embolism  (n=1)  in the 
280 mg cohort, grade 3 hyponatremia (n=1) and prolonged grade 3/4 neutropenia (n=1) in the 
400 mg cohort, grade 4 thrombocytopenia (n=1) in the 750 mg cohort, grade 3 asymptomatic 
QTc prolongation with grade 3 neutropenia (n=1) in the 900 mg cohort and grade 4 febrile 
neutropenia (n=1) and grade 4 thrombocytopenia (n=1) in the 1200 mg cohort. The grade 3 
mucositis  observed  in the 50 mg cohort  was later determined  to be due to herpes  simplex  virus 
(HSV)  infection.  A DLT  related  to mucositis  has not been  observed  since.  Four  cases  of Grade 
1 or 2 mucositis  have  been  observed  in doses  up to 350 mg; mucositis  has not been  observed  at 
higher  doses.  The grade  3 pulmonary  embolism  was observed  in a patient  with NSCLC  who 
Array BioPharma 
Amend ed Protoco l Version 10 Confid ential Page 62 
Protoco l No. CMEK162X2 110 / C422 1005 
PFIZER  CONFIDENTIAL   
 had diffuse bilateral lung disease and a central venous catheter. The grade 3 hyponatremia was 
asymptomatic and readily corrected with saline infusion. Grade 3 or 4 neutropenia and/or 
thrombocytopenia not meeting DLT criteria were seen in increasing frequency starting from 
600 mg up to 1200 mg. Asymptomatic grade 1 or 2 QTc prolongation were observed in 
increasing frequency  starting at 600 mg up to 1200 mg; 1 patient (25%) in the 600 mg cohort,  
2 patients (25%) in the 750 mg cohort, 4 patients (31%) in the 900 mg cohort, and 3 patients 
(100%) in the 1200 mg cohort. The most frequently reported treatment -related AEs include 
fatigue,  nausea,  anemia,  asthenia,  neutropenia,  vomiting,  leukopenia,  increased  blood  creatinine, 
decreased  appetite,  diarrhea,  hypoalbuminemia,  lymphocytopenia,  myalgia,  thrombocytopenia, 
dizziness, erythema, hyperglycemia, mucosal inflammation and stomatitis. The majority have 
been grades 1 or 2 and reversible.  
The MTD of LEE011 for the 3 weeks on/1 week off schedule is 900 mg. The study continues 
with exploration  of alternate  dosing  schedules  and further  assessment  of safety,  tolerability,  and 
preliminary anti -tumor activity of LEE011.  
Please  refer  to the  current LEE011  Investigator’s  Brochure for  additional details.  
1.2.3.2.1  Clinical  pharmacokinetics  of LEE011  
Preliminary pharmacokinetics data for LEE011 demonstrate that peak plasma concentrations 
were achieved by 1 to 5 hours (range of median T max values) following oral dosing. LEE011 
pharmacokinetics data up to 1200 mg exhibit slightly over -proportional increases in exposure 
across  the dose range  tested.  Steady -state is reached  by day 8 and effective  T1/2 values  based  on 
accumulation  (T1/2, acc) ranged  from  24 hours  (50 mg QD dose)  to 40 hours  (600 mg QD dose), 
and 31 hours  (900 mg QD dose).  The accumulation  ratio (Racc) across  the studied  daily  dose of 
50 to 1200 mg ranged from 1.55 - to 2.94 -fold. 
Please  refer  to the current  LEE011  Investigator’s  Brochure  for additional  details.  
1.2.4  Overview  of combination  treatment  
1.2.4.1  Pre-clinical  studies  with combinations  of RAF and MEK  - inhibitors  
Combining inhibitors of sequential steps in the MAPK signal transduction pathway have the 
potential to provide several advantages when compared to single agent treatments. These 
advantages could include reduction or elimination of the emergence of resistance that might 
arise  in the single  agent  setting,  greater  overall  efficacy  via more  complete  pathway  suppression, 
and provision of the ability to dose -reduce one or more of the drugs to avoid or minimize 
toxicities. To assess whether either of these latter two benefits might be the case, the effect of 
combining LGX818 and MEK162 on the in vitro proliferation of cell line models that harbor 
BRAFV600E alterations was examined. These studies were carried out in both melanoma and 
colorectal cancer -derived cell lines with standard measures of synergy used to determine 
whether  the combination  was, dose-shifting,  able to boost  the overall  effects  of the single  agents, 
or both ( Lehar 2009 ). These studies indicated a statistically significant synergy (p = <0.0001, 
one-tailed T -Test) for the combination when compared to the single agents ( Caponigro 2011 , 
Novartis,  data on file).  In cell  lines  where  significant  synergy  was measured  (5/6 CRC  and 6/12 
melanoma) both dose -shifting and effect boosts were observed. In addition, in cases where 
synergy was not observed, combining the two inhibitors resulted in dose -additivity.  
Array BioPharma 
Amend ed Protoco l Version 10 Confid ential Page 63 
Protoco l No. CMEK162X2 110 / C422 1005 
PFIZER  CONFIDENTIAL   
 In vivo , the combination of LGX818 and MEK162 has been evaluated in a mouse primary 
xenograft  model  of human  melanoma  that expresses  BRAFV600E.  While  there  was increase  in 
the degree of tumor regression observed in the combination groups compared to single -agent 
MEK162  (3 mg/kg  or 10 mg/kg  bid) or LGX818  (3 mg/kg  bid) respectively,  the most  dramatic 
effect was on the duration of response. Over the course of 116 days of treatment, the vast 
majority of tumors developed resistance to single -agent MEK162 (8/8 at low dose and 7/8 at 
high dose)  or LGX818  (6 out of 7). In contrast,  treatment  with LGX818  and low dose MEK162 
combination,  resulted  in only one out of eight  tumors  developing  clear  resistance  and no tumors 
developed  resistance  to combination  treatment  of LGX818  and high dose MEK162.  These  data 
support  the hypothesis  that combining  RAF  and MEK  inhibitors  will result  in a more  sustained 
tumor response.  
Collectively these in vitro and in vivo results strongly suggest that combining these inhibitors 
in the clinic in the BRAFV600E setting is likely to result in an increase of anti -tumor activity 
compared to either single agent.  
1.2.4.2  Clinical  studies  with combinations  of selective  RAF and MEK  - 
inhibitors  
The concept  of dual,  vertical  inhibition  of the ERK/MAPK - pathway  is currently  being  explored 
within a Phase I/II clinical trial. [Study [STUDY_ID_REMOVED]] investigates the safety, PKs, PDs and 
clinical activity of the combination of the BRAF -inhibitor GSK2118436 (GlaxoSmithKline) 
and the selective MEK1/2 - inhibitor GSK1120212 in patients with advanced BRAF - mutation 
positive  tumor  types.  One hundred  nine patients  have  been  enrolled  in the study  and preliminary 
results were presented at ASCO 2011 ( Infante 2011 ). Both investigational drugs could be 
administered at full dose in combination, GSK2118436 150 mg BID and GSK1120212 2mg 
QD, showing  a significant  tumor  shrinkage  in the majority  of the patients  with an ORR  of 70%. 
The combination  was well tolerated  and the most  common  AEs included  pyrexia,  fatigue,  rash, 
diarrhea and nausea. Interestingly, patients experienced less skin toxicities compared to 
monotherapy.  
BRAF -inhibitors including PLX4032, XL -281 and GSK2118436 are associated with 
hyperproliferative skin lesions (ie, keratoacanthomas and squamous -cell carcinomas) in up to 
31% of patients  (Flaherty  2009 ; Flaherty  2010 ; Kefford  2010 ), indicating  that BRAF  inhibitors 
can paradoxically activate the RAF/MEK/ERK pathway and promote growth in RAS 
mutant/BRAF  wt tumors  (Hatzivassiliou  2010 ; Cichowski  2010 ). The decreased  occurrence  of 
SCC in the GSK2118436/GSK1120212 combination trial, suggests that MEK inhibitors by 
acting downstream of RAF in the RAF/MEK/ERK pathway, may potentially block 
inappropriate signal transduction, originating either from the cell surface or due to RAS/RAF 
mutations, further strengthening the rationale for combining MEK inhibitors with BRAF 
inhibitors in the clinic.  
1.2.4.3  Pre-clinical  studies  with combinations  of RAF,  MEK  and CDK  - 
inhibitors  
Increased CDK4/6 activity and the accompanying loss of G1/S phase cell cycle control is a 
hallmark of melanoma. This increased activity can occur as a result of several non -exclusive 
events.  For instance,  one consequence  of ERK/MAPK  pathway  activation  due to oncogenic  
Array BioPharma 
Amend ed Protoco l Version 10 Confid ential Page 64 
Protoco l No. CMEK162X2 110 / C422 1005 
PFIZER  CONFIDENTIAL   
 lesions  in BRAF  and NRAS  is the elevation  of cyclin  D1 levels  which  in turn interact  with and 
activate the CDK4/6 kinases. In addition, molecular alterations that directly increase CDK4/6 
activity such as loss of expression of the CDKN2A gene, which encodes p16 a negative 
regulator CDK4/6, and amplification of CCND1, the gene encoding CyclinD1  are collectively 
observed  in a majority  of melanomas.  Further  underscoring  the importance  of CDK4/6  kinases 
in melanoma, combining the CDK4/6 inhibitor LEE011 with either LGX818 or MEK162 in 
BRAF and NRAS -mutant models of melanoma, respectively, leads to both improved efficacy 
and prolonged anti -tumor responses in vivo (RD-2012 -50372, RD -2012 -50370).  
The effect of simultaneously combining LGX818, MEK162 and LEE011 on the proliferation 
of BRAF -mutant  melanoma  cell lines  in vitro  was examined.  The cell lines  used were  the A-375 
and WM -266-4 models, both of which are highly sensitive to LGX818 and MEK162, and 
derivatives  of each of these  lines  engineered  to express  one of several  proteins  known  to confer 
resistance to RAF inhibitors including NRASQ61K ( Nazarian 2010 ), BRAF p61 ( Poulikakos 
2011 ), MEK1C121S, and MEK1P124L ( Emery 2009 ). When a fixed ratio of MEK162 and 
LGX818 (1:1, 0 –2.7uM) was combined with LEE011 (0 –10uM), either synergy or dose - 
additivity was observed in all models. Synergy was observed in both the parental A -375 and 
WM-266-4 cell lines as well as in the NRASQ61K -expressing variant of A -375. In all other 
models either weak synergy or dose -additive effects were observed.  
Collectively these results suggest that adding the CDK4/6 inhibitor LEE011 to the 
LGX818/MEK162  combination  in the clinic  in BRAFV600  mutant  patients  is likely  to further 
increase the anti -tumor activity of the LGX818/MEK162 combination.  
1.2.4.4  Clinical  studies  with combinations  of selective  RAF,  MEK  and CDK4/6 
inhibitors  
No studies are currently reported and/or ongoing with a selective RAF, MEK and CDK4/6 
inhibitor triple combination.  
1.3 Anticipated  risks  and safety  considerations  of the study  drug 
combinations  
1.3.1  Dual combination LGX818 and MEK162  
While preliminary  clinical data available from ongoing studies with LGX818 and MEK162 as 
single agents suggest overlapping toxicities for the proposed combination which may 
potentially  be dose-limiting,  including  effects  on the skin (e.g. rash),  initial  reports  with similar 
class of compounds have shown that selective BRAF inhibitor combines safely with MEK 
inhibitor  with a decreased  occurrence  of skin toxicities  (rash,  SCC).  This data suggests  that the 
combination of LGX818 with MEK162 may have an improved safety profile compared the 
respective single agent therapies.  
Retinal  toxicity  (CSR),  GI toxicity  (i.e. diarrhea;  nausea/vomiting),  body  edema,  and elevations 
in CPK are associated specifically with MEK162. HFSR, photosensitivity and hyperesthesia 
were  reported  with the use of LGX818.  MEK162  also caused  ectopic  soft tissue  mineralization 
in pre -clinical toxicology studies, exclusively in rats. However, the plasma exposure margins 
for soft tissue  mineralization  in rats are 60-fold above  those  seen in humans  at 60 mg bid. To 
Array BioPharma 
Amend ed Protoco l Version 10 Confid ential Page 65 
Protoco l No. CMEK162X2 110 / C422 1005 
PFIZER  CONFIDENTIAL   
 date there have been no reports of a calcium -phosphate imbalance, including ectopic 
calcifications, associated with the clinical use of MEK162.  
Based  on the available  data,  no significant  metabolism -based  DDI is foreseen  with the LGX818 
and MEK162 combination. Although LGX818 is a UGT1A1 inhibitor and MEK162 is a 
UGT1A1  substrate,  the average  concentration  of LGX818  with 50 mg ME QD dose is expected 
to be well below  the IC50  (~4 uM).  LGX818  is both a substrate  as well as an inhibitor/inducer 
of CYP3A.The inhibition and induction effects of LGX818 on CYP3A do not appeared to be 
significant since the human PK profile on Day15 was similar to Day 1 and no accumulation 
was observed.  
LGX818  is a BCRP  inhibitor  (IC50  at 10-25 uM) and MEK162  is a BCRP  substrate.  Since  the 
concentration of LGX818 in the gut is expected to be ~0.4 mM with a 50 mg dose (assuming 
all drug dissolved  in 250 mL volume),  there  is a potential  for increased  MEK162  exposure  due 
to BCRP -inhibition  by LGX818.  A rat ADME  study  showed  that 50% MEK162  was absorbed 
after oral dose.  If human  is similar  to rat, the maximum  potential  increase  in MEK162  exposure 
is 100% with the LGX818 and MEK162 combination.  
For the safety of the study patients, the starting dose of the combination will include a 75% 
fraction of the single agent MTD of MEK162. As the MTD of LGX818 is still under 
consideration,  the starting  dose will be selected  based  on a well tolerated  dose from  the ongoing 
[CLGX818X2101]  clinical  study.  Doses  of LGX818  and MEK162  will be alternately  escalated 
for each compound  during  dose escalation  (see Section  6.2.3  and Section  6.2.4.2  for provisional 
dose levels and details on the dose escalation process). Furthermore, appropriate eligibility 
criteria and specific DLT criteria as well as specific dose modification and stopping rules are 
included  in this protocol.  Recommended  guidelines  for prophylactic  or supportive  treatment  for 
expected toxicities are provided in Section 6.1.2 and Appendix 3 . The PKs of MEK162 and 
LGX818 will also be assessed in the current study to further evaluate the potential for a PK 
drug-drug interaction.  
1.3.2  Triple  combination  LGX818  and MEK162  and LEE011  
Based on the most frequent observed adverse events described for the LGX818 and MEK162 
dual combination (see current LGX818 Investigator Brochure or MEK162 Investigator 
Brochure) and for LEE011 (see Section 1.2.3.2 and current LEE011 Investigators Brochure), 
overlapping toxicities can be expected for gastrointestinal events (such as nausea, vomiting, 
diarrhea) as well as fatigue.  
Since (asymptomatic) QTc prolongation has been observed with LEE011 as a single agent, 
additional collection of post -dose ECGs are implemented into this trial for the triple 
combination. ECGs be collected in triplicate (vs. single ECGs) and the entry criteria for the 
triple -combination  study  exclude  patients  with congenital  long QT syndrome  or family  history 
of unexpected sudden cardiac death and/or hypokalemia CTCAE Grade ≥ 3, and patients who 
are currently receiving treatment with agents that are known to cause QTc prolongation in 
humans. During study treatment with the triple combination, use of concomitant medication 
known to cause QTc prolongation is prohibited.  
LEE011 inhibited CYP3A4 -catalyzed marker substrate reactions in vitro in human liver 
microsomes  with Ki values  of 35 μM. Time -dependent  inhibition  of CYP3A4  was observed  
Array BioPharma 
Amend ed Protoco l Version 10 Confid ential Page 66 
Protoco l No. CMEK162X2 110 / C422 1005 
PFIZER  CONFIDENTIAL   
 with a Ki value of 5 μM and a Kinact value of 0.0245 min -1. Since LGX818 is a substrate for 
CYP3A4, LEE011 has a potential to increase PK exposures of LGX818. In vitro studies 
indicated that LEE011 was mainly metabolized by CYP3A4. Since LGX818 is a more potent 
inducer than an inhibitor of CYP3A4, LGX818 may decrease the exposure of LEE011.  
Quantitative assessment of potential drug -drug interaction was performed using a dynamic 
physiologically based PK (PBPK) model in Simcyp and the simulation confirmed the 
qualitative assessment. At LGX818 450 mg QD and LEE011 200 mg QD, the model predicts 
29% and 14% increase in AUC and Cmax of LGX818, respectively, as well as 47% and 30% 
decrease in AUC and Cmax of LEE011, respectively.  
MEK162 is mainly metabolized by glucuronidation and is not a strong CYP3A4 inhibitor. In 
vitro data and some clinical data suggest MEK162 might have CYP3A4 induction potential. 
However,  no significant  PK exposure  changes  for LGX818  were  observed  in the LGX818  and 
MEK162 dual -combination phase up to date. Even if the induction occurs between MEK162 
and LEE011,  it will likely  decrease  LEE011  exposure  and therefore  will not pose a safety  risk. 
Overall the PK drug -drug interaction between MEK162 and LEE011 is expected to be minor 
and not pose significant safety risk.  
In this ongoing  [CMEK162X2110]  study,  the PK profiles  of LGX818  and MEK162  when  given 
in combination  were  generally  similar  to those  in their corresponding  single  agent  studies.  With 
increasing  LGX818  doses  (50mg,  100mg,  200mg,  400mg,  450mg  and 600mg),  the PK exposure 
of MEK162  did not change.  These  data indicated  that no significant  PK drug-drug interactions 
between LGX818 and MEK162 were observed.  
For the safety of the study patients to be treated with the triple combination, the starting dose 
of LEE011 in the triple combination will include a 1/9 fraction of the single agent MTD of 
LEE011  (i.e. MTD  900 mg QD 3 week  on/1 week  off schedule),  i.e 100 mg QD. For the starting 
dose of LGX818  and MEK162,  the RP2D  of 450mg  QD and 45mg  BID was selected  as a well- 
tolerated dose from the ongoing CMEK162X2110 clinical study for the dual combination. 
Doses of LEE011 and possibly of LGX818 will be alternately escalated for each compound 
during dose escalation (see Section 6.2.3 and Section 6.2.4.2 for provisional dose levels and 
details  on the dose escalation  process).  Furthermore,  appropriate  eligibility  criteria  and specific 
DLT criteria as well as specific dose modification and stopping rules are included in this 
protocol. Recommended guidelines for prophylactic or supportive treatment for expected 
toxicities are provided in Section 6.1.2 and Appendix 3 . Specific safety  assessments (i.e. post - 
dose ECGs/  triplicate  ECGs)  will be performed  to monitor  cardiac  safety  during 
triple -combination study treatment. The PKs of MEK162, LGX818 and LEE011 will also be 
assessed in the current study to further evaluate the potential for a PK drug -drug interaction.  
 
2 Rationale  
[Any language regarding the triple combination of LGX818/MEK162/LEE011 in this 
Section is not applicable to the USA and Singapore]  
Array BioPharma 
Amend ed Protoco l Version 10 Confid ential Page 67 
Protoco l No. CMEK162X2 110 / C422 1005 
PFIZER  CONFIDENTIAL   
 2.1 Study  rationale  and purpose  
About half of the patients with melanoma have an activating mutation in BRAF that results in 
the activation  of the RAF/MEK/ERK  pathway  and plays an important role in the development 
of melanoma. BRAF mutations may also be present in up to 15% of patients with colorectal 
cancer  and are associated  with a poorer  clinical  outcome.  A number  of preclinical  studies  have 
validated BRAF as a therapeutic target in melanoma, and two selective BRAF inhibitors, 
PLX4032 and GSK2118436, have shown clinical activity in patients with BRAF V600E 
mutated melanoma. The selective BRAF inhibitor, vemurafenib/PLX4032 (Zelboraf®), was 
recently approved by the FDA for the treatment of patients with unresectable or metastatic 
melanoma with the BRAF V600E mutation. However, data also indicate that the duration of 
response  to BRAF  inhibitors  is often  short  lived  (median  PFS ~ 6 to 7 months),  with resistance 
developing quickly. LGX818 is a highly potent and selective BRAF inhibitor, and preclinical 
data suggest that LGX818 could lead to more sustained clinical responses in patients with 
advanced and/or metastatic BRAF V600 mutant melanoma compared to competitor RAF 
inhibitors ( Stuart 2011 ) (see also Section 1.2.1 ). 
The redundancy within the multiple signaling pathways activated in cancer, along with the 
likelihood of drug resistance, suggests that combination therapy strategies will be required for 
effective disease management ( Smalley 2009 ). There is preclinical evidence of emerging 
resistance  to BRAF - and MEK1/2 - inhibitors  treatment  through  MEK1 -mutations 
(Montagut  2008 ; Emery  2009 ). As demonstrated  pre-clinically,  the combination  of a BRAF  and 
a MEK1/2 - inhibitor may help to prevent the emergence of resistance to single agent small 
molecule inhibitor therapy, targeting the RAF/MEK/ERK pathway by dual node inhibition 
(Emery 2009; Fremin 2010 ). The concept of a simultaneous, dual, vertical pathway inhibition 
of the RAF/MEK/ERK pathway  is currently  being explored by  the combination treatment of a 
selective  MEK1/2 - (GSK1120212)  and BRAF - inhibitor  (GSK2118436)  in cancer  patients  with 
advanced BRAF mutation positive tumor types. Preliminary results presented at ASCO 2011 
(Infante  2011 ) [Study  [STUDY_ID_REMOVED]]  shows  significant  tumor  shrinkage  in the majority  of the 
patients with an ORR of 70%. Furthermore, results from the [STUDY_ID_REMOVED] study show that 
selective BRAF inhibitor combines safely with MEK inhibitor with a decreased occurrence of 
cutaneous  side effect,  such as rash and SCC  in comparison  to single  agent  therapy,  which  further 
strengthen the rationale for combining MEK inhibitors with BRAF inhibitor in the clinic.  
Together, this provides a strong rationale for the combination therapy of selective RAF and 
MEK inhibitors in patients with BRAF V600 dependent advanced or metastatic solid tumor.  
The addition of LEE011 to the dual combination of LGX818 and MEK162 in BRAF -mutant 
melanoma in vitro models displays either additivity or modest synergy. Therefore the triple 
combination will be evaluated in order to (1) investigate whether LEE011 can be safely 
combined with LGX818 and MEK162, (2) whether effects observed in vitro are either 
recapitulated or enhanced in patients and to (3) evaluate whether an improved anti -tumor 
activity  and prolonged anti -tumor response can be shown with the triple combination over the 
dual combination.  
The population of BRAF mutant melanoma patients who are naïve for prior treatment with a 
selective  BRAF  inhibitor,  was chosen  for the Phase  II arm A, to allow  a preliminary  assessment  
Array BioPharma 
Amend ed Protoco l Version 10 Confid ential Page 68 
Protoco l No. CMEK162X2 110 / C422 1005 
PFIZER  CONFIDENTIAL   
 whether the triple combination is at least as active as the dual combination, with a comparable 
safety profile.  
The primary purpose of the proposed dose -finding Phase Ib study is to estimate the MTD(s) 
and/or the recommended Phase II dose(s) (RP2D(s)) of the dual (LGX818 and MEK162) and 
triple (LGX818 and MEK162  and LEE011) combinations  in patients  with locally  advanced or 
metastatic melanoma, mCRC or any other solid tumor upon agreement with the Sponsor, 
positive  for either  V600E  BRAF  mutation,  or any other  BRAF  mutation  at the V600  codon  (e.g. 
V600K/D/R).  
Once  the MTD/RP2D  has been  determined  for the dual combination,  additional  patients  will be 
enrolled in three Phase II arms to further assess the clinical anti -tumor efficacy of the 
combination.  The Phase  II arm 1 will assess  the disease  control  rate (DCR)  of the LGX818  and 
MEK162  combination  in patients  with BRAF  V600  mutant  metastatic  CRC.  In the Phase  II arm 
2, the study will assess the objective response rate (ORR) of the combination in metastatic 
BRAF mutant melanoma patients who have progressed after prior treatment with a selective 
BRAF  inhibitor  (e.g. PLX4032,  GSK2118436).  In the Phase  II arm 3, the study  will assess  the 
objective response rate (ORR) of the combination in metastatic BRAF mutant melanoma 
patients who are naïve to prior treatment with a selective BRAF inhibitor. The DCR (defined 
as patients  with CR or PR or SD) rather  than the ORR  (defined  as patients  with CR or PR) will 
be used to evaluate  clinical  benefit  in Phase  II arm 1, as only a limited  number  of patients  with 
BRAF  mutant  mCRC  have  experienced  tumor  shrinkage in  clinical studies  with RAF  or MEK 
inhibitors (see Section 1.1.3 ), with more patients achieving stable disease (SD) than response. 
Also  an interim  analysis  for futility  will be performed  in arm 1 after 50% of the total number  of 
patients  in this arm have  completed  four cycles  of treatment,  to allow  stopping  early  for futility 
when there is no treatment effect. All three Phase II arms will further assess the safety of the 
LGX818 and MEK162 combination.  
For the triple combination, once the MTD/RP2D has been determined additional metastatic 
BRAF mutant melanoma patients who are naïve to prior treatment with a selective BRAF 
inhibitor will be enrolled in arm A to assess the ORR of this triple combination. The safety  of 
the triple combination will also be assessed in the Phase II population.  
2.2 Rationale  for the study  design  
The design  of this Phase  Ib/II,  open  label,  dose escalation  study  was chosen  in order  to establish 
a dose of the dual (LGX818 and MEK162) and triple (LGX818 and MEK162 and LEE011) 
combinations for which the safety and tolerability is acceptable, in patients with BRAF V600 
dependent advanced solid tumors. The dose escalation will be guided by a Bayesian logistic 
regression model (BLRM). During the Phase II part, depending on  the observed  DLT  rate, the 
BLRM will be re -run to confirm that the current dose combination still satisfies the overdose 
criteria. Refer to Section 10.4.2.2 for further information. In the Phase II part of the study, a 
Bayesian  design  will be used in order  to estimate  the true DCR  for the dual-combination  arm 1 
population  and the true ORR  for the dual-combination  arms  2 and 3, and the triple -combination 
arm A populations.  
The current  open -label  dose escalation  study  design  using  a BLRM  is a well-established  method 
to estimate  the MTD(s)  and/or  RP2D(s)  in cancer  patients.  The adaptive  BLRM  will be guided  
Array BioPharma 
Amend ed Protoco l Version 10 Confid ential Page 69 
Protoco l No. CMEK162X2 110 / C422 1005 
PFIZER  CONFIDENTIAL   
 by the escalation with overdose control (EWOC) principle to control the risk of DLT in future 
patients on study. The use of Bayesian response adaptive models for small datasets has been 
accepted by  EMEA (“Guideline on clinical trials in small populations”, February  1, 2007) and 
endorsed by numerous publications ( Babb 1998 ; Neuenschwander 2008 ; Neuenschwander 
2010 ), and its development and appropriate use is one aspect of the FDA’s Critical Path 
Initiative.  
2.3 Rationale  for dose  and regimen  selection  
Refer  to Section  6.2.2  for detailed  information  on the rationale  for the starting  dose and regimen 
selection.  
2.4 Rationale  for choice  of combination  drugs  
Data  from  pre-clinical  and clinical  studies  suggest  that by simultaneous,  dual,  vertical  pathway 
inhibition  of the RAF/MEK/ERK  signaling  pathways,  the LGX818  and MEK162  combination 
could  lead to increased  clinical  efficacy  and possibly  prevent  and/or  overcome  early  resistance 
to either single agent in  patients with BRAF V600 -dependent advanced solid tumors (see also 
Section  1.2.1.2 , Section  1.2.2.2  and Section  1.2.4.1 ). Data  from  preclinical  studies  suggest  that 
by simultaneous triple -pathway inhibition of the RAF/MEK/ERK and CDK/cyclin signaling 
pathways, the LGX818 and MEK162 and LEE011 combination could possibly  prevent and/or 
overcome resistance to and lead to increased clinical efficacy compared to the LGX818 and 
MEK162 dual combination.  
 
3 Objectives  and endpoints  
[Any language regarding the triple combination of LGX818/MEK162/LEE011 in this 
Section is not applicable to the USA and Singapore]  
Objectives  and related  endpoints  are described  in Table  3-1. 
 
Table  3-1 Objectives  and related  endpoints   
Objective  Endpoint  Analysis  
Primary   Refer  to Section  10.4 
Array BioPharma 
Amend ed Protoco l Version 10 Confid ential Page 70 
Protoco l No. CMEK162X2 110 / C422 1005 
PFIZER  CONFIDENTIAL   
  
 
Objective  Endpoint  Analysis  
Phase Ib: To estimate the MTD(s) and/or 
RP2D(s)  of oral LGX818  in combination  with 
oral MEK162, and of oral LGX818 in 
combination with oral MEK162 and oral 
LEE011 in patients with BRAF V600 - 
dependent advanced solid tumors  
 
Phase II: To assess clinical efficacy of the 
LGX818  and MEK162  dual combination  and 
LGX818 and MEK162 and LEE011 triple 
combination in the respective Phase II 
populations:  
Arm 1: metastatic  BRAF  V600  mutant  mCRC 
patients (dual combination)  
 
Arm 2: metastatic BRAF V600 mutant 
melanoma  patients  who have  progressed  after 
prior selective BRAFi treatment (dual 
combination)  Phase  Ib: Incidence  of Dose  Limiting 
Toxicities  
 
 
 
 
 
 
 
 
 
 
Phase  II arm 1: Disease  control  rate 
(DCR) as per RECIST v1.1  
 
Phase II arms 2 and 3 / arm A: 
Objective  Response  Rate  (ORR)  as 
per RECIST v1.1  
Arm 3/ Arm A: metastatic  BRAF  V600  mutant 
melanoma patients who are naïve to prior 
selective BRAFi treatment (dual and triple 
combination)  
Secondary  Refer  to Section  10.5 
/ Section 10.5.4  
Phase Ib + II: 
To characterize  the safety  and tolerability  of 
LGX818 and MEK162 in combination, and 
LGX818 and MEK162 and LEE011 in 
combination  
Phase Ib 
To determine the single  and multiple dose PK 
profile of the LGX818 and MEK162 
combination,  and of the LGX818  and MEK162 
and LEE011 combination  
 
To assess preliminary clinical anti -tumor 
activity of the LGX818 and MEK162 
combination,  and of the LGX818  and MEK162 
and LEE011 combination  
Phase II 
To further assess clinical efficacy of the 
LGX818  and MEK162  dual combination  and of 
the LGX818 and MEK162 and LEE011 triple 
combination in the Phase II populations  
To characterize  baseline  molecular  status  of 
molecules relevant to RAF/MEK/ERK and 
EGFR/PI3K/AKT signaling in tumor tissue  Phase Ib+II 
Incidence and severity of AE 
 
 
 
Phase Ib 
Time vs. plasma concentration,  
basic  PK parameters  of LGX818  and 
MEK162 and LEE011 and known 
active metabolite(s)  
 
ORR  as per  RECIST v1.1 
 
 
 
Phase II 
PFS, time to response (TTR), 
duration  of response  (DOR)  as per 
RECIST  v1.1,  and Overall  Survival 
(OS) 
Baseline molecular status 
(mutation/amplification/expression)  
in tumor  tissue  of potential  predictive 
markers of tumor response or 
resistance (BRAF, HRAS, KRAS, 
NRAS, PTEN, cKIT, PIK3CA, 
MAP2K1, MAP2K2, ARAF, c -MET, 
RAF1, EGFR)  
 
Array BioPharma 
Amend ed Protoco l Version 10 Confid ential Page 71 
Protoco l No. CMEK162X2 110 / C422 1005 
PFIZER  CONFIDENTIAL   
 
 
 
 
 
 
 
 
 
4 Study  design  
[Any  language  regarding  the triple  combination  of LGX818/MEK162/LEE011 in  this 
Section is not applicable to the USA and Singapore]  
- 
 - 
Array BioPharma 
Amend ed Protoco l Version 10 Confid ential Page 72 
Protoco l No. CMEK162X2 110 / C422 1005 
PFIZER  CONFIDENTIAL   
 
4.1 Description  of study  design  
This is a multi -center, open -label, dose finding, Phase Ib dose escalation study  to estimate the 
MTD(s) and/or RP2D(s) for the dual combination of LGX818 and MEK162 and triple 
combination of LGX818 and MEK162 and LEE011, followed each independently  by a Phase 
II part to assess the clinical efficacy and to further assess the safety of the combinations in 
selected patient populations. Oral LGX818 and MEK162 will be administered once daily and 
BID,  respectively, on a continuous schedule. Oral LGX818 and MEK162 and LEE011 will be 
administered once daily on a continuous schedule (LGX818), BID on a continuous schedule 
(MEK162) and once daily three weeks on, one week off (LEE011), respectively. Patients will 
be treated until progression of disease, unacceptable toxicity develops, or withdrawal of 
informed consent, whichever occurs first. Continued treatment beyond progression of disease 
will be allowed under certain circumstances (see Section 6.1.5 ) Provisional dose levels are 
given in Table 6 -1 and Table 6 -2. A cycle is defined as 28 days.  
Figure  4-1 Study  Design  
 
Molecular pre -screening  
Patients whose tumors have a documented mutation of BRAF V600 will be enrolled based on 
available local documentation. For patients for whom the molecular status is not known and 
who have a tumor which is routinely screened for a BRAF mutation at a local laboratory, the 
mutation  can be determined  on either  fresh  or archival  tumor  by local  routine  procedure  without 
the need for signing the Molecular pre -screening Informed Consent. However, patients for 
whom molecular status is not known at the time of consideration for enrollment in this study 
and who have  a tumor  which  is not routinely  screened  for a BRAF  mutation  at a local  laboratory, 
will sign a Molecular  pre-screening  Informed  Consent  allowing  for the collection  of fresh  tumor 
sample or use of archival tumor tissue for local assessment of the mutational status. Only  once 
the BRAF V600 mutational status is known or determined, the patient is allowed to sign the 
Study Informed Consent Form and start screening (see also Section 7.1.1 ). 
Array BioPharma 
Amend ed Protoco l Version 10 Confid ential Page 73 
Protoco l No. CMEK162X2 110 / C422 1005 
PFIZER  CONFIDENTIAL   
 Screening period  
Upon signing the Study Informed Consent Form, patients will be evaluated against study 
inclusion  and exclusion  criteria.  Eligible  patients  will be enrolled  in the study  within  14 days of 
the commencement  of the screening  assessments  and evaluations  (Table  7-1 and Section  7.1.2 ). 
Dose escalation (Phase Ib) 
The dose escalation part of the trial will be conducted in adult patients with BRAF V600 - 
dependent advanced solid tumors (see also Section 5.1 ). This part of the trial is expected to 
enroll at least 18 patients for the dual combination (LGX818 and MEK162) and at least 12 
patients for the triple combination (LGX818 and MEK162 and LEE011).  
For the dual combination, dose escalation will start at 50mg QD for LGX818 and 45mg BID 
for MEK162. Provisional dose levels are given in Table 6 -1. For the triple combination, dose 
escalation will start at 450mg QD LGX818 and 45mg BID MEK162 and 100mg QD LEE011. 
Provisional  dose levels  are given  in Table  6-2. When  enrollment  of a cohort  is complete,  further 
enrollment  will only resume  after the investigators  and the Sponsor  have  jointly  decided  on the 
next dose escalation step of the combination. At each decision time point, the adaptive BLRM 
provides the upper boundary for the combinations that meet the EWOC criteria. Safety and 
tolerability data, PK, PD, and efficacy, as well as the recommendations from the Bayesian 
model are used to determine the dose combination for the next cohort(s) at a dose escalation 
teleconference. If deemed appropriate and supported by the available and relevant safety, PK, 
PD and efficacy  data (and in agreement between the Sponsor and the Investigators), the dosing 
regimen of LGX818 may be changed to BID and/or every -other -day (QOD) dosing (as long as 
the new initial  dosing  regimen  will not exceed  the maximum  total daily  dose tested  in this study). 
Should  the new dosing  regimen  of LGX818  be explored,  this will be achieved  by enrollment  of 
patients into a new cohort.  
Various dose pairs will be explored following the recommendation of an adaptive Bayesian 
logistic  regression  model  (BLRM)  for dose escalation  with overdose  control  (EWOC)  until the 
MTD  is determined  and/or  until a consensus  between  the Sponsor  and Investigators  is reached 
and it is considered that there is no benefit of further increasing the dose. At least 6 patients 
eligible for the dose determining set (DDS) must be treated at the dose(s) declared to be the 
MTD/RP2D. At this time the RP2D, a dose less than or equal to the MTD, will be estimated 
based on a review of the totality  of the available study  data. Note: more than one combination 
and/or dosing schedule may  be defined as MTD/RP2D. In the case that all dose combinations 
are considered  to be too toxic  by the BLRM  after the first cohort,  no MTD/RP2D  can be defined.  
Phase II 
Following MTD/RP2D declaration, for the dual -combination patients will be enrolled in three 
Phase II arms. Phase II arm 1 will consist of 28 patients with non -resectable advanced BRAF 
V600 mutant metastatic colorectal cancer (mCRC) for whom no further effective standard 
therapy  is available.  An interim  analysis  for futility  will be performed  in arm 1 after 50% of the 
total number  of patients  in this arm have  completed  four cycles  of treatment,  to allow  stopping 
early  for futility  when  there  is no treatment  effect.  The Phase  II arm 2 will consist  of 41 patients 
with locally  advanced or  metastatic  BRAF V600  mutant  melanoma who have  progressed after 
Array BioPharma 
Amend ed Protoco l Version 10 Confid ential Page 74 
Protoco l No. CMEK162X2 110 / C422 1005 
PFIZER  CONFIDENTIAL   
 previous treatment with a selective BRAF inhibitor. The Phase II arm 3 will consist of 40 
patients with locally advanced or metastatic BRAF V600 mutant melanoma who are naïve to 
previous  treatment  with a selective  BRAF  inhibitor.  An interim  analysis for futility  will not be 
performed for arms 2 and 3, as signs of clinical activity  have been reported for both MEK162 
and LGX818 as single agent in patients with BRAF mutant melanoma patients (see Section 
1.2.1.2 and Section 1.2.2.2.1 ). 
For the triple  combination  following  MTD/RP2D  declaration,  40 patients  with locally  advanced 
or metastatic BRAF V600 mutant melanoma who are naïve to previous treatment with a 
selective BRAF inhibitor will be enrolled in the Phase II arm A.  
If more than one dose combination or dosing schedule has been defined as MTD/RP2D, the 
Sponsor may decide to open the Phase II arms for more than one MTD/RP2D and/or start the 
Phase II arms with different dose combinations or schedules. This decision will be driven by 
the data available  and will be discussed  and agreed  on between  the Sponsor  and the investigators.  
30-day safety  follow -up assessments  
After study drug discontinuation, all patients must complete End of Treatment assessments 
within  14 days and the safety  follow -up assessments  for 30 days after the last dose of the study 
treatment (see also Section 7.1.4 and Section 7.1.5.1 ). 
Study evaluation completion (SEC)  
Note: As of protocol amendment 10, patients will be considered to have completed the 
study after the 30 -day safety evaluation or 30 days after treatment discontinuation, 
whichever is earlier.  
The study  evaluation  completion  (SEC)  eCRF  page  records  the end of study  for every  individual 
patient. For details on the time point of completion of SEC, please refer to Section 7.1.4.  
Disease  progression  and Survival  follow -up assessments  (Phase  II only)  
Note: As of protocol amendment 10, post -treatment disease progression follow -up (if 
applicable) and/or survival follow -up (including documentation of subsequent 
antineoplastic therapies)  will no longer  be performed  for any patient  in the Phase  II part 
of the study.  
Patients  enrolled  in the Phase  II part of the study  who discontinue  study  treatment  for any reason 
other than disease progression will be followed up for progression of disease as detailed in 
Table 7 -1 and Section 7.1.5.2 . All patients enrolled in the Phase II part of the study will be 
followed for survival (for details see Section 7.1.5.3 ). 
4.2 Timing  of interim  analyses  and design  adaptations  
An interim  analysis  for futility  will be performed  during  the Phase  II part of the study  in arm 1 
dual combination (BRAF mutant mCRC patients) after 50% of the total number of patients in 
this arm have  completed  four cycles  of treatment,  to allow  stopping  early  for futility  when  there 
is no treatment effect (see also Section 4.1 -Phase II and Section 10.7 ). 
Array BioPharma 
Amend ed Protoco l Version 10 Confid ential Page 75 
Protoco l No. CMEK162X2 110 / C422 1005 
PFIZER  CONFIDENTIAL   
 4.3 Definition  of end of the study  
Note: As of protocol amendment 10, the end of study will be when the last patient on 
treatment  completes  the 30-day follow -up visit or 30 days  after  treatment  discontinuation.  
End of study  (Last  Patient  Last Visit  [LPLV])  will be upon  completion  of the follow -up period 
for the last patient treated with either the dual (LGX818 and MEK162) or triple (LGX818 and 
MEK162 and LEE011) combination as described in Section 4.1. This will occur once the last 
patient in the Phase II part has died or all patients have completed SEC, or have been lost to 
follow -up or withdrew consent, whichever occurs first.  
4.4 Early  study  termination  
The study  can be terminated  at any time for any reason  by the Sponsor.  Should  this be necessary, 
the patient should be seen as soon as possible and the same assessments should be performed 
as described in Section 7.1.4 for a prematurely withdrawn patient. The Investigator may be 
informed  of additional  procedures  to be followed  in order  to ensure  that adequate  consideration 
is given to the protection of the patient’s interests. The Investigator will be responsible for 
informing IRBs and/or IECs of the early termination of the trial.  
 
5 Population  
[Any language regarding the triple combination of LGX818/MEK162/LEE011 in this 
Section is not applicable to the USA and Singapore]  
5.1 Patient  population  
The dose escalation will be conducted in adult patients with locally advanced or metastatic 
melanoma,  metastatic  colorectal  cancer  (mCRC)  or any other  solid  tumor  upon  agreement  with 
the Sponsor (like serous ovarian, biliary tract or pancreatic carcinomas; see also Section  1.1.1 
and Table 1 -1) harboring the BRAF V600E mutation, or any other BRAF V600 mutation, 
whose disease has progressed despite previous anti -neoplastic therapy or for whom no further 
effective standard therapy is available. Once MTD/RP2D has been determined with either the 
dual and triple  combination,  additional  patients  will be enrolled  in the respective  Phase  II parts 
of the study. Patients with BRAF V600 mutant mCRC for whom no further effective standard 
therapy  is available,  will be enrolled  in arm 1 dual combination  of the Phase  II part of the study. 
Patients with locally advanced or metastatic BRAF V600 mutant melanoma who have 
progressed after previous treatment with a selective BRAF inhibitor will be enrolled in the 
Phase II arm 2 dual combination. Patients with locally advanced or metastatic BRAF V600 
mutant  melanoma  who are naïve  to previous  treatment  with a selective  BRAF  inhibitor  will be 
enrolled in the Phase II arm 3 dual combination and in the triple combination Phase II arm A.  
Patients  enrolled  in this study  are not permitted  to participate  in parallel  investigational  drug or 
device  studies.  Additionally,  patients  who have  completed  the study  must  not be re-enrolled  for 
a second course of treatment.  
The investigator  or designee  must  ensure  that only patients  who meet  all the following  inclusion 
and none of the exclusion criteria are offered enrollment in the study.  
Array BioPharma 
Amend ed Protoco l Version 10 Confid ential Page 76 
Protoco l No. CMEK162X2 110 / C422 1005 
PFIZER  CONFIDENTIAL   
 5.2 Inclusion  criteria  
Patients  eligible  for inclusion  in this  study  have  to meet all of the following  criteria:  
1. Age ≥ 18 years.  
2. For the dose escalation (Phase Ib): Histologically confirmed diagnosis of locally 
advanced or metastatic melanoma (stage IIIB to IV per American Joint Committee on 
Cancer  [AJCC]),  or confirmed  diagnosis  of non-resectable  advanced  metastatic  colorectal 
cancer  (mCRC),  or any other  indication  upon  agreement with  the Sponsor,  whose disease 
has progressed despite previous anti -neoplastic therapy or for whom no further effective 
standard therapy is available.  
For Phase  II arm 1 dual  combination:  Confirmed  diagnosis  of non-resectable  advanced 
metastatic colorectal cancer (mCRC) for whom no further effective standard therapy is 
available.  
For Phase II arm 2 dual combination: Histologically confirmed diagnosis of locally 
advanced or metastatic melanoma (stage IIIB to IV per American Joint Committee on 
Cancer  [AJCC])  in patients  who have  progressed  after previous  treatment  with a selective 
BRAF inhibitor.  
 
3. For Phase II arm 3 dual combination and Phase II arm A triple combination: 
Histologically confirmed diagnosis of locally advanced or metastatic melanoma (stage 
IIIB to IV per American  Joint  Committee  on Cancer  [AJCC])  in patients  who are naïve  to 
previous treatment with a selective BRAF inhibitor.  
4. Written  documentation  of BRAF  V600E  mutation,  or any other  BRAF  V600  mutation.  
5. Evidence  of measurable  disease  as determined  by RECIST  v1.1.  
6. World  Health  Organization  (WHO) Performance  Status  ≤ 2. 
7. Negative  serum  pregnancy  test within  72 hours  prior  to the first study  dose in all women 
of childbearing potential.  
8. Able  to understand  and voluntarily  sign the informed  consent  form,  and ability  to comply 
with the study visit schedule and other protocol requirements. Written informed consent 
must be obtained prior to any screening procedures.  
9. For Phase  II: Availability  of a fresh  tumor  biopsy  at Screening/Baseline,  unless  sufficient 
fresh tumor tissue was collected during local molecular pre -screening which can be 
submitted to the Sponsor -designated laboratory at Screening. If a tumor biopsy was 
collected  after the last anti-neoplastic  treatment  within  2 months  prior  to study  enrollment, 
the archival tissue of this tumor biopsy will be acceptable for enrollment instead of the 
fresh tumor biopsy (for further details please see also Section 7.2.4 ). 
5.3 Exclusion  criteria  
Patients  eligible  for this study  must  not meet  any of the following  criteria:  
1. Progressive  disease  following  prior  treatment  with RAF -inhibitors  in combination  with 
MEK -inhibitors.  
2. Symptomatic  or untreated  leptomeningeal  disease.  
3. Symptomatic brain metastases. Patients previously treated or untreated for brain 
metastases  that are asymptomatic  in the absence  of corticosteroid  therapy  are allowed  to 
Array BioPharma 
Amend ed Protoco l Version 10 Confid ential Page 77 
Protoco l No. CMEK162X2 110 / C422 1005 
PFIZER  CONFIDENTIAL   
 enroll. Brain metastases must be stable with verification by imaging (e.g. brain MRI 
completed at screening demonstrating no current evidence of progressive brain 
metastases).  Patients  are not permitted  to receive  enzyme  inducing  anti-epileptic  drugs. 
For the triple combination:  patients presenting any brain metastases detected by 
CT/MRI of the brain at screening are excluded.  
4. Known acute or chronic pancreatitis.  
5. History or current evidence of retinal disease (e.g. central serous retinopathy (CSR), 
retinal vein occlusion (RVO)) or ophthalmopathy as assessed by ophthalmologic 
examination  at baseline  that would  be considered  a risk factor  for CSR/RVO  (e.g.,  optic 
disc cupping, visual field defects, IOP > 21 mmHg).  
6. Clinically  significant  cardiac  disease  and/or  recent  cardiac  events  including  any of the 
following:  
• CHF requiring treatment (NYH grade ≥ 2), LVEF < 45% as determined by MUGA 
scan or ECHO (for addition of LEE011 in the triple combination please note: patients 
with LVEF  less than institutional  lower  limit  of normal  are also excluded  from  study), 
or uncontrolled hypertension (please refer to WHO -ISH guidelines)  
• History  or presence  of clinically  significant  ventricular  arrhythmias  or atrial 
fibrillation  
• Clinically  significant resting  bradycardia within  12 months  prior to  starting study  drug 
• Unstable  angina  pectoris  or symptomatic  pericarditis  within  12 months  prior  to 
starting study drug.  
• Acute  Myocardial  Infarction  (AMI)  within  12 months  prior  to starting  study  drug.  
• QTcF  > 480 msec  for dual combination.  For addition  of LEE011  in the triple 
combination, mean triplicate QTcF > 450 ms at screening or indeterminate 
(i.e., unreadable or not interpretable) at screening.  
• For addition  of LEE011  in the triple  combination,  any of the following  within 
12 months prior to starting study drug: history or presence of ventricular  
tachyarrhythmia,  complete  left bundle  branch  block,  or right  bundle  branch  block  and 
left anterior hemi block (bifascicular block).  
• For addition  of LEE011  in the triple  combination,  congenital  long QT syndrome  or 
family history of unexpected sudden cardiac death.  
• For addition of LEE011 in the triple combination, any  heart disease that requires the 
use of a cardiac  pacemaker  or implantable  cardioverter  defibrillator  ≤ 3 months  prior 
to starting study drug or any other clinically significant heart disease  
(e.g. documented  congestive heart  failure,  documented cardiomyopathy).  
7. Patients  with any of the following  laboratory  values  at Screening/baseline:  
• Absolute  neutrophil count (ANC) <1,500/mm3 [1.5 x 109/L] 
• Platelets  < 100,000/mm3 [100 x 109/L] 
• Hemoglobin < 9.0 g/dL 
• Serum  creatinine  >1.5 x ULN  or calculated  or directly  measured  CrCl  < 50% LLN 
(lower limit of normal)  
• Serum total bilirubin >1.5 x ULN  
Array BioPharma 
Amend ed Protoco l Version 10 Confid ential Page 78 
Protoco l No. CMEK162X2 110 / C422 1005 
PFIZER  CONFIDENTIAL   
 • AST/SGOT  and/or  ALT/SGPT  > 2.5 x ULN,  or > 5 x ULN  if liver metastases  are 
present  
• For addition of LEE011 in the triple combination, serum magnesium, potassium, 
sodium,  inorganic  phosphate  and calcium  (corrected  for serum  albumin)  < LLN  or not 
correctable with supplement to within normal limits prior to study  treatment start, and 
PT/INR >1.5 x ULN or aPTT >1.5 x ULN  
8. Impairment  of gastrointestinal  (GI) function  or GI disease  that may significantly  alter the 
absorption of oral LGX818, MEK162 or LEE011 (e.g., ulcerative diseases, uncontrolled 
nausea, vomiting, diarrhea, malabsorption syndrome, small bowel resection).  
9. Previous or concurrent malignancy.  Exceptions:  adequately  treated  basal  cell or squamous 
cell skin cancer;  in situ carcinoma  of the cervix,  treated  curatively  and without  evidence  of 
recurrence for at least 3 years prior to study entry; or other solid tumor treated curatively, 
and without evidence of recurrence for at least 3 years prior to study entry.  
10. Pregnant  or nursing  (lactating)  women,  where  pregnancy  is defined  as the state of a female 
after conception and until the termination of gestation, confirmed by a positive hCG 
laboratory test (> 5 mIU/mL).  
Women of child -bearing potential, defined as all women physiologically capable of 
becoming  pregnant,  are not allowed  to participate  in this study  UNLESS  they are using 
highly effective methods of contraception throughout the study and for 3 months after 
study drug discontinuation. Highly effective contraception methods include:  
• Total  abstinence  or 
• Male or female sterilization  
• Combination of any  two of the following (a+b or a+c or b+c) 
a. Use of oral, injected,  or implanted  hormonal  methods  of contraception  
b. Placement  of an intrauterine  device  (IUD)  or intrauterine  system  (IUS)  
c. Barrier methods of contraception: condom or occlusive cap (diaphragm or 
cervical/vault  caps)  with spermicidal  foam/gel/film/cream/vaginal  suppository  
Post-menopausal women are allowed to participate in this study. Women are considered 
post-menopausal and not of child bearing potential if they  have had 12 months of natural 
(spontaneous) amenorrhea with an appropriate clinical profile (e.g. age appropriate, 
history of vasomotor symptoms) or six months of spontaneous amenorrhea with serum 
Follicle -Stimulating Hormone (FSH) levels > 40 mIU/mL or have had surgical bilateral 
oophorectomy (with or without hysterectomy) or tubal ligation at least six weeks prior to 
screening. In the case of oophorectomy alone, only when the reproductive status of the 
woman  has been  confirmed  by follow -up hormone  level  assessment  is she considered  not 
of child bearing potential.  
Sexually  active  males  must  use a condom  during  intercourse  while  taking  the drug and for 
5 T1/2 after stopping treatment and should not father a child in this period. A condom is 
required to be used also by  vasectomized men in order to prevent delivery  of the drug via 
seminal fluid.  
11. History  of thromboembolic  or cerebrovascular  events  within  the last 6 months,  including 
transient ischemic attack, cerebrovascular accident, deep vein thrombosis, or pulmonary 
embolism.  
Array BioPharma 
Amend ed Protoco l Version 10 Confid ential Page 79 
Protoco l No. CMEK162X2 110 / C422 1005 
PFIZER  CONFIDENTIAL   
 12. Patients who have received radiation therapy (that includes > 30% of the bone marrow 
reserve), chemotherapy, biological therapy (e.g., antibodies) within ≤ 4 weeks (6 weeks 
for nitrosourea, mitomycin -C), or who have been treated with continuous or intermittent 
small molecule therapeutics or investigational agents within 5 -half-lives  of the agent (or ≤ 
4 weeks  when  half-life is unknown)  prior  to starting  study  drug or who have  not recovered 
from the side effects of such therapy (except alopecia).  
13. Patients  who have  undergone  any major  surgery  within  the last 2 weeks  prior  to starting 
study drug or who would not have fully recovered from previous surgery.  
14. Known Human Immunodeficiency  Virus (HIV) infection.  
15. Other  severe,  acute,  or chronic  medical  or psychiatric  condition  or laboratory  abnormality 
that may increase  the risk associated  with study  participation  or study  drug administration 
or that may interfere with the interpretation of study results and, in the judgment of the 
investigator, would make the patient inappropriate for the study.  
16. For addition  of LEE011  in the triple  combination,  patients  who are currently  receiving 
treatment with agents that are known to cause QTc prolongation or induce torsades de 
pointes in humans and cannot be discontinued 7 days prior to Cycle 1 Day 1.  
17. For addition of LEE011 in the triple combination, patients who are currently receiving 
treatment  with drugs  or herbal  medications  that are strong  inducers  of CYP3A4  enzyme  or 
substrates of CYP3A4 with a narrow therapeutic index (NTI) and cannot be discontinued  
7 days prior to Cycle 1 Day 1. See Appendix 4 , Table 14 -9, and Table 14 -10 for a partial 
list of CYP3A4 substrates or inducers.  
18. Patients  who are currently  receiving  strong  systemic  inhibitors  of CYP3A4  (refer  to Table 
14-10 in Appendix 4 for a partial list of CYP3A4 inhibitors).  
 
6 Treatment  
[Any language regarding the triple combination of LGX818/MEK162/LEE011 in this 
Section is not applicable to the USA and Singapore]  
6.1 Investigational  treatment,  other  study  treatment,  supportive 
treatment  
6.1.1  Dosing regimen  
The investigator  or responsible  site personnel  should  instruct  the patient  to take the study  drugs 
as per protocol  (promote  compliance).  All dosages  planned  and dispensed  to the patient  and all 
dose changes and all missed doses during the study must be recorded on the Dosage 
Administration Record eCRF. Drug accountability must be performed on a regular basis. 
Patients  will be instructed  to return  unused  study  drugs  to the site at the end of each cycle.  The 
site personnel will ensure that the appropriate dose of each study drug is administered at each 
visit and will provide the patient with the correct amount of drugs for subsequent dosing.  
On days when blood collection is scheduled at the clinic, patients will take the study drugs 
(either in the dual or triple combination) in the clinic under the supervision of the investigator 
or designee. On all other days patients will take the study drugs at home.  
Array BioPharma 
Amend ed Protoco l Version 10 Confid ential Page 80 
Protoco l No. CMEK162X2 110 / C422 1005 
PFIZER  CONFIDENTIAL   
 Patients  should  be instructed  to swallow  the capsules  and tablets  whole  and not to chew,  crush 
or open them.  
If vomiting  occurs  during  the course  of treatment,  no re-dosing  of the patient  is allowed  before 
the next scheduled dose. The occurrence and frequency of any vomiting and/or diarrhea (or 
increase stool frequency) during treatment must be noted in the adverse events section of the 
eCRF.  In addition,  on the days of full pharmacokinetic  sampling,  the exact  time of any episodes 
of vomiting and diarrhea (or increase stool frequency) within the first 4 hours post -dosing on 
that day must be noted in a separate section of the eCRF.  
Any doses  that are missed  should  be skipped  and should  not be replaced  or made  up during  the 
evening dosing or on a subsequent day, whichever applies.  
Patients must avoid consumption of grapefruit, grapefruit hybrids, pummelos, starfruit, or 
Seville  (sour)  oranges  during  the entire  study  and preferably  7 days before  the first dose of study 
medications, due to potential CYP3A4 interaction with the study  medications. Orange juice is 
allowed.  
6.1.1.1  Administration  of dual combination  (LGX818  and MEK162)  
LGX818  capsules  will be co-administered  orally  initially  once  daily  with MEK162  tablets  twice 
daily.  The study  drugs  will be administered  as a flat-fixed  dose,  and not by body  weight  or body 
surface area.  
• Patients  must  be instructed  to take the study  drug combination  of one or more  tablets  of 
MEK162 and one or more capsules of LGX818 together with a large glass of water 
(~250 ml) daily in the morning at approximately the same time every day. On all dose 
administration days patients can take MEK162 and LGX818 with or without food.  
• The second daily dose of MEK162 should be taken together with a glass of water 
irrespective of food. In case the dosing regimen of LGX818 is changed to BID (see 
Section  4.1), the evening  dose of MEK162  should  be taken  together  with 2nd (i.e. evening) 
daily dose of LGX818.  
• The prescribed  BID doses  for MEK162  (and LGX818  in case the dosing  schedule  would 
be changed to BID) should be taken 12 ± 2 hours apart.  
• In case the dosing regimen of LGX818 is changed to an once -a-day every -other -day 
(QOD)  dosing  schedule  (see Section  4.1), the patients  must  be instructed  to take the first 
dose of the study drug combination on Day 1 of Cycle 1 and afterwards on alternating 
days (D3, D5, D7 etc.). On the non -dosing days of LGX818 (i.e. D2, D4, D6 etc), 
MEK162  should  be taken  at approximately  the same  time every  morning,  with a glass  of 
water irrespective of food. There should be at least one day and not more than 2 days 
without LGX818 dosing between cycles.  
6.1.1.2  Administration  of triple  combination  (LGX818  and MEK162  and 
LEE011)  
LGX818  and LEE011  capsules  will be co-administered  orally  once  daily  with MEK162  tablets 
twice daily. The study  drugs will be administered as a flat -fixed dose, and not by  body weight 
or body surface area.  
Array BioPharma 
Amend ed Protoco l Version 10 Confid ential Page 81 
Protoco l No. CMEK162X2 110 / C422 1005 
PFIZER  CONFIDENTIAL   
 • Patients must be instructed to take the study drug combination of one or more tablets of 
MEK162 and one or more capsules of LGX818 and LEE011 together with a large glass of 
water  (~250  ml) daily  in the morning  at approximately  the same  time every  day. On all dose 
administration days patients can take MEK162 and LGX818 and LEE011 with or without 
food.  
• The second  daily  dose of MEK162  should  be taken  together  with a glass  of water 
irrespective of food.  
• The prescribed  BID doses  for MEK162  should  be taken 12  ± 2 hours  apart.  
• LEE011  will be taken  for 21 consecutive  days followed  by a 7-day planned  break  (3 weeks 
on, 1 week off schedule). LGX818 and MEK162 are taken on a continuous schedule.  
6.1.2  Supportive treatment/precautions  
Because  the LGX818  and MEK162  or LGX818  and MEK162  and LEE011  combination  could 
trigger  photosensitizing  reactions,  it is recommended  that patients  should  be instructed  to avoid 
exposure  of skin and eye to direct  sunlight  as much  as possible  and to apply  sun protection  (e.g. 
sunscreen, sunglasses and protective clothing), for the duration of the trial and for at least 1 
week after discontinuation of trial treatment. Any symptoms of photosensitivity must be 
reported on the Adverse Event eCRFs and institutional standard -of-care treatment should be 
initiated promptly.  
For skin toxicity or nausea/vomiting prophylactic treatment may be initiated in all patients at 
the dose level where these toxicities have been observed and in all further patients if at least 1 
patient has experienced skin toxicity or nausea/ vomiting ≥ CTCAE Grade 3 or if at least 2 
patients experienced skin toxicity or nausea/ vomiting ≥ CTCAE Grade 2. However anti - 
emetics may be applied for treatment if the patient has experienced nausea/vomiting CTCAE 
Grade ≥ 1, at the discretion of the physician.  
For rash-like events,  institutional  standard -of-care treatment  should  be initiated  promptly  upon 
occurrence of such events. Treatment of rash may include, but is not limited to, topical or oral 
antibiotics, topical or oral anti -inflammatories, topical or oral corticosteroids and oral anti - 
histamines. The use of emollients and sunscreens has not been evaluated with LGX818/ 
MEK162  or LGX818  /MEK162  /LEE011  but may be used prophylactically  or as treatment  for 
rash (see also Appendix 3 , Section 14.3.1 for guidelines for the treatment of study drug 
combination induced skin toxicity).  
Because hand foot skin reaction (HFSR) has been reported in some patients during LGX818 
single agent treatment, it is recommended that patients are educated prior to starting study 
treatment which activities to avoid like activities that cause friction on hands and feet, and on 
supportive measures for prevention and/or management of HFSR. As guidance for 
recommendations on supportive measures for prevention and/or management, the publication 
with recommendations of an international panel of experts of ( van Moos R et al 2008 ) can be 
used (see also Section  14.3.2 ). A visit at a podiatrist  may also be recommended  at the discretion 
of the investigator.  Any symptoms  of HFSR  must  be reported  on the Adverse  Event  eCRFs  and 
should be treated further according to institutional standard -of-care.  
Array BioPharma 
Amend ed Protoco l Version 10 Confid ential Page 82 
Protoco l No. CMEK162X2 110 / C422 1005 
PFIZER  CONFIDENTIAL   
 Optimal therapy for vomiting or diarrhea will be based on institutional standard -of-care with 
consideration  of the medications  to be used with caution  listed  in this protocol  (see Section  6.4.2 
and Appendix 4 ). 
Patients  with edema  may be treated  with diuretic  medications  if indicated.  
For stomatitis/mucositis -like events,  institutional  standard -of-care treatment  should  be initiated 
promptly upon occurrence of such events.  
6.1.3  Ancillary  treatments  
Not applicable.  
6.1.4  Guidelines  for continuation  of treatment  
Not applicable.  
6.1.5  Treatment duration  
Patients may continue treatment with LGX818 and MEK162 or LGX818 and MEK162 and 
LEE011  combination  until disease  progression,  unacceptable  toxicity  occurs  that precludes  any 
further treatment and/or treatment is discontinued at the discretion of the investigator or by 
patient  refusal  (withdrawal  of consent).  Continued  treatment  beyond  progression  of disease  will 
be allowed only under special circumstances. For example when according to the assessment 
of the investigator, a patient with progression of disease may benefit from continuation of 
LGX818 and MEK162 or LGX818 and MEK162 and LEE011 treatment, treatment beyond 
progression can be considered. Therefore, if it is judged by the investigator in agreement with 
the Sponsor to be in the best interest of the patient, that patient may  remain on study  treatment 
as long as the patient continues to benefit from the study drug treatment per investigator 
assessment. Special circumstances can be defined by, for example, cystic lesions, mixed 
responses,  and new brain  metastasis  which  is treatable  with stereotactic  radiotherapy  or surgery, 
but not requiring whole brain radiotherapy.  
Dosing  beyond  progression is  not allowed in  the following cases:  
• Patients  with rapid  progression  of disease  at critical  anatomical  sites (e.g. cord 
compression) requiring urgent alternative medical intervention.  
• Patients  who have  clinically  relevant  worsening  of laboratory  values.  
• Patients  who have  a clinically  significant  decline  in performance  status  at time of 
progression.  
• Patients  in the triple  combination  of LGX818  and MEK162  and LEE011  that appear  with 
new brain metastases.  
6.2 Dose  escalation  guidelines  
6.2.1  Definition of treatment cycle  
A complete  treatment  cycle  is defined  as 28 days of daily  continuous  treatment  of LGX818  and 
MEK162 and of 21 consecutive days of LEE011  treatment  followed  by a 7-day planned break 
in combination  with daily  continuous  treatment  of LGX818  and MEK162.  The first dose of 
Array BioPharma 
Amend ed Protoco l Version 10 Confid ential Page 83 
Protoco l No. CMEK162X2 110 / C422 1005 
PFIZER  CONFIDENTIAL   
 LGX818  plus MEK162  or LGX818  plus MEK162  plus LEE011  defines  Day 1 of Cycle  1. All 
treatment cycles have duration of 28 days. There will be no delays between cycles, i.e. study 
day 29 represents Cycle 2 Day 1.  
6.2.2  Starting dose rationale 
LGX818  and MEK162  dual combination  
The starting dose  for the study  drug combination  is 50mg  QD for  LGX818  and 45mg  BID for 
MEK162, and is based on available data from the ongoing first in human studies 
([CLGX818X2101] ) (Novartis) and (ARRAY -162-111) (Array Biopharma) respectively. The 
MTD  of single  agent  MEK162  was established  at 60mg/d  twice  daily.  The MTD  of LGX818  is 
still under  investigation,  and current  data indicate  that 50mg  of LGX818  is a well-tolerated  dose 
(the most  severe  toxicity  observed  at doses  ≤ 100 mg micro -emulsion  formulation  LGX818  thus 
far was a CTCAE grade 3 HFSR toxicity  at 100mg/day (see also Section 1.2.1.2 ). Taking into 
consideration  all information  currently  available  about  the dose-DLT  relationships  of LGX818 
and MEK162 as single agents and the uncertainty about the toxicity of the combination, the 
prior  distribution  of DLT  rates  derived  from  the BLRM  presented  in Appendix  5 indicates  that 
the proposed starting dose combination meets the escalation with overdose control (EWOC) 
criteria. Before the first patient first visit, the prior distribution for LGX818 will be updated 
with the most  recent  data from  the LGX818X2101  trial and the model  will be re-run in order  to 
confirm the proposed starting dose for LGX818 is still eligible, i.e. fulfills the EWOC criteria.  
LGX818 and MEK162 and LEE011 triple combination  
The starting dose for the triple study drug combination is 450mg QD for LGX818 and 45mg 
BID for MEK162  (both  continuous  schedule)  and 100mg  QD for LEE011  (3 weeks  on, 1 week 
off schedule), and is based on available RP2D dual -combination data from this ongoing study 
and on the first in human  study  (CLEE011X2101)  (Novartis),  respectively.  The MTD  of single 
agent  LEE011  was established  at 900mg/d  once  daily  on a three  week  on, one week  off schedule. 
The MTD of single agent LGX818 was established at 450mg/d once daily, and the MTD of 
single agent MEK162 was established at 60mg/d twice daily. The RP2Ds for the LGX818 and 
MEK162  dual combination  were  determined  at 450mg  LGX818  QD + 45mg  MEK162  BID and 
at 600mg LGX818 QD + 45mg MEK162 BID.  
Quantitative  DDI assessment  using  Simcyp  simulation  predicts  29% and 14% increase  in AUC 
and Cmax of LGX818, respectively, as well as 47% and 30% decrease in AUC and Cmax of 
LEE011,  respectively  when  450 mg QD LGX818  and 200 mg QD LEE011  are co-administered. 
In clinic, LGX818 has been tested at up to 700 mg QD dose and the observed adverse events 
are reversible  and manageable.  While  the potential  DDI between  the two molecules  may result 
in LGX818  concentrations  higher  than the currently  established  RP2D,  it is not expected  to pose 
a significant  risk. In addition,  no significant  DDI risk is expected  between  45 mg BID MEK162 
and 100 mg QD LEE011. Therefore, the starting dose of 450mg QD for LGX818 and 45mg 
BID for MEK162  (both  continuous  schedule)  and 100mg  QD (3 weeks  on, 1 week  off schedule) 
for LEE011 is considered acceptable.  
Escalating  doses  of LEE011  will be used in combination  with the 450mg  LGX818  QD + 45mg 
MEK162  BID (i.e. RP2D  of LGX818  and MEK162  dual combination).  The starting  dose of 
Array BioPharma 
Amend ed Protoco l Version 10 Confid ential Page 84 
Protoco l No. CMEK162X2 110 / C422 1005 
PFIZER  CONFIDENTIAL   
 LEE011  is proposed  at 100mg  (1/9 of single  agent  MTD).  Depending  on the PK and toxicities 
observed and in accordance with the recommendations from the BLRM, escalating doses of 
LEE011  might  also be evaluated  in combination  with the 600mg  LGX818  QD + 45mg  MEK162 
BID (i.e. 2nd RP2D of LGX818 and MEK162 dual combination).  
Taking into consideration all information currently available about the dose -DLT relationships 
of LGX818 and MEK162 and LEE011 as single agents, as well as LGX818/MEK162 dual 
combination and the uncertainty about the toxicity of the triple combination, the prior 
distribution of DLT rates derived from the BLRM presented in Appendix 6 indicates that the 
proposed  starting  dose combination meets  the escalation  with overdose  control  (EWOC) criteria.  
Before  the first patient  is dosed  with the triple  combination,  the Bayesian  model  will be updated 
with the most recent data from the ongoing LEE011 single agent trial and CMEK162X2110 
dual (LGX818 and MEK162) combination study, to confirm that the proposed starting dose 
combination is still appropriate (i.e. fulfills the EWOC criteria). If the proposed starting doses 
do not meet  the criteria,  a lower  dose combination  that satisfies  the EWOC  criteria  will be used.  
6.2.3  Provisional dose levels  
Provisional  dose levels  for the dual and triple  combination  are listed  in Table  6-1 and Table  6-2, 
respectively. With the exception of starting dose level 1, actual dose levels will be determined 
following a discussion with participating investigators during dose escalation teleconferences. 
Dose escalation will continue until MTD(s)/RP2D(s) is/are reached.  
 
Table  6-1 Provisional  dose  levels  dual combination   
Dose level  LGX818 mg QD MEK162 mg BID 
-1 30 45 
-1a 50 30 
1 (starting dose)  50 45 
2 100 45 
3 100 60 
3a* 150 45 
4 150 60 
5 200 45 
5a* 200 60 
* “#” dose  levels  and “#a”  dose  levels  may be  explored  in parallel.  
Table  6-2 Provisional  dose  levels  triple  combination  
 
Dose level  LGX818 mg QD MEK162 mg BID LEE011 mg QD 
-1 300 30 50 
0 450 45 100 
1 450 45 200 
2 450 45 300 
3 450 45 400 
4 450 45 800 
5 450 45 900 
Array BioPharma 
Amend ed Protoco l Version 10 Confid ential Page 85 
Protoco l No. CMEK162X2 110 / C422 1005 
PFIZER  CONFIDENTIAL   
  
 
Dose level  LGX818 mg QD MEK162 mg BID LEE011 mg QD 
NB. If LGX818  is escalated  from 450 mg to 600 mg, the dose  of MEK162  and LEE011  with remain  fixed  during 
that escalation step. Dose levels of 600mg LGX818 in combination with MEK162 and LEE011 might be 
explored in parallel with a dose level of 450mg LGX818 in combination with MEK162 and LEE011.  
 
At all decision  time points,  the adaptive  Bayesian  logistic  model  permits  alterations  in the dose 
increments based on the observed DLTs. Only one of the 2 or 3 combination partners can be 
escalated (e.g., for provisional dose level 3 dual combination only  MEK162 is escalated from 
45 mg to 60 mg, and for provisional dose level 3a only LGX818 is escalated from 100 mg to 
150 mg when compared to dose level 2) and the maximum inter -cohort dose escalation is 
limited to 100%, (i.e. up to 100% and 0% increase for LGX818 and MEK162 respectively or 
0% and up to 100%  increase  for LGX818  and MEK162  respectively  for dual combination.  i.e. 
up to 33% and 0% and 0% increase  for LGX818  and MEK162  and LEE011  respectively  or 0% 
and 0% and up to 100%  increase  for LGX818  and MEK162  and LEE011  respectively  for triple 
combination.)  Note,  however,  that dose levels  may be explored  in parallel,  as illustrated  in Table 
6-1 and Table  6-2 above. If  a decision  is made  to explore  two dose levels  at the same  time,  the 
next dose escalation  decision  will be made  after patients  in all dose cohorts  have  finished  cycle 
1. 
Based on the BLRM rules, it will be possible for intermediate dose levels or doses higher than 
the highest provisional dose given or doses lower than the lowest provisional dose given in 
Table 6 -1 and Table 6 -2 to be explored. Recommendation to study these dose levels will take 
into account the Bayesian model inference, as well as the consideration of the totality of the 
available study data (safety, PK and PD) (see Section 6.2.4.2 ). 
Process  to establish  the MTD/RP2D  with new MEK162  tablet  variants  if needed 
based on results of CMEK162X2108/ CMEK162A2101 relative bioavailability 
studies  
If based  on the results  of the two relative  bioavailability  studies,  the MTD/RP2D  of the LGX818 
and MEK162  combination  will need  to be established  (in case dose escalation  is ongoing  at that 
time) or re -established (in case MTD/RP2D was already determined with original MEK162 
tablet  at that time)  with one or both of the two new MEK162  tablet  variants,  a new cohort  of 3 
to 6 patients will be enrolled using either the MEK162 smaller tablet or new MEK162 tablet 
variant in combination with LGX818.  
The patients in this cohort will be treated at the highest dose (or MTD/RP2D as applicable) of 
the LGX818 and MEK162 drug combination, that has been evaluated previously in at least 3 
patients and for which safety  data was reviewed and was found to satisfy  the overdose control 
criteria of the Bayesian model, and will be followed for at least one cycle. The dose of the 
MEK162 smaller tablet and/or new MEK162 tablet variant will be adjusted to the dose of the 
original MEK162 tablet as established in the healthy volunteer relative bioavailability studies 
([CMEK162X2108] and [CMEK162A2101] respectively). The dose of the original MEK162 
tablet will be multiplied by the established factors (as obtained by the CMEK162X2108 or 
CMEK162A2101 studies) to achieve a comparable exposure with the MEK162 smaller tablet 
and/or new MEK162 tablet variant. The dose will be rounded to the lowest dose considering 
the MEK162 tablet available strength.  
Array BioPharma 
Amend ed Protoco l Version 10 Confid ential Page 86 
Protoco l No. CMEK162X2 110 / C422 1005 
PFIZER  CONFIDENTIAL   
 If at the following dose escalation teleconference meaningful differences in terms of safety, 
tolerability  and/or  PK are observed  between  the MEK162  smaller  and original  tablet  and/or  the 
new MEK162  tablet  variant  and the original  MEK162  tablet  both in combination  with LGX818, 
then dose adjustments  (escalation  or de-escalation)  may be made  to new cohorts  in accordance 
with the recommendations  of the BLRM  until a dose level  fulfilling  the overdose  control  criteria 
and/or  achieving  appropriate  PK is reached.  Dose  escalation  will continue  until the MTD/RP2D 
is determined (according to procedures outlined in Section 6.2.4 ). 
Based upon the above outlined evaluation, the patients ongoing on treatment with the original 
MEK162  tablet  may transition  to the MEK162  smaller  tablet  or new MEK162 tablet  variant  at 
the equivalent dose of MEK162, while continuing the same dose level with LGX818.  
6.2.4  Criteria  for dose  escalation  and determination  of MTD  
6.2.4.1  Definition  and estimation  of MTD  
The primary objective of the study is to estimate the maximum tolerated dose(s) (MTD(s)) 
and/or  RP2D(s)  for the (LGX818  and MEK162)  dual and (LGX818  and MEK162  and LEE011) 
triple  combination.  The MTD  is defined  as the highest  drug dosage  not causing  in the first cycle 
of treatment medically unacceptable, dose -limiting toxicity (DLT) in more than 35% of the 
treated  patients.  AEs and laboratory  abnormalities  considered  to be DLTs  are defined  in Table 
6-2. Since several combinations may correspond to this definition more than one MTD/RP2D 
may be identified with different doses of the combination partners.  
The applied adaptive Bayesian methodology provides an estimate of the dual - and triple -drug 
combinations not exceeding the dual - and triple -combination MTDs. Typically the MTD is a 
tested  dose with maximum  probability  of targeted toxicity  (DLT  rate between  16%-35%). The 
use of EWOC principle limits the risk that a potential next dose will exceed the MTD  
(Section 10.4.2 ). 
6.2.4.2  Dose  escalation  
For the purposes  of dose escalation  decisions,  each cohort  will consist  of 3 to 6 newly  enrolled 
patients who will be treated at the specified combination dose levels. The first cohort will be 
treated with the starting combination doses as shown in Table 6 -1 and Table 6 -2. 
Patients  must  complete  a minimum  of 1 cycle  of treatment  with the minimum  safety  evaluation 
and drug exposure or to have had a DLT within the first cycle of treatment to be considered 
evaluable for dose escalation decisions. Dose escalation decisions will occur when the cohort 
of patients  has met these  criteria.  If a patient  drops -out for reason  other  than adverse  event  prior 
to becoming evaluable for the DDS, a new patient may be recruited to the cohort until the 
required number is reached (see Section 7.1.4.2 ). If only 2 of the 3 patients in a cohort are 
evaluable and neither patient has experienced a treatment -related toxicity >  CTCAE grade 1, 
dose escalation decisions may be considered.  
Dose escalation decisions will be made by Investigators and Sponsor study personnel (see 
Section  6.2.4.2.1 ). Decisions  will be based  on a synthesis  of all relevant  data available  from  all 
dose levels evaluated in the ongoing study including safety information, DLTs, all CTCAE 
Grade  ≥ 2 toxicity  data during  Cycle  1, PK, and PD data from  evaluable  patients.  The 
Array BioPharma 
Amend ed Protoco l Version 10 Confid ential Page 87 
Protoco l No. CMEK162X2 110 / C422 1005 
PFIZER  CONFIDENTIAL   
 recommended  combination  doses  for the next cohort  of patients  will be guided  by the Bayesian 
logistic  regression  model  (BLRM)  with EWOC  principle  (Section  2.2). The adaptive  Bayesian 
methodology  provides an estimate of all combination dose levels of LGX818 and MEK162 or 
LGX818 and MEK162 and LEE011 that do not exceed the corresponding MTD and 
incorporates all DLT information at all dose levels for this estimation. In general, the next 
combination dose will have the highest chance that the DLT rate will fall in the target interval 
(16-35%) and will always satisfy the EWOC principle. In all cases, the combination dose for 
the next cohort will not exceed a 100% increase from the previous combination dose. Smaller 
increases in doses may  be recommended by the Investigators and Sponsor upon consideration 
of all of the available clinical data. Clinically relevant toxicities to be taken into consideration 
for dose recommendations will be those assessed as unrelated to disease, disease progression, 
inter-current illness, or concomitant medications. In addition, for certain toxicities such as 
hematologic  toxicity  (e.g.,  lymphopenia),  and toxicities  not associated  with end-organ  damage 
(e.g., nausea, pain, headache, fever, alopecia), toxicity ≥ CTCAE G2 must be observed in at 
least two thirds of the patients in the previous cohort, to impact the dose escalation. The 
likelihood of appearance of keratoacanthomas (KA) and/or squamous cell carcinomas (SCC) 
with specific  and potent  BRAF  inhibitors  is high (~ 35%)  and occurs  early  during  the course  of 
treatment  (median  time of 4-12 weeks),  as reported  for the selective  BRAF  inhibitors  PLX4032 
and GSK2118436  (Flaherty  2010 ; Kefford  2010 ; Robert  2011 ). No metastatic  evolution  of RAF 
inhibitor -induced SCCs has been reported so far. Patients will be carefully monitored for the 
occurrence  of this anticipated  on-target  side-effect.  However,  in the context  of this study,  these 
benign KA and SCC tumors will not be considered for the dose escalation decisions, unless 
judged to be clinically significant by the investigators. If needed to better define the dose - 
toxicity  relationship,  additional  patients  may be enrolled  to the current  combination  dose level, 
to a preceding combination dose level, or to an intermediate combination dose level before 
proceeding with further dose escalation.  
If the first 2 patients in a cohort experience a DLT, further enrollment to that cohort will stop 
and the BLRM  will be updated  with this new information.  Re-evaluation  of the available  safety, 
PK, and PD data will occur. By  incorporating information gained at the preceding dose levels, 
additional  patients  may be enrolled  at this combination  dose level  or a lower  combination  dose 
level as agreed by Investigators and Sponsor personnel and if the BLRM predicts that the risk 
that this dose exceeds the MTD remains below 25% (EWOC).  
Dose escalation will continue until identification of the MTD or a suitable lower dose for the 
Phase II part of the study. This will occur when the following conditions are met:  
1. at least 6 patients  have  been  treated  at this combination  dose 
2. this combination  dose satisfies  one of the following  conditions:  
• the posterior  probability  of targeted  toxicity  at this combination  dose exceeds  50% 
and is the highest among potential doses, or  
• a minimum of 18 patients have already been treated on the trial for the dual 
combination  or a minimum  of 12 patients  have  been  treated  on the trial for the triple 
combination.  
3. it is the dose recommended  for the next cohort  of patients  (either  per the model  or by 
review of all clinical data by the Sponsor and Investigators in a dose escalation 
teleconference, see Section 6.2.4.2.1 ) 
Array BioPharma 
Amend ed Protoco l Version 10 Confid ential Page 88 
Protoco l No. CMEK162X2 110 / C422 1005 
PFIZER  CONFIDENTIAL   
 To better understand the safety,  tolerability,  efficacy, PD  and PK of LGX818 and MEK162 or 
LGX818 and MEK162 and LEE011 study drug combinations, additional cohorts of 1 to 6 
patients  may be enrolled  at preceding  dose levels,  or to intermediate  dose levels  before  or while 
proceeding with further dose escalation.  
If a decision is made to escalate to a higher dose level but one or more additional patient(s) 
treated at the preceding dose level experiences a DLT during the first cycle of treatment, then 
the BRLM  will be updated  with this new information  before  any additional  patients  are enrolled 
at that higher  dose level.  Subjects  ongoing  will continue  treatment  at their assigned  dose levels.  
6.2.4.2.1  Implementation  of dose  escalation  decisions  
To implement  dose escalation  decisions,  the available  toxicity  information  (including  AEs and 
laboratory abnormalities that are not DLTs), the recommendations from the BLRM, and the 
available PK and PD information will all be evaluated by the Investigators and Sponsor study 
personnel (including the study physician and statistician) during a dose decision meeting by 
teleconference. Drug administration at the next higher dose level may not proceed until the 
Investigator receives written confirmation from the Sponsor indicating that the results of the 
previous dose level were evaluated and that it is permissible to proceed to a higher dose level.  
6.2.4.2.2  Intra-patient  dose  escalation  
Intra -patient  dose escalation  is not permitted  at any time within  the first four Cycles  of treatment. 
After the fourth cycle is completed, individual patients may be considered for treatment at a 
dose of LGX818 or MEK162 or LEE011 higher than the dose to which they were initially 
assigned.  Only  one of the investigational  study  drugs  will be escalated  at any one time.  In order 
for a patient to be treated at a higher dose of either LGX818 or MEK162 or LEE011, he or she 
must have tolerated the lower dose pair for at least four cycles of therapy, e.g., he or she must 
not have  experienced  at the lower  dose pair originally  assigned  a toxicity  of CTCAE  Grade  ≥ 2 
for which relationship to study drug cannot be ruled out. Moreover, the new, higher dose pair 
with which the patient is to be treated must be a dose pair that has completed evaluation in a 
dose escalation meeting and that has not exceeded the MTD estimated by the Bayesian model 
given all available data.  
There is no limit to the number of times a patient may  have his or her dose of either LGX818 
or MEK162 or LEE011 increased. In  any further escalation, again only one study  drug will be 
increased at any time. Any further increases after the initial intra -patient dose escalation are 
subject  to the same  rules  as for the initial  intra-patient  escalation.  Consultation  with the Sponsor 
must  occur  prior  to any intra-patient  dose escalation  occurring.  These  changes  must  be recorded 
on the Dosage Administration Record eCRF.  
6.2.5  Definitions  of dose  limiting  toxicities  (DLTs)  
A dose -limiting toxicity (DLT) is defined as an adverse event or abnormal laboratory value 
assessed as  at least possibly  related  to the study  medication,  as clinically  relevant,  as unrelated 
to disease,  disease  progression,  inter-current  illness,  or concomitant  medications,  which  occurs  
≤ 28 days following the first dose of LGX818 and MEK162 or LGX818 and MEK162 and 
LEE011  (Cycle  1) and meets  any of the criteria  listed  in Table  6-3, as applicable.  Toxicity  will 
Array BioPharma 
Amend ed Protoco l Version 10 Confid ential Page 89 
Protoco l No. CMEK162X2 110 / C422 1005 
PFIZER  CONFIDENTIAL   
 be assessed  using  the NCI Common  Toxicity  Criteria  for Adverse  Events  (CTCAE),  version  
4.03 unless  otherwise  specified.  
Whenever a patient experiences toxicity  that fulfills the criteria for a DLT, treatment with the 
study  drug combination  will be interrupted  and the toxicity  will be followed  up as described  in 
Section 6.2.6 . For the purposes of dose escalation and determination of the MTD, DLTs that 
occur  during  the first cycle  will be necessarily  considered  and included  in the BLRM,  including 
those in which the event has started in cycle 1 and the confirmation of the DLT occurs in 
subsequent cycles.  
The investigator must notify the Sponsor immediately of any DLT observed. The investigator 
must notify the Sponsor immediately of any unexpected CTCAE grade ≥ 3 adverse events or 
laboratory abnormalities.  
The rules for re -initiation and dose modification of LGX818 and MEK162 or LGX818 and 
MEK162 and LEE011 treatment are outlined in Section 6.3 . 
Table 6 -3 Criteria  for defining  dose -limiting  toxicities  for dual and triple 
combination  
 
Toxicity  Any of the  following  criteria:  
Blood  and lymphatic  system 
disordersa Febrile  neutropenia (ANC   1.0 x 109/L with fever  38.5°C)b 
Investigations (Blood)  Absolute  Neutrophil  count  CTCAE  Grade  3 for > 7 consecutive  days 
Absolute Neutrophil count CTCAE Grade 4 
Platelet  count  CTCAE  Grade  3 for > 7 consecutive  days  and/or  with signs  of 
bleeding  
Platelet count CTCAE Grade 4 
Skin and subcutaneous 
tissue disorders:  
Rash,  HFSR  and/or 
photosensitivity  Rash,  HFSR  or photosensitivity  CTCAE  Grade  3 > 7 consecutive  days  despite 
skin toxicity treatment (as per local practice)  
Rash, HFSR or photosensitivity CTCAE Grade 4 
Eye disorders -Retinopathy  / 
Uveitis  CSR/  CSR -like events  CTCAE  Grade  3 for > 21 consecutive  days  confirmed 
by ophthalmologic examination  
CSR/  CSR -like events  CTCAE  Grade  4 confirmed  by ophthalmologic 
examination  
Eye disorders - RVO Any grade  
Eye disorders - any other  CTCAE Grade 3 for > 14 consecutive days 
CTCAE  Grade  4 
Gastrointestinal  disorders  Diarrhea  CTCAE  Grade  ≥ 3 ≥ 48 hrs, despite  the use of optimal  anti-diarrhea 
therapy  
Nausea  or vomiting  CTCAE  Grade  ≥ 3 ≥ 48 hrs, despite  the use of optimal 
anti-emetic therapy  
Pancreatitis CTCAE Grade ≥ 3 
Investigations (Renal)  Serum creatinine CTCAE Grade ≥ 3 
Investigations (Hepatic)c Blood  bilirubin  (total  bilirubin)  CTCAE  Grade  ≥ 3 
AST or ALT CTCAE  Grade  ≥3 in conjunction  with blood  (total)  bilirubin  CTCAE 
Grade ≥ 2 of any duration  
AST or ALT CTCAE  Grade  3 for > 7 consecutive days 
AST or ALT CTCAE Grade 4. 
Serum alkaline phosphatase CTCAE Grade 4 > 7 consecutive days 
Array BioPharma 
Amend ed Protoco l Version 10 Confid ential Page 90 
Protoco l No. CMEK162X2 110 / C422 1005 
PFIZER  CONFIDENTIAL   
  
Toxicity  Any of the  following  criteria:  
Investigations (Metabolic)  Serum  lipase  and/or  serum  amylase  (asymptomatic)  CTCAE  Grade  3 > 7 
consecutive days  
Serum lipase and/or serum amylase (asymptomatic) CTCAE Grade 4 
Cardiac disorders  ≥ CTCAE  Grade  3 
Investigations (Cardiac)  Serum  CK/CPK  CTCAE  Grade  3 for > 14 consecutive  days  if clinically 
significant (symptomatic)  
Serum CK/CPK CTCAE Grade 4 for > 14 consecutive days 
QTcF  interval  ≥ 501 ms on at least  two separate  ECGs  (only  for triple 
combination)  
Vascular disorders  Persistent  hypertension  CTCAE  Grade  ≥ 3 requiring  more  than one drug or 
more intensive therapy than previously  
General disorders and 
administration  site conditions  Fatigue CTCAE Grade 3 for > 7 consecutive days 
Edema  CTCAE  grade  3 for > 14 consecutive  days 
Other Adverse Eventsd Any other  CTCAE  Grade  ≥ 3 toxicity  (except  SCCe) 
a. ≥ CTCAE  grade  3 anemia  will not be considered  a DLT unless  judged  to be a hemolytic  process  secondary 
to study drug. ≥ CTCAE grade 3 lymphopenia will not be considered a DLT unless clinically significant.  
b. Not according  to CTCAEv4.03  
c. For any CTCAE grade ≥  3 hepatic toxicity that does not resolve within 7 days to CTCAE Grade ≤  1 (or 
CTCAE  Grade  ≤ 2 if liver infiltration  with tumor  present),  an abdominal  CT scan  has to be performed  to 
assess if it is related to disease progression.  
d. An AE must  be clinically  significant  to be defined  as a DLT:  study  drug-related  fever,  alkaline  phosphatase 
elevation, electrolyte abnormalities (including K, NA, Cl, HCO 3, Mg, Ca, PO 4) that are CTCAE grade 3 
abnormalities will not be considered a DLT unless clinically significant.  
e. SCC  has been  reported  to be an on-target  side-effect  that is manageable  and will not be considered  a DLT. 
6.2.6  Follow -up for toxicities  
Patients  whose  treatment  is interrupted  or permanently  discontinued  due to an adverse  event  or 
clinically significant laboratory value, must be followed up at least once a week (or more 
frequently if required by institutional practices, or if clinically indicated) for 4 weeks, and 
subsequently at approximately 4 -week intervals, until resolution or stabilization of the event, 
whichever comes first.  
Appropriate clinical experts such as an ophthalmologist, dermatologist or cardiologist should 
be consulted as deemed necessary. Further guidelines and recommendations for the 
management of specific study drug combination induced toxicities are provided in Table 6 -4. 
6.2.6.1  Follow -up evaluations  for appearance  of keratoacanthoma  (KA)  and/or 
squamous cell carcinoma (SCC)  
The skin of patients treated with the LGX818 and MEK162 or LGX818 and MEK162 and 
LEE011 combination will be examined regularly to monitor for the possible development of 
KA and/or  SCC,  as these  have  been  reported  to occur  under  selective  BRAF  inhibitor  treatment 
(see Section 1.2.4.2 ). Dermatologic evaluations for this adverse effect will be performed at 
Screening/baseline, every 2 months thereafter and at End of Treatment.  
In case of occurrence of KA and/or SCC, patients will undergo complete surgical excision of 
the skin lesion following institutional standards.  
Array BioPharma 
Amend ed Protoco l Version 10 Confid ential Page 91 
Protoco l No. CMEK162X2 110 / C422 1005 
PFIZER  CONFIDENTIAL   
 6.2.6.2  Follow -up evaluations  for appearance  of central  serous  retinopathy 
(CSR)  
The patients treated with the LGX818 and MEK162 or LGX818 and MEK162 and LEE011 
combination  will be examined  regularly  to monitor  for the possible  development  of CSR,  as the 
appearance of CSR has been associated with MEK162 treatment (see Section 1.3 ). 
Ophthalmologic examinations to check for this adverse effect will be performed at 
Screening/baseline,  at Day 15 of Cycle  1, at Days  1 and 15 of Cycle  2, on Day 1 of every  month 
thereafter and at End of Treatment.  
Patients who have been on LGX818/MEK162 dual -combination and or 
LGX818/MEK162/LEE011 triple -combination treatment for ≥ 24 months (Cycle 25 Day 1 
onward) without a retinal AE should be evaluated for visual acuity at each scheduled patient 
visit and at the End of Treatment visit. A full ophthalmic examination is required if clinically 
indicated and at the End of Treatment visit.  
Patients developing a CTCAE grade 1 or 2 CSR can be maintained on the study drug 
combination as is detailed in Table 6 -4. For these patients it is recommended to follow up the 
CSR with an ophthalmological exam every two weeks (CTCAE Grade 1) or weekly (CTCAE 
Grade 2) for 8 weeks, and subsequently at approximately a 4 -weeks interval. The study drug 
dosages of patients developing CSR > CTCAE grade 2 should be interrupted/modified 
according to Table 6 -4 and should be followed as described above ( Section 6.2.6 ). 
6.3 Dose  modifications  
6.3.1  Dose modification and dose delay  
Patients will be monitored for adverse events at each visit with the NCI CTCAE version 4.03 
used for all grading.  If a patient  develops  toxicity,  the dose may be adjusted  as outlined  in Table 
6-4, which  includes  criteria  for interruption  and re-initiation  of LGX818  and/or  MEK162  and/or 
LEE011,  as applicable.  All dose modifications  should  be based  on the worst  preceding  toxicity 
(CTCAE version 4.03).  
All dosing interruptions and changes must be recorded on the Dosage Administration Record 
eCRF.  
If a patient  experiences  a DLT,  study  treatment  should  be interrupted  and the toxicity  should  be 
followed as described in Section 6.2.6 . 
6.3.2  Treatment  interruption  and treatment  discontinuation  
Each  patient  is only allowed  a maximum  of two dose reductions  after which  the patient  will be 
discontinued  from  the study  treatment.  In addition,  a patient  should  discontinue  treatment  with 
the LGX818 and MEK162 dual or LGX818 and MEK162 and LEE011 triple combination if, 
after treatment is resumed at a lower dose, the toxicity recurs with the same or worse severity. 
However, the patient may continue to receive study treatment at the next lower dose level, if 
appropriate, at the discretion of the Investigator and in discussion with the Sponsor. If, after 
interruption of treatment and resolution, treatment is resumed at the same dose following the 
criteria  in Table  6-4 and the same  toxicity  recurs  with the same  or worse  severity,  next treatment 
re-initiation  must  resume  at the next lower  dose level  irrespective  of duration.  For each patient,  
Array BioPharma 
Amend ed Protoco l Version 10 Confid ential Page 92 
Protoco l No. CMEK162X2 110 / C422 1005 
PFIZER  CONFIDENTIAL   
 once a dose level reduction has occurred, the dose level may not be re -escalated during 
subsequent  treatment  cycles,  except  in cases  where  LGX818  dosing  was reduced  to 450mg  QD 
during MEK162 dosing interruption.  
Dose  reduction  for LGX818  and/or  MEK162  and/or  LEE011,  as applicable  means  treatment  at 
the next lower dose level of the respective study drug. For LGX818 and LEE011, this is the 
next lower previously  tested dose level. For MEK162 this is the next lower dose level (please 
see Table 6 -1 and Table 6 -2). If a patient requires a dose interruption of >21 days from the 
intended day  of the next scheduled dose, then the patient must be discontinued from the study 
treatment  unless  the patient  has experienced  objective  evidence  of clinical  benefit.  If the patient 
has experienced objective evidence of clinical benefit, and in the opinion of the investigator it 
is in the best interest of the patient to remain on study, then following discussion with the 
sponsor, the patient may continue on study treatment.  
Array  BioPharma  
Amended  Protocol  Version  10 Confidential  Page  93 
Protocol  No. CMEK162X2110  / C4221005  
PFIZER  CONFIDENTIAL   
  
 
Table  6-4 Criteria  for interruption  and re-initiation  of LGX818/MEK162/LEE011  triple -combination  treatment  
 
Recommended  Dose  Modifications  for (dual)  LGX818  and MEK162  or (triple)  LGX818  and MEK162  and LEE011 
combination study treatment  
Worst  Toxicity  CTCAE  v4.03  Grade  
(unless otherwise specified )a  
Recommended  Dose  Modifications  any time during  a cycle  of therapy  
No toxicity  Maintain dose level 
Blood  and lymphatic  system  disorders  
Anemia (Hemoglobin)  
Grade 1 (≥10.0 – LLN g/dL) 
Grade  2 (≥8.0  – <10.0  g/dL)  
 
Grade 3 (<8.0 g/dL)  
 
 
Grade  4 (life threatening  consequences; 
urgent intervention indicated)   
No dose adjustment required  
 
 
Interrupt  LEE011  dosing  until recovery  to ≤ Grade  2; then re-initiate  LEE011  at same  dose  level.  Maintain  dose 
level of LGX818 and MEK162.  
 
Discontinue patient from study drug treatment.  
Febrile neutropenia  
ANC < 1.0 x 109/L, fever ≥ 38.5°Cb 
Grade  3 (ANC  <1.0 x 109/L with a single  
temperature  of >38.3  ºC [101 ºF] or a sustained 
temperature of ≥38 ºC [100.4 ºF] for more than 
one hour)  
 
Grade  4 (life-threatening  consequences;  urgent 
intervention indicated)   
 
Interrupt dosing until resolved, then   1 dose level 
 
Interrupt  dosing  until improvement  to ANC  ≥ 1.0 x 109/L with no fever. 
Restart at the next lower dose level.  
If febrile neutropenia recurs, discontinue patient from study drug treatment.  
 
 
Discontinue patient from study drug treatment.  
Array  BioPharma  
Amended  Protocol  Version  10 Confidential  Page  94 
Protocol  No. CMEK162X2110  / C4221005  
PFIZER  CONFIDENTIAL   
  
Recommended  Dose  Modifications  for (dual)  LGX818  and MEK162  or (triple)  LGX818  and MEK162  and LEE011 
combination study treatment  
Worst  Toxicity  CTCAE  v4.03  Grade  
(unless  otherwise specified )a Recommended  Dose  Modifications  any time during  a cycle  of therapy  
Investigations  (Blood)  
Neutropenia (neutrophil count [ANC] decreased)  
 
Grade 1 (ANC < LLN – 1.5 x 109/L) Maintain  dose  level of LGX818  and MEK162  (and LEE011  if applicable) 
or Grade 2 (ANC < 1.5 – 1.0 x 109/L) 
 
Grade  3 (ANC < 1.0  – 0.5 x 109/L) Interrupt  dosing  of LGX818  and MEK162  (and LEE011  if applicable) until  resolved to  ≤ Grade  2, then:  
- If resolved in ≤ 7  days, maintain dose level  of LGX818 and MEK162  (and LEE011 if applicable)  
-  If resolved  in > 7 days,  then  1 dose  level*  of LGX818  (and LEE011  if applicable)  and maintain  dose  level 
of MEK162  
 
Grade 4 (ANC < 0.5 x 109/L) Interrupt  dosing  of LGX818  and MEK162  (and LEE011  if applicable)  until resolved  to ≤ Grade  2, then  1 dose 
level* of LGX818 and MEK162 (and LEE011 if applicable)  
Thrombocytopenia (platelet count decreased)  
 
Grade  1 (PLT < LLN – 75 x 109/L) Maintain dose level of LGX818 and MEK162 (and LEE011 if applicable)  
 
Grade  2 (PLT < 75 – 50 x 109/L) Interrupt  dosing  of LGX818  and MEK162  (and LEE011  in patients  treated  in triple -combination  arm) until 
resolved  to ≤ Grade  1 
 
Grade  3 (PLT < 50 – 25 x 109/L) Interrupt  dosing  of LGX818  and MEK162  (and LEE011  in patients  treated  in triple -combination  arm) until 
resolved  to ≤ Grade  1, then:  
-  If resolved  in ≤ 7 days,  then maintain  dose  level of LGX818  and MEK162  (and LEE011  in patients  treated 
in triple -combination arm).  
-  If resolved  in > 7 days  and/or  with signs  of bleeding,  then  1 dose  level*  of LGX818  and MEK162 
(and LEE011 in patients treated in triple -combination arm)  
 
Grade  4 (PLT  < 25 x 109/L) Discontinue patient from study drug treatment.  
Array  BioPharma  
Amended  Protocol  Version  10 Confidential  Page  95 
Protocol  No. CMEK162X2110  / C4221005  
PFIZER  CONFIDENTIAL   
  
Recommended  Dose  Modifications  for (dual)  LGX818  and MEK162  or (triple)  LGX818  and MEK162  and LEE011 
combination study treatment  
Worst  Toxicity  CTCAE  v4.03  Grade  
(unless  otherwise specified )a Recommended  Dose  Modifications  any time during  a cycle  of therapy  
Gastrointestinal  disorders  
Diarrhea  
 
Grade 1  Maintain  dose  level of LGX818  and MEK162  (and LEE011  in patients  treated  in triple -combination  arm), 
but initiate anti -diarrhea treatment.  
 
Grade 2  Interrupt  dosing  of LGX818  and MEK162  (and LEE011  in patients  treated  in triple -combination  arm) until 
resolved to Grade ≤ 1 with proper therapy and monitoring and then maintain dose level of LGX818 and 
MEK162 (and LEE011 in patients treated in triple -combination arm)  
- For 2nd occurrence  of diarrhea  Grade  2 within  15 days,  interrupt  dosing  of LGX818  and MEK162  (and LEE011 
if applicable) until resolved to Grade ≤ 1, then reduce MEK162 and LGX818 (and LEE011 in patients treated 
in triple -combination arm) by 1 dose level* and maintain dose level of LGX818 (and LEE011 in patients  
treated  
in triple -combination  arm) 
 
Grade 3  Interrupt dosing of LGX818 and MEK162 (and LEE011 in patients treated in triple -combination arm) until 
resolved  to Grade  ≤ 1, then reduce  dose  of LGX818  and MEK162  (and LEE011  in patients  treated  in triple - 
combination arm) by 1 dose level*.  
 
Grade 4 Discontinue patient from study drug treatment.  
 
Note : Anti-diarrhea  medication  is recommended  at the first sign of abdominal  cramping,  loose  stools  or overt  diarrhea.  
Nausea / Vomiting  
 
Grade 1 Maintain  dose level of LGX818 and MEK162 (and LEE011 in patients treated in triple -combination arm) 
 
Grade 2  Interrupt dosing until recovery to G1 with proper therapy and monitoring – Re-initiate MEK162 and LGX818 
(and LEE011  in patients  treated  in triple -combination  arm) at same  dose  level – If recurs  at G2, interrupt  dosing 
of MEK162 and LGX818 (and LEE011 in patients treated in triple -combination arm) until recovery to G1  
and then re -initiate at next lower dose level 
Array  BioPharma  
Amended  Protocol  Version  10 Confidential  Page  96 
Protocol  No. CMEK162X2110  / C4221005  
PFIZER  CONFIDENTIAL   
  
Recommended  Dose  Modifications  for (dual)  LGX818  and MEK162  or (triple)  LGX818  and MEK162  and LEE011 
combination study treatment  
Worst  Toxicity  CTCAE  v4.03  Grade  
(unless  otherwise specified )a Recommended  Dose  Modifications  any time during  a cycle  of therapy  
Nausea / Vomiting (continued)  
 
Grade 3  Interrupt dosing of LGX818 and MEK162 (and LEE011 in patients treated in triple -combination arm), until 
resolved  to Grade  ≤ 1, then  1 dose  level*  of LGX818  and MEK162  (and LEE011  in patients  treated  in triple - 
combination arm)  
 
Grade 4 Discontinue patient from study drug treatment.  
 
Note : Interrupt  dosing  for ≥ grade  3 vomiting  or nausea  only if the vomiting  or nausea  cannot  be controlled  with optimal  antiemetics  (as per local practice).  
Pancreatitis  
 
Grade 1 Maintain  dose level of LGX818 and MEK162 (and LEE011 in patients treated in triple -combination arm) 
 
Grade 2  Interrupt dosing until recovery to G1 with proper therapy and monitoring – Re-initiate MEK162 and LGX818 
(and LEE011  in patients  treated  in triple -combination  arm) at same  dose  level – If recurs  at G2, interrupt  dosing 
of MEK162 and LGX818 (and LEE011 in patients treated in triple -combination arm) until recovery to G1 and 
then re -initiate at next lower dose level  
 
Grade ≥3 Discontinue patient from study drug treatment.  
Investigations  (Renal)  
Serum creatinine  
 
Grade  1 (> ULN  – 1.5 x ULN)  Maintain  dose level of LGX818 and MEK162 (and LEE011 in patients treated in triple -combination arm) 
 
Grade  2 (> 1.5  – 3.0 x ULN)  Interrupt  dosing  until recovery  to G1 with proper  therapy  and monitoring  – Re-initiate  MEK162  and LGX818  
(and LEE011  in patients  treated  in triple -combination  arm) at same  dose  level – If recurs  at G2, interrupt  dosing 
of MEK162 and LGX818 (and LEE011 in patients treated in triple -combination arm) until recovery to G1 and 
then re -initiate at next lower dose level  
 
Grade ≥3 Discontinue patient from study treatment.  
Array  BioPharma  
Amended  Protocol  Version  10 Confidential  Page  97 
Protocol  No. CMEK162X2110  / C4221005  
PFIZER  CONFIDENTIAL   
  
Recommended  Dose  Modifications  for (dual)  LGX818  and MEK162  or (triple)  LGX818  and MEK162  and LEE011 
combination study treatment  
Worst  Toxicity  CTCAE  v4.03  Grade  
(unless  otherwise specified )a Recommended  Dose  Modifications  any time during  a cycle  of therapy  
Investigations  (Hepatic**)  
Bilirubin:  total bilirubin  without  ALT/AST  increase  above  baseline  value  (confirmed  48-72hr later)c 
 
 
Grade  1 (> ULN  – 1.5 x ULN)  Maintain  dose level of LGX818 and MEK162 (and LEE011 in patients treated in triple -combination arm) with 
LFTs monitored  bi-weekly.  
 
Grade  2 (> 1.5  – 3.0 x ULN)  Interrupt  dosing  of LGX818  and MEK162  (and LEE011  in patients  treated  in triple -combination  arm) until 
resolved  to Grade ≤  1, then:  
- If resolved  in ≤ 21 days,  then maintain  dose  level of LGX818  and MEK162  (and LEE011  in patients  treated 
in triple -combination arm)  
- If resolved  in > 21 days,  then  1 dose  level*  of LGX818  and MEK162  (and LEE011  in patients  treated 
in triple -combination arm)  
- If not resolved  within  28 days,  or if toxicity  recurs,  discontinue  patient  from all study  drug treatment.  
Repeat  liver enzyme  and bilirubin tests  twice weekly  for 2 weeks  after dose resumption.  
 
Grade 3 (> 3.0 x ULN)  Interrupt  dosing  of LGX818  and MEK162  (and LEE011  in patients  treated  in triple -combination  arm) until 
resolved to Grade ≤ 1, then  1 dose level  
- Repeat  liver enzyme and bilirubin  tests twice  weekly for  2 weeks after dose resumption  
- If not resolved  within  28 days,  or if toxicity  recurs,  discontinue  patient  from all study  drug treatment.  
 
Grade  4 (> 10.0 x ULN)  Discontinue patient from study treatment.  
 
Note : If Grade  3 or 4 hyperbilirubinemia  is due to the indirect  (non-conjugated)  component  only,  and hemolysis  as the etiology  has been  ruled  out as per institutional 
guidelines  (e.g.,  review  of peripheral  blood  smear  and haptoglobin  determination),  then  1 dose  level*  and continue  treatment  at the discretion  of the investigator.  
AST or ALT  without bilirubin elevation  > 2 ULN  (confirmed 48 -72hr later)c 
 
 
Grade 1  Maintain  dose  level of LGX818  and MEK162  (and LEE011  in patients  treated  in triple -combination  arm) 
and monitor LFTs biweekly.  
Array  BioPharma  
Amended  Protocol  Version  10 Confidential  Page  98 
Protocol  No. CMEK162X2110  / C4221005  
PFIZER  CONFIDENTIAL   
  
Recommended  Dose  Modifications  for (dual)  LGX818  and MEK162  or (triple)  LGX818  and MEK162  and LEE011 
combination study treatment  
Worst  Toxicity  CTCAE  v4.03  Grade  
(unless  otherwise specified )a Recommended  Dose  Modifications  any time during  a cycle  of therapy  
AST or ALT without  bilirubin elevation >  2 ULN (confirmed  48-72hr later)c (continued)  
 
 
Grade 2  Interrupt  dosing  of LGX818  and MEK162  (and LEE011  in patients  treated  in triple -combination  arm) until 
resolved to Grade ≤ 1 (or Grade ≤ 2 in case of liver metastasis), then:  
- If resolved  in ≤ 21 days,  maintain  dose  level of LGX818  and MEK162  (and LEE011  for triple -combination 
arm).  
- If resolved  in > 21 days,  then  1 dose  level*  of LGX818  and MEK162  (and LEE011  for triple -combination 
arm).  
- If not resolved  within  28 days,  discontinue  patient  from all study  drug treatment.  
Repeat  liver enzyme and  bilirubin tests  twice weekly  for 2  weeks after  dose resumption.  
 
Grade  3 (> 3.0 x ULN)  Omit  dose  of LGX818  and MEK162  (and LEE011  in patients  treated  in triple -combination  arm) until resolved  
to ≤ baseline  grade,  then  1 dose  level of dose  level of LGX818  and MEK162  (and LEE011  in patients  treated 
in triple -combination arm). If not recovered to ≤ baseline grade within 28 days, discontinue patient from all  
study drug treatment.  
Repeat  liver enzyme  and bilirubin  tests  twice  weekly  for 2 weeks  after  dose  resumption.  If toxicity 
recurs, discontinue patient from all study drug treatment.  
 
Grade  4 (> 10.0 x ULN)  Discontinue  patient  from study  drug treatment.  
AST or ALT and Bilirubind 
 
 
For patients with normal ALT and AST and total  Discontinue  patient  from study  drug treatment. 
bilirubin at baseline:  AST or ALT > 3.0 x ULN  
combined  with total bilirubin  > 2 x ULN without 
evidence of cholestasise 
 
For patients with elevated AST or ALT or total  Discontinue  patient  from study  drug treatment. 
bilirubin at baseline: baseline: (AST or ALT  
> 2 x baseline  AND  > 3.0 x ULN)  OR (AST  or ALT 
8.0 x ULN) — whichever is lower — combined 
with (total bilirubin > 2 x baseline AND > 2.0 x 
ULN)  
Array  BioPharma  
Amended  Protocol  Version  10 Confidential  Page  99 
Protocol  No. CMEK162X2110  / C4221005  
PFIZER  CONFIDENTIAL   
  
Recommended  Dose  Modifications  for (dual)  LGX818  and MEK162  or (triple)  LGX818  and MEK162  and LEE011 
combination study treatment  
Worst  Toxicity  CTCAE  v4.03  Grade  
(unless  otherwise specified )a Recommended  Dose  Modifications  any time during  a cycle  of therapy  
Investigations  (Metabolic)  
Asymptomatic amylase and/or lipase elevation  
 
Grade  1 (> ULN  – 1.5 x ULN)  Maintain  dose level of LGX818 and MEK162 (and LEE011 in patients treated in triple -combination arm) 
and initiate  appropriate  medical  therapy  and monitoring.  
 
Grade  2 (> 1.5  – 2.0 x ULN)  Interrupt  dosing  until recovery  to G1 with proper  therapy  and monitoring – Re-initiate  MEK162  and LGX818  
(and LEE011  in patients  treated  in triple -combination  arm) at same  dose  level – If recurs  at G2, interrupt  dosing 
of MEK162 and LGX818 (and LEE011 in patients treated in triple -combination arm) until recovery to G1 and 
then re -initiation at next lower dose level.  
 
Grade  3 (> 2.0  – 5.0 x ULN)  Interrupt  dosing  of LGX818  and MEK162  (and LEE011  in patients  treated  in triple -combination  arm) until 
resolved  to Grade ≤  2, then:  
- If resolved  in ≤ 7 days,  maintain  dose  level of LGX818  and MEK162  (and LEE011  in patients  treated 
in triple -combination arm)  
- If resolved  in  7 days,   1 dose  level*  of LGX818  and MEK162  (and LEE011  in patients  treated 
in triple -combination arm).  
 
Grade  4 (> 5.0 x ULN)  Discontinue patient from study drug treatment.  
 
Note : A CT scan  or other  imaging  study  to assess  the pancreas,  liver,  and gallbladder  must  be performed  within  1 week  of the first occurrence  of any grade  ≥ 3 
of amylase  and/or  lipase.  In cases  of asymptomatic  elevations  of lipase  and/or  amylase  with imaging  study  which  does  not show  damage  to pancreas,  liver, 
and gallbladder, if the patient is asymptomatic Grade 2 elevations of lipase and/or amylase occur again at the reduced dose, patients will be discontinued  
permanently  from study treatment.  
Array  BioPharma  
Amended  Protocol  Version  10 Confidential  Page  100 
Protocol  No. CMEK162X2110  / C4221005  
PFIZER  CONFIDENTIAL   
  
Recommended  Dose  Modifications  for (dual)  LGX818  and MEK162  or (triple)  LGX818  and MEK162  and LEE011 
combination study treatment  
Worst  Toxicity  CTCAE  v4.03  Grade  
(unless  otherwise specified )a Recommended  Dose  Modifications  any time during  a cycle  of therapy  
Cardiac  disorders  
Cardiac genera l 
 
Grades 1 or 2 Maintain  dose level of LGX818 and MEK162 (and LEE011 in patients treated in triple -combination arm) 
 
Grade 3  Interrupt dosing of LGX818 and MEK162 (and LEE011 in patients treated in triple -combination arm) until 
resolved  to Grade  ≤ 1, then  1 dose  level*  of LGX818  and MEK162  (and LEE011  for triple -combination  arm) 
 
Grade 4 Discontinue patient from study drug treatment.  
Investigations  (cardiac)  
Creatine  phosphokinase  (CPK)  
 
Grade 1 (> ULN – 2.5 x ULN)  Maintain  dose  level of LGX818  and MEK162  (and LEE011  in patients  treated  in triple -combination  arm) 
or Grade 2 (> 2.5 – 5.0 x ULN)  
 
Grade  3 (> 5.0 – 10.0 x ULN)  If asymptomatic : Maintain  dose  level of LGX818  and MEK162  (and LEE011  in triple -combination  arm) 
If symptomatic : Interrupt  dosing  of MEK162  and maintain  dose  of LGX8181 (and LEE011  in patients  treated 
in triple -combination arm) until resolved to Grade ≤ 1, then:  
- If resolved  in ≤ 14 days,  then  1 dose  level*  of MEK  162 and maintain  dose  level of LGX8182 (and LEE011 
in patients treated in triple -combination arm)  
- If unresolved after > 14 days, then discontinue patient from study drug treatment.  
 
Grade  4 (> 10.0 x ULN)  Interrupt  dosing  of MEK162  and maintain  dose  of LGX8181 (and LEE011  in triple -combination  arm) until 
resolved to CTCAE Grade ≤ 1, then:  
- If resolved  in ≤ 14 days,  then  1 dose  level of MEK162  and maintain  dose  level of LGX8182 (and LEE011 
in patients treated in triple -combination arm)  
- If unresolved after >  14 days, then discontinue patient from study drug treatment.  
 
1 If the LGX818 dose  is > 450mg QD, then  the LGX818  dose must  be reduced to 450mg QD  during the MEK162 dosing interruption.  
2 If the LGX818  dose  was reduced  to 450mg  QD during  an MEK162  interruption,  it must  be re-escalated  to the previous  dose  once  MEK162  dosing  resumes.  
Array  BioPharma  
Amended  Protocol  Version  10 Confidential  Page  101 
Protocol  No. CMEK162X2110  / C4221005  
PFIZER  CONFIDENTIAL   
  
Recommended  Dose  Modifications  for (dual)  LGX818  and MEK162  or (triple)  LGX818  and MEK162  and LEE011 
combination study treatment  
Worst  Toxicity  CTCAE  v4.03  Grade  
(unless  otherwise specified )a Recommended  Dose  Modifications  any time during  a cycle  of therapy  
Left ventricle  (LV) systolic  dysfunction  (not according  to CTCAE)  
 
Asymptomatic decrease of > 10% in left ventricle  Interrupt  dosing  of MEK162  until LVEF  recovers  (defined  as ≥ LLN and decrease  ≤ 10% compared  to baseline). 
ejection fraction (LVEF) compared to baseline  - If the LVEF recovers ≤ 21 days, then  1 dose level of MEK162, maintain dose of LGX818 and LEE011  
and the ejection fraction is below the institution’s  in patients  treated  in triple -combination  arm, monitor  LVEF  2 weeks  after restarting  on MEK162, 
lower limit of normal and CTCAE Grade 2  every 4 weeks for 12 weeks and subsequently as per protocol  
- If the LVEF  recovers  > 21 days,  then discontinue  patient  from study  drug treatment  and closely  monitor  LVEF 
until resolution (or for 16 weeks).  
 
Grade ≥ 3 Discontinue patient from study drug treatment.  
Electrocardiogram QTcF interval prolonged  
 
Grade  1 (QTcF  450-480 ms)f Maintain  dose  level(s).  Perform  steps  1-4 as directed  in “For all grades.”  
 
Grade 2 (QTcF 481 -500 ms)f Interrupt  dosing  of MEK162  and LGX818  (and LEE011  in patients  treated  in triple -combination  arm).  Perform  
steps  1-4 as directed  in “For all grades.”  
Perform a repeat ECG within 1 hour of the first QTcF of ≥ 481 ms. Repeat ECG as clinically indicated until the 
QTcF  returns  to < 481 ms, restart  MEK162  and LGX818  at the same  dose  (if triple  combination,  restart  LEE011 
with dose reduced one level.  
If QTcF  ≥ 481 ms recurs,  MEK162  and LGX818  (and LEE011  in patients  treated  in triple -combination  arm) 
should be reduced by 1 dose level.  
Repeat  ECGs  7 days  and 14 days  after dose  resumption  (then  as clinically  indicated)  for any patients 
who had therapy interrupted due to QTcF ≥ 481 ms.  
Grade 3 (QTcF ≥ 501 ms on at least  Interrupt  dosing  of MEK162  and LGX818  (and LEE011  in triple -combination  arm).  Perform  steps  1-4 as 
two separate ECGs)f directed in “For all grades.”  
Transmit  ECG  immediately  and confirm  prolongation/abnormalities  with central  assessment.  Perform  a repeat  
ECG within one hour 
of the first QTcF of > 501 ms. 
If QTcF  remains  ≥ 501 ms, consult  with a cardiologist  (or qualified  specialist)  and repeat  cardiac  monitoring  as 
clinically indicated until the QTcF returns to < 481 ms.  
• If QTcF  returns  to < 481 ms, reduce  MEK162  and LGX818  (and LEE011  in triple -combination  arm) by 1 
dose level.  
Array  BioPharma  
Amended  Protocol  Version  10 Confidential  Page  102 
Protocol  No. CMEK162X2110  / C4221005  
PFIZER  CONFIDENTIAL   
  
Recommended  Dose  Modifications  for (dual)  LGX818  and MEK162  or (triple)  LGX818  and MEK162  and LEE011 
combination study treatment  
Worst  Toxicity  CTCAE  v4.03  Grade  
(unless  otherwise specified )a Recommended  Dose  Modifications  any time during  a cycle  of therapy  
• If QTcF  remains  ≥ 481 ms after performing  steps  1-4 as directed  in “For all grades,”  discontinue  all study 
treatments.  
Repeat  ECGs  7 days  and 14 days  after dose  resumption  (then  as clinically  indicated)  for any patients  who had 
therapy interrupted due to QTcF ≥ 501 ms  
If QTcF  of ≥ 501 ms recurs,  discontinue  patient  from study  drug treatment.  
Electrocardiogram QTcF interval prolonged (continued)  
 
Grade  4 g (QTcF  ≥ 501  or > 60 ms change  Discontinue  patient from study drug treatment,  then: 
from baseline and Torsades de pointes  - Obtain local cardiologist consultation.  
or polymorphic ventricular tachycardia,  - Perform a repeat ECG within one hour  of the first QTcF of ≥ 501 ms. 
or signs/symptoms of serious arrhythmia)  - If QTcF remains  ≥ 501 ms, repeat  ECG as  clinically  indicated, but  at least  once a  day until  the QTcF  
returns to < 501 ms. 
 
For all grades:  
• Check  the quality  of the ECG  and the QT value  and repeat  if needed.  
• Perform  analysis  of serum  electrolytes  (K+, Ca++,  Phos,  Mg++).  If outside  of the normal  range,  interrupt  LGX818  and MEK162  and LEE011  administration,  correct 
with supplements or appropriate therapy as soon as possible, and repeat electrolytes until documented as normal.  
• Review  concomitant  medication  usage  for the potential  to inhibit  CYP3A4  and/or  to prolong  the QT interval.  
• Check compliance with correct dose and administration of LGX818 and MEK162 and LEE011.  
Vascular  disorders  
Hypertension  
 
Grade 1 Maintain  dose  level of LGX818  and MEK162  (and LEE011  in patients  treated  in triple -combination arm) 
 
Grade 2  Interrupt  dosing  until recovery  to G1 with proper  therapy  and monitoring  – Re-initiate  study  drugs  at same  dose 
level.  
If recurs  at G2, interrupt  study  drugs  until recovery  to G1  and then  re-initiate  at next lower  dose  level.  
 
Grade 3 (requiring more than one drug or more  Interrupt  dosing  of LGX818  and MEK162  (and LEE011  in triple -combination  arm),  until resolved  to Grade  ≤ 1, 
intensive therapy than previously)  then  1 dose level* of LGX818 and MEK162 (and LEE011 in triple -combination arm)  
 
Grade 4 (life -threatening)  Discontinue patient from study drug treatment.  
Array  BioPharma  
Amended  Protocol  Version  10 Confidential  Page  103 
Protocol  No. CMEK162X2110  / C4221005  
PFIZER  CONFIDENTIAL   
  
Recommended  Dose  Modifications  for (dual)  LGX818  and MEK162  or (triple)  LGX818  and MEK162  and LEE011 
combination study treatment  
Worst  Toxicity  CTCAE  v4.03  Grade  
(unless  otherwise specified )a Recommended  Dose  Modifications  any time during  a cycle  of therapy  
Eye disorders  
Retinal events  
 
Grade 1  Maintain  dose  level of LGX818  and MEK162  (and LEE011  in patients  treated  in triple -combination  arm) 
and increase frequency of ophthalmic monitoring to at least every 14 days (see also Section 6.2.6.2 ). 
 
Grade 2  Maintain  dose  level of LGX818  and MEK162  (and LEE011  in patients  treated  in triple -combination  arm) 
and increase frequency of ophthalmic monitoring to at least weekly (see also Section 6.2.6.2 ). Refer  
the patient to a retinal specialist within one week for further evaluation.  
- If resolved  to Grade  ≤ 1 in ≤ 21 days,  then maintain  dose  level of MEK162  and LGX818  (and LEE011 
in patients treated in triple -combination arm)  
- If not resolved  to Grade  ≤ 1 in ≤ 21 days,  then  1 dose  level*  of MEK162  and LGX818  (and maintain  dose 
of LEE011 in patients treated in triple -combination arm).  
- At any time if symptoms  worsen,  or persist  with the same  severity  for more  than 7 days,  reduce  1 dose 
levelf of LGX818 and MEK162 (and LEE011 in patients treated in triple -combination arm).  
 
Grade 3  Interrupt  dosing  of LGX818  and MEK162,  (and LEE011  if applicable)  until recovery  to Grade  1. Re-initiate 
study drugs at next lower dose level.  If recurs at Grade 3, discontinue patient from study.  
- If resolved  to Grade  ≤ 1 in ≤ 21 days,  then  1 dose  level*  of MEK162  and LGX818  (and maintain  dose  level 
of LEE011 in patients treated in triple -combination arm)  
- If not resolved  to Grade  ≤ 1 in ≤ 21 days,  then discontinue  patient  from study  drug treatment  and refer 
the patient to an ophthalmologist for monitoring.  
 
Grade  4 (retinopathy)  Discontinue  patient from study drug treatment and refer the patient to an ophthalmologist for monitoring.g 
 
Note : Results  and images  of ophthalmic  examinations  must  be made  available  upon  request.  This includes  scans/images  of OCTs  
Retinal  vein occlusion  (RVO)h 
 
Any grade  Discontinue patient from study drug treatment and refer the patient to an ophthalmologist for monitoring.  
 
Note : Results and  images of  ophthalmic examinations  should be made  available upon request.  
Array  BioPharma  
Amended  Protocol  Version  10 Confidential  Page  104 
Protocol  No. CMEK162X2110  / C4221005  
PFIZER  CONFIDENTIAL   
  
Recommended  Dose  Modifications  for (dual)  LGX818  and MEK162  or (triple)  LGX818  and MEK162  and LEE011 
combination study treatment  
Worst  Toxicity  CTCAE  v4.03  Grade  
(unless  otherwise specified )a Recommended  Dose  Modifications  any time during  a cycle  of therapy  
Other eye events (i.e. retinal detachment)  
Grades 1 or 2  Maintain  dose  level of LGX818  and MEK162  (and LEE011  in patients  treated  in triple -combination  arm) 
and increase frequency of ophthalmic monitoring to at least every 14 days.  
At any time if symptoms  worsen,  or persist  with the same  severity  for more  than 7 days,  reduce  1 dose  level 
of LGX818 and MEK162.c 
Grade 3  Interrupt  dosing  of LGX818  and MEK162  (and maintain  dose  level of LEE011  in patients  treated  in triple - 
combination arm) and refer patient to ophthalmologist monitoring within one week.g 
- If resolved  to Grade  ≤ 1 in ≤ 21 days,  reduce  1 dose  levelh of LGX818  and MEK162  
- If not resolved  to Grade  ≤ 1 in > 21 days,  discontinue  patient  from study  drug treatment  and refer the patient 
to an ophthalmologist for monitoring.h 
 
Grade 4 Discontinue  patient from study drug treatment and refer the patient to an ophthalmologist for monitoring.g 
Skin  and subcutaneous  tissue  disorders  
Rash  / hand  foot skin reaction  (HFSR)  / photosensitivity  / Toxic  Epidermal  Necrolysis  (TEN)  
 
Grade 1  Maintain  dose  level of LGX818  and MEK162  (and LEE011  in patients  treated  in triple -combination  arm), 
but consider initiating appropriate skin toxicity therapy (See Appendix 3).  
 
Grade 2  Maintain  dose  level of LGX818  and MEK162  (and LEE011  in patients  treated  in triple -combination  arm), 
but initiate/intensify appropriate skin toxicity therapy.  
 
Grade 3 despite skin toxicity therapy  Interrupt  dosing  of LGX818  and MEK162  (and LEE011  in patients  treated  in triple -combination  arm),  
until resolved to Grade ≤  1 then:  
- If resolved in ≤ 7 days,   1 dose level* of LGX818 and MEK162 (and LEE011 in triple -combination arm) 
- If not resolved  after  7 days,  discontinue  patient  from study  drug treatment.  
 
Grade 4 despite skin toxicity therapy  Discontinue patient from study drug treatment.  
Array  BioPharma  
Amended  Protocol  Version  10 Confidential  Page  105 
Protocol  No. CMEK162X2110  / C4221005  
PFIZER  CONFIDENTIAL   
  
Recommended  Dose  Modifications  for (dual)  LGX818  and MEK162  or (triple)  LGX818  and MEK162  and LEE011 
combination study treatment  
Worst  Toxicity  CTCAE  v4.03  Grade  
(unless  otherwise specified )a Recommended  Dose  Modifications  any time during  a cycle  of therapy  
Respiratory,  thoracic  and mediastinal  disorders  
ILD/Pneumonitis  Maintain  dose  level of LGX818;  adjust  dose  of MEK162  (and LEE011  in patients  treated  in triple -combination 
arm) according to Grade below  
 
Grade 1  No dose  interruption  or adjustment  of MEK162  (or LEE011  in patients  treated  in triple -combination  arm) is 
required. Initiate appropriate medical therapy and monitor as clinically indicated  
 
Grade 2 Interrupt  dosing of MEK162 (and LEE011 in patients  treated in triple -combination arm) for ≤ 21 days.  
-If resolved  to Grade  ≤ 1 in ≤ 21 days,  reduce  1 dose  levelh of MEK162  (and LEE011  in patients  treated 
in triple -combination arm), performing an individualized benefit -risk assessment  
-If not resolved  to Grade  ≤ 1 in ≤ 21 days,  then discontinue  patient  from study  drug treatment. 
If Grade 2 recurs, discontinue patient from study drug treatment  
Grade 3/4 Discontinue patient from study drug treatment  
General  disorders  and administration  site conditions  
Fatigue  
 
Grades 1 or 2 Maintain  dose level of LGX818 and MEK162 (and LEE011 in patients treated in triple -combination arm) 
 
Grade 3  Interrupt  dosing  of LGX818  and MEK162  (and LEE011  in patients  treated  in triple -combination  arm) 
until resolved to Grade ≤ 1, then:  
- If resolved  in ≤ 7 days,  maintain  dose  level of LGX818  and MEK162  (and LEE011  in triple -combination  arm) 
- If not resolved  after  7 days,  then  1 dose  level*  of LGX818  and MEK162  (and LEE011  in patients  treated 
in triple -combination arm)  
Edema  
 
Grades 1 or 2 Maintain  dose level of LGX818 and MEK162 (and LEE011 in patients treated in triple -combination arm) 
Array  BioPharma  
Amended  Protocol  Version  10 Confidential  Page  106 
Protocol  No. CMEK162X2110  / C4221005  
PFIZER  CONFIDENTIAL   
  
Recommended  Dose  Modifications  for (dual)  LGX818  and MEK162  or (triple)  LGX818  and MEK162  and LEE011 
combination study treatment  
Worst  Toxicity  CTCAE  v4.03  Grade  
(unless  otherwise specified )a Recommended  Dose  Modifications  any time during  a cycle  of therapy  
Grade 3  Interrupt  dosing  of LGX818  and MEK162  (and LEE011  in patients  treated  in triple -combination  arm) 
until resolved to Grade ≤ 1, then:  
- If resolved  in ≤ 14 days,  then  1 dose  level*  of MEK162  and maintain  dose  of LGX818  (and LEE011 
in patients treated in triple -combination arm)  
- If not resolved after  14 days, then discontinue patient from study drug treatment.  
Other  adverse  events  
Grades 1 or 2 Maintain  dose level of LGX818 and MEK162 (and LEE011 in patients treated in triple -combination arm) 
 
Grade 3  Interrupt dosing of LGX818 and MEK162 (and LEE011 in patients treated in triple -combination arm) until 
resolved  to Grade  ≤ 1, then  1 dose  level*  of LGX818  and MEK162  (and LEE011  in triple -combination  arm) 
 
Grade 4 Discontinue  patient from  study drug treatment.  
a All dose modifications should be  based on the worst preceding toxicity.  
b Not CTCAE  grading  
c Dose  reduction  below  50 mg QD for LGX818,  and below  15 mg BID for MEK162  is not allowed.  
d All patients  with ALT or AST >5.0x  ULN and total bilirubin  > 1.5x ULN in the absence  of cholestasis  must  immediately  be withdrawn  from study  treatment  and every 
attempt should be made to carry out the liver event follow -up assessments as described below in Section 6.3.3 . 
If combined elevations of AST or ALT and total bilirubin do not meet the defined thresholds, please follow the instructions f or isolated elevation of total bilirubin and 
isolated elevation of AST/ALT, and take a conservative action based on the degree of the elevations (e.g. discontinue treatme nt at the situation when omit dose is 
needed  for one parameter  and discontinue  treatment  is required  for another  parameter).  After  all elevations  resolve  to the defined  thresholds  that allow  treatment  re- 
initiation, re -start the treatment either at the same dose or at one dose lower if meeting a criterion for dose reduction  
e “Cholestasis”  defined  as: ALP elevation  (>2.0  x ULN and R value  (ALT/ALP  in x ULN)  ,2.0) in patients  without  bone  metastasis,  or elevation  of ALP liver function  in 
patients with bone metastasis.  
f All values  refer to the average  of triplicate  measurements.  
g Ophthalmic  monitoring  mandated  for retinal  event,  posterior  uveitis,  RVO:  further  evaluation  with specialized  retinal  imaging  (e.g. ocular  coherence  tomography, 
angiography).  
h Except:  1) lymphopenia  unless  clinically  significant,  2) occurrence  of KA and/or  cutaneous  SCC,  3) alkaline  phosphatase,  4) AEs not considered  clinically  significant 
like alopecia study drug -related fever, electrolyte abnormalities (including K, NA, Cl, HCO 3, Mg, Ca, PO 4). 
*  1 dose  level refers  to: next lower  previously  tested  dose  level of LGX818  and LEE011  and the next lower  dose  level of MEK162  (please  see Table  6-1 and Table  6- 
2). 
Array  BioPharma  
Amended  Protocol  Version  10 Confidential  Page  107 
Protocol  No. CMEK162X2110  / C4221005  
PFIZER  CONFIDENTIAL   
  
Recommended  Dose  Modifications  for (dual)  LGX818  and MEK162  or (triple)  LGX818  and MEK162  and LEE011 
combination study treatment  
Worst  Toxicity  CTCAE  v4.03  Grade  
(unless  otherwise specified )a Recommended  Dose  Modifications  any time during  a cycle  of therapy  
** Confounding  factors  and/or  alternative  causes  for increased  transaminases  should  be excluded  before  dose  interruption/reduction.  They  include  but are not limited 
to: concomitant medications, herbal preparations or dietary supplements, infection, hepato -biliary disorder or obstruction, new or progressive liver metastasis, and 
alcohol intake.  
Array  BioPharma  
Amended  Protocol  Version  10 Confidential  Page  108 
Protocol  No. CMEK162X2110  / C4221005  
PFIZER  CONFIDENTIAL   
  
6.3.3  Additional  follow -up for hepatic  toxicities  in patients  receiving  LEE011  
Hepatic toxicity monitoring includes the following LFTs: albumin, ALT, AST, total bilirubin 
(fractionated if total bilirubin > 2 x ULN), alkaline phosphatase (fractionated if alkaline 
phosphatase  is grade  2 or higher)  and GGT.  For patients  with Gilbert  Syndrome:  total and direct 
bilirubin  must  be monitored,  intensified  monitoring  applies  to changes  in direct  bilirubin  only.  
Close observation is recommended in case of AST, ALT, and/or bilirubin increase requiring 
dose interruption, which involves:  
• Repeating  liver enzyme  and serum  bilirubin  tests two or three  times  weekly . Frequency  of 
re-testing can decrease to once a week or less if abnormalities stabilize or return to normal 
values.  
• Obtaining a more detailed history  of current symptoms.  
• Obtaining a more detailed history  of prior and/or concurrent diseases, including history  of 
any pre -existing liver conditions or risk factors.  
• Obtaining a  history  of concomitant drug  use (including non -prescription medications, herbal 
and dietary supplements), alcohol use, recreational drug use, and special diets.  
• Ruling  out acute  viral hepatitis  types  A, B, C, D, and E; hepatotropic  virus  infections  (CMV, 
EBV or HSV); autoimmune or alcoholic hepatitis; NASH; hypoxic/ischemic hepatopathy; 
and biliary tract disease.  
• Obtaining a history  of exposure to environmental chemical agents.  
• Obtaining additional tests to evaluate liver function, as appropriate (e.g., INR, direct 
bilirubin).  
• Considering gastroenterology  or hepatology  consultations.  
• Assessing  cardiovascular  dysfunction  or impaired  liver oxygenation,  including  hypotension 
or right heart failure as possible etiologies for liver dysfunction.  
• Considering  a liver biopsy,  as clinically  indicated  to assess  pathological  change  and degree 
of potential liver injury.  
6.4 Concomitant  medications  
6.4.1  Permitted concomitant therapy  
The patient must be told to notify the investigational site about any new medications he/she 
takes  after the start of the study  drug combination.  All medications  (other  than study  drugs)  and 
significant non -drug therapies (including herbal medicines, physical therapy and blood 
transfusions) administered during the study must be listed on the Concomitant 
medications/Significant non -drug therapies eCRF.  
Patients  taking  concomitant  medication  chronically  should  be maintained  on the same  dose and 
dose schedule throughout the study period, as medically feasible. The days of full PK blood 
sampling should be representative of the other study days with regard to the use of the 
chronically administered concomitant medications. However, if a concomitant medication is 
used intermittently  during the study, this medication should be avoided on the days of full PK 
sampling, if medically feasible.  
Array  BioPharma  
Amended  Protocol  Version  10 Confidential  Page  109 
Protocol  No. CMEK162X2110  / C4221005  
PFIZER  CONFIDENTIAL   
 The use of bisphosphonates regardless of indication is allowed for the LGX818 and MEK162 
dual combination (prophylactic treatment is not allowed for bisphosphonates with LEE011) 
provided patients have been on stable doses for at least 2 weeks prior to study entry. Stable 
doses should be maintained during the treatment period. Patients requiring initiation of 
bisphosphonates during the course of the study should be discontinued due to progressive 
disease unless disease progression can be completely ruled out and this is clearly documented 
in the patients’ source documentation.  
Chronic dosing of corticosteroids such as dexamethasone and prednisone is known to lead to 
induction  of CYP3A  enzymes,  thereby  potentially  increasing  the risk of reducing  drug exposure 
for CYP3A  substrates  to subtherapeutic  levels.  The following  forms  of corticosteroid  treatment 
are permitted:  
• Topical  applications  (e.g. rash),  inhaled  sprays  (e.g. obstructive  airway  diseases),  eye drops, 
or local injections (e.g., intra -articular);  
• A short duration (< 5 days) of systemic corticosteroids ≤ to the anti -inflammatory  potency 
of 4 mg dexamethasone (e.g., for chronic obstructive pulmonary disease, or as an 
antiemetic).  
Refer to the LGX818 Investigator’s Brochure, MEK162 Investigator’s Brochure and LEE011 
Investigator’s  Brochure  as applicable  for information  on possible  interactions  with other  drugs.  
Approved Covid -19 vaccines are permitted, including those under an EUA.  The timing of 
COVID -19 vaccine administration is at the investigator’s discretion. The administration of a 
COVID -19 vaccine  would  be recorded  as a concomitant  medication  and standard  AE collection 
and reporting processes would be followed.  
 
 
6.4.2  Permitted  concomitant  therapy  requiring  caution  and/or  action  for 
LGX818 and MEK162  
LGX818 is a reversible inhibitor of CYP1A2, CYP2B6, CYP2C8/9, CYP2D6, CYP3A4, and 
UGT1A1. It is also a time dependent inhibitor of CYP3A4. Permitted medications to be used 
with caution in this study include those that are sensitive substrates of CYP1A2, CYP2B6, 
CYP2C8/9, CYP2D6, CYP3A4, and UGT1A1, or those substrates that have a narrow 
therapeutic index (NTI).  
There is a potential for LGX818 to induce CYP3A4 at concentrations >10 -50 uM, which may 
reduce the effectiveness of hormonal contraception methods. Therefore, the use of at least one 
form  of non-hormonal  contraception  will be needed  during  the participation  in this study.  Please 
see Section  5.3 exclusion  criterion 10  for use of contraception methods  required  for this study.  
LGX818  has been  identified  to be primarily  metabolized  by CYP3A4  in vitro . It is advised  that 
LGX818 should be taken with caution when co -administered with moderate inhibitors of 
CYP3A4 or strong inducers of CYP3A4 (NB. strong systemic inhibitors of CYP3A4 are 
prohibited (please see Section 6.4.3 ). 
In vitro data showed that both LGX818 and MEK162 are substrates of P -gp. Thus, the use of 
drugs  that are known  to inhibit  or induce  P-gp should  be used with caution.  LGX818  is a BCRP  
Array  BioPharma  
Amended  Protocol  Version  10 Confidential  Page  110 
Protocol  No. CMEK162X2110  / C4221005  
PFIZER  CONFIDENTIAL   
 and P-gp inhibitor.  It is also a potent  inhibitor  of the renal  transporters  OAT1,  OAT3  and OCT2 
and the hepatic transporters OATP1B1 and OATP1B3. Therefore the co -administration of 
drugs that are known to be sensitive or NTI substrate of BCRP, P -gp, OAT1, OAT3, OCT2, 
OATP1B1, and OATP1B3 should be used with caution.  
MEK162  is a substrate  for many  CYP  isoforms,  in particular  CYP1A2  and CYP2C19.  The risk 
of metabolic interaction caused by an effect on an individual isoform is therefore minimized. 
Nevertheless, caution should be used in patients receiving concomitant treatment with other 
drugs that are either potent inhibitors or inducers of these enzymes.  
Patients receiving such medications above must be carefully monitored for potentiating of 
toxicity due to any individual concomitant medication, and may require dose titration of the 
drug substance. Investigators should use caution when prescribing co -medications, as clinical 
experience with  these compounds  in patients  with cancer  is often limited.  Investigators  should 
contact the Sponsor when they are unsure whether a drug should be prescribed to a patient in 
the clinical study. All concomitant medications and dietary supplements must be documented 
on the eCRFs. Please refer to Appendix 4 for a list of medications to be used with caution as 
mentioned above.  
6.4.2.1  Additional  permitted  concomitant  therapy  requiring  caution  and/or 
action for addition of LEE011 in the triple combination  
LEE01  is a moderate  substrate  of P-glycoprotein  (P-gp). LEE011  is a weak  reversible  inhibitor 
of CYP1A2. It  is recommended  that substrates  metabolized  predominantly  by CYP1A2 with a 
narrow  therapeutic  index  be taken  with caution.  LEE011  was found  to inhibit  the mitoxantrone - 
resistant protein (MXR or BCRP), and human bile salt export pump (BSEP).  Medications to 
be used with caution during triple -combination treatment with LEE011 in this study  are listed 
below  (see Appendix  4, as this list is not comprehensive  and is only meant  to be used as a guide. 
Please  contact  the medical  monitor  with any questions).  These  medications  should  be excluded 
from patient use if possible. If they must be given based on the investigator’s judgment, then 
use with caution and consider a LEE011 interruption if the concomitant medication is only 
needed for a short time.  
• Moderate  inhibitors  or inducers  of CYP3A4/5  (may  increase  or decrease  LEE011 
exposure, respectively)  
• Sensitive  substrates  of CYP3A4/5  that do  not have  narrow  therapeutic  index  (LEE011  may 
increase exposure to these medications)  
• Strong  inhibitors  of BSEP  (based  on in vitro  data co-administration  with LEE011  may 
lead to intrahepatic cholestasis)  
• Medications  that carry  a possible  risk for QT prolongation  (may  precipitate  QT 
prolongation and TdP)  
• Sensitive  substrates  of the renal  transporters,  MATE1,  OCT2  and BCRP  (has a potential  to 
increase  exposure  to substrates  of these  transporters,  although  no animal  or clinical  data are 
available to support these statements)  
• Strong  inhibitors/inducers  of P-gp. 
Array  BioPharma  
Amended  Protocol  Version  10 Confidential  Page  111 
Protocol  No. CMEK162X2110  / C4221005  
PFIZER  CONFIDENTIAL   
 6.4.3  Prohibited concomitant therapy  dual and triple combination  
• Other  investigational  therapies  must not  be used while  the patient is  on study  treatment.  
• Anticancer  therapy  (chemotherapy,  biologic  or radiation  therapy,  palliative  radiotherapy 
covering  > 25% of the bone  marrow  reserve,  and surgery)  other  than the study  treatment 
must not be given to patients while the patient is on study treatment. If such agents are 
required for a patient, then the patient must be withdrawn from the study.  
• The concomitant use of strong systemic CYP3A4 inhibitors would likely significantly 
increase  the exposure  of LGX818  and thus should  not be used during  this study  (please 
refer to Table 14 -10 in Appendix 4 for a partial list of CYP3A4 inhibitors).  
6.4.3.1  Additional  prohibited  concomitant  therapy  for addition  of LEE011  in 
the triple combination  
• Prophylactic  treatment  with bisphosphonates  is not allowed  with LEE011.  
• Strong  inhibitors  or inducers  of CYP3A4/5  (may  significantly  increase  or decrease 
ribociclib exposure, respectively)  
• Substrates  of CYP3A4/5  with a narrow  therapeutic  index  (LEE011  may increase  exposure 
to these medications resulting in toxicity to these medications)  
• Medications with a known risk for QT prolongation and/or TdP (may precipitate QT 
prolongation  and TdP in combination  with LEE011).  See Table  14-12 and the LEE011 
Investigator’s Brochure for a complete list of agents that are known to cause QTc 
prolongation in humans.  
• Other  investigational  and antineoplastic  therapies  
• Herbal preparations/medications that are strong inhibitors or inducers of CYP3A4/5. 
These include but are not limited to: St. John’s wort, Kava, ephedra (ma huang), gingko 
biloba, dehydroepiandrosterone (DHEA), yohimbe, saw palmetto, black cohosh and 
ginseng.  Patients  should  stop using  all herbal  medications  and dietary  supplements  at least 
7 days prior to first dose of study treatment.  
 
See Appendix  4 for a partial  list of CYP3A4  substrates  or inducers.  
6.5 Patient  numbering,  treatment  assignment  and randomization  
6.5.1  Patient numbering  
Each  patient  is identified  in the study  by a Subject  Number  (Subject  No.),  that is assigned  when 
the patient has signed the Molecular pre -screening Informed Consent Form (if applicable) or 
Study  Informed  Consent  Form  and is retained  as the primary  identifier  for the patient  throughout 
his/her entire participation in the trial. The Subject No. consists of the Center Number (Center 
No.) (as assigned by the Sponsor to the investigative site) with a sequential patient number 
suffixed to it, so that each subject is numbered uniquely across the entire database. Once 
assigned, the Subject No. must not be reused for any  other subject and the Subject No. for that 
individual must not be changed, even if the patient is re -screened.  
If the patient fails screening for any reason, the reason will be entered into the Screening log 
eCRF.  
Array  BioPharma  
Amended  Protocol  Version  10 Confidential  Page  112 
Protocol  No. CMEK162X2110  / C4221005  
PFIZER  CONFIDENTIAL   
 6.5.2  Treatment assignment and randomization  
The assignment  of a patient  to a particular  cohort  will be coordinated  by the sponsor. 
No randomization will be performed in this study.  
6.6 Study  drug  supply  
6.6.1  Study drug preparation and dispensation  
The Investigator  needs  to instruct  the patient  to take the study  drugs  as per protocol.  The 
investigational drugs to be used in this trial are:  
• LGX818,  supplied  as capsules  for oral use of dosage  strengths  of 10, 25, 50 and 100 mg. 
• MEK162,  supplied  as film-coated  tablets  for oral use of dosage  strength  15 mg. 
• LEE011,  supplied  as capsules  for oral use of dosage  strength  of 50 and 200 mg. 
Other  strengths  might  be made  available  during  development  of the study  drugs  if deemed 
necessary.  
All dosages  prescribed  to the patient  and all dose changes  during  the study  must  be recorded  on 
the Dosage Administration Record eCRF.  
As of protocol  amendment  3, two new MEK162  tablet  variants  were  introduced  as described  in 
the Amendment 3 rationale and Section 6.2.3 : 
• MEK162  smaller  tablet  
• new MEK162  tablet  variant  
Both  new tablet  variants  are available in  a 15 mg dosage strength.  
6.6.2  Study drug packaging and labeling  
LGX818 capsules, MEK162 tablets and LEE011 capsules are packaged in HDPE bottles with 
child resistant closures.  
Study  drug labels  will be in the local  language  and comply  with the legal  requirements  of each 
country.  They  will include  storage  conditions  for the drug but no information  about  the patient.  
As of protocol amendment 3, the MEK162 smaller tablet and new MEK162 tablet variant as 
described in this protocol, will be distinguishable by the following naming on the study drug 
labels:  
• MEK162  15mg_NVS  FMI (refers  to the MEK162  smaller  tablet).  
• MEK162  15mg_NVS  CSF (refers  to the new MEK162  tablet  variant).  
6.6.3  Drug supply  and storage  
Study  drugs  will be centrally  supplied  by the Sponsor  or a Sponsor -designated  CRO,  and must 
be received  by a designated  person  at the study  site, handled  and stored  safely  and properly,  and 
kept in a secured  location  to which  only the investigator  and designated  assistants  have  access. 
Upon receipt, the study drugs should be stored according to the instructions specified on the 
drug labels.  
Array  BioPharma  
Amended  Protocol  Version  10 Confidential  Page  113 
Protocol  No. CMEK162X2110  / C4221005  
PFIZER  CONFIDENTIAL   
 6.6.4  Study drug compliance and accountability  
6.6.4.1  Study drug compliance  
At the day of a scheduled visit to the clinic, the patient will take the study drugs under 
supervision of the Investigator or designee. The time of dose administration must be recorded 
in the Dose Administration Record eCRF. For all other study days, the patient will take the 
study drugs at home.  
Compliance  will be assessed  by the investigator  and/or  study  personnel  at each patient  visit and 
information provided by the patient and/or caregiver will be captured in the Drug 
Accountability  Form.  This information  must  be captured  in the source  document  at each patient 
visit.  
Patients will be instructed to write down the date and time of administration in a patient diary 
provided  by the sponsor.  The investigator  or designee  must  check  compliance  and note any drug 
interruptions in the Dose Administration record page of the eCRFs.  
6.6.4.2  Study drug accountability  
The investigator or designee must maintain an accurate record of the shipment and dispensing 
of study  treatment (including Lot numbers) according to local institutional guidelines for drug 
accountability. Drug accountability  will be noted by the field monitor during site visits and at 
the completion of the study. Patients will be asked to return all unused study treatment and 
packaging on a regular basis, at the end of the study or at the time of study treatment 
discontinuation.  
At study  close -out, and, as appropriate  during  the course  of the study,  the investigator  will return 
all used and unused study  treatment, packaging, drug labels, and a copy  of the completed drug 
accountability to the Sponsor’s monitor or to the Sponsor address provided in the investigator 
folder at each site.  
6.6.5  Disposal and destruction  
The drug supply  can be returned  to and destroyed  by the clinical  supply  vendor,  as appropriate. 
Study drug destruction at the investigational site will only be permitted if authorized by the 
Sponsor in a prior agreement and if permitted by local regulations.  
 
7 Visit  schedule  and assessments  
[Any language regarding the triple combination of LGX818/MEK162/LEE011 in this 
Section is not applicable to the USA and Singapore]  
7.1 Study  flow and visit schedule  
Note:  As of protocol  amendment  10, all efficacy  and safety  assessments  will be completed 
per local standard -of-care, or otherwise as clinically indicated. See Table 7 -2. 
Table 7 -1 and Table  7-2 list all of the assessments and indicates with an “X”, the visits when 
they are performed.  All data obtained  from  these  assessments  must  be supported  in the patient’s  
Array  BioPharma  
Amended  Protocol  Version  10 Confidential  Page  114 
Protocol  No. CMEK162X2110  / C4221005  
PFIZER  CONFIDENTIAL   
 source documentation. The table indicates which assessments produce data to be entered into 
the database (D) or remain in source documents only (S) (“Category” column).  
All screening assessments must be completed within 14 days before the first dose, with the 
exception of pregnancy  test, which must be performed within 72 hrs before the first dose. The 
Screening/baseline  imaging  assessments  must  be completed  within  21 days before  first dose of 
study  treatment, except whole -body  bone scans, if applicable, which can be performed within 
6 weeks of study  treatment start. For PK sampling, the samples may  be obtained ± 1 day  from 
the scheduled date (except for PK sampling on Cycle 1 Day  1) under the LGX818 QD or BID 
dosing  schedule.  In case QOD  dosing  would  be introduced  for LGX818,  the PK sampling  must 
be performed  on the specified  day of dosing.  For all other  on-treatment  visits,  there  is a ± 3-day 
window  on assessments  to take into account  scheduling  over public  or religious  holidays  if not 
explicitly  specified  otherwise.  For on-study  imaging  assessments,  a ± 7 day window  is allowed, 
except for the tumor assessment on C1D28 which must be performed between week 3 and 4 
after starting  the study  drug combination  (C1D28  tumor  assessment  not applicable  for Phase  II 
parts). Patients who have been on the LGX818/MEK162 dual -combination and 
LGX/MEK162/LEE011 triple -combination treatment for ≥  24 months (Cycle 25 Day 1 
onwards) will be evaluated for all potential sites of tumor lesions every  8-12 weeks (± 7 days) 
until disease progression. Every effort must be made to follow the schedule outlined in Table 
7-1 and Table 7 -2. 
Assessments  which  are indicated  to be performed  at Screening/baseline  and on Cycle  1 Day 1, 
need only to be repeated at Cycle 1 Day 1 if Screening/baseline assessment was more than 3 
days earlier.  
Array  BioPharma  
Amended  Protocol  Version  10 Confidential  Page  115 
Protocol  No. CMEK162X2110  / C4221005  
PFIZER  CONFIDENTIAL   
  
 
Table  7-1 Visit  evaluation  schedule  
 
 
Category  
 
Reference  to Section  
Molecular  
Pre-Screening  
Screening  /Baseline   
 
 
 
 
 
 
 
Cycle  1  
 
 
 
 
 
 
 
Cycle  2  
 
 
 
 
 
 
 
Subsequent cycles   
 
 
 
 
 
 
 
EOT 
30-day safety  FUm 
Disease  progression 
FU (Phase II only)  
SECa 
Survival  FU (Phase  II 
only)  
Visit Name    1 2 3 4 5 6 7 8  10 201 11 202  13 14  777   778  
Day of cycle     -14 
to-1 1 2 8 15 16 22 28 1 8 15 22 28 1 15 28 ≤14d 
from  last 
dose      
Molecular pre - 
screening  Informed  
Consent, if applicable  D 7.1.1  / 
11.3 X                      
Documented  BRAF 
mutation  D 7.1.1   X                     
Obtain Study 
Informed  Consent  D 7.1.2  / 
11.3  X                     
Demography  D 7.1.2.3  Xb X                     
Inclusion  / Exclusion 
criteria  D 5.2 / 5.3  X                     
Relevant  medical 
history/current  
medical conditions  D 7.1.2.3   X                     
Diagnosis  and extent 
of cancer  D 7.1.2.3   X                     
Prior  antineoplastic 
therapy  D 7.1.2.3   X                     
Prior/concomitant 
medications  D 7.1.2.3   X CONTINUOUS     
Array  BioPharma  
Amended  Protocol  Version  10 Confidential  Page  116 
Protocol  No. CMEK162X2110  / C4221005  
PFIZER  CONFIDENTIAL   
  
 
Category  
 
Reference  to Section  
Molecular  
Pre-Screening  
Screening  /Baseline   
 
 
 
 
 
 
 
Cycle  1  
 
 
 
 
 
 
 
Cycle  2  
 
 
 
 
 
 
 
Subsequent cycles   
 
 
 
 
 
 
 
EOT 
30-day safety  FUm 
Disease  progression 
FU (Phase II only)  
SECa 
Survival  FU (Phase  II 
only)  
Visit Name    1 2 3 4 5 6 7 8  10 201 11 202  13 14  777   778  
Day of cycle     -14 
to-1 1 2 8 15 16 22 28 1 8 15 22 28 1 15 28 ≤14d 
from  last 
dose      
Physical examination  S 7.2.2.1   X X  Xc X  Xc  X  Xc   X C3c,d  X     
Vital signs  D 7.2.2.2   X X  Xc X  Xc  X  Xc   X C3c,d  X     
Performance  status 
(WHO)  D 7.2.2.3   X X  Xc X    X  Xc   X C3c,d  X     
Height  D 7.2.2.4   X                     
Weight  D 7.2.2.4   X X       X     X   X     
Hematology  D 7.2.2.5.1   X X  X X  X  X  X   X C3  X     
Clinical  chemistry  D 7.2.2.5.2   X X  X X  X  X  X   X C3  X     
Additional  LFT D 7.2.2.5.2            X  X   C4       
Coagulation  D 7.2.2.5.3   X X       X     X   X     
Urinalysis  (and 24h 
urine collection if 
applicable)  D 7.2.2.5.4   X X   X    X     X   X     
Pregnancy  test D 7.2.2.5.5   X        X     X   X     
Dermatologic 
evaluation  D 7.2.2.6   X             Day 1 of odd-numbered 
Cycles (C3, C5, etc.)  X     
Ophthalmologic 
examination  D 7.2.2.7   X    X    X  X   Xe   X     
ECG  12-leadf D 7.2.2.8.1 / 
7.2.2.8.2   X X   X    X  X   X   X     
Array  BioPharma  
Amended  Protocol  Version  10 Confidential  Page  117 
Protocol  No. CMEK162X2110  / C4221005  
PFIZER  CONFIDENTIAL   
  
 
Category  
 
Reference  to Section  
Molecular  
Pre-Screening  
Screening  /Baseline   
 
 
 
 
 
 
 
Cycle  1  
 
 
 
 
 
 
 
Cycle  2  
 
 
 
 
 
 
 
Subsequent cycles   
 
 
 
 
 
 
 
EOT 
30-day safety  FUm 
Disease  progression 
FU (Phase II only)  
SECa 
Survival  FU (Phase  II 
only)  
Visit Name    1 2 3 4 5 6 7 8  10 201 11 202  13 14  777   778  
Day of cycle     -14 
to-1 1 2 8 15 16 22 28 1 8 15 22 28 1 15 28 ≤14d 
from  last 
dose      
Cardiac imaging  D 7.2.2.8.3   X        X     C5, 
C8 
C11g   X     
Tumor  imaging 
assessments 
(RECIST 1.1)  D 7.2.1   X       Xc,h     X C4, 
C6 
Xi   X  Xj   
Brain  MRI/CT  D 7.2.1   Xk                     
Phone calls for 
Disease  progression 
FU (if applicable)  S 7.2.1                     X 
(monthly)    
Adverse  events  D 8 X 
(procedure - 
related  
SAEs only) CONTINUOUS     
Array  BioPharma  
Amended  Protocol  Version  10 Confidential  Page  118 
Protocol  No. CMEK162X2110  / C4221005  
PFIZER  CONFIDENTIAL   
  
 
Category  
 
Reference  to Section  
Molecular  
Pre-Screening  
Screening  /Baseline   
 
 
 
 
 
 
 
Cycle  1  
 
 
 
 
 
 
 
Cycle  2  
 
 
 
 
 
 
 
Subsequent cycles   
 
 
 
 
 
 
 
EOT 
30-day safety  FUm 
Disease  progression 
FU (Phase II only)  
SECa 
Survival  FU (Phase  II 
only)  
Visit Name    1 2 3 4 5 6 7 8  10 201 11 202  13 14  777   778  
Day of cycle     -14 
to-1 1 2 8 15 16 22 28 1 8 15 22 28 1 15 28 ≤14d 
from  last 
dose      
LGX818  
administration  D 6.1.1  / 
6.6   CONTINUOUS       
MEK162  
administration  D 6.1.1  / 
6.6   CONTINUOUS       
LEE011  
administration (only 
for triple  combination)  D 6.1.1  / 
6.6   3 weeks on, 1 week off schedule  
(once  daily for 21 days  followed by  a 7-day rest [28-day cycle]).       
Blood  for PK (up to 
cycle 10) – not for 
PhII arm 1 unless  if 
required  D 7.2.3    X X  X X   X     X        
Archival tumor 
sample (paraffin 
block/slides)  with an 
accompanying  
pathology report  D 7.2.4.1   X                     
Fresh tumor sample 
from biopsy/resection  D 7.2.4.1  X (if 
needed)  Xl     X           X 
(at 
relapse)   X 
(at 
relapse)    
Array  BioPharma  
Amended  Protocol  Version  10 Confidential  Page  119 
Protocol  No. CMEK162X2110  / C4221005  
PFIZER  CONFIDENTIAL   
  
 
Category  
 
Reference  to Section  
Molecular  
Pre-Screening  
Screening  /Baseline   
 
 
 
 
 
 
 
Cycle  1  
 
 
 
 
 
 
 
Cycle  2  
 
 
 
 
 
 
 
Subsequent cycles   
 
 
 
 
 
 
 
EOT 
30-day safety  FUm 
Disease  progression 
FU (Phase II only)  
SECa 
Survival  FU (Phase  II 
only)  
Visit Name    1 2 3 4 5 6 7 8  10 201 11 202  13 14  777   778  
Day of cycle     -14 
to-1 1 2 8 15 16 22 28 1 8 15 22 28 1 15 28 ≤14d 
from  last 
dose      
Fresh skin biopsy 
(only  applicable  for 
those  patients  from 
whom fresh tumor  
sample is collected)  D 7.2.4.2   X     X           X 
(at 
relapse)   X 
(at 
relapse)    
Blood  for genetic 
analysis  D 7.2.4.3        X 
(or any 
other  
visit)                
Phone calls for 
survival  follow -up 
(every 3 months)  S 7.1.5                     X  X 
Antineoplastic 
therapies since 
discontinuation  of 
study treatment  D 7.1.5                   X X X  X 
End of study 
evaluation  D 7.1.5                      Xa  
Array  BioPharma  
Amended  Protocol  Version  10 Confidential  Page  120 
Protocol  No. CMEK162X2110  / C4221005  
PFIZER  CONFIDENTIAL   
  
 
Category  
 
Reference  to Section  
Molecular  
Pre-Screening  
Screening  /Baseline   
 
 
 
 
 
 
 
Cycle  1  
 
 
 
 
 
 
 
Cycle  2  
 
 
 
 
 
 
 
Subsequent cycles   
 
 
 
 
 
 
 
EOT 
30-day safety  FUm 
Disease  progression 
FU (Phase II only)  
SECa 
Survival  FU (Phase  II 
only)  
Visit Name    1 2 3 4 5 6 7 8  10 201 11 202  13 14  777   778  
Day of cycle     -14 
to-1 1 2 8 15 16 22 28 1 8 15 22 28 1 15 28 ≤14d 
from  last 
dose      
a. SEC eCRF should be completed once the 30 -day safety follow -up period is completed for the Phase Ib patients and for those Phase II patients who have progressed 
during  study  treatment.  For patients  enrolled  in the Phase  II parts  who discontinue  study  treatment  for any reason  other  than disease  progression,  the SEC eCRF  should 
be completed upon progression, the initiation of subsequent anticancer therapies or death.  
b. For only those  patients  who have  signed  the molecular  pre-screening  IC; does  not have  to be repeated  at Screening  for these  patients.  
c. Not applicable for patients enrolled in the Phase II parts of the study.  
d. C3=only during Cycle 3 
e. Patients  who have  been  on the LGX818/MEK162  dual-combination  and LGX818/MEK162/LEE011  triple -combination  treatment  for ≥ 24 months  (Cycle  25 Day 1 onward) 
without a retinal AE should be evaluated for visual acuity at each scheduled patient visit and at the End of Treatment visit.  A full ophthalmic examination is required  
if clinically  indicated  and at the End of Treatment  visit. 
f. All ECGs  should  be performed  either  before  blood  sample  collection  or at least  0.5 hours  after blood  sample  collection.  
g. Day 1  of every  third cycle until  Cycle 11 (i.e.  Day 1  of Cycle 5,  8 and 11)  and Day  1 of every  fourth Cycle thereafter  (i.e. Day 1 of Cycle  15, 19 etc.).  
h. Should be performed between week 3 and 4 of Cycle 1. 
i. Patients  who have been  on either  combination treatment  for ≥ 24 months (Cycle  25 Day  1 onward) will  have CT/MRI  scans every  8-12 weeks  (± 7 days).  
j. Patients  who have  been  on either  combination  treatment  for ≥ 24 months  (Cycle  25 Day 1 onward)  and then discontinue  study  treatment  for any reason  other  than disease 
progression will have CT/MRI scans every 8 -12 weeks (± 7 days).  
k. Applicable only  for patients  enrolled in  the triple -combination  part of the study.  
l. Fresh  sample  should  only be collected  at Screening/baseline  if insufficient  fresh  tumor  tissue  was collected  during  local molecular  pre-screening.  Fresh  tumor  samples  are 
mandatory for all patients in Phase II of the study at Screening/Baseline, although archival tissue is acceptable in some cas es, (refer to Section 7.2.4.1.1 ). 
m. Following  the 30-day follow -up, when  clinically  appropriate,  it is recommended  patients  be monitored  with physical  examinations,  dermatological  examinations,  and chest 
CT scans  for cutaneous  and non-cutaneous  secondary  malignancies  for up to 6 months  after the last encorafenib  dose  or until initiation  of another  antineoplastic  therapy.  
Array  BioPharma  
Amended  Protocol  Version  10 Confidential  Page  121 
Protocol  No. CMEK162X2110  / C4221005  
PFIZER  CONFIDENTIAL   
  
 
Table  7-2 Visit  evaluation  schedule  for patients  as of Amendment  10 
 
 
 
 
 
Procedure or  Assessmenta As of Amendment 10 Category  
 
 
Protocol  Section  Treatment  
 
 
EOT 
 
 
30-day safety  FU 
 
 
Study  Evaluation 
Completion  
 
Per local 
standard -of-care 
(Recommended  
every  4 weeks)   
 
 
Recommended 
every  
8-12 weeks  
Physical examinationb S 7.2.2.1  X  X   
Vital signs / weight  D 7.2.2.2  X  X   
Performance Status (WHO)  D 7.2.2.3  X  X   
Single ECG 12 -lead D 7.2.2.8.1 / 
7.2.2.8.2   X X   
Hematology  D 7.2.2.5.1  X  X   
Clinical  chemistry  D 7.2.2.5.2  X  X   
Coagulation  D 7.2.2.5.3  X  X   
Dipstick Urinalysisc D 7.2.2.5.4  Xc  X   
Pregnancy testd D 7.2.2.5.5  X  X   
Cardiac imaginge D 7.2.2.8.3   as clinically 
indicated  X   
Visual acuityf D 7.2.2.7  X  X   
Ophthalmologic  examinationf D 7.2.2.7   as clinically 
indicated  X   
Dermatologic examinationb D 7.2.2.6    X   
LGX818/MEK162  (Dual  combination  patients) - 
Dispense and/or assess compliance  D 6.1.1  / 6.6 X     
LGX818/MEK162/LEE011  (Triple combination 
patients)  - Dispense  and/or  assess  compliance  D 6.1.1  / 6.6 X     
Adverse events  D 8 X  X X  
Concomitant  medications  D 7.1.2.3  X  X X  
Tumor imaging assessments (RECIST 1.1) D 7.2.1  Per institutional  standar -of-care    
End of study evaluationg D 7.1.5      X 
Array  BioPharma  
Amended  Protocol  Version  10 Confidential  Page  122 
Protocol  No. CMEK162X2110  / C4221005  
PFIZER  CONFIDENTIAL   
  
 
 
 
 
Procedure or  Assessmenta As of Amendment 10 Category  
 
 
Protocol  Section  Treatment  
 
 
EOT 
 
 
30-day safety  FU 
 
 
Study  Evaluation 
Completion  
 
Per local 
standard -of-care 
(Recommended  
every  4 weeks)   
 
 
Recommended 
every  
8-12 weeks  
a. The minimally  required  procedures/assessments  are indicated;  these  or any additional  procedures/assessments  can be repeated  more  frequently  per 
standard -of-care or if clinically indicated.  
b. Following the 30 -day Safety Follow -up, when clinically appropriate, it is recommended patients be monitored with physical examinations, dermatological 
examinations,  and chest  CT scans  for cutaneous  and non-cutaneous  secondary  malignancies  for up to 6 months  after the last LGX818  dose  or until initiation  of 
another antineoplastic therapy.  
c. To be conducted  if clinically indicated.  
d. Local  urine  test for women  of childbearing  potential  only. 
e. Assessed  by ECHO  or MUGA.  The same  method  should  be used  throughout  the study.  Patients  who develop  signs/symptoms  of CHF at any point  during  the study 
are required to have an evaluation by ECHO or MUGA.  
f. Patients who have been on the LGX818/MEK162 dual combination and LGX818/MEK162/LEE011 triple combination treatment for ≥ 24 m onths (Cycle 25 Day 1 
onward)  without  a retinal  AE should  be evaluated  for visual  acuity  per local standard -of-care (recommended  every  4 weeks)  and at the End of Treatment  visit. A full 
ophthalmic examination is required if clinically indicated and at the End of Treatment visit.  
g. SEC eCRF  should  be completed  once  the 30-day safety  follow -up period is  completed  or 30 days  after treatment discontinuation.  
Array  BioPharma  
Amended  Protoco l Version 10 Confide ntial Page  123 
Protocol  No. CMEK162X2110  / C4221005  
PFIZER  CONFIDENTIAL   
  
7.1.1  Molecular Pre -screening assessments  
Potential eligible patients must have documentation on the BRAF V600 mutational status of 
their disease. For patients considered for enrollment in this study, whose BRAF mutational 
status is unknown, archival or fresh tumor tissue should be provided to a local laboratory to 
identify  the presence  of a BRAF  V600  mutation  (a V600E  mutation,  or any other  BRAF  V600 
mutation) prior to start of screening.  
Patients who have a tumor which is not routinely screened for a BRAF mutation at a local 
laboratory, will be asked to sign and date an IRB/IEC approved Molecular pre -screening 
Informed  Consent  Form  before  the collection  of the fresh  tumor  tissue  or use of archival  tumor 
tissue. A copy must be given to the patient or to the person signing the form.  
If confirmed  that the patient’s  tumor  harbors  a BRAF  V600  mutation  the patient  will be allowed 
to sign the Study Informed Consent Form and start screening.  
7.1.2  Screening  
The Study IRB/IEC approved Informed Consent Form (ICF) must be signed and dated before 
any screening procedures are performed (procedures which are part of the clinical routine 
during  the initial  diagnostic  work -up of the patient  may be performed  before  obtaining  the ICF). 
A copy of the ICF must be given to the patient or to the person signing the form. The 
Investigator or designee must record the date when the study informed consent was signed in 
the medical records of the patient.  
Patients  will be evaluated  against  study  inclusion  and exclusion  criteria  and safety  assessments. 
For details of assessments, refer to Table 7 -1. All Screening/baseline imaging scans must be 
completed within 21 days prior to the first dose of study treatment. All other screening 
assessments must be completed within 14 days prior to the first dose.  
7.1.2.1  Eligibility  screening  
When the patient is considered eligible for study treatment, the Investigator should complete 
the Patient  Registration  Form  and send it to the Sponsor.  The allocation  of patients  to treatment 
cohorts will be handled by the Sponsor.  
7.1.2.2  Information  to be collected  on molecular  pre- screening  and screening 
failures  
Patients who sign an ICF but fail to be started on study treatment for any reason will be 
considered a screen failure. Both patients who sign a Molecular pre -screening ICF and are 
considered ineligible after molecular pre -screening, as well as patients who are found not 
eligible after signing the Study ICF, will be considered as screening failures and data will be 
handled in the same manner.  
For all screening  failures,  the only information  collected  on the eCRF  will be the Screening  Log 
and the Demography pages.  
Array  BioPharma  
Amended  Protoco l Version 10 Confide ntial Page  124 
Protocol  No. CMEK162X2110  / C4221005  
PFIZER  CONFIDENTIAL   
 7.1.2.3  Patient  demographics  and other  baseline  characteristics  
Data to be collected will include general patient demographics, relevant medical history and 
current medical conditions, prior concomitant medications, diagnosis and extent of tumor, 
baseline tumor mutation status and details of prior anti -neoplastic treatments.  
7.1.3  Treatment period  
Note:  As of protocol  amendment  10, all efficacy  and safety  assessments  will be completed 
per local standard -of-care practice, or otherwise as clinically indicated. See Table 7 -2. 
During  the treatment  period,  the patient  must  follow  the Investigators  instructions  with regards 
to contraception, concomitant medications, and dosing regimen (see Section 6.1.1 for dosing 
regimen  guidelines).  There  is no fixed  treatment  duration;  patients  may continue  treatment  with 
the LGX818 and MEK162 dual combination or LGX818 and MEK162 and LEE011 triple 
combination until disease progression, unacceptable toxicity  occurs that precludes any further 
treatment and/or treatment is discontinued at the discretion of the investigator or by patient 
refusal (withdrawal of consent).  
If a patient remains on study although the patient required a dose interruption of > 21 days, 
because  the patient  had experienced  objective  evidence  of clinical  benefit  and in the opinion  of 
the investigator  it is in the best interest  of the patient  to remain  on study  (see also Section  6.3.2 ), 
then this decision and report of a discussion with the sponsor, must be reported in the source 
documentation and in a comment in the eCRF.  
If a patient  remains  on study  although  the patient’s  disease  progressed  (see also Section  6.1.5 ), 
then this  decision and documentation of a discussion with the sponsor, must be reported in the 
source documentation and as an investigator comment in the eCRF.  
For details of the frequency of the visits and assessments during the treatment period, refer to 
Table 7 -1 and Table 7 -2. 
7.1.4  End of treatment  visit,  including  premature  withdrawal  and study 
completion visit  
Note: As of protocol amendment 10, patients will be considered to have completed the 
study after the 30 -day safety evaluation or 30 days after treatment discontinuation, 
whichever is earlier. Post -treatment disease progression follow -up (if applicable) and/or 
survival follow -up (including  documentation of subsequent antineoplastic therapies) will 
no longer be performed for any patient in the Phase II part of the study; see Table 7 -2. 
Patients who discontinue study  treatment should be scheduled for an End of Treatment (EOT) 
visit as soon as possible and within 14 days after the last study  drug dose, at which time all of 
the assessments listed for the EOT visit will be performed. For patients who had to interrupt 
study treatment for more than 14 days and then permanently discontinue study treatment 
without restarting, the EOT visit should be scheduled as soon as possible after the decision of 
discontinuation.  An EOT  eCRF  page  should  be completed,  giving  the date and primary  reason 
for stopping the study  treatment. At a minimum, all patients who discontinue study  treatment, 
including those who refuse to return for a final visit, will be contacted for safety evaluations 
during the 30 days following the last dose of study treatment.  
Array  BioPharma  
Amended  Protoco l Version 10 Confide ntial Page  125 
Protocol  No. CMEK162X2110  / C4221005  
PFIZER  CONFIDENTIAL   
 Patients who discontinue study treatment should also return for 30 -day safety FU (see 
Section  7.1.5.1 ), Disease  progression  FU (if applicable,  see Section  7.1.5.2 ) and survival  FU 
(only for Phase II patients, see Section 7.1.5.3 ) assessments at the visits according to Table 
7-1 and Table  7-2 and should  not be considered  withdrawn  from  the study.  If patients  refuse  
to return  for these  visits  or are unable  to do so, every  effort  should  be made  to contact  them  or 
a knowledgeable informant by telephone to obtain the FU information.  
If a patient  discontinues  study  treatment,  but continues  study  assessments  in the FU period,  the 
patient remains on study until such time as he/she completes protocol criteria for ending study 
assessments. At that time, the reason for study completion should be recorded on the Study 
Evaluation Completion (SEC) eCRF page.  
The SEC eCRF page records the end of study for every individual patient and should be 
completed  for all patients  enrolled  in the Phase  Ib part  and those  patients  enrolled  in the Phase 
II part who have  progressed  during  study  treatment,  once  the 30-day safety  follow -up period  is 
completed. For patients enrolled in the Phase II part who discontinue study treatment for any 
reason  other  than disease  progression,  the SEC eCRF  should  be completed  upon  progression  or 
the initiation  of subsequent  anticancer  therapies  or death.  Note:  the survival  FU assessments  do 
continue beyond the SEC for all patients enrolled in the Phase II part.  
7.1.4.1  Criteria for premature patient  withdrawal  
Patients  may voluntarily  withdraw  from  the study  or be dropped  from  it at the discretion  of the 
investigator  at any time.  Patients  may be withdrawn  from  the study  if any of the following  occur:  
• Unacceptable  AE(s),  or failure  to tolerate  study  treatment  
• Delay  in dosing > 21 consecutive days 
• Pregnancy  of the patient  
• Patient  withdrew  consent  
• Lost to follow -up 
• Disease  progression  
• Initiation  of new cancer  therapy  
7.1.4.2  Replacement policy  
Dose  Escalation  (Phase  Ib) part: Patients  will not be replaced  on study.  However,  if a patient 
is considered as non -evaluable for the DDS, enrollment of a new patient to the current cohort 
will be considered  if there  is less than the required  number  of evaluable  patients.  Enrollment  of 
new patients  may be considered  until at least the minimum  number  (3) or at most  the maximum 
number (6) of evaluable patients is achieved within the cohort ( Section  10.8). Minimum and 
maximum numbers of evaluable patients per cohort are defined in Section 6.2.4.2 . 
Phase  II part: During the  Phase II  part no  replacement will  be needed.  
Array  BioPharma  
Amended  Protoco l Version 10 Confide ntial Page  126 
Protocol  No. CMEK162X2110  / C4221005  
PFIZER  CONFIDENTIAL   
 7.1.5  Follow -up period  
Patients  lost to follow -up should  be recorded  as such on the eCRF.  For patients  who are lost to 
follow -up, the investigator should show "due diligence" by documenting in the source 
documents  steps  taken  to contact  the patient,  e.g., dates  of telephone  calls,  registered  letters,  etc. 
7.1.5.1  30-day safety follow -up period  
All patients must have safety evaluations for 30 days after the last dose of study treatment. 
Information related to AEs (including concomitant medication taken for ongoing AEs) and 
ongoing  anti-neoplastic  treatments  will be collected  for 30 days after the last dose of study  drug. 
All AEs suspected  to be related  to study  treatment  should  be followed  up weekly,  or as clinically 
indicated, until resolution or stabilization.  
7.1.5.2  Disease  progression  follow -up period  
Note:  As of protocol  amendment  10, no post-treatment  disease  progression  follow -up will 
be performed.  
Patients  enrolled  in the Phase  II part of the study  who discontinue  study  treatment  for any reason 
other than disease progression will be followed up monthly via a phone call and will have 
CT/MRI  scans  every  8 weeks  (± 7 days)  as detailed  in Table  7-1 and Section  7.2.1 , until disease 
progression or the initiation of subsequent anticancer therapies, or death, or until all patients 
have completed SEC, or have been lost to follow -up or withdrew consent, whichever occurs 
first. 
Patients who have been on the LGX818/MEK162 dual -combination or 
LGX818/MEK162/LEE011 triple -combination treatment for ≥ 24 months (Cycle 25 Day 1 
onward)  and then discontinue  study  treatment  for any reason  other  than disease  progression  will 
be followed up by CT/MRI scans every 8 -12 weeks (±  7 days) as detailed in Table 7 -1 and 
Section 7.2.1 , until disease progression, death, removal of consent to follow, the initiation of 
subsequent  anticancer  therapies  or until End of Study  (see Section  4.3), whichever  occurs  first. 
7.1.5.3  Survival  follow -up period  
Note: As of protocol amendment 10, no survival or subsequent antineoplastic therapy 
information will be collected.  
All patients enrolled in the Phase II part of the study will be followed for survival every 3 
months per phone call until death, or until all patients have completed SEC, or have been lost 
to follow -up or withdrew  consent,  whichever  occurs  first. Possible  newly  started  antineoplastic 
therapies during this FU period must be recorded on the Antineoplastic therapy since 
discontinuation eCRF.  
7.2 Assessment  types  
7.2.1  Efficacy  assessments  
Tumor response will be evaluated locally by the investigator according to the guideline based 
on RECIST version 1.1 (see Appendix 1 ). Each subject will be evaluated for all potential sites 
of tumor  lesions  at Screening/baseline,  at the end of Cycle  1 (not applicable  for patients  enrolled  
Array  BioPharma  
Amended  Protoco l Version 10 Confide ntial Page  127 
Protocol  No. CMEK162X2110  / C4221005  
PFIZER  CONFIDENTIAL   
 in the Phase  II part of the study)  and Cycle  2 and then every  8 weeks  (2 cycles)  thereafter  during 
the study  treatment until disease progression. Screening/baseline imaging assessments may  be 
performed  within  21 days of treatment  start,  except  whole -body  bone  scans,  if applicable,  which 
can be performed  within  6 weeks  of treatment  start.  On-study  tumor  assessments  have  a ± 7 day 
window, except for the tumor assessment on C1D28 which must be performed between week  
3 and 4 after starting the study drug combination. Patients who have been on the 
LGX818/MEK162 dual - or triple -combination treatment for ≥  24 months (Cycle 25 Day 1 
onward) will be evaluated for all potential sites of tumor lesions every 8 -12 weeks (±  7 days) 
until disease progression.  
There  will be a tumor  assessment  at End of Treatment  (± 3 days)  if the patient  discontinues  for 
any reason  other  than disease  progression  and the last tumor  assessment  has been  performed  > 
21 days prior to this day. Subjects included in the Phase II part of the study, who discontinue 
study  treatment  due to another  reason  than disease  progression,  should  be followed  up monthly 
via a phone call and undergo tumor assessments every 8 weeks (±  7 days) until disease 
progression  or initiation  of subsequent  anti-neoplastic  therapy,  or death,  whichever  occurs  first 
(Section  7.1.5.2 ). Patients  who have been on either dual - or triple -combination treatment  for ≥ 
24 months  (Cycle  25 Day 1 onward)  and then discontinue  study  treatment  for any reason  other 
than disease progression will have CT/MRI scans every 8 -12 weeks (± 7 days).  
At Screening/baseline  the following  should  be performed:  
• A CT scan with intravenous  (i.v.)  contrast  of chest,  abdomen  and pelvis  is required  for all 
patients.  
• In subjects  with a history  of asymptomatic  brain  metastases,  a brain  MRI  or CT scan must 
be performed.  
• In subjects  participating  in the triple -combination  part of the study  a brain  MRI  or CT with 
intravenous (i.v.) contrast scan to assess CNS disease must be performed. Contrast 
enhanced brain MRI is preferred, however, if MRI contrast is contraindicated, then brain 
MRI without contrast or brain CT with/without contrast is acceptable.  
• If clinically indicated, a whole -body bone scan (i.e., if bone metastases are suspected or 
known at baseline) should be performed. Sites may use a whole -body bone imaging 
method per their local standard -of-care (e.g., Tc99m bone scan, NaF PET scan, or whole - 
body  bone  MRI).  Skeletal  lesions  identified  on a whole -body  bone  scan at baseline,  which 
are not visible on the chest, abdomen and pelvis CT (or MRI) scan should be imaged at 
baseline using localized CT, MRI or x -ray. 
• Color  photography  if skin lesions  are present  (it is recommended  to include  a ruler  to 
estimate the size of the lesion).  
Every effort must be made to assess each lesion that is measured at Screening/baseline by the 
same method throughout the study so that the comparison is consistent.  
At all post-Screening/baseline  assessments  the following  should  be performed:  
• All patients are required to undergo chest, abdomen and pelvis CT or MRI  scans.  
• Brain  MRI  or CT scan,  if metastases  were  documented  at baseline.  
• Skeletal lesions identified at baseline should continue to be imaged at subsequent 
scheduled  visits  using  localized  CT, MRI  or x-ray if not visible  on the chest,  abdomen  and 
Array  BioPharma  
Amended  Protoco l Version 10 Confide ntial Page  128 
Protocol  No. CMEK162X2110  / C4221005  
PFIZER  CONFIDENTIAL   
 pelvis  CT or MRI  scan.  After  baseline,  whole -body  bone  scans  need  not be repeated, 
unless clinically indicated.  
• Color  photography  of any skin lesions  documented  at baseline  (it is recommended  to 
include a ruler to estimate the size of the lesion).  
• Additional  tumor  assessments  (e.g. MRI  or CT of the brain)  may be performed  if there  is 
symptomatic  evidence  suggesting  the possibility  of disease  progression  based  on clinical 
symptoms or physical exam at any time.  
Criteria  required  for determining  partial  or complete  response  should  be present  for at least 
4 weeks.  All complete  and partial  responses  must  be confirmed  by a second  assessment  at least 
4 weeks  later.  Note:  sites must  make  sure for patients  enrolled  in the Phase  Ib part of the study 
that at least 4 weeks are scheduled between the tumor assessments on C1D28 and C2D28 to 
allow confirmation of response.  
CT scans should be acquired with i.v. contrast. If a patient is known to have a medical 
contraindication  to CT i.v. contrast  agent  or develops  a contraindication  during  the study,  a CT 
scan without i.v. contrast of the chest and MRI with i.v. contrast, if possible, of the abdomen 
and pelvis may be performed. A CT scan of the brain, preferably with i.v. contrast, may be 
performed if MRI is contra -indicated.  
Chest  x-ray or ultrasound  should  not be  used for tumor  response  assessments in  this study.  
Any lesions that have been subjected to loco -regional therapies (e.g., radiotherapy, ablation, 
etc.) should  not be considered  measurable,  unless  they have  clearly  progressed  since  the therapy. 
Previously treated lesions that have not progressed should be considered non -measurable and 
therefore, assessed as non -target lesions.  
While FDG -PET scans are not required for this study, sites may perform combined PET/CT 
scans per their local standard -of-care, provided the CT is of similar diagnostic quality as a CT 
performed without PET, including the utilization of oral and intravenous contrast media. If 
acquired according to local standard -of-care, FDG -PET may be relied upon to document 
progressive disease in accordance with RECIST v1.1 ( Appendix 1 ). 
Each  center  should  have  a designated  radiologist  responsible  for the interpretation  of scans  and 
response evaluations for study subjects. Preferably, a single radiologist should perform all 
evaluations for an individual subject.  
7.2.2  Safety  and tolerability assessments  
Note:  As of protocol amendment 10,  safety  assessments  will be performed  as indicated  in 
Table 7 -2. 
Safety will be monitored by assessing the procedures listed below as well as collecting of the 
adverse  events  at every  visit.  For details  on AE collection  and reporting,  refer  to Section  8. All 
safety assessments should be performed pre -dose unless specified otherwise.  
Array  BioPharma  
Amended  Protoco l Version 10 Confide ntial Page  129 
Protocol  No. CMEK162X2110  / C4221005  
PFIZER  CONFIDENTIAL   
 7.2.2.1  Physical  examination  
Note:  As of protocol  amendment  10, physical  examinations  will be performed  as outlined 
in Table 7 -2. 
A complete physical examination will be performed at Screening/baseline and will include the 
examination  of general  appearance,  skin,  neck  (including  thyroid),  eyes,  ears, nose,  throat,  lungs, 
heart, abdomen, back, lymph nodes, extremities, peripheral vascular system and neurologic 
system.  If indicated  based  on medical  history  and/or  symptoms,  rectal,  external  genitalia,  breast, 
and pelvic exams will be performed.  
A short  physical  exam  (examination  of general  appearance)  will be at all visits  during  treatment 
unless the investigator considers a complete physical examination is necessary.  
Physical  examinations will  take place  at the  following visits  irrespective of  the time  of dosing:  
• Screening/Baseline  
• Cycle  1 Days  1, 8, 15 and 22 (for Phase  II: Cycle  1 Days  1 and 15) 
• Cycles  2 and 3: at Day 1 and  Day 15 (for Phase  II: Cycles  2 and 3  at Day 1) 
• Cycle  4 and  Onwards: Day  1 
• EOT  
Physical examination findings collected during the study will be considered source data and 
will not be required  to be reported,  unless  otherwise  noted.  Any untoward  physical  examination 
findings  that are identified  during  the active  collection  period  and meet  the definition  of an AE 
or SAE (Appendix  7Appendix  7Appendix  7Appendix  7Appendix  7) must  be reported  according 
to the processes  in Section  8.1.1  and Appendix  7. Significant  new findings  that begin  or worsen 
after informed consent must be recorded on the Adverse Event page of the patient’s eCRF.  
7.2.2.2  Vital signs  
Note:  As of protocol  amendment  10, vital  signs  will be performed  as outlined 
in Table 7 -2. 
Vital signs include blood pressure, temperature and pulse measurements. After the patient has 
been  sitting  for five minutes,  with back  supported  and both feet placed  on the floor,  systolic  and 
diastolic  blood  pressure  will be measured  three  times  using  an automated  validated  device  (e.g. 
OMRON),  with an appropriately  sized  cuff. The repeat  sitting  measurements  will be made  at 1- 
to 2-minute  intervals  and the mean  of the three  measurements  will be used.  In case the cuff sizes 
available are not large enough for the patient's arm circumference, a sphygmomanometer with 
an appropriately sized cuff may be used.  
Vital  signs  will take place  pre-dose at: 
• Screening/Baseline  
• Cycle  1 Days  1, 8, 15 and 22 (for Phase  II: Cycle  1 Days  1 and 15) 
• Cycles  2 and 3: at Day 1 and Day  15 (for Phase  II: Cycle  3 at Day 1) 
• Cycle  4 and  onwards: Day  1 
• EOT  
Array  BioPharma  
Amended  Protoco l Version 10 Confide ntial Page  130 
Protocol  No. CMEK162X2110  / C4221005  
PFIZER  CONFIDENTIAL   
 7.2.2.3  Performance status  
Note:  As of protocol  amendment  10, WHO  Performance  Status  will be performed  as 
outlined in Table 7 -2. 
Assessment  of WHO  Performance  Status  (Table  7-3) will be performed  at screening  and 
regularly throughout the whole study period irrespective of the time of dosing:  
• Screening/Baseline  
• Cycle  1 Days  1, 8 and 15 (for Phase  II: Cycle  1 Days  1 and 15) 
• Cycles  2 and 3: Day 1 and Day  15 (for Phase  II: Cycles  2 and  3 at Day 1) 
• Cycle  4 and  onwards: Day  1 
• EOT  
Performance  status  should  be obtained  on the scheduled  day, even  if study  medication  is being 
held.  
Table  7-3 WHO  performance  status  scale  
0 Fully  active,  able to carry  on all pre-disease  performance  without  restriction.  
1 Restricted  in physically  strenuous  activity  but ambulatory  and able to carry  out work  of a light or sedentary 
nature, e.g., light housework, office work.  
2 Ambulatory  and capable  of all self-care but unable  to carry  out any work  activities.  Up and about  more 
than 50% of waking hours.  
3 Capable  of only limited  self-care,  confined  to bed or chair  more  than 50% of waking  hours.  
4 Completely  disabled.  Cannot  carry  on any self-care.  Totally  confined  to bed or chair.  
7.2.2.4  Height and weight  
Note:  As of protocol  amendment  10, weight  information  will be collected  as outlined 
in Table 7 -2. 
Height  in centimeters  (cm)  and body  weight  (to the nearest  0.1 kilogram  [kg] in indoor  clothing, 
but without shoes) will be measured.  
Height information will be collected only at Screening/baseline. Weight information will be 
collected at Screening/baseline, Day 1 of each cycle and at EOT irrespective of dosing time.  
7.2.2.5  Laboratory  evaluations  
Note:  As of protocol  amendment  10, laboratory  evaluations  will be performed  as 
outlined in Table 7 -2. 
Sites will use their local laboratories for the analysis of all safety lab samples collected at the 
time points indicated in the Visit Schedule ( Table 7 -1 and Table  7-2). More frequent 
assessments may be performed if clinically indicated, or at the investigator’s discretion, and 
these should be recorded on the Unscheduled Visit eCRFs.  
Abnormal  laboratory  values  that are clinically  relevant  (e.g.,  require  an interruption  or delay  to 
study treatment, lead to clinical symptoms, or require therapeutic intervention) must be 
documented in the Adverse Event eCRF. If any abnormal laboratory value constitutes an AE, 
then these must be recorded on the Adverse Event eCRF.  
Array  BioPharma  
Amended  Protoco l Version 10 Confide ntial Page  131 
Protocol  No. CMEK162X2110  / C4221005  
PFIZER  CONFIDENTIAL   
 The Sponsor will be provided with a copy of the site’s local laboratory certification and 
tabulation  of the normal  ranges  for each parameter  required  at study  start and should  be kept up 
to date on an ongoing basis. In addition, if at any time a patient has laboratory parameters 
obtained from a different outside laboratory, the Sponsor must be provided with a copy of the 
certification and a tabulation of the normal ranges for that laboratory.  
7.2.2.5.1  Hematology  
The following will be assessed:  
WBC  count  plus differential  (total  neutrophil  including  bands,  lymphocyte,  monocyte, 
eosinophil,  basophil  and other  counts),  RBC  count,  hemoglobin,  hematocrit  and platelet  count.  
Hematology  assessments will be  performed pre -dose at: 
• Screening/baseline  
• Cycle  1 Days  1, 8, 15 and 22. (For Cycle  1 Day 1, before  first dose unless  screening 
samples were collected <72 hrs prior).  
• Cycles  2 and 3:  Day 1 and Day 15 
• Cycles  4 and  onwards: Day  1 
• EOT  
7.2.2.5.2  Clinical chemistry  
The following will be  assessed:  
Sodium,  potassium,  chloride,  bicarbonate,  total calcium,  inorganic  phosphate,  magnesium,  urea 
or blood urea nitrogen (BUN), creatinine, uric acid, bilirubin (total, indirect and direct), AST, 
ALT, creatine  phosphokinase  (CPK) (if total CPK is elevated ≥  CTCAE  Grade  2, then weekly 
measure isoenzymes in blood, and myoglobin in blood and urine until resolved to ≤ CTCAE 
Grade 1), albumin, total protein, alkaline phosphatase, lactate dehydrogenase  (LDH), glucose, 
amylase, lipase.  
The following  do not need  to be collected  during  Phase  II: chloride,  urea (BUN),  and uric acid. 
These parameters will be measured pre -dose at:  
• Screening/baseline  
• Cycle  1 Days  1, 8, 15 and 22. (For Cycle  1 Day 1, before  first dose unless  screening 
samples were collected <72 hrs prior).  
• Cycles  2 and 3:  Day 1 and Day 15 
• Cycles  4 and  onwards: Day  1 
• EOT  
Additional  liver function  test (LFT  = AST,  ALT,  alkaline  phosphatase  and bilirubin  (total, 
indirect and direct)) will be assessed at the following times:  
• Cycle 2:  Day 8 and  Day 22 
• Cycle 4: Day  15 
Total  cholesterol, triglycerides,  HDL, and  LDL (to be  collected for  Phase Ib only):  
Array  BioPharma  
Amended  Protoco l Version 10 Confide ntial Page  132 
Protocol  No. CMEK162X2110  / C4221005  
PFIZER  CONFIDENTIAL   
 • Cycle 1 Day  1 
• Cycle 2 Day  1 and  Day 1 of every  other subsequent  cycle (C4D1,  C6D1 etc.) 
• EOT  
TSH  (free  T4, and free T3 should  also be measured  only if clinically  indicated)  will be assessed 
at the following times (to be collected for the Phase Ib part of the protocol only):  
• Cycle 1 Day  1 
• Day 1 of every  3 months (Cycle  4, 7 etc) 
• EOT  
7.2.2.5.3  Coagulation  
Coagulation profiles will include a prothrombin time (PT) or international normalized ratio  
(INR), activated partial thromboplastin time (aPTT), and fibrinogen  
Coagulation  profiles  will be performed  at: 
• Screening/baseline  
• Cycle  1 Day  1 before  first dose,  unless  screening  samples  were  collected  <72 hrs prior  
• Day 1 of all subsequent cycles  
• EOT  
7.2.2.5.4  Urinalysis  
Urine color and appearance should be evaluated. A macroscopic urinalysis (dipstick or other 
equivalent method according to local practice), including bilirubin, ketones, leukocytes, protein, 
glucose, blood, and specific gravity should be performed.  
Abnormal findings will be followed up with a microscopic evaluation and/or additional 
assessments  as clinically  indicated.  A microscopic  evaluation  (WBC/HPF,  RBC/HPF,  and any 
other  evaluations  depending  on macroscopic  findings)  need  only be performed  if the urinalysis 
result is abnormal (except for institutions where microscopic urinalysis is not available).  
Urinalysis  will be performed  at: 
• Screening/baseline  
• Cycle  1 Days  1 and 15 (Day  1 before  first dose,  unless  screening  samples  were  collected  
<72 hrs prior)  
• Day 1 of all subsequent  cycles  
• EOT  
Note : If at Screening/baseline there is documentation of [+2] result or higher for protein from 
urinalysis,  a 24-hour urine  collection  for total protein  and measured  creatinine  clearance  (CrCl) 
must  be obtained.  Whenever  a 24-hour urine  collection  is performed,  the total volume  of urine 
must be recorded on the appropriate eCRF.  
Array  BioPharma  
Amended  Protoco l Version 10 Confide ntial Page  133 
Protocol  No. CMEK162X2110  / C4221005  
PFIZER  CONFIDENTIAL   
 7.2.2.5.5  Pregnancy and assessments of fertility  
All females  of childbearing  potential  will have  a serum  pregnancy  test ≤72 hrs before  first dose 
of study  drug and a urine  or serum  during  study  treatment  (Day  1 of Cycle  2 and onwards)  and 
at the End of Treatment visit.  
A positive urine pregnancy  test requires immediate interruption of study  treatment until serum 
β-HCG is performed and found to be negative. If positive, the patient must be discontinued 
from the study.  
7.2.2.6  Dermatologic evaluations  
Note:  As of protocol  amendment  10, dermatologic  evaluations  will be performed  as 
outlined in Table 7 -2. 
Skin evaluations will be performed by dermatologists at Screening/baseline, every 8 weeks 
thereafter (±1 week; Day 1 of Cycle 3, 5 etc.) and at the End of Treatment visit to look for the 
appearance  of squamous  cell carcinoma  or keratoacanthomas.  This assessment  can be done  pre- 
or post -dose.  
In the occurrence  of these  lesions,  the lesions  should  be removed  and the patient  must  be treated 
as per institutional practice.  
7.2.2.7  Ophthalmologic examination  
Note:  As of protocol  amendment  10, ophthalmological  evaluations  will be performed  as 
outlined in Table 7 -2. Patients who have been on dual or triple combination treatment 
for ≥ 24 months (Cycle 25 Day 1 onward) without a retinal AE should be evaluated for 
visual acuity per local standard -of-care (recommended every 4 weeks) and at the EOT 
visit. A full ophthalmological examination is required if clinically indicated and at the 
EOT visit.  
Full ophthalmological  examination  including  slit lamp  examination,  visual  acuity  testing,  visual 
field testing, tonometry (IOP), OCT and indirect fundoscopy (with dilation) with attention to 
retinal abnormalities (especially CSR and RVO), should be performed by an ophthalmologist 
at the following time points and as clinically indicated:  
• Screening/baseline  
• Cycle 1 Day  15 
• Cycle  2 Days  1 and 15 
• Day 1 of all subsequent  Cycles*  
• EOT  
*Patients  who have  been  on dual- or triple -combination  treatment  for ≥ 24 months  (Cycle  25 
Day 1 onward) without a retinal AE should be evaluated for visual acuity at each 
scheduled patient visit and at the End of Treatment visit. A full ophthalmic examination 
is required if clinically indicated and at the End of Treatment visit.  
For patients with clinical suspicion of retinal changes additional assessments of fluorescein 
angiography  and/or  focal  ERG  (where  feasible)  are recommended  and should  be performed  
Array  BioPharma  
Amended  Protoco l Version 10 Confide ntial Page  134 
Protocol  No. CMEK162X2110  / C4221005  
PFIZER  CONFIDENTIAL   
 upon the discretion of the treating physician. Any observed abnormalities and/or changes to  
Screening/baseline must be documented in the Adverse Event eCRF.  
7.2.2.8  Cardiac assessments  
Note:  As of protocol  amendment  10, cardiac  assessments  will be performed  as outlined 
in Table 7 -2. 
 
7.2.2.8.1  Electrocardiogram (ECG) schedule for the  dual combination  
At Screening/baseline a standard 12 lead ECG (local assessment) will be performed to assess 
eligibility. Subsequent 12 -lead ECGs are to be conducted at the following time points:  
• Cycle  1 Days  1 and 15 predose  
• Cycle  2 Days  1 and 15 predose  
• Day 1 of all  subsequent  cycles predose  
• EOT  
For all patients, prior to the first administration of the LGX818 and MEK162 combination on 
Cycle 1 Day 1, three sequential 12 lead ECGs, separated by at least 5 -10 minutes, must be 
performed.  The average  of the triplicate  ECG  measurements  will serve  as the patient’s  baseline 
value for post -dose comparisons. Single ECGs  will be performed for the other  pre-dose ECGs 
during the study at the indicated time points, at EOT and if clinically indicated.  
7.2.2.8.2  Electrocardiogram  (ECG)  schedule  for the triple  combination  
At Screening/baseline a standard 12 lead ECG (local assessment) will be performed to assess 
eligibility.  Subsequent  triplicate  12-lead ECGs  are to be conducted  at the following  time points:  
• Cycle 1  Days  1 and  15: pre -dose,  1.5 hrs  (± 0.5 hr)  and 4  hr (±  0.5 hr) post -dose 
• Cycle  2 Day  1: pre-dose,  1.5 hrs (± 0.5 hr) and 4 hr (± 0.5 hr) post-dose 
• Cycle 2 Day  15: pre -dose 
• Day 1 of subsequent  cycles:  pre-dose 
• EOT  
All ECGs for patients treated with the triple study drug combination should be taken before a 
blood  sample  or at least 0.5 hours  after a blood  sample  to avoid  potential  effects  of blood -draw 
on ECG readout.  
For any patients  who had therapy  interrupted  due to QTcF  ≥ 481 ms, ECGs  should  be repeated 
7 days and 14 days after dose resumption (then as clinically indicated). For all patients 
experiencing a grade 3 QTcF interval prolongation, hypokalemia, hypomagnesaemia and 
oxygenation status should be monitored.  
All ECGs (except the screening ECG) for patients treated with either the dual or triple study 
drug combination will be independently reviewed by a central laboratory. Instructions for the 
collection and transmission of ECGs to the independent reviewer will be provided in the ECG 
Manual. Interpretation of the tracing must be made by a qualified physician and documented 
on the ECG eCRF page. Each ECG tracing print -out should be labeled with the study  number, 
patient  initials  (where  regulations  permit),  patient  number,  date,  and kept in the source  
Array  BioPharma  
Amended  Protoco l Version 10 Confide ntial Page  135 
Protocol  No. CMEK162X2110  / C4221005  
PFIZER  CONFIDENTIAL   
 
fu addition  to LGX818 MEK162/AR00426032  and LEE0l1/LE   803 anal ses documen ts at the study  site. Clinically significant abnoimalities present when the patient  signed 
infonned consent should be reported  on the relevant  medi cal histoiy/cmTent medical  conditions 
eCRF pa ge. Clin ically sign ificant findin gs must be discussed wi th the Sponsor's Medical 
Monitor prior to enrolling the patient in the study. New or worse ned clinically s ignifi cant 
findin gs occmT ing afte r infoimed  consent must be recorded on the AE eCRF page . 
7.2.2.8.3  Card iac imaging - MUGA (multiple gated acquisit ion) scan or 
echocardiogram  
• The left ventricular heait function will be evaluate d by ECHO or MUGA at 
Screening/base line, during  the study  on Da y 1 of Cycle 2 , Day 1 of eveiy third cycle until 
Cycle 11 (i.e. Day 1 of Cy cle 5, 8 and 11) and Day  1 of eve ry fomth  Cycle thereafter  (i.e. 
Day 1 of Cycle 15, 19 etc.), at the End of Treatme nt visit and if  clinically indicated 
iiTespective of the time of dosing . The same procedure should be used throughout the 
study.  
7.2.3  Pharmacokinetics  
The blood sampling regiine ns for deteimining  the phaimacokinetics of MEK162 and its priinaiy 
active metabolite AR00 426032, LGX818, and LEE0ll and its metabolite LEQ 803 after oral 
admin istration of the dual or triple combinatio n as applicable , ai·e give n in Table 7-3 (dose 
escalation)  and Table  7-4 (dual-combin ation Phase II aims  2 and 3, and aim 1 ifrequii·ed as per 
instruction from Sponsor/ triple -combination Phase II aim A). Blood sa mple s for LGX818, 
MEK162 /AR00 426032 and LEE011 /LEQ803 (as app licable) plasma conce ntr·ation 
measurements  will be collected  and evaluated  on all patients enrolled in the dose escalation and 
on a selected numb er of patients in the dual-combination  Phase II anns 2 and 3 (an d aim 1 if 
requii·ed as per instruction from the Sponsor for assess ment of the potential iinpact of 
demographic diffe rences (e.g. Japanese vs Caucasia n) and triple - combination Phase II aim A, 
paits of the study.  
 
Plasma sam ples remaining from the analysis may be retained by the Spo nsor fo r additional 
investigatio ns (e.g. long teim s tability, reproducibility) . 
A detai led description of the planned  phaimacokinetic  analyses  is given in Sectio n 10.5.3. 
7.2.3.1  Pharmacokinetic  blood  sample  collection  and handling  
7.2.3.1.1  Blood collect ion plan 
Dose Escalation : From all patients tr·eated in the dose escalation part , blood for full 
phaimacokinetic  profiling of LGX818  and MEKl 62, and LEE011 if  applicable wi ll be collected 
on Cycle 1 Days 1 and  15 (includin g a 24  hr post dose  sample on the follow ing day;  see Table 
7-4). Additio nally, pre-dose sa mple s will be collected o n Day 1 of Cycle 2 t hrough Cycle 10. 
Array  BioPharma  
Amended  Protoco l Version 10 Confide ntial Page  136 
Protocol  No. CMEK162X2110  / C4221005  
PFIZER  CONFIDENTIAL   
 Dual  combination  Phase  II arm 1: No PK sampling  will be performed  for patients  enrolled  in 
this arm. The exception to this is for newly enrolled patients in which an assessment of the 
potential impact of demographic differences on the PK of the LGX818 and MEK162 
combination may be made, if required as per instruction from the Sponsor.  
Dual combination Phase II arms 2 and 3 : From the first 10 patients in each arm, and if 
required as per instruction from the Sponsor, from additional patients in which an assessment 
of the potential impact of demographic differences on the PK of the LGX818 and MEK162 
combination  may be made.  Blood  for pharmacokinetic  profiling  of LGX818  and MEK162  will 
be collected  on Cycle  1 Days  1 and 15 (including  a 24 hr post dose sample  on the following  
day; see Table 7 -4) to study the  CCI     of the study  drug dual combination. The 4 - and 
6-hour post-dose samples  collected  during  dose escalation  are replaced  with a 5-hour post-dose 
sample  for these  patients  to collect  less blood  from  the patients  but still cover  the PK profile  of 
the study  drugs. Additionally, pre -dose samples will be collected on Day  1 of Cycle 2 through 
Cycle 10 for those patients.  
PK blood  sample  collection  time points  will remain  the same  if the dosing  schedule  of LGX818 
would change to a BID and/or QOD dosing schedule.  
Triple -combination Phase II arm A : From the first 10 patients, blood for pharmacokinetic 
profiling of LGX818 and MEK162 and LEE011 will be collected on Cycle 1 Days 1 and 15  
(including a 24 hr post dose sample on the following day; see Table 7 -4) to study the  CCI  
of the study  drug triple combination. Additionally, pre -dose samples will be collected on  
Day 1 of Cycle  2 through  Cycle  10 for  those patients.  
For all patients from whom PK samples are collected (either treated with the dual or triple 
combination),  exact  dates  and clock  times  of drug administration  and actual  PK blood  draw  will 
be recorded on the appropriate eCRF. Any sampling problems (e.g. patient took study drug 
before  draw  took place)  must  be noted  in the comments  section  of the eCRF  and on appropriate 
source  documentation.  The time of the last meal  should  be recorded  on PK sampling  days Cycle 
1 Days 1 and 15 on the appropriate eCRF.  
If vomiting  or diarrhea  occurs  within  4 hrs following  study  drugs  administration  on the days of 
full PK blood sampling, the exact time (using the 24 -h clock) of any vomiting or diarrhea 
episode should be recorded in a separate section of the eCRF in addition to recording this on 
the AE eCRF.  
Complete instructions for sample collection, processing, handling and shipment will be 
provided in the [CMEK162X2110 Laboratory Manual] . 
Table  7-4 Schedule  of blood  sample  collections  for PK in dose  escalation  
 
 
 
Cycle   
 
 
Day PK 
collection 
No. 
LGX818  PK 
Sample 
No 
LGX818  PK 
collection 
No. 
MEK162  PK 
sample 
No. 
MEK162  PK 
collection 
No. 
LEE011a PK 
sample 
No. 
LEE011a  
 
Scheduled time 
relative  to dosing  
1 1 101 101 201 201 501 501 Pre-dose*  
1 1 101 102 201 202 501 502 0.5 hr post dose 
1 1 101 103 201 203 501 503 1.5 hr post dose 
1 1 101 104 201 204 501 504 2.5 hr post dose 
1 1 101 105 201 205 501 505 4 hr post dose 
Array  BioPharma  
Amended  Protoco l Version 10 Confide ntial Page  137 
Protocol  No. CMEK162X2110  / C4221005  
PFIZER  CONFIDENTIAL   
  
 
 
 
Cycle   
 
 
Day PK 
collection 
No. 
LGX818  PK 
Sample 
No 
LGX818  PK 
collection 
No. 
MEK162  PK 
sample 
No. 
MEK162  PK 
collection 
No. 
LEE011a PK 
sample 
No. 
LEE011a  
 
Scheduled time 
relative  to dosing  
1 1 101 106 201 206 501 506 6 hr post dose 
1 1 101 107 201 207 501 507 8 hr post dose 
1 2 102 108 202 208 502 508 24 hr post dose 
immediately  prior to 
dosing on C1D2  
1 15 103 109 203 209 503 509 Pre-dose*  
1 15 103 110 203 210 503 510 0.5 hr post dose 
1 15 103 111 203 211 503 511 1.5 hr post dose 
1 15 103 112 203 212 503 512 2.5 hr post dose 
1 15 103 113 203 213 503 513 4 hr post dose 
1 15 103 114 203 214 503 514 6 hr post dose 
1 15 103 115 203 215 503 515 8 hr post dose 
1 16 104 116 204 216 504 516 24 hr post dose 
immediately  prior to 
dosing on C1D16**  
2 1 105 117 205 217 505 517 Pre-dose*  
3 1 106 118 206 218 506 518 Pre-dose*  
4 1 107 119 207 219 507 519 Pre-dose*  
5 1 108 120 208 220 508 520 Pre-dose*  
6 1 109 121 209 221 509 521 Pre-dose*  
7 1 110 122 210 222 510 522 Pre-dose*  
8 1 111 123 211 223 511 523 Pre-dose*  
9 1 112 124 212 224 512 524 Pre-dose*  
10***  1 113 125 213 225 513 525 Pre-dose*  
NA NA NA 1001+  NA 2001+  NA 5001+  Unscheduled****  
*Collect  PK sample  immediately  prior to the start of oral study  drug combination  (LGX818  and MEK162  or 
LGX818 and MEK162 and LEE011) administration.  
**Schedule  PK collection  together  with collection  fresh  tumor  and skin biopsy  (if applicable).  If it is not possible 
to collect  the tumor  and skin biopsy  on C1D16,  then an additional  unscheduled  pre-dose  PK sample  should  be 
collected on the day fresh tumor biopsy and skin biopsy is collected. For patients for who a fresh skin/tumor 
biopsy is not collected, the C1D16 PK sample should be collected on the scheduled time point and day. The 
PK sample  at this time point  should  be collected  prior to the collection  of the blood  for genetic  analysis  sample.  
*** Pre-dose  PK samples  will be collected  up to Cycle  10 only. 
****Applies  only to samples  collected  before  effective  date of Protocol  Amendment  Version  09. Unscheduled 
PK samples will be uniquely, sequentially numbered 1001, 1002 etc. for LGX818 and 2001, 2002 etc for 
MEK162 and 5001, 5002 etc for LEE011.  
a only for patients treated with the triple study drug combination.  
Table 7 -5 Schedule of blood sample collections for PK in dual -combination 
Phase  II arms  2 and 3, (and  arm 1 if requireda) / triple -combination 
Phase II arm A  
 
 
 
Cycle   
 
 
Day PK 
collection 
No. 
LGX818  PK 
Sample 
No 
LGX818  PK 
collection 
No. 
MEK162  PK 
sample 
No. 
MEK162  PK 
collection 
No. 
LEE011b PK 
sample 
No. 
LEE011b  
 
Scheduled time 
relative  to dosing  
1 1 301 301 401 401 601 601 Pre-dose*  
1 1 301 302 401 402 601 602 0.5 hr post -dose  
Array  BioPharma  
Amended  Protoco l Version 10 Confide ntial Page  138 
Protocol  No. CMEK162X2110  / C4221005  
PFIZER  CONFIDENTIAL   
  
 
 
 
Cycle   
 
 
Day PK 
collection 
No. 
LGX818  PK 
Sample 
No 
LGX818  PK 
collection 
No. 
MEK162  PK 
sample 
No. 
MEK162  PK 
collection 
No. 
LEE011b PK 
sample 
No. 
LEE011b  
 
Scheduled time 
relative  to dosing  
1 1 301 303 401 403 601 603 1.5 hr post dose 
1 1 301 304 401 404 601 604 2.5 hr post dose 
1 1 301 305 401 405 601 605 5 hr post dose 
1 1 301 306 401 406 601 606 8 hr post dose 
1 2 302 307 402 407 602 607 24 hr post dose 
immediately  prior to 
dosing on C1D2  
1 15 303 308 403 408 603 608 Pre-dose*  
1 15 303 309 403 409 603 609 0.5 hr post -dose  
1 15 303 310 403 410 603 610 1.5 hr post dose 
1 15 303 311 403 411 603 611 2.5 hr post dose 
1 15 303 312 403 412 603 612 5 hr post dose 
1 15 303 313 403 413 603 613 8 hr post dose 
1 16 304 314 404 414 604 614 24 hr post dose 
immediately  prior to 
dosing on C1D16**  
2 1 305 315 405 415 605 615 Pre-dose*  
3 1 306 316 406 416 606 616 Pre-dose*  
4 1 307 317 407 417 607 617 Pre-dose*  
5 1 308 318 408 418 608 618 Pre-dose*  
6 1 309 319 409 419 609 619 Pre-dose*  
7 1 310 320 410 420 610 620 Pre-dose*  
8 1 311 321 411 421 611 621 Pre-dose*  
9 1 312 322 412 422 612 622 Pre-dose*  
10***  1 313 323 413 423 613 623 Pre-dose*  
NA NA NA 3001+  NA 4001+  NA 6001+  Unscheduled****  
a Only for newly  enrolled  patients  in which  an assessment  of the potential  impact  of demographic  differences 
on the PK of the LGX818 and MEK162 combination may be made, if this assessment is required.  
b Only for patients treated with the triple study drug combination.  
*Collect  PK sample  immediately  prior to the start of oral study  drug combination  (LGX818  and MEK162  or 
LGX818 and MEK162 and LEE011) administration.  
**Schedule  PK collection  together  with collection  fresh  tumor  and skin biopsy.  If it is not possible  to collect  the 
tumor  and skin biopsy  on C1D16,  then an additional  unscheduled  pre-dose  PK sample  should  be collected  on 
the day fresh tumor biopsy and skin biopsy is collected. The PK sample at this time point should be collected 
prior to the collection of the blood for genetic analysis sample.  
*** Pre-dose  PK samples  will be collected  up to Cycle  10 only. 
**** Applies  only to samples  collected  before  effective  date of Protocol  Amendment  Version  09. Unscheduled 
PK samples will be uniquely, sequentially numbered 3001, 3002 etc. for LGX818 and 4001, 4002 etc for 
MEK162 and 6001, 6002 etc for LEE011.  
 
 
7.2.3.2  Analytical  method  
For all samples collected, one tube will be shipped to each analytical lab for analysis. Refer to 
the [CMEK162X2110  Laboratory  Manual]  for detailed  instructions  for the collection,  handling, 
and shipping of samples.  
Array  BioPharma  
Amended  Protoco l Version 10 Confide ntial Page  139 
Protocol  No. CMEK162X2110  / C4221005  
PFIZER  CONFIDENTIAL   
 Plasma LGX81 8 concentratio ns will be measured at the Sponsor or designated C RO using a 
validated liquid chrom atograp hy-tandem mass spectrometiy  (LC/MS/MS) assay . The lower 
limit of quantitation (LLOQ ) is cmTentl y 1.0 ng/mL. 
Plasma co ncenti·ations of MEK162 and its metabolite, AR00426032 , will be measured by the 
Sponsor (or designated CRO using a validated LC/MS/MS assay  with an LLOQ of 5.0 ng/mL. 
Plasma co ncentl'ations of LEE0ll and its metabolite, LEQ 803 wi ll be measured (only 
applicable for ti·iple  comb ination) at the Sponsor or at a designated  CRO  using a validated  liquid 
chrom atograp hy-tandem mass specti·ometiy assay ( LC/MS/MS). The lower limit of 
quantitation (LLOQ ) is cmTe ntly 1.0 ng/mL. 
7.2.4  Biomarkers  
Note:  As of protocol amendment 10 , biomarker samples at time  of relapse will  no longer 
be collected.  
As outlined in Table 7-6, tumor, samples  will be collected before  and/or during 
ti·eatmentwith the LGX 818 andMEK162 orLGX818 andMEK1 62 andLEE0l  1 dual and ti·iple 
combin ation  res ective l to investi  ate the effect of the dm at the molecular andcellu lar level  

Array  BioPharma  
Amended  Protoco l Version 10 Confide ntial Page  140 
Protocol  No. CMEK162X2110  / C4221005  
PFIZER  CONFIDENTIAL   
 Table 7 -6 Biomarker  sample  collection  schedule  
Visit Details  
Tumor  Biopsy Sample s 
Screening/baseline Phase lb: A fresh tumor  biopsy  at Screening /base line is highly  recommended if 
access ible, and required from a t least one pa tient of each dose level". 
 
Phase II: A fresh tumor biopsy a t Screening /base line is mandatory for all 
patients, however archival tissue  is accep table in some cases,  please see  
Section  7.2.4.1.1. 
Cycle 1 Day 16 ( + 5 days..  ) A fresh  on-treatment tumor  biopsy  is highly  recommended, if access ible and if a 
fresh  tumor biopsy  was co llected at Screening /base line, at C1D16 (+ 5 days.. ) 
before the patients receive their morning dose on that day. This biopsy is 
required from a t least one patient of each  dose  level during the dose  esca lation, 
and from a t least 15 metastatic melanoma  patients eac h enrolled in Phase II 
arm 2 and  3 dual combination and in Phase II arm A triple combination, and at 
least 6 metastatic CRC pa tients • enrolled in Phase II arm1 dual combination. 
.. For scheduling purposes the biopsy can  be taken 5 days a fter the speci fied 
time point  or earlier during  Cycle  1 at the discre tion o f the investigator on Day 8 
(always pre-morning dose on  the scheduled day  and always paired with a pre- 
dose  PK sample (excep t for Phase II arm 1 dual combination if no PK is 
collected)). 
At time of relapse  If feas ible acco rding to the in vestigator, collection o f a fresh tumor biopsy  is 
strongly encouraged upon  patient relapse (irrespec tive of whether a fresh tumor 
biopsy was collected a t Screening /Base line or on -treatment). This sample will 
be used to investigate changes  in pa thway signa ling and potential mechanisms 
of resistance. The sample should  be collected while the patient is still on study 
treatment or as soon as possible a fter study treatment discon tinuation. For 
Phase II patients who are followed for disease progression a fter study 
treatment discon tinuation, a fresh tumor biopsy should only  be co llected if the 
patient  relapses  within 2 months of study drugs discontinuation. 
Archival tumor sample with Requested  from all patients and  required for those  in the Phase lb and II parts 
an acco mpanying pathology  not providing  a fresh tumor biopsy samp le. Sample  should be a para ffin 
report , at  embedded block  (preferred ) or a represen tative number o f slides  as described  
Screening/baseline in the (CMEK162X2110  Laboratory  Manual] . 
• evaluable paired tumor biopsies (pre and  on-treatment (i.e. Screening/baseline and  C1D16  + 5 days, or 
C1D8)) 

Array  BioPharma  
Amended  Protoco l Version 10 Confide ntial Page  141 
Protocol  No. CMEK162X2110  / C4221005  
PFIZER  CONFIDENTIAL   
 
7.2.4.1  Biomarker  assessments  in tumor  
7.2.4.1.1  Screen ing/basel ine tumor  sample  
Representative tumor tissue (archival and/or fresh tumor sample) wi ll be required from all 
patie nts at Sc reening/base line. F or patie nts enrolled in the Phase II paii o f the study, a fresh 
tumor biopsy at Screening/base line is mand ato1y for all patients , unless sufficie nt fresh tumor 
tissue was co llected dming local moleculai · pre-screening which can be submitted to the 
Sponsor-designate d laborato1y at Sc reening (please refer to [CMEK162X2110 Laborato1y 
Manual] for details  on collection , handling and shipm ent). If a tumor biopsy  was collected after 
the last anti-neoplas tic treatment within 2 months prior to study enrollment, the  archival tissue 
of this tumor biopsy wi ll be acceptab le for enrollment instead o f the fresh tumor biopsy . This 
sample will be used to investigate the of molecules in addition to BRAF that 
ai·e relevant  to RAF/MEK./ERK  and PI3K/AKT  signaling pathways,  (e.g. NRAS,  PTEN, c-Kit, 
PIK3CA , etc.), to investigate the PTEN protein expression (IHC) and to potentia lly identify 
other predictive markers of efficacy . In addition, these samples are planned to be used for 
assess ment of ot her genetic ab nonnalities in the RAF/MEK./ERK and EGFR/PI3 K/AKT 
signa ling pathways , other pa thways t hat may interact wit h the RAF/MEK./ERK and 
EGFR/PI3K/AKT  signalin g pathways,  or ai·e thought to be important in cancer. 
 
 
Array  BioPharma  
Amended  Protoco l Version 10 Confide ntial Page  142 
Protocol  No. CMEK162X2110  / C4221005  
PFIZER  CONFIDENTIAL   
 
 
 
 
7.2.4.1.4 Collection of tumor  biopsies 
Two b iopsy passes must be obtained for all fresh tumor biopsies. The proce ssing is descr ibed 
in Table 7-7. Detailed instruction s for the collection , hand ling, and shipme nt of samples are 
outlined in the [CME K162X2 110 L aborato 1y Manual]. 
Table  7-7 Processing  requirements  for fresh  tumor  biopsy  samples  
Tumor fragme nt 
number Processing  requirements   
1 Forma lin-fixed paraffin - embedded  (FFPE ) To be processed /embed ded 
together  2 Forma lin-fixed paraffin - embedded  (FFPE ) 
 

Array  BioPharma  
Amended  Protoco l Version 10 Confide ntial Page  143 
Protocol  No. CMEK162X2110  / C4221005  
PFIZER  CONFIDENTIAL   
 
 
 
 
 
 
 
- 

Array  BioPharma  
Amended  Protoco l Version 10 Confide ntial Page  144 
Protocol  No. CMEK162X2110  / C4221005  
PFIZER  CONFIDENTIAL   
  
 
7.2.5  Other assessments  
No additional tests will be perfo1med on patie nts entered into this study. 
 
8 Safety  monitoring  and reporting  
8.1 Adverse  events  and Serious  Adverse  Events  
The definiti ons of an AE and an SAE  can be found in Section  14.7, Appendix  7. 
AEs will be repo1ied by the patie nt (or, when approp riate, by a caregiver , Slmogate,  or the 
patie nt's legally authorized represe ntative).  
The investigato r and any qualified designees are responsible for detecting , doclllllenting, and 
recording eve nts that meet the definition of an AE or SAE an d remain responsible to pursue 
and obtain adeq uate infonnatio n both to dete nnine the outcome and to assess  whether the 
event meets t he criteria for classificat ion as an SAE  or cause d the patie nt to disco ntinue the 
study  treatment. 
Each patient will be questio ned about the occmTe nce of AEs in a nonleading manner.  
In addition, the investigato r may be  requested by  Pfizer  Safety  to obtain specific follow-up 
info1matio n in an exped ited fas hion. 
8.1.1  Time  Period  and Frequency  for Collecting  AE and SAE Information  
The time period for actively  eliciting and collecting AEs  and SAEs  ("active  collectio n period") 
for each  patie nt beg ins from  the time the patient provides infor med co nsent, which is obtained 
before  the patie nt's paiiicipatio n in the study (ie, before undergo ing anystudy related  proced ure 
and/or receiv ing study treatment) , through  and inclu ding a minimlllll  of 30 calendar  days, except 
as indicated below , after the last admin istration of t he study treat ment. 
Follow-up by the investigator continues throughout an d after the ac tive collectio n period a nd 
until the AE or SAE  or its sequelae resolve or stabilize at a level  accep table to the investigator 
and Pfizer co ncurs with that assess ment. 
For patie nts who are screen failures, the active  collectio n period ends when screen failure status 
is dete1 mined. 
If the patient withdraws from the study  and also withdraws  consent for the collectio n of future 
info1mation, the active co llectio n period ends when consent is withdraw n. 
If a patient definitively  discontinues or temporarily discontinues study treatment beca use of  an 
AE or SA E, the AE  or SAE  must be recorded on the CRF and  the SAE repor ted using the CT 
SAE Repo 1i Fo1m. 
Investigators  ai·e not obligated  to actively see k AEs or SAEs after the patient has concluded 
study pa1iicipatio n. Howeve r, if the investigato r learns of any SAE,  including a death, at any 
time after a patient has completed the study, and he/she considers the event to be reaso nably 

Array  BioPharma  
Amended  Protoco l Version 10 Confide ntial Page  145 
Protocol  No. CMEK162X2110  / C4221005  
PFIZER  CONFIDENTIAL   
 related  to the study  treatment,  the investigator  must  promptly  report  the SAE  to Pfizer  using  the 
CT SAE Report Form.  
Patients  who sign the molecular  pre-screening  ICF 
For patients  who sign the molecular  pre-screening  ICF (see Section  4.1 and Section  7.1.1 ), AEs 
which occur after signature of this consent will only  be captured if they meet the definition of 
serious as outlined in Section 14.7.2 and are associated with study related procedures (e.g. an 
invasive procedure such as biopsy). Once the study ICF is signed, all AEs per the descriptions 
below will be captured in the AE eCRF.  
Patients  who sign the study  ICF 
For patients  whose  BRAF  mutational  status  is known  and sign the study  ICF, AEs that begin  or 
worsen after informed consent should be recorded in the AE eCRF. Conditions that were 
already  present  at the time of informed  consent  should  be recorded  in the Medical  History  eCRF. 
Adverse event monitoring should be continued for at least 30 days following the last dose of 
study treatment. Adverse events (including lab abnormalities that constitute AEs) should be 
described using a diagnosis whenever possible, rather than individual underlying signs and 
symptoms. When a clear diagnosis cannot be identified, each sign or symptom should be 
reported as a separate Adverse Event.  
Adverse events will be assessed according to the Common Terminology Criteria for Adverse 
Events (CTCAE) version 4.03. If CTCAE grading does not exist for an adverse event, the 
severity  of mild,  moderate,  severe,  and life-threatening, corresponding to Grades 1 - 4, will be 
used. CTCAE Grade 5 (death) will not be used in this study; rather, information about deaths 
will be collected though a Death form.  
The occurrence of adverse events should be sought by  non-directive questioning of the  patient 
(subject) during the screening process after signing informed consent and at each visit during 
the study. Adverse events also may be detected when they are volunteered by the patient 
(subject) during the screening process or between visits, or through physical examination, 
laboratory  test, or other  assessments.  As far as possible,  each adverse  event  should  be evaluated 
to determine:  
1. The severity  grade  (CTCAE  Grade  1-4) 
2. Its duration (start  and end dates)  
3. Its relationship to the study  treatment (reasonable possibility  that AE is related: No, Yes) 
4. Action  taken  with respect  to study  or investigational  treatment  (none,  dose adjusted, 
temporarily interrupted, permanently discontinued, unknown, not applicable)  
5. Whether  medication  or therapy  taken  (no concomitant  medication/non -drug therapy, 
concomitant medication/non -drug therapy)  
6. Whether  it is serious,  where  a serious  adverse  event  (SAE)  is defined  as in Section  8.2.1  
All adverse events should be treated appropriately. If a concomitant medication or non -drug 
therapy is given, this action should be recorded on the Adverse Event eCRF.  
Once  an adverse  event  is detected,  it should  be followed  until its resolution  or until it is judged 
to be permanent,  and assessment  should  be made  at each visit (or more  frequently,  if necessary)  
Array  BioPharma  
Amended  Protoco l Version 10 Confide ntial Page  146 
Protocol  No. CMEK162X2110  / C4221005  
PFIZER  CONFIDENTIAL   
 of any changes in severity, the suspected relationship to the study treatment, the interventions 
required to treat it, and the outcome.  
8.1.1.1  Reporting  SAEs  to Pfizer  Safety  
All SAEs  occurring  in a patient  during  the active  collection  period  as described  in Section  8.1.1 . 
are reported to Pfizer Safety on the CT SAE Report Form immediately upon awareness and 
under no circumstance should this exceed 24 hours, as indicated in Section 14.7, Appendix 7 . 
The investigator will submit any updated SAE data to the sponsor within 24  hours of it being 
available.  
If a patient begins a new anticancer therapy, SAEs occurring during the above indicated active 
collection  period  must  still be reported  to Pfizer  Safety  irrespective  of any intervening  treatment. 
Note  that a switch  to a commercially  available  version  of the study  treatment  is considered  as a 
new anticancer therapy for the purposes of SAE reporting.  
8.1.1.2  Recording  Nonserious AEs  and SAEs  on the CRF 
All nonserious  AEs and SAEs  occurring  in a patient  during  the active  collection  period,  which 
begins after obtaining informed consent as described in Section 11.3, will be recorded on the 
AE section of the CRF.  
The investigator is to record on the CRF all directly observed and all spontaneously reported 
AEs and SAEs reported by the patient.  
If a patient begins a new anticancer therapy, the recording period for nonserious AEs ends at 
the time the new treatment  is started;  however,  SAEs  must  continue  to be recorded  on the CRF 
during the above indicated active collection period.  Note that a switch to a commercially 
available version of the study treatment is considered as a new anticancer therapy for the 
purposes of SAE reporting.  
8.1.2  Methods  of Detecting  AEs and SAEs  
The method of recording, evaluating, and assessing causality of AEs and SAEs and the 
procedures  for completing  and transmitting  SAE  reports  are provided  in Section  14.7,  Appendix 
7. 
Care will be taken not to introduce bias when detecting AEs and/or SAEs.  Open -ended and 
nonleading verbal questioning of the patient is the preferred method to inquire about AE 
occurrences.  
8.1.3  Follow -up of AEs and SAEs  
After the initial AE/SAE report, the investigator is required to proactively follow each patient 
at subsequent  visits/contacts.  For each event,  the investigator  must  pursue  and obtain  adequate 
information  until resolution,  stabilization,  the event  is otherwise  explained,  or the patient  is lost 
to follow -up. 
In general, follow -up information will include a description of the event in sufficient detail to 
allow  for a complete  medical  assessment  of the case and independent  determination  of possible 
causality. Any  information  relevant  to the event,  such as concomitant  medications  and illnesses,  
Array  BioPharma  
Amended  Protoco l Version 10 Confide ntial Page  147 
Protocol  No. CMEK162X2110  / C4221005  
PFIZER  CONFIDENTIAL   
 must  be provided.  In the case of a patient  death,  a summary  of available  autopsy  findings  must 
be submitted as soon as possible to Pfizer Safety.  
Further  information  on follow -up procedures  is given  in Section  14.7,  Appendix  7. 
8.1.4  Regulatory  Reporting Requirements for SAEs  
Prompt notification by the investigator to the sponsor of an SAE is essential so that legal 
obligations and ethical responsibilities towards the safety of patients and the safety of a study 
treatment under clinical investigation are met.  
The sponsor has a legal responsibility to notify both the local regulatory authority and other 
regulatory agencies about the safety of a study treatment under clinical investigation.  The 
sponsor will comply with country  specific regulatory requirements relating to safety  reporting 
to the regulatory authority, IRBs/ECs, and investigators.  
Investigator safety reports must be prepared for SUSARs according to local regulatory 
requirements and sponsor policy and forwarded to investigators as necessary.  
An investigator who receives SUSARs or other specific safety information (e.g., summary or 
listing of SAEs) from the sponsor will review and then file it along with the Investigator’s 
Brochure for the study and will notify the IRB/EC, if appropriate according to local 
requirements.  
8.1.5  Exposure  During  Pregnancy  or Breastfeeding  and Occupational 
Exposure  
Exposure to the study treatment under study during pregnancy or breastfeeding and 
occupational  exposure  are reportable  to Pfizer  Safety  within  24 hours  of investigator 
awareness.  
8.1.5.1  Exposure During Pregnancy  
An EDP  occurs  if: 
• A female patient is found to be pregnant while receiving or after discontinuing study 
treatment.  
• A male patient who is receiving or has discontinued study treatment exposes a female 
partner prior to or around the time of conception.  
• A female  is found  to be pregnant  while  being  exposed  or having  been  exposed  to study 
treatment due to environmental exposure. Below are examples of environmental 
exposure during pregnancy:  
• A female family  member or healthcare provider reports that she is pregnant 
after having been exposed to the study treatment by ingestion.  
• A male family  member or healthcare provider who has been exposed to the 
study treatment by ingestion then exposes his female partner prior to or 
around the time of conception.  
Array  BioPharma  
Amended  Protoco l Version 10 Confide ntial Page  148 
Protocol  No. CMEK162X2110  / C4221005  
PFIZER  CONFIDENTIAL   
 The investigator must report EDP to Pfizer Safety within 24 hours of the investigator’s 
awareness, irrespective of whether an SAE has occurred.  The initial information submitted 
should  include  the anticipated  date of delivery  (see below  for information  related  to termination 
of pregnancy).  
• If EDP occurs in a patient or a patient’s partner, the investigator must report this 
information to Pfizer Safety on the CT SAE Report Form and an EDP Supplemental 
Form, regardless of whether an SAE has occurred.  Details of the pregnancy will be 
collected after the start of study treatment and until 30 days after last dose.  
• If EDP occurs in the setting of environmental exposure, the investigator must report 
information to Pfizer Safety using the CT SAE Report Form and EDP Supplemental 
Form.  Since the exposure information does not pertain to the patient enrolled in the 
study,  the information  is not recorded  on a CRF;  however,  a copy  of the completed CT 
SAE Report Form is maintained in the investigator site file.  
Follow -up is conducted  to obtain  general  information  on the pregnancy  and its outcome  for all 
EDP reports with an unknown outcome.  The investigator will follow the pregnancy until 
completion (or until pregnancy termination) and notify Pfizer Safety of the outcome as a 
follow -up to the initial EDP Supplemental Form.  In the case of a live birth, the structural 
integrity of the neonate can be assessed at the time of birth.  In the event of a termination, the 
reason(s) for termination should be specified and, if clinically  possible, the structural integrity 
of the terminated fetus should be assessed by gross  visual  inspection  (unless  preprocedure  test 
findings are conclusive for a congenital anomaly and the findings are reported).  
Abnormal pregnancy outcomes are considered SAEs.  If the outcome of the pregnancy meets 
the criteria for an SAE (ie, ectopic pregnancy,  spontaneous  abortion,  intrauterine  fetal demise, 
neonatal death, or congenital anomaly [in a live born baby, a terminated fetus, an intrauterine 
fetal demise, or a neonatal death]), the investigator should follow the procedures for reporting 
SAEs.  Additional information about pregnancy outcomes that are reported to Pfizer Safety  as 
SAEs follows:  
• Spontaneous  abortion  including  miscarriage  and missed  abortion;  
• Neonatal deaths that occur within 1 month of birth should be reported, without regard 
to causality, as SAEs.  In addition, infant deaths after 1 month should be reported as 
SAEs when the investigator assesses the infant death as related or possibly related to 
exposure to the study treatment.  
Additional  information  regarding  the EDP  may be requested  by the sponsor.  Further  follow -up 
of birth  outcomes  will be handled  on a case by case basis  (e.g.,  follow -up on preterm  infants  to 
identify  developmental delays).  In the case of paternal exposure, the investigator will provide 
the patient  with the Pregnant  Partner  Release  of Information  Form  to deliver  to his partner.  The 
investigator must document in the source documents that the patient was given the Pregnant 
Partner Release of Information Form to provide to his partner.  
8.1.5.2  Exposure During Breastfeeding  
An exposure  during  breastfeeding  occurs  if: 
Array  BioPharma  
Amended  Protoco l Version 10 Confide ntial Page  149 
Protocol  No. CMEK162X2110  / C4221005  
PFIZER  CONFIDENTIAL   
 • A female patient is found to be breastfeeding while receiving or after discontinuing 
study treatment.  
• A female is found to be breastfeeding while being exposed or having been exposed to 
study  treatment (ie, environmental exposure).  An example of environmental exposure 
during  breastfeeding  is a female  family  member  or healthcare  provider  who reports  that 
she is breastfeeding after having been exposed to the study treatment by inhalation or 
skin contact.  
The investigator  must  report  exposure  during  breastfeeding  to Pfizer  Safety  within  24 hours  of 
the investigator’s awareness, irrespective of whether an SAE has occurred.  The information 
must  be reported  using  the CT SAE  Report  Form.  When  exposure  during  breastfeeding  occurs 
in the setting of environmental exposure, the exposure information does not pertain to the 
patient  enrolled  in the study,  so the information  is not recorded  on a CRF.  However,  a copy  of 
the completed CT SAE Report Form is maintained in the investigator site file.  
An exposure  during  breastfeeding  report  is not created  when  a Pfizer  drug specifically  approved 
for use in breastfeeding women (e.g., vitamins) is administered in accord with authorized use. 
However, if the infant experiences an SAE associated with such a drug, the SAE is reported 
together with the exposure during breastfeeding.  
8.1.5.3  Occupational Exposure  
An occupational exposure occurs when a person receives unplanned direct contact with the 
study treatment, which may or may not lead to the occurrence of an AE.  Such persons may 
include healthcare providers, family members, and other roles that are involved in the trial 
patient’s care.  
The investigator must report occupational exposure to Pfizer Safety within 24 hours of the 
investigator’s awareness, regardless of whether there is an associated SAE.  The information 
must be reported using the CT SAE Report Form.  Since the information does not pertain to a 
patient  enrolled  in the study,  the information  is not recorded  on a CRF;  however,  a copy  of the 
completed CT SAE Report Form is maintained in the investigator site file.  
8.1.6  Cardiovascular  and Death  Events  
Cardiovascular events are to be managed per the dose modification guidelines in Section 6.3. 
Additionally, cardiovascular events  will be reported per AE and SAE reporting guidelines  and 
ECG criteria, as detailed in Section 8.1 and Section 14.7, Appendix 7 and Section 7.2.2.8 , 
respectively.  AEs and SAEs  that result  in death are  to be reported  per the reporting  guidelines 
as outlined in Section 8.1 and Section 14.7, Appendix 7 . 
8.1.7  Disease -Related  Events  and/or  Disease  Related  Outcomes  Not 
Qualifying as AEs or SAEs  
Not applicable.  
8.1.8  Adverse  Events of  Special Interest  
Not applicable.  
Array  BioPharma  
Amended  Protoco l Version 10 Confide ntial Page  150 
Protocol  No. CMEK162X2110  / C4221005  
PFIZER  CONFIDENTIAL   
 8.1.8.1  Lack of Efficacy  
Lack  of efficacy  is reportable  to Pfizer  Safety  only if associated  with an SAE.  
8.1.9  Medical Device Deficiencies  
Not applicable.  
8.1.10  Medication Errors  
Medication  errors  may result  from  the administration  or consumption  of the study  treatment  by 
the wrong patient, or at the wrong time, or at the wrong dosage strength.  
Exposures  to the study  treatment  under  study  may occur  in clinical  trial settings,  such as 
medication errors.  
 
Safety Event  Recorded  on the AE CRF  Reported  on the CT SAE  Report  Form 
to Pfizer Safety Within 24 Hours of 
Awareness  
Medication  errors  Only  if associated  with an 
AE or SAE  Only  if associated with an SAE 
 
Medication  errors  include:  
• Medication errors involving patient exposure to the study  treatment;  
• Potential  medication  errors  or uses outside  of what  is foreseen  in the protocol  that do 
or do not involve the study patient.  
In the event of  a medication dosing  error, the sponsor  should be notified  within 24 hours.  
If applicable,  any associated  AE(s),  serious  and nonserious,  are recorded  on the AE page  of 
the CRF.  
Medication  errors  should  be reported  to Pfizer  Safety  within  24 hours  on a CT SAE  Report 
Form only when associated with an SAE . 
8.2 Treatment  Overdose  
There  is no known  antidote  for an overdose  of either  LGX818,  MEK162  or LEE011.  Supportive 
measures should be instituted.  
In the event  of an overdose,  the investigator/treating  physician  should:  
1. Contact the medical monitor within 24 hours.  
2. Closely  monitor the patient for any  AEs/SAEs  and laboratory  abnormalities  for at least 
5 half -lives or 28 calendar days after the overdose of study treatment (whichever is 
longer).  Closely monitor the patient for any AEs/SAEs.  
3. Document  the quantity  of the excess  dose as well as the duration  of the overdose  in the 
CRF.  
4. Overdose  is reportable to Safety  only when associated with an SAE . 
Array  BioPharma  
Amended  Protoco l Version 10 Confide ntial Page  151 
Protocol  No. CMEK162X2110  / C4221005  
PFIZER  CONFIDENTIAL   
 Decisions regarding dose interruptions or modifications will be made by the Investigator in 
consultation with the Sponsor Medical Monitor based on the clinical evaluation of the patient.  
8.3 Warnings  and precautions  
No evidence available at the time of the approval of this study protocol indicated that special 
warnings or precautions were appropriate, other than those noted in the provided Investigator 
Brochure. Additional safety information collected between IB updates will be communicated 
in the form of Investigator Notifications. This information will be included in the patient 
informed consent and should be discussed with the patient during the study as needed.  
8.4 Data  Monitoring  Committee  
A Data Monitoring Committee (DMC) will not be in place for this trial. Instead, the Sponsor 
will convene  a joint teleconference  with the participating  Investigators  of the dose escalation  at 
the end of each treatment cohort. At the dose escalation teleconference the clinical course 
(available safety information including both DLTs and all ≥ CTCAE Grade 2 toxicity data 
during  Cycle  1, PK and PD data as appropriate)  for each patient  in the current  dose cohort  will 
be described in detail. Updated safety data on other ongoing patients, including data in later 
cycles, will be discussed as well.  
Dose  escalation  decisions  will be based  on a clinical  synthesis  of all relevant  available  data and 
not solely  on DLT  information.  Selection  of the actual  dose for the next cohort  of patients  will 
be guided by the BLRM (with EWOC) recommendation, and a medical review of available 
relevant clinical, PK, PD and laboratory data. The parties i.e. study Investigators and the 
Sponsor, must reach a consensus on whether to declare MTD, escalate the dose any  further, or 
whether to de -escalate and/or expand recruitment into particular cohorts. The Sponsor will 
prepare minutes from these meetings and circulate them to all concerned ( Section 6.2.4.2.1 ). 
 
9 Data  collection  and management  
9.1 Data  confidentiality  
Information about study subjects will be kept confidential and managed under the applicable 
laws and regulations. Those regulations require a signed subject authorization informing the 
subject of the following:  
• What  protected  health  information  (PHI)  will be collected  from  subjects  in this study  
• Who  will have  access  to that information  and why 
• Who will use or disclose that information  
• The rights of a research subject to revoke their authorization for use of their PHI. 
In the event that a subject revokes authorization to collect or use PHI, the investigator, by 
regulation, retains the ability  to use all information collected prior to the revocation of subject 
authorization. For subjects that have revoked authorization to collect or use PHI, attempts 
should  be made  to obtain  permission  to collect  at least vital status  (i.e. that the subject  is alive) 
at the end of their scheduled study period.  
Array  BioPharma  
Amended  Protoco l Version 10 Confide ntial Page  152 
Protocol  No. CMEK162X2110  / C4221005  
PFIZER  CONFIDENTIAL   
 The data collection system for this study uses built -in security features to encrypt all data for 
transmission in both directions, preventing unauthorized access to confidential participant 
information. Access to the system will be controlled by a sequence of individually assigned 
user identification  codes  and passwords,  made  available  only to authorized  personnel  who have 
completed prerequisite training.  
9.2 Site monitoring  
Before  study  initiation,  at a site initiation  visit or at an investigator’s  meeting,  Sponsor  personnel 
(or designated  CRO)  will review  the protocol  and eCRFs  with the investigators  and their staff. 
During the study, the field monitor will visit the site regularly to check the completeness of 
patient records, the accuracy of entries on the eCRFs, the adherence to the protocol to Good 
Clinical  Practice,  the progress  of enrollment,  and to ensure  that study  treatment  is being  stored, 
dispensed,  and accounted  for according  to specifications.  Key study  personnel  must  be available 
to assist the field monitor during these visits.  
The investigator must maintain source documents for each patient in the study, consisting of 
case and visit notes (hospital or clinic medical records) containing demographic and medical 
information, laboratory data, electrocardiograms, and the results of any other tests or 
assessments.  All information  recorded  on eCRFs  must  be traceable  to source  documents  in the 
patient's file. The investigator must also keep the original signed informed consent form (a 
signed copy is given to the patient).  
The investigator  must  give the monitor  access  to all relevant  source  documents  to confirm  their 
consistency  with the eCRF  entries.  The Sponsor’s  monitoring  standards  require  full verification 
for the presence of informed consent, adherence to the inclusion/exclusion criteria and 
documentation  of SAEs.  Additional  checks  of the consistency  of the source  data with the eCRFs 
are performed according to the study -specific monitoring plan.  
9.3 Data  collection  
The designated  investigator  staff will enter  the data required  by the protocol  into the Electronic 
Case Report Forms (eCRF). The eCRFs have been built using fully validated secure web - 
enabled  software  that conforms  to 21 CFR  Part 11 requirements,  Investigator  site staff will not 
be given  access  to the EDC  system  until they have  been  trained.  Automatic  validation  programs 
check  for data discrepancies  in the eCRFs  and allow  modification  or verification  of the entered 
data by the investigator staff.  
The Principal  Investigator  is responsible  for assuring  that the data entered  into eCRF  is complete, 
accurate, and that entry and updates are performed in a timely manner.  
PK and biomarker (blood and tissue) samples drawn during the course of the study will be 
collected from the Investigator sites and analyzed by a Sponsor -assigned laboratory or 
contracted central labs. ECG data (except the screening/baseline ECG) collected during the 
study  will be reviewed  and processed  centrally  by a specialist  CRO.  Designated  investigational 
site staff will enter the information required by  the protocol into the appropriate eCRF (and/or 
designated laboratory requisition forms that are printed on 2 or 3 -part, non -carbon -required 
paper). Field monitors will review the eCRFs and laboratory paper requisition forms for 
accuracy  and completeness  and instruct  site personnel  to make  any required  corrections  or 
Array  BioPharma  
Amended  Protoco l Version 10 Confide ntial Page  153 
Protocol  No. CMEK162X2110  / C4221005  
PFIZER  CONFIDENTIAL   
 additions.  One copy  of the requisition  form  will be forwarded  to each analytical  laboratory  with 
the respective  sample(s)  by the field monitor  or by the designated  investigational  site staff;  and 
one copy will be retained at the investigational site.  
9.4 Database  management  and quality  control  
Sponsor  personnel  (or designated  CRO)  will review  the data entered  by investigational  staff for 
completeness and accuracy. Electronic data queries stating the nature of the problem and 
requesting clarification will be created for discrepancies and missing values and sent to the 
investigational site via the EDC system. Designated investigator site staff are required to 
respond promptly to queries and to make any necessary changes to the data.  
Concomitant  treatments  entered  into the database  will be coded  using  the WHO  Drug  Reference 
List, which employs the Anatomical Therapeutic Chemical classification system. Medical 
history/current medical conditions and adverse events will be coded using the Medical 
dictionary for regulatory activities (MedDRA) terminology.  
Biomarker and PK samples and ECG (except screening/baseline) will be processed centrally, 
and the results for these will be sent electronically to the Sponsor (or a designated CRO).  
After  database  lock,  the investigator  will receive  a CD-ROM  or paper  copies  of the patient  data 
for archiving at the investigational site.  
 
10 Statistical  methods  and data analysis  
[Any language regarding the triple combination of LGX818/MEK162/LEE011 in this 
Section is not applicable to the USA and Singapore]  
Data will be analyzed by the Sponsor and/or designated CRO. Any data analysis carried out 
independently by the investigator must be submitted to the Sponsor before publication or 
presentation.  
It is planned that the data from participating centers in this protocol will be combined, so that 
an adequate number of patients will be available for analysis. Data will be summarized with 
respect to demographic and baseline characteristics, efficacy and safety observations and 
measurements and all relevant PK and PD measurements.  
Categorical data will be presented as frequencies and percentages. For continuous  data,  mean, 
standard deviation, median, 25th and 75th percentiles, minimum, and maximum will be 
presented.  
An initial  clinical  study  report  (CSR)  will be presented  based  on the Ph Ib/II patients’  data from 
the dual study  drug combination.  The cut-off for reporting  will be either  LPFV  + 18 months  or 
when  80% of the patients  treated  with the dual study  drug combination  can be assessed  for PFS, 
whichever occurs first.  
Additional data for any patients continuing to receive the LGX818 and MEK162 dual 
combination past the cut off point for the initial reporting, as allowed by  the protocol, and the 
Phase  Ib/II patients’  data from  the LGX818  and MEK162  and LEE011  triple  combination  will 
be summarized in a final CSR that will be prepared when all patients have completed or 
discontinued from the study.  
Array  BioPharma  
Amended  Protoco l Version 10 Confide ntial Page  154 
Protocol  No. CMEK162X2110  / C4221005  
PFIZER  CONFIDENTIAL   
 The following  rules  will be followed  for reporting  results  unless  stated  otherwise:  
• Phase Ib dose escalation data : Cohorts of patients treated with the same dose 
combination  and regimen  during  the dose escalation  part will be pooled  into a common 
treatment group. All summaries, listings, figures and analyses will be displayed / 
performed by treatment group unless otherwise specified.  
• Phase  II data : Data will be summarized and listed by  study  arm. 
Screen failure patients are those who signed the informed consent, but never started the study 
treatment for any  reason. For these patients, the eCRF data collected, Section 7.1.2.2 , will not 
be included in any analysis, but will be reported in the CSR as separate listings.  
10.1 Analysis  sets 
10.1.1  Full Analysis  Set 
The FAS includes all patients who received at least one dose of LGX818 or MEK162 or 
LEE011.  Patients  will be classified  according  to the planned  treatment  regimen  (dose,  schedule, 
tablet  variant).  The FAS will be used for all listings  of raw data.  Unless  otherwise  specified  the 
FAS will be the default analysis set used for all analyses.  
10.1.2  Safety  Set 
The safety set includes all patients who received at least one dose of LGX818 or MEK162 or 
LEE011, and have at least one valid post -baseline safety assessment. The statement that a 
patient had no AEs (on the AE eCRF) constitutes a valid safety assessment.  
Patients  will be classified  according  to treatment  received,  where  treatment  received  is defined 
as: 
• The treatment  assigned  if it was received  at least once,  or 
• The first treatment  received  when  starting  therapy  with study  treatment  if the assigned 
treatment was never received.  
10.1.3  Dose -Determining  Set 
The dose-determining  set (DDS)  includes  all patients  from  the safety  set who either  completed 
a minimum exposure requirement and have sufficient safety evaluations or discontinued 
prematurely due to a dose limiting toxicity (DLT).  
A patient is considered to have met the minimum exposure requirement if having received at 
least 75% of the planned combination doses (i.e. 21 out of 28 planned daily doses for QD or 
BID,  11 out of 14 planned  doses  for an every  other  day dosing  schedule,  and 16 days out of 21 
days for 3 week on, 1 week off dosing schedule) of study treatment within the first Cycle of 
dosing. The length of a cycle is 28 days.  
Patients  who do not experience  DLT  during  the first cycle  will be considered  to have  sufficient 
safety evaluations if they have been observed for ≥ 28 days following the first dose, and are 
considered  by both the Sponsor  and Investigators  to have  enough  safety  data to conclude  that a 
DLT did not occur.  
Array  BioPharma  
Amended  Protoco l Version 10 Confide ntial Page  155 
Protocol  No. CMEK162X2110  / C4221005  
PFIZER  CONFIDENTIAL   
 10.2 Patient  demographics/other  baseline  characteristics  
Demographic and other baseline data including disease characteristics will be summarized 
descriptively for all patients in the FAS.  
10.3 Treatments  (study  treatment,  concomitant  therapies, 
compliance)  
10.3.1  Study  treatment  
The actual dose and duration  in days of LGX818 and MEK162 and LEE011 treatment as well 
as the dose intensity  (computed  as the ratio of actual  dose received  and actual  duration)  and the 
relative dose intensity (computed as the ratio of dose intensity and planned dose 
received/planned duration), will be listed and summarized by means of descriptive statistics. 
The summary data will be presented for each treatment cycle individually, as well as for all 
study days as a single category. The daily doses of LGX818, MEK162, and LEE011 for each 
patient will be summarized using descriptive statistics (e.g. mean, median, and modal doses). 
The FAS will be used. For patients who switch to the new MEK162 tablet variants, dose 
intensity will be calculated based on the bioavailability ratio between the original and new 
MEK162 tablet variants if the new and old variants are not similar. Details will be provided in 
report analysis plan (RAP).  
10.3.2  Concomitant therapies  
Concomitant medications and significant non -drug therapies prior to and after the start of the 
study  drug treatment  will be listed  by patient  and summarized  by ATC  (Anatomical  therapeutic 
chemical classification system) term by means of contingency tables.  
10.3.3  Compliance  
Compliance to the protocol will be assessed by the number and proportion of patients with 
protocol deviations. These will be identified prior to database lock and will be listed and 
summarized.  
10.4 Primary  objective  
Phase Ib 
The primary  purpose  of the Phase  Ib part of the study  is to estimate  the MTD(s)  and/or  RP2D(s) 
of the LGX818 and MEK162 dual combination and MTD(s) and/or RP2D(s) of LGX818 and 
MEK162  and LEE011  triple  combination  in patients  with solid  tumors  harboring  a BRAF  V600 
mutation  (see Section  3). The corresponding  method  of analysis  is an adaptive  Bayesian  logistic 
regression model (BLRM) guided by the escalation with overdose control (EWOC) principle 
(Babb 1998 ). 
Phase II 
The primary  purpose  of the Phase  II part of the study  is to assess  the efficacy  of the RP2D(s)  of 
the dual combination of  LGX818 and  MEK162  combination in  patients with  metastatic BRAF  
Array  BioPharma  
Amended  Protoco l Version 10 Confide ntial Page  156 
Protocol  No. CMEK162X2110  / C4221005  
PFIZER  CONFIDENTIAL   
 V600 mutant mCRC (arm 1), in patients with metastatic BRAF V600 mutant melanoma who 
have  progressed  after prior  treatment  with selective  BRAF  inhibitor  (arm  2) and in patients  with 
metastatic  BRAF  V600  mutant  melanoma  who are naïve  to prior  treatment  with selective  BRAF 
inhibitor (arm 3). The primary purpose of the Phase II part of triple combination of LGX818 
and MEK162 and LEE011 is to assess the efficacy of the RP2D(s) in patients with metastatic 
BRAF  V600  mutant  melanoma  who are naïve  to prior  treatment  with selective  BRAF  inhibitor 
(arm A).  
10.4.1  Variable 
Phase Ib  
Estimation  of the MTD  of the combination  treatment  will be based  upon  the estimation  of the 
probability of DLT in Cycle 1 for patients in the dose -determining set. This probability is 
estimated by the model in Section 10.4.2. Note that more than one dose -combination of dual 
combination (LGX818 and MEK162) or triple combination (LGX818 and MEK162 and 
LEE011)  may be identified  as a MTD,  and more  than one RP2D  may be established  for further 
evaluation in the phase II part of the study.  
The dose determining  set (DDS)  will be used for all dose determining  analyses.  
Phase II 
 
Dual combination (LGX818 and MEK162)  
For arm 1, the primary  variable  is the Disease  Control  Rate (DCR)  at week  16. DCR  is defined 
as the proportion of patients with a best overall response of complete response (CR), partial 
response (PR) or stable disease (SD). Estimation of the true DCR in this part of the study will 
be based upon observed DCR for patients in the FAS. The true DCR is estimated using a 
Bayesian  design.  The primary  analysis  of the DCR  will be based  on the local  review  of overall 
lesion responses.  
For arms 2 and 3 , the primary  variable is the Objective Response Rate (ORR), defined as the 
proportion  of patients  with a best overall  response  of complete  response  (CR)  or partial  response 
(PR).  Estimation  of the true ORR  in this part of the study  will be based  upon  observed  ORR  for 
patients  in the FAS.  The true ORR  is estimated  using  a Bayesian  design.  The Primary  analysis 
of the ORR will be based on the local review of overall lesion responses.  
Triple combination (LGX818 and MEK162 and LEE011)  
For arm A, the primary variable is the Objective Response Rate (ORR), defined as the 
proportion  of patients  with a best overall  response  of complete  response  (CR)  or partial  response 
(PR).  Estimation  of the true ORR  in this part of the study  will be based  upon  observed  ORR  for 
patients  in the FAS.  The true ORR  is estimated  using  a Bayesian  design.  The Primary  analysis 
of the ORR will be based on the local review of overall lesion responses.  
Array  BioPharma  
Amended  Protoco l Version 10 Confide ntial Page  157 
Protocol  No. CMEK162X2110  / C4221005  
PFIZER  CONFIDENTIAL   
 10.4.2  Statistical  hypothesis,  model,  and method  of analysis  
10.4.2.1  Phase Ib 
An adaptive BLRM guided by the EWOC principle will guide the dose escalation of the 
combination treatment to its MTD(s)/RP2D(s). A 5 -parameter BLRM for combination 
treatment will be fitted on the dose -limiting toxicity data (i.e. absence or presence of DLT) 
accumulated throughout the dose escalation, for modeling the dose -DLT relationship of 
LGX818 (capsule formulation) and MEK162 when given in combination. While developing 
dual combination (LGX818 and MEK162) all information available about the dose -DLT 
relationship  of the single  agents  LGX818  (i.e., from  [LGX818X2101]  study  on both the capsule 
and micro -emulsion  formulations)  and MEK162  [ARRAY -162-111 study]  will be summarized 
in prior  distributions, based on a meta -analytical  predictive  approach  to properly  down -weight 
the information. The 5 parameter BLRM will be extended to a 10 -parameter BLRM to model 
the dose-DLT  relationship of LGX818 (capsule  formulation)  and MEK162  and LEE011  when 
given in combination. Three week on 1 week off DLT data from [CLEE011X2101] will be 
summarized in prior distributions based on a meta -analytical predictive approach to properly 
down -weight the information.  
The 5-parameter  BLRM  for MEK162  original  tablet  
The 5 -parameter BLRM is formulated in the following way: Let π 1(d1) be the probability of a 
DLT if LGX818 is given as a single agent at dose d 1, and π 2(d2) the probability of a DLT if 
MEK162 is given as a single agent at dose d 2. The dose -response relationship is then modeled 
as: 
LGX818:  logit(π1(d1))  = log(α1)  + β1log(d1/d1*)  
MEK162  original  tablet:  logit(π2(d2))  = log(α2)  + β2log(d2/d2*) 
Odds(π12(d1,d2))) = π12(d1,d2)/(1 - π12(d1,d2))  
= exp(η12(d 1/d1*)(d 2/d2*))(π1(d1)+  π2(d2)  - π1(d1)π2(d2))/((1 - π1(d1))(1 - π2(d2))),  
where  
• logit(π .(d.)) = log[π .(d.)/{1- π.(d.)}], π(d) is the probability  of a DLT  at dose d, 
• π12(d1,d2)  is the probability  of a DLT  given  the combination doses  
• d1*= 100mg  and d2*= 60mg  are the reference  doses  of LGX818  and MEK162  original 
tablet respectively,  
• α1, α2, β1, β2 > 0 and -∞ < η12 < ∞ is a scalar.  With  η12 the interaction  term between 
LGX818 and MEK162 original tablet.  
For further  details  on the statistical  model  including  the prior  specification  for the model 
parameters refer to Appendix 5 . 
The 5-parameter  BLRM  for MEK162  smaller  tablet/  new tablet  variant  
The 5 -parameter BLRM is formulated in the following way: Let π 1(d1) be the probability of a 
DLT  if LGX818  is given  as a single  agent  at dose d1, and π3(d3) the probability  of a DLT  if 
Array  BioPharma  
Amended  Protoco l Version 10 Confide ntial Page  158 
Protocol  No. CMEK162X2110  / C4221005  
PFIZER  CONFIDENTIAL   
 MEK162 is given as a single agent at dose d 3. The dose -response relationship is then modeled 
as: 
LGX818:  logit(π1(d1))  = log(α1)  + β1log(d1/d1*)  
MEK162  smaller  tablet/  new tablet  variant:  logit(π3(d3))  = log(α3)  + β3log(d3/d3*) 
Odds(π13(d1,d3))) = π13(d1,d3)/(1 - π13(d1,d3))  
= exp(η13(d 1/d1*)(d 3/d3*)))(π1(d1)+  π3(d3)  - π1(d1)π3(d3))/((1 - π1(d1))(1 - π3(d3))),  
where  
• logit(π .(d.)) = log[π .(d.)/{1- π.(d.)}], π(d) is the probability  of a DLT  at dose d, 
• π13(d1,d3) is the probability  of a DLT  given the combination doses  
• d1*= 100mg  and d3* are the reference  doses  of LGX818  and MEK162  respectively.  The 
value  of d3* will be determined  prior  to first DETC  for the MEK162  smaller  tablet/  new 
tablet variant.  
• α1, α3, β1, β3 > 0 and -∞ < η13 < ∞ is a scalar.  With  η13 the interaction  term between 
LGX818 and MEK162 smaller tablet/new tablet variant.  
For further  details  on the statistical  model  including  the prior  specification  for the model 
parameters refer to Appendix 5.  
The 10-parameter  BLRM  
The 10 -parameter BLRM is formulated in the following way: Let λ1(d1) be the probability  of 
DLT if LGX818 is given as a single agent at QD dose d1, λ2(d2) the probability of DLT if 
MEK162  is given  as a single  agent  at BID dose d2, and λ3(d3)  the probability  of DLT  if LEE011 
is given as a single agent at 3 week on 1 week off dose of d3.  
The single  agent  dose-DLT  relationships  are then modeled  as: 
LGX818: logit(π1(d1)) = log(α1) + β1log(d1/d1*) 
MEK162:  logit(π2(d2))  = log(α2)  + β2log(d2/d2*) 
LEE011: logit(π4(d4)) = log(α4) + β3log(d4/d4*)  
The dose-DLT  relationships  of the dual combinations  of LGX818+MEK162, 
LGX818+LEE011 and MEK162+LEE011 are modeled as:  
Odds(π12(d1,d2)))  = π12(d1,d2)/(1 - π12(d1,d2))  
= exp(η12(d 1/d1*)(d 2/d2*))(π1(d1)+  π2(d2)  - π1(d1)π2(d2))/((1 - π1(d1))(1 - π2(d2))), 
Odds(π14(d1,d4))) = π14(d1,d4)/(1 - π14(d1,d4))  
= exp(η14(d 1/d1*)(d 4/d4*)))(π1(d1)+  π4(d4)  - π1(d1)π4(d4))/((1 - π1(d1))(1 - π4(d4))), 
Odds(π24(d2,d4))) = π24(d2,d4)/(1 - π24(d2,d4))  
= exp(η24(d 4/d4*)(d 2/d2*)))(π2(d2)+  π4(d4)  – π2(d2)π4(d4))/((1 - π2(d2))(1 - π4(d4))), 
The dose -DLT relationship of the triple combination is subsequently modeled as: 
Odds(π124(d1, d2,d4))) = π124 (d1, d2,d4)/(1 - π124(d1,d2,d4))  
Array  BioPharma  
Amended  Protoco l Version 10 Confide ntial Page  159 
Protocol  No. CMEK162X2110  / C4221005  
PFIZER  CONFIDENTIAL   
 = exp(η124(d1/d1*)(d2/d2*)(d4/d4*)+ η12(d1/d1*)(d2/d2*)+ η14(d1/d1*)(d4/d4*)+ 
η24(d2/d2*)(d4/d4*))(  π1(d1)+  π2(d2)+  π4(d4)  – π1(d1)π2(d2) -π1(d1)π4(d4) -π2(d2)π4(d4)+  
π1(d1)π2(d2)  π4(d4))/((1 - π1(d1))(1 - π2(d2))(1 - π4(d4))),  
where logit(π.(d.)) = log[π.(d.)/{1 - π.(d.)}], d1* = 100mg (QD), d2* = 60mg (BID) and d4* = 
400mg (3 week on 1 week off) are the reference doses of LGX818, MEK162 and LEE011 
respectively, α1, α2, α4, β1, β2 , β4> 0 and -∞ < ζ12, ζ13, ζ23, ζ124 < ∞ are constants.  
For further details on the statistical model including the prior specification for the model 
parameters refer to Appendix 6 . 
Dose  recommendation  
Dose recommendation will be based on posterior summaries including the mean, median, 
standard deviation, 95% - credible interval, and the probability that the true DLT rate for each 
dose combination lies in one of the following categories:  
• [0%,  16%)  under -dosing  
• [16%, 35%) targeted toxicity  
• [35%, 100%] excessive toxicity  
Following the principle of EWOC, after each cohort of patients the dose combination 
recommended by the BLRM is the one with the highest posterior probability of DLT in the 
target interval [16%, 35%) among the doses fulfilling the overdose criterion that there is less 
than 25% chance of excessive toxicity.  
In addition, the maximum inter -cohort combined dose escalation across the 2 combination 
partners  is limited  to 100%,  where  100%  refers  to the sum of the relative  escalation  for each of 
the combination partners, e.g. 100% and 0% increase for LGX818 and MEK162 respectively, 
0% and 100% increase for LGX818 and MEK162 respectively, etc.  
Summaries  of the posterior  distribution  of model  parameters  and posterior  distribution  of DLT 
rates  based  on the DLT  data from  all patients  enrolled  in the study  and included  in the DDS  will 
be produced.  
10.4.2.2  Phase II 
Efficacy  will be assessed  using  the local  CT/MRI  assessments  evaluated  under  RECIST  version 
1.1, Appendix 1 . The Best Overall Response (BOR) for each patient and individual lesion 
measurements will be listed. The (BOR) is the best response recorded from the start of the 
treatment until disease progression. Based on patients’ BOR during study, the Objective 
Response Rate (ORR) and the Disease control Rate (DCR) are then calculated.  
The ORR is defined as the proportion of patients with a best overall response of Complete 
Response (CR) or Partial Response (PR). The DCR is defined as CR or PR or Stable Disease 
(SD).  
Patients  who withdrew  prematurely  due to progression  of disease  without  having  any post-dose 
tumor assessment will be classified as treatment failures. Similarly, patients who died due to 
their disease without having any post -dose tumor assessment will be classified as treatment 
failures.  
Array  BioPharma  
Amended  Protoco l Version 10 Confide ntial Page  160 
Protocol  No. CMEK162X2110  / C4221005  
PFIZER  CONFIDENTIAL   
 Arm 1 dual combination:  patients  with metastatic  BRAF  V600  mutant  mCRC  
A Bayesian design will be used in order to estimate the true DCR. Inferential statements will 
be based on the uncertainty of this quantity. For a Bayesian design it is required to specify a 
prior distribution for the parameter of interest, in this case DCR.  
For the current  study,  the prior  clinical  assumption  for a MEK  inhibitor  in BRAF  V600  mutant 
mCRC at pre -specified dose -levels will be used in order to derive a minimally informative 
unimodal Beta prior distribution that reflects the level of uncertainty around the DCR before 
starting  the current  trial. At completion  of the study,  this prior  distribution  will be updated  with 
all the data available in this part of the study.  
Once updated, the distribution summarizes the probability  that the true DCR at the dose of the 
LGX818 and MEK162 combination used in the Phase II lies in the following categories:  
• [0, 20%) unacceptable efficacy  
• [20%, 30%) limited efficacy  
• [30%, 40%) moderate efficacy  
• [40%, 100%] clinically  relevant efficacy  
If the observed  DCR  is equal  or greater  than 30% (i.e. 9 or more  patients  with BOR  of SD, PR 
or CR),  then this will be considered  as evidence  of clinically  relevant  anti-tumor  efficacy  of the 
LGX818  and MEK162  combination  in BRAF  V600  mutant  mCRC.  Note  that for a sample  size 
of 28, if at least 9 patients  with DCR  are observed,  then the true DCR  has posterior  risk of being 
in the unacceptable efficacy category of less than 10% ( Section 10.8 ). If the observed DCR is 
less than 20% then inactivity will be declared.  
A minimally  informative  Beta prior  distribution  of the true DCR  is derived  as follows:  a priori 
it is assumed that the true mean of the DCR equals 30%. A true DCR of 30% is the midpoint 
between limited and moderate efficacy and serves as a compromise between a skeptical view 
assuming  the treatment  has only limited  efficacy  and an optimistic  view  assuming  the treatment 
has moderate efficacy.  
The parameters  of the minimally  informative  Beta prior  distribution  of the DCR  are then derived  
noting  that b = 1 and a (a + b ) = 0 . 30 i.e.  a = 0 . 428 and b = 1 
Arm 2 dual combination:  patients  with metastatic  BRAF  V600  mutant  melanoma 
who have progressed after prior treatment with selective BRAF inhibitor  
A Bayesian design will be used in order to estimate the true ORR. Inferential statements will 
be based on the uncertainty of this quantity. For a Bayesian design it is required to specify a 
prior distribution for the parameter of interest, in this case ORR:  
For the current  study,  the prior  clinical  assumption  for a MEK  inhibitor  in BRAF  V600  mutant 
melanoma at pre -specified dose -levels will be used in order to derive a minimally  informative 
unimodal Beta prior distribution that reflects the level of uncertainty around the ORR before 
starting  the current  trial. At completion  of the study,  this prior  distribution  will be updated  with 
all the data available in this part of the study.  

Array  BioPharma  
Amended  Protoco l Version 10 Confide ntial Page  161 
Protocol  No. CMEK162X2110  / C4221005  
PFIZER  CONFIDENTIAL   
 Once updated, the distribution summarizes the probability  that the true ORR at the dose of the 
LGX818 and MEK162 combination used in the Phase II lies in the following categories:  
• [0, 10%) unacceptable efficacy  
• [10%,15%) limited efficacy  
• [15%, 20%) moderate efficacy  
• [20%, 100%] clinically  relevant efficacy  
If the observed ORR is equal or greater than 15% (i.e. 7 or more patients with BOR of PR or 
CR), then this will be considered as evidence of clinically relevant anti -tumor efficacy of the 
LGX818 and MEK162 combination in BRAF  V600 mutant melanoma. Note that for a sample 
size of 41, if at least 7 responses  (CR or PR) are observed,  then the true ORR  has posterior  risk 
of being  in the unacceptable  efficacy  category  of less than 10% (Section  10.8).  If the observed 
ORR is less than 10% then inactivity will be declared.  
A minimally  informative  Beta prior  distribution  of the true ORR  is derived  as follows:  a priori 
it is assumed that the true mean of the ORR equals 15%. A true ORR of 15% is the midpoint 
between limited and moderate efficacy and serves as a compromise between a skeptical view 
assuming  the treatment  has only limited  efficacy  and an optimistic  view  assuming  the treatment 
has moderate efficacy.  
The parameters  of the minimally  informative  Beta prior  distribution  of the ORR  are then derived  
noting  that b = 1 and a (a + b ) = 0 . 15 i.e. a = 0 . 176 and b = 1 
Arm 3  dual combination / Arm A triple combination: patients with metastatic 
BRAF  V600  mutant  melanoma  who are naïve  to prior  treatment  with selective 
BRAF inhibitor  
A Bayesian design will also be used in order to estimate the true ORR in these populations. 
Inferential  statements  will be based  on the uncertainty  of this quantity.  For a Bayesian  design  it 
is required to specify a prior distribution for the parameter of interest, in this case ORR:  
For the current study, a minimally informative unimodal Beta prior distribution 
(Neuenschwander  et al 2008 ) is developed  for ORR.  The prior  distribution  reflects  the level  of 
uncertainty around the ORR before starting the current trial. At completion of the study, this 
prior distribution will be updated with all the data available in this part of the study.  
Once updated, the distribution summarizes the probability  that the true ORR at the dose of the 
dual combination  (LGX818  and MEK162)  and triple  combination  (LGX818  and MEK162  and 
LEE011) used in the Phase II lies in the following categories:  
• [0, 30%) unacceptable efficacy  
• [30%, 40%) limited efficacy  
• [40%, 50%) moderate efficacy  
• [50%, 100%] clinically  significant efficacy  
If the observed ORR is equal to or greater than 40% (i.e. 16 or more patients with BOR of PR 
or CR for a sample size of 40), then this will be considered as evidence of clinically relevant 
anti-tumor efficacy of the dual combination (LGX818 and MEK162) or triple combination 
(LGX818  and MEK162  and LEE011)  in BRAF  V600  mutant  melanoma  patients  who have  not 

Array  BioPharma  
Amended  Protoco l Version 10 Confide ntial Page  162 
Protocol  No. CMEK162X2110  / C4221005  
PFIZER  CONFIDENTIAL   
 
been previou sly treated wit h selective BRAF inh ibitor. Note that for a sample s ize of 40 , if at 
least 16 respo nses (CR or PR) are observed , then the hue ORR  has poste rior risk of being in the 
unacceptable efficacy catego 1y of less than 10% (Section 10.8). If the observed ORR is less 
than 30% t hen inact ivity wi ll be declared. A minimally infonnative Beta pr ior dish·ibution of 
the h11e ORR  is derived  as follows: a priori  it is assumed  that the h11e mean of the ORR  equals 
40%. A  hue ORR of 40% i s the midpoint between limited and moderate efficacy  and serves as 
a compromise between a skeptical v iew assuming the h·eatment has only limited efficacy and 
an optimistic view as suming the h·eatine nt has moderate efficacy . 
The parameters  of the minima lly infonnative Beta  prior dish·ibution of the ORR  are then derived 
noting that b =l and a/(a+b)=0.4 i.e. a=0.67 and b=l. 
Re-assessment  of the MTD/RP2D  
A re-asses sment of the dual-comb ination MT D/RP2D will be perfonned (using dual - 
combination data  only) after at  least 10  patients in the Phase II paii (aim 1 + aim 2 + aim 3) of 
the study have been h'eated for at least one cycle. A re-assessment of the h'iple-combinatio n 
MTD/RP2D  will be perfo 1med after at least 10 patients in the Phase II paii  of the study  have 
been h ·eated with the h ·iple combinatio n for at least one cycle . The BLRM will be re-nm to 
confnm t hat the cmTent dose combination sti ll satisfies the overdose criteria for the model. If 
this combination fails to satisfy the criteria, a change to the doses l mder study wi ll be made 
subject  to the BLRM recommendat ion. If different RP2D s ai·e used for ann 1 , aim 2 and aim 3, 
respective ly, then the above re-asses sment will be done by RP2D rather than combining t he 
aims. 
Emollme nt in the Phase II anns will not be inte 1n1pted due to this re-assessment of the 
MTD/RP2D.  
10.4.3  Handling  of missing  values /censoring/discontinuations  
Patients who are ineligible for the DDS may be replaced a s descr ibed in Section 7.1.4.2 . 
Continuing events (e.g. AEs, concom itant medicatio n, etc) will be summarized using the data 
cut-off date as the date of completion , with an ind icatio n within listings that the event is 
continuing . For patients who discontinue the study with ongoing events , the discontinuatio n 
date will be used as the completion  date of the event  with the approp riate censoring as descr ibed 
in the above pai·agraph.  
Patie nts for whom no best  overall response can be assessed at the time of the primaiy  analysis 
will be h·eated as h·eatinent failmes. 
The reason fo r discontinuation from study  will be smnmai ·ized and listed , along with dates  of 
first a nd last study dmg h'eatine nt, dmation of expo sme to study dmg h'eatment and date of 
discontinuation for each patient. 
Othe r missing data will simply  be noted as missing on appropr iate tables/listing s. 
10.4.4  Supportive  analyses  
 
Array  BioPharma  
Amended  Protoco l Version 10 Confide ntial Page  163 
Protocol  No. CMEK162X2110  / C4221005  
PFIZER  CONFIDENTIAL   
 If deemed  necessary,  a sensitivity  analysis  will be performed  using  central  imaging  assessments 
according  to RECIST  v1.1 (see Appendix  1, Section  14.1). The same  method  of analysis  as for 
the primary analysis will be used, using the FAS.  
10.5 Secondary  objectives  
10.5.1  Efficacy  
Phase Ib. A secondary objective of the Phase Ib is to assess preliminary clinical anti -tumor 
activity  of the combination  in patients  with BRAF  V600 -dependent  advanced  solid  tumors.  For 
all efficacy analyses the FAS will be used.  
Anti-tumor  activity  will be assessed  using  the Investigator  imaging  assessments  under  RECIST 
version 1.1, Appendix 1 . The Best Overall Response (BOR) for each patient and individual 
lesion measurements will be listed. The (BOR) is the best response recorded from the start of 
the treatment  until disease  progression.  ORR  will be estimated  for this patient  population.  TTR 
and DOR will be assessed if at least one responder is observed.  
Phase  II. Local  imaging  assessments  will be used for all Phase  II efficacy  assessments  of tumor 
activity. The FAS will be used.  
Overall survival (OS) is defined as the time from start of treatment to date of death due to any 
cause.  If a patient  is not known  to have  died,  survival  will be censored  at the date of last contact. 
Kaplan -Meier  estimates  with confidence  intervals  for median  survival  and survival  probabilities 
for specific time points will be presented.  
The secondary  endpoint progression -free survival (PFS) will be analyzed using Kaplan -Meier 
estimates (including plots) with 95% confidence interval for median survival. If a patient has 
not had an event,  he/she  will be censored  at the date of last adequate  response  assessment.  PFS 
is defined as the number of days from the first day of treatment to the date of the first 
documented progression of disease or date of death, whichever occurs first. PFS will be 
summarized by arm.  
Kaplan -Meier estimates based on all responders with 95% confidence intervals will be 
presented for the secondary  endpoint duration of overall response (DOR). This analysis based 
on responders will be used as a descriptive analysis. DOR is the time between the date of first 
documented response (CR or PR) and the date of documented progression or censoring. 
Censoring  will occur  at the last adequate  tumor  assessment  date at which  continued  response  is 
documented.  
The secondary endpoint time to response (TTR) is the time between the date of first treatment 
administration and the first documented response (CR or PR). Patients who did not achieve a 
confirmed  PR or CR will be censored  at the last adequate  tumor  assessment  date when  they did 
not progress, or at maximum follow -up (i.e. FPFV to LPLV used for analysis) when they had 
an event for PFS.  
If deemed necessary, analyses of TTR and DOR as described above, will be performed using 
central imaging assessments (RECIST v1.1). FAS will be applied.  
Array  BioPharma  
Amended  Protoco l Version 10 Confide ntial Page  164 
Protocol  No. CMEK162X2110  / C4221005  
PFIZER  CONFIDENTIAL   
 10.5.2  Safety  
For all safety analyses, the safety set will be used, unless otherwise specified. The assessment 
of safety will be based mainly on the frequency of adverse events and on the number of 
laboratory  values  that fall outside  of pre-determined  ranges.  All individual  safety  data reported 
in the clinical data base will be listed by patient and dose level.  
The overall observation period will be divided into three mutually  exclusive segments:  
• pre-treatment  period:  from  day of patient’s  informed  consent  signature  to the day before 
first dose of study treatment.  
• on-treatment  period:  from  day of first dose of study  treatment  to 30 days after last dose of 
study medication.  
• post-treatment  period: starting at day  31 after last dose of study  treatment.  
10.5.2.1  Adverse  events  
The incidence  of treatment -emergent adverse  events  (new  or worsening  from  baseline)  will be 
summarized by primary system organ class, severity based on the National Cancer Institute’s 
Common Terminology Criteria for Adverse Events (CTCAE) version 4.03, type of adverse 
event, and relationship to the study  drug by  dose level on the pool of patients recruited during 
the dose escalation  part of the study  as well as on the complete  pool of patients  (including  dose 
escalation and Phase II parts). Deaths reportable as SAEs and non -fatal serious adverse events 
will be listed  by patient  and tabulated  by primary  system  organ  class,  type of adverse  event,  and 
dose level.  
DLTs  will be listed  and their incidence  summarized  by primary  system  organ  class,  worst  grade 
based on the CTCAE version 4.03, type of adverse event, and by dose level in the dose 
escalation part. The dose -determining set will be used for these summaries.  
Details  of analysis  to be performed  are given  in the Reporting  and Analysis  Plan (RAP).  
10.5.2.2  Laboratory  abnormalities  
All laboratory values will be converted into SI units and the severity grade calculated using 
CTCAE, version 4.03. Parameters for which a grading does not exist will be classified into 
low/normal/high group by means of laboratory normal ranges.  
For each laboratory  test (e.g. hematology, biochemistry etc) a listing of laboratory values will 
be provided by laboratory parameter, patient, and dose level. The frequency of notable 
laboratory abnormalities (i.e., newly  occurring CTC grade 3 or 4 laboratory toxicities) will be 
displayed by parameter, cycle and dose level. Similarly, the frequency of all laboratory 
abnormalities  will be displayed  by parameter,  worst  CTCAE  grade  experienced  and dose level. 
A separate listing will display notable laboratory abnormalities.  
Laboratory data will be summarized by presenting grade shift tables for those parameters for 
which  CTCAE  allows  classification.  All remaining  data will be summarized  by presenting  shift 
tables based on normal ranges.  
Laboratory data will be also be displayed by presenting summary statistics of raw data and 
change from baseline values (means, medians, standard deviations, ranges).  
Array  BioPharma  
Amended  Protoco l Version 10 Confide ntial Page  165 
Protocol  No. CMEK162X2110  / C4221005  
PFIZER  CONFIDENTIAL   
 10.5.2.3  Other Safety  data 
Any other safety information collected will be listed and notable values will be flagged. Any 
statistical tests performed to explore the data will be used only to highlight any interesting 
comparisons that may warrant further consideration. Additionally, the following outputs will 
be produced:  
ECG  
• shift table baseline  to worst  on-treatment result  for overall assessments  
• listing  of ECG evaluations  for all  patients with  at least  one abnormality.  
Vital signs  
• shift table baseline to worst on -treatment result  
• table  with descriptive  statistics  at baseline,  one or several  post-baseline  time points  and 
change from baseline to this/these post -baseline time points.  
Ocular  
• Listing  of ocular  assessment  for all patients  with at least one abnormality  will be 
presented.  
10.5.2.4  Tolerability  
Tolerability  of study  drug treatment will be assessed by  summarizing the number of treatment 
dose interruptions and dose reductions. Reasons for dose interruption and dose reductions will 
be listed  by patient  and summarized.  Cumulative  dose,  dose intensity  and relative  dose intensity 
of MEK162, LGX818 and LEE011 will be listed by patient and summarized. Categories for 
relative  dose intensity  of the combination  MEK162,  LGX818  and LEE011  will be specified  as 
< 0.5, ≥ 0.5 - < 0.75, ≥ 0.75 - < 0.9, ≥ 0.9 - < 1.1 and ≥ 1.1. The number and proportion of 
patients within each category will be presented.  
10.5.3  Pharmacokinetics  
A secondary  objective  of this study  is to determine  the single  and multiple  dose pharmacokinetic 
profile  of the dual combination  (MEK162  and LGX818),  and the triple  combination  (LGX818 
and MEK162 and LEE011).  
For plasma  LGX818,  the LLOQ  is 1.0 ng/mL,  for MEK162  is 5.0 ng/mL  and LEE011  is 
1.0 ng/mL. All concentrations below the LLOQ or missing data will be labeled as such in the 
concentration  data listings.  Concentrations  below  the LLOQ  will be treated  as zero in summary 
statistics. The parameters displayed on Table 10 -1 will be estimated and reported.  
Descriptive graphical  plots  of individual  and mean  plasma  concentration  (per treatment)  along 
with its time course will be generated. Further graphical exploratory analyses will be carried 
out if deemed appropriate. Pharmacokinetic parameters for each dose cohort will be analyzed 
by descriptive  statistics,  including  the mean,  SD, CV%  or median  (range).  Since  tmax is generally 
evaluated by a non -parametric method, median values and ranges will be given for this 
parameter.  
Array  BioPharma  
Amended  Protoco l Version 10 Confide ntial Page  166 
Protocol  No. CMEK162X2110  / C4221005  
PFIZER  CONFIDENTIAL   
 Assessment of dose -proportionality, inter - and intra -individual variability and steady -state 
attainment will be conducted. If appropriate, an analysis of variance (ANOVA) will be 
performed  on log-transformed  AUCs  and Cmax using a linear mixed effect model to assess day 
effect.  
Details of PK analysis presented will be given in the Reporting and Analysis Plan. Any other 
exploratory analysis will be conducted if necessary.  
Table  10-1    PK parameters  
Variable  Definition  
Cmax Maximum  observed  plasma  concentration  after drug administration  [mass  x volume-1] 
Cmax,ss  Maximum  observed plasma  concentration during  a dosing  interval at  steady state  [mass x volume-1] 
Ctrough  Measured  concentration  at the end of a dosing  interval  at steady  state  (taken  directly  before  next 
administration) [mass x volume-1] 
tmax Time  to reach C max [time]  
tmax,ss  Time  to reach C max at steady state [time]  
AUC tau Area  under  the concentration -time curve  during  a dosing  interval  [mass  x time x volume-1] 
AUC inf Area  under  the concentration -time curve  from time zero to infinity  with extrapolation  of the terminal 
phase [mass x time x volume-1] 
AUC tau,ss  Area  under  the concentration -time curve  during  a dosing  interval  at steady  state  [mass  x time x 
volume-1] 
t1/2 Elimination  half-life associated  with the terminal  slope  (z) of a semi  logarithmic  concentration -time 
curve [time]  
CL/F Apparent  total plasma  clearance  of drug after oral administration  [volume  x time-1] 
V/F Apparent volume of distribution [volume]  
RA Accumulation ratio calculated as AUC tau,ss/AUC tau,dose1  
In addition, in case drug accumulation is observed upon multiple dosing, additional PK 
parameters  describing  drug accumulation  will be added  to the analysis  (i.e. effective  half-life).  
10.5.3.1  Data  handling  principles  
10.5.3.1.1  Analysis sets 
Only  PK blood  samples  with date and time and for which  the last prior  dose dates  and times  are 
adequately recorded will be included in the PK analyses. Samples taken from patients who 
vomited within 4 hrs of dosing will be excluded from the analysis. The FAS will be used.  
10.5.3.1.2  Basic  tables, figures  and listings  
Descriptive  statistics  (mean,  standard  deviation,  CV%  or median  (range))  will be presented  for 
all parameters for each dose cohort. When a geometric mean is presented, it will be stated as 
such.  CL/F  will be assessed  for MEK162,  LGX818  and LEE011,  as applicable,  and only median 
values and ranges will be given for t max. 
Descriptive graphical plots of individual plasma concentration by time will be generated, as 
will mean concentration time profiles for MEK162, LGX818 and LEE011, as applicable. 
Further graphical exploratory analyses will be carried out if deemed appropriate.  
Array  BioPharma  
Amended  Protoco l Version 10 Confide ntial Page  167 
Protocol  No. CMEK162X2110  / C4221005  
PFIZER  CONFIDENTIAL   
 
10.5.3.1.3  Advanced data  analysis  methods  
 
10.5.4  Biomarker s 
10.5.4.1  Outline  of the data analy sis 
As a project st andard, only patient pre -selection and PD m arkers collected in the clinical 
database will be a nalyzed by the Sponsor. Since this clinical trial was not designed to address 
specific hypotheses related to patient pre -selection or PD marker s, the analysis of this data 
should b e viewed as explorato 1y and hypotheses generating. Analytical re sults from such 
analyses may be used to generate additional hypotheses that mu st then be verified w ith data 
derived from subsequent clinical trials. No adjustmen t for multipl e comparisons is planned. 
If the numb er of samples is inadequat e to perfonn a rigorous data analysis, then the ava ilable 
data w ill only be listed. Additional analyses that may be perfo1m ed after the complet ion of the 
end-of-study clinical study repo1t will be documented in separate repo1ts. These analyses may 
includ e but are not limit ed to the meta-analysis of data from this study combined with data from 
other studie s or the a nalysis of patient pre-selection or PD m arkers generated fr om sample s 
collected durin g the study but an alyzed after th e data base lock and completi on of the clinical 
study repo1t. The data analysis will be described in an addendum of the RAP  or in a stand-alone 
analysis plan document, as appropri ate. 
10.5.4.2  Data  handling  principles  
All me asurement s below their respective LLOQ s or missing data will be labeled as such in the 
concentration data listings. Measurement s below the LLOQ  will be treated as zero in  summ aiy 
statistics. C hange from baseline analyses will only be perfonned on patients with m easurable 
sainple s and pr e- and p ost-treatm ent time p oints. 
10.5.4.3  Data  analy sis principles  
10.5.4.3.1  Analysis sets 
The FAS w ill be used for all an alyses. The number of patients with measureable samples will 
be iden tified in the  summari es and relevant propo1tions will be calculated against this numb er 
of patients. 
Array  BioPharma  
Amended  Protoco l Version 10 Confide ntial Page  168 
Protocol  No. CMEK162X2110  / C4221005  
PFIZER  CONFIDENTIAL   
 
10.5.4.3.2  Basic  tables, figures  and listings 
To characterize ba seline molecular status of molecules relevant to RAF /MEKIMA PK an d 
EGFR/PI3K./A KT signaling in tumor tissue in the Phase II parts of the study, baseline molecular 
status (mutation/amplifi cation/expression) in tum or tissue of potential predi ctive marker s 
(BRAF , HRA S, KRA S, NRAS, PTEN, cKIT, PIK3CA , MAP2Kl, MAP2K2, ARAF , c-MET , 
RAFI , EGFR ) will be  summari zed by  patient group. All biomarker assessments obtained from 
the full complem ent of fresh pre- and post-treatment  paired tumor/skin bi opsies collected in the 
trial will be listed by  patient and time point and summ arized using descriptive statistics by  time 
point. 
All biomarker assessments only collected at baseline will be listed by pat ient and summ arized 
using desc riptive statistics. 
All biomarker  assessments obtained from tumor sample s from patients with disease progression 
will be li sted by biomarker and by patie nt. 
10.5.4.3.3  Advanced ana lysis methods 
 
10.5.5  Resource  utilization  
Not applicable. 
10.5.6  Patient -reported  outcome s 
Not applicable. 
 
10.7 Interim  analysis  
An int erim an alysis for fu tility will be pe rfo1med in the phase II BRAF V600 mut ant mCRC 
aim (dual-combination ann 1), when 14 patients (50% of the total sampl e size) have completed 
4 cycles of treatmen t. As mentioned in Section 10.8, study results ai·e successful if  9 responses 
ai·e observed a t the end of the trial. At the interim an alysis, if the predictive pro bability of 
success is < 13%, i.e. if less than 3 responses (DCR at we ek 16) are observed, this study ai·m 
will be stoppe d for futility. 
10.8 Sample  size calculation 
Phase lb 
Dose e scalation: Cohorts of 3 to 6 evaluable pat ients will be emolled in th e dose escalation 
pait inclu ding at least six patients at the MTD/RP 2D level, as described  in Section  6.2.4 . 
Array  BioPharma  
Amended  Protoco l Version 10 Confide ntial Page  169 
Protocol  No. CMEK162X2110  / C4221005  
PFIZER  CONFIDENTIAL   
 Multiple cohorts may be sequentially enrolled to the same dose level. Additional cohorts of 1 
to 6 patients may be enrolled at any dose level below the estimated MTD/RP2D for further 
elaboration of safety and PK parameters as required. At least 18 patients are expected to be 
treated in the dual -combination dose -escalation part of the study, for the model to have 
reasonable operating characteristics relating to its MTD recommendation (see Appendix 5 for 
details).  At least 12 patients  are expected  to be treated  in the triple -combination  dose- escalation 
part of the study.  
Phase II 
Arm 1 dual combination: Based on the prior distribution and decision rules described in 
Section 10.4 , it was explored how likely  it is to wrongly  declare activity given the true DCR = 
20%, and how likely it is to correctly declare activity given the true DCR = 40%, when 28 
patients are evaluated.  
• If the true DCR  = 20%,  the probability  to wrongly  declare  activity  (i.e. seeing  at least 9 
patients with SD or better) is 9.0%.  
• If the true DCR  = 40%,  the probability  to correctly  declare  activity  (i.e. seeing  at least 9 
patients with SD or better) is 85.2%.  
If 9 out of 28 patients have at least SD or better, then the posterior risk of the true DCR being 
in the unacceptable category is 7.0%.  
Note:  if the interim  analysis  is performed,  the probability  to correctly  declare  activity  if the true 
DCR = 40% is 82.3%.  
Arm 2 dual combination: Based on the prior distribution and decision rules described in 
Section 10.4 , it was explored how likely  it is to wrongly  declare activity given the true ORR = 
10%, and how likely it is to correctly declare activity given the true ORR = 20%, when 41 
patients are evaluated:  
• If the true ORR  = 10%,  the probability  to wrongly  declare  activity  (i.e. seeing  at least 7 
responses) is 11.0%.  
• If the true ORR  = 20%,  the probability  to correctly  declare  activity  (i.e. seeing  at least 7 
responses) is 73.9%.  
If 7 out of 41 patients have PR or CR, then the posterior risk of the true ORR being in the 
unacceptable category is 9.8%.  
Arm 3 dual combination / Arm A triple combination: Based on the prior distribution and 
decision rules described in Section 10.4, it was explored how likely it is to wrongly declare 
activity given the true ORR = 30%, and how likely it is to correctly declare activity given the 
true ORR = 50%, when 40 patients are evaluated:  
• If the true ORR=30%,  the probability  of wrongly  declaring  at least moderate  efficacy  (i.e. 
at least 16 responses) is 11.5%.  
• If the true ORR=50%,  the probability  of correctly  declaring  at least moderate  efficacy  (i.e. 
seeing at least 16 responses) is 92.3%.  
If 16 out of 40 patients have PR or CR, then the posterior risk of the true ORR being in the 
unacceptable category is 9.0%.  
Array  BioPharma  
Amended  Protoco l Version 10 Confide ntial Page  170 
Protocol  No. CMEK162X2110  / C4221005  
PFIZER  CONFIDENTIAL   
 11 Ethical  considerations  and administrative  procedures  
11.1 Regulatory  and ethical  compliance  
This clinical study was designed, shall be implemented and reported in accordance with the 
ICH Harmonized Tripartite Guidelines for Good Clinical Practice, with applicable local 
regulations (including European Directive 2001/20/EC and US Code of Federal Regulations 
Title 21), and with the ethical principles laid down in the Declaration of Helsinki.  
11.2 Responsibilities  of the investigator  and IRB/IEC/REB  
The protocol and the proposed informed consent form must be reviewed and approved by a 
properly constituted Institutional Review Board/Independent Ethics Committee/Research 
Ethics  Board  (IRB/IEC/REB)  before  study  start.  A signed  and dated  statement  that the protocol 
and informed consent have  been approved by  the IRB/IEC/REB must be given to the Sponsor 
before study initiation. Prior to study start, the investigator is required to sign a protocol 
signature page confirming his/her agreement to conduct the study in accordance with these 
documents and all of the instructions and procedures found in this protocol and to give access 
to all relevant data and records to the Sponsor’s monitors, auditors, Sponsor Clinical Quality 
Assurance representatives, designated agents of the Sponsor, IRBs/IECs/REBs and regulatory 
authorities as required.  
11.3 Informed  consent  procedures  
Eligible patients may only be included in the study after providing written (witnessed, where 
required by law or regulation), IRB/IEC/REB -approved informed consent or, if incapable of 
doing so, after such consent has been provided by a legally acceptable representative of the 
patient.  In cases  where  the patient’s  representative  gives  consent,  the patient  should  be informed 
about the study to the extent possible given his/her understanding. If the patient is capable of 
doing so, he/she should indicate assent by personally signing and dating the written informed 
consent document or a separate assent form. Informed consent must be obtained before 
conducting any  study -specific procedures (i.e. all of the procedures described in the protocol). 
The process of obtaining informed consent should be documented in the patient source 
documents.  The date when  a subject’s  Informed  Consent  was actually  obtained  will be captured 
in their eCRFs.  
The Sponsor will provide investigators in a separate document with a proposed informed 
consent  form  (ICF)  that is considered  appropriate  for this study  and complies  with the ICH GCP 
guideline and regulatory requirements. Any changes to this ICF suggested by the investigator 
must be agreed to by the Sponsor before submission to the IRB/IEC/REB, and a copy of the 
approved version must be provided to the Sponsor’s monitor after IRB/IEC/REB approval.  
Women of child bearing potential should be informed that taking the study medication may 
involve unknown risks to the fetus if pregnancy were to occur during the study and agree that 
in order to participate in the study they must adhere to the contraception requirement for the 
duration of the study. If there is any question that the patient will not reliably comply, they 
should not be entered in the study.  
For this study,  the following  ICFs  apply:  
Array  BioPharma  
Amended  Protoco l Version 10 Confide ntial Page  171 
Protocol  No. CMEK162X2110  / C4221005  
PFIZER  CONFIDENTIAL   
 • Molecular  pre-screening  consent  form  (if applicable)  
• Study  consent  form;  one for dual study  treatment  combination  and one for triple  study 
treatment combination [the ICF for triple study treatment combination (LGX818 / 
MEK162 / LEE011) is not applicable for the USA and Singapore].  
11.4 Discontinuation  of the study  
The Sponsor reserves the right to discontinue this study under the conditions specified in the 
clinical  study  agreement.  Specific  conditions  for terminating  the study  are outlined  in 
Section 4.4 . 
11.5 Publication  of study  protocol  and results  
The Sponsor assures that the key design elements of this protocol will be posted in a publicly 
accessible database such as clinicaltrials.gov. In addition, upon study completion and 
finalization of the study  report the results of this study will be either submitted for publication 
and/or posted in a publicly accessible database of clinical study results.  
11.6 Data  Sharing  
Pfizer provides researchers secure access to patient -level data or full CSRs for the purposes of 
“bonafide scientific research” that contributes to the scientific understanding of the disease, 
target, or compound class. Pfizer will make available data from these trials 24 months after 
study  completion.  Patient -level  data will be anonymized  in accordance  with applicable  privacy 
laws and regulations. CSRs will have personally identifiable information redacted.  
Data requests are considered from qualified researchers with the appropriate competencies to 
perform  the proposed  analyses.  Research  teams  must  include  a biostatistician.  Data  will not be 
provided to applicants with significant conflicts of interest, including individuals requesting 
access for commercial/competitive or legal purposes.  
11.7 Study  documentation,  record  keeping  and retention  of 
documents  
Each participating site will maintain appropriate medical and research records for this trial, in 
compliance  with Section  4.9 of the ICH E6 GCP,  and regulatory  and institutional  requirements 
for the protection  of confidentiality  of subjects.  As part of participating  in an Array  BioPharma - 
sponsored study, each site will permit authorized representatives of the sponsor(s) and 
regulatory  agencies  to examine  (and when  required  by applicable  law, to copy)  clinical  records 
for the purposes of quality assurance reviews, audits and evaluation of the study safety and 
progress.  
Source data are all information, original records of clinical findings, observations, or other 
activities  in a clinical  trial necessary  for the reconstruction  and evaluation  of the trial. Examples 
of these original documents and data records include, but are not limited to, hospital records, 
clinical and office charts, laboratory notes, memoranda, subjects’ diaries or evaluation 
checklists, pharmacy  dispensing records, recorded data from automated instruments,  copies  or 
transcriptions certified after verification as being accurate and complete, microfiches, 
photographic  negatives,  microfilm  or magnetic  media,  x-rays,  and subject  files and records  kept 
Array  BioPharma  
Amended  Protoco l Version 10 Confide ntial Page  172 
Protocol  No. CMEK162X2110  / C4221005  
PFIZER  CONFIDENTIAL   
 at the pharmacy,  at the laboratories,  and medico -technical  departments  involved  in the clinical 
trial. 
Data  collection  is the responsibility  of the clinical  trial staff at the site under  the supervision  of 
the site Principal Investigator.  The study  case report form (CRF) is the primary  data collection 
instrument  for the study.  The investigator  should  ensure  the accuracy,  completeness,  legibility, 
and timeliness  of the data reported  in the CRFs  and all other  required  reports.  Data  reported  on 
the CRF, that are derived from source documents, should be consistent with the source 
documents or the discrepancies should be explained. All data requested on the CRF must be 
recorded.  Any missing  data must  be explained.  Any change  or correction  to a paper  CRF  should 
be dated, initialed, and explained (if necessary) and should not obscure the original entry. For 
electronic  CRFs an audit trail will be maintained by  the system.  The investigator  should  retain 
records of the changes and corrections to paper CRFs.  
The investigator/institution should maintain the trial documents as specified in Essential 
Documents  for the Conduct  of a Clinical  Trial  (ICH  E6 Section  8) and as required  by applicable 
regulations and/or guidelines. The investigator/institution should take measures to prevent 
accidental or premature destruction of these documents.  
Essential documents (written and electronic) should be retained for a period of not less than 
fifteen (15) years from the completion of the Clinical Trial unless Sponsor provides written 
permission to dispose of them or, requires their retention for an additional period of time 
because of applicable laws, regulations and/or guidelines  
11.8 Confidentiality  of study  documents  and patient  records  
The investigator  must  ensure  anonymity  of the patients;  patients  must  not be identified  by names 
in any documents submitted to the Sponsor. Signed informed consent forms and patient 
enrollment log must be kept strictly confidential to enable patient identification at the site.  
11.9 Audits  and inspections  
Source data/documents must be available to inspections by the Sponsor or designee or Health 
Authorities.  
11.10  Financial  disclosures  
Financial disclosures should be provided by study personnel who is directly involved in the 
treatment or evaluation of patients at the site - prior to study start.  
 
12 Protocol adherence  
Investigators ascertain they will apply due diligence to avoid protocol deviations. Under no 
circumstances should the investigator contact the Sponsor or its agents, if any, monitoring the 
study  to request approval of a protocol deviation, as no authorized deviations are permitted. If 
the investigator  feels  a protocol  deviation  would  improve  the conduct  of the study  this must  be 
considered a protocol amendment, and unless such an amendment is agreed upon by the 
Sponsor  and approved  by the IRB/IEC/REB  it cannot  be implemented.  All significant  protocol 
deviations will be recorded and reported in the CSR.  
Array  BioPharma  
Amended  Protoco l Version 10 Confide ntial Page  173 
Protocol  No. CMEK162X2110  / C4221005  
PFIZER  CONFIDENTIAL   
 12.1 Amendments  to the protocol  
Any change or addition to the protocol can only be made in a written protocol amendment that 
must be approved by the Sponsor, Health Authorities where required, and the IRB/IEC/REB. 
Only amendments that are required for patient safety may be implemented prior to 
IRB/IEC/REB  approval.  Notwithstanding  the need  for approval  of formal  protocol  amendments, 
the investigator is expected to take any  immediate action required for the safety of any patient 
included  in this study,  even  if this action  represents  a deviation  from  the protocol.  In such cases, 
the Sponsor should be notified of this action and the IRB/IEC/REB at the study site should be 
informed within 10 working days.  
Array  BioPharma  
Amended  Protoco l Version 10 Confide ntial Page  174 
Protocol  No. CMEK162X2110  / C4221005  
PFIZER  CONFIDENTIAL   
 13 References  (available  upon  request)  
Altekruse SF, Kosary CL, Krapcho M, et al (2010) SEER Cancer Statistics Review, 1975 - 
2007,  National  Cancer  Institute.  Bethesda,  MD, http://seer.cancer.gov/csr/1975_2007/,  based 
on November 2009 SEER data submission, posted to the SEER web site, 2010.  
Amado  RG, Wolf  M, Peeters  M, et al (2008)  Wild -type KRAS  is required  for panitumumab 
efficacy in patients with metastatic colorectal cancer. J Clin Oncol; 26: 1626 -34. 
Anderson  CM, Buzaid  AC, Legha  SS (1995)  Systemic  treatments  for advanced  cutaneous 
melanoma. Oncology (Williston Park); 9, 1149 -58: discussion 1163 -4, 1167 -8. 
Ascierto  P, et al (2012)  Efficacy  and safety  of oral MEK162  in patients  with locally  advanced 
and unresectable or metastatic cutaneous melanoma harboring BRAFV600 or NRAS 
mutations (abstract 8511). ASCO 2012, Chicago, Il.  
Atkins  MB, Lotze  MT, Dutcher  JP, et al (1999)  High -dose recombinant  interleukin  2 therapy 
for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 
1993. J Clin Oncol; 17: 2105 -16. 
Babb  J, Rogatko  A, Zacks  S (1998)  Cancer  phase  I clinical  trials:  Efficient  dose escalation 
with overdose control. Statist. Med.; 17: 1103 -1120.  
Brose  MS, Volpe  P, Feldman  M, et al (2002)  BRAF  and RAS  mutations  in human  lung 
cancer and melanoma. Cancer Res; 62: 6997 -7000.  
Brower  V (2010)  BRAF  inhibitors:  research  accelerates  in wake  of positive  findings.  J Natl 
Cancer Inst; 102: 214 -5. 
Chang F, Steelman LS, Lee JT, et al (2003) Signal transduction mediated by the 
Ras/Raf/MEK/ERK  pathway  from  cytokine  receptors  to transcription  factors:  potential 
targeting for therapeutic intervention. Leukemia; 17: 1263 -93. 
Chapman  PB, Einhorn  LH, Meyers  ML, et al (1999)  Phase  III multicenter  randomized  trial of 
the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin 
Oncol; 17: 2745 -51. 
Chapman  PB, Hauschild  A, Robert  C, et al (2011)  Improved  survival  with vemurafenib  in 
melanoma with BRAF V600E mutation. N Engl J Med; 364: 2507 -16. 
Cho KH, Shin SY, Rath O, et al (2009) Positive - and negative -feedback regulations 
coordinate  the dynamic  behavior  of the Ras-Raf-MEK -ERK  signal  transduction  pathway.  J 
Cell Sci; 122: 425 -435. 
Cichowski  K, Janne  PA (2010)  Drug  discovery:  inhibitors  that activate.  Nature;  464: 358-9. 
Cohen  Y, Xing  M, Mambo  E, et al (2003)  BRAF  mutation  in papillary  thyroid  carcinoma.  J 
Natl Cancer Inst; 95: 625 -7. 
Davies  H, Bignell  GR, Cox C, et al (2002)  Mutations  of the BRAF  gene  in human  cancer. 
Nature; 417: 949 -54. 
Array  BioPharma  
Amended  Protoco l Version 10 Confide ntial Page  175 
Protocol  No. CMEK162X2110  / C4221005  
PFIZER  CONFIDENTIAL   
 Diepgen  TL, Mahler  V (2002)  The epidemiology  of skin cancer.  Br J Dermatol;  146 Suppl 
61: 1 -6. 
Emery  CM, Vijayendran  KG, Zipser  MC, et al (2009)  MEK1  mutations  confer  resistance  to 
MEK and B -RAF inhibition. Proc Natl Acad Sci U S A; 106: 20411 -6. 
Engstrom  P, Arnoletti  J, Benson  A, et al (2009)  The NCCN  clinical  practice  guidelines  in 
oncology: colon cancer. J Natl Compr Canc Netw; 7 (8): 778 -831. 
Flaherty  K, Puzanov  I, Sosman  J, et al (2009)  Phase  I study  of PLX4032:  proof  of concept  for 
V600E BRAF mutation as a therapeutic target in human cancer. ASCO 2009, Orlando, 
Florida.  
Flaherty  KT, Puzanov  I, Kim KB, et al (2010)  Inhibition  of mutated,  activated  BRAF  in 
metastatic melanoma. N Engl J Med; 363(9): 809 –819. 
Fremin  C, Meloche  S (2010)  From  basic  research  to clinical  development  of MEK1/2 
inhibitors for cancer therapy. J Hematol Oncol; 3: 8.  
Fukushima  T, Suzuki  S, Mashiko  M, et al (2003)  BRAF  mutations  in papillary  carcinomas  of 
the thyroid. Oncogene; 22: 6455 -7. 
Grothey  A, Goldberg  RM (2004)  A review  of oxaliplatin  and its clinical  use in colorectal 
cancer. Expert Opin Pharmacother; 5: 2159 -70. 
Hatzivassiliou  G, Song  K, Yen I, et al (2010)  RAF  inhibitors  prime  wild-type RAF  to activate 
the MAPK pathway and enhance growth. Nature; 464: 431 -5. 
Hodi  FS, O'Day  SJ, McDermott  DF, et al (2010)  Improved  survival  with ipilimumab  in 
patients with metastatic melanoma. N Engl J Med.; Aug 19;363(8):711 -23. 
Infante  JR, Fecher  LA, Nallapareddy  S, et al. (2010)  Safety  and efficacy  results  from  the first- 
in-human study of the oral MEK 1/2 inhibitor GSK1120212. ASCO 2010. J Clin Oncol ; 
28:15s, (suppl; abstr 2503).  
Infante  J, et al. (2011)  Phase  I/II study  to access  safety,  pharmacokinetics,  and efficacy  of the 
oral MEK1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral inhibitor 
GSK2118436 (GSK436). ASCO 2011, Tampa, Florida.  
Jemal  A, Siegel  R, Ward  E, et al (2009)  Cancer  statistics,  2009.  CA Cancer  J Clin;  59: 225- 
49. 
Johannessen  CM, Boehm  JS, Kim SY, et al (2010)  COT  drives  resistance  to RAF  inhibition 
through MAP kinase pathway reactivation. Nature; 468: 968 -72. 
Karapetis  CS, Khambata -Ford  S, Jonker  DJ, et al (2008)  K-ras mutations  and benefit  from 
cetuximab in advanced colorectal cancer. N Engl J Med; 359: 1757 -65. 
Kefford  R, Arkenau  H, Brown  MP, et al (2010)  Phase  I/II study  of GSK2118436,  a selective 
inhibitor  of oncogenic  mutant  BRAF  kinase,  in patients  with metastatic  melanoma  and other 
solid tumors. ASCO 2010, Chicago, IL.  
Array  BioPharma  
Amended  Protoco l Version 10 Confide ntial Page  176 
Protocol  No. CMEK162X2110  / C4221005  
PFIZER  CONFIDENTIAL   
 Kim KB, Lewis K, Pavlick A, et al. (2011) A phase II study of the MEK1/MEK2 inhibitor 
GSK1120212 in metastatic BRAF -V600E or K mutant cutaneous melanoma patients 
previously  treated  with or without  a BRAF  inhibitor.  8th International  congress  of the society 
for melanoma research. Pigment cell & melanoma research: 24, 5: abstract LBA1 -3. 
Kopetz  S, Desai  J, Chan  E, et al (2010)  PLX4032  in metastatic  colorectal  cancer  patients  with 
mutant BRAF tumors). ASCO 2010, Chicago, IL.  
Lea IA, Jackson  MA, Li X, et al (2007)  Genetic  pathways  and mutation  profiles  of human 
cancers: site - and exposure -specific patterns. Carcinogenesis; 28: 1851 -8. 
Lehar  J, Krueger  AS, Avery  W, et al (2009)  Synergistic  drug combinations  tend to improve 
therapeutically relevant selectivity. Nat Biotechnol; 27: 659 -66. 
Lundberg AS, Weinberg RA (1998) Functional inactivation of the retinoblastoma protein 
requires  sequential  modification  by at least two distinct  cyclin -cdk complexes.  Molecular  and 
Cellular Biology; 18 (2):753 -761. 
McCubrey  JA, May WS, Duronio  V, et al (2000)  Serine/threonine  phosphorylation  in 
cytokine signal transduction. Leukemia; 14: 9 -21. 
Montagut  C, Sharma  SV, Shioda  T, et al (2008)  Elevated  CRAF  as a potential  mechanism  of 
acquired resistance to BRAF inhibition in melanoma. Cancer Res; 68: 4853 -61. 
Van Moos R, Thuerlimann B, Chair M , et al (2008) Pegylated liposomal doxorubicin - 
associated  hand -foot syndrome:  Recommendations  of an international  panel  of experts.  Eur J 
Cancer; 1016: 1 -10. 
Nakazawa  K, Dobashi  Y, Suzuki  S, et al (2005)  Amplification  and overexpression  of c-erbB - 
2, epidermal growth factor receptor, and c -met in biliary  tract cancers. J Pathol; 206: 356 -65. 
Nazarian  R, Shi H, Wang  Q, et al (2010)  Melanomas  acquire  resistance  to B-RAF(V600E) 
inhibition by RTK or N -RAS upregulation. Nature: 468: 973 -7. 
Neuenschwander  B, Branson  M, Gsponer  T (2008)  Critical  aspects  of the Bayesian  approach 
to Phase I cancer trials. Statistics in Medicine; 27(13): 2420 -2439.  
Neuenschwander  B, Capkun -Niggli  G, Branson  M, et al (2010)  Summarizing  historical 
information on controls in clinical trials. Clin Trials; 7: 5 -18. 
Nikiforova  MN, Kimura  ET, Gandhi  M, et al (2003)  BRAF  mutations  in thyroid  tumors  are 
restricted  to papillary  carcinomas  and anaplastic  or poorly  differentiated  carcinomas  arising 
from papillary carcinomas. J Clin Endocrinol Metab; 88: 5399 -404. 
Poulikakos  PI, Persaud  Y, Janakiraman  M, et al (2011)  RAF  inhibitor  resistance  is mediated 
by dimerization of aberrantly spliced BRAF(V600E). Nature; 23; 480 (7377): 387 -390. 
Rajagopalan  H, Bardelli  A, Lengauer  C, et al (2002)  Tumorigenesis:  RAF/RAS  oncogenes 
and mismatch -repair status. Nature; 418: 934.  
Ribas  A, Kim KB, Schuchter  LM, et al (2011)  BRIM -2: An open -label,  multicenter  phase II 
study of vemurafenib in previously treated patients with BRAF V600E mutation -positive 
metastatic melanoma. ASCO 2011. J Clin Oncol; 29: (suppl; abstr 8509).  
Array  BioPharma  
Amended  Protoco l Version 10 Confide ntial Page  177 
Protocol  No. CMEK162X2110  / C4221005  
PFIZER  CONFIDENTIAL   
 Robert  C, Arnault  JP, Mateus  C, et al (2011)  RAF  inhibition  and induction  of cutaneous 
squamous cell carcinoma. Current opinion in Oncology; 23: 177 -182. 
Roberts  PJ, Der CJ (2007)  Targeting  the Raf-MEK -ERK  mitogen -activated  protein  kinase 
cascade for the treatment of cancer. Oncogene; 26: 3291 -310. 
Scholl  FA, Dumesic  PA, Khavari  PA (2005)  Effects  of active  MEK1  expression  in vivo. 
Cancer Lett; 230: 1 -5. 
Serrone  L, Zeuli  M, Sega  FM, et al (2000)  Dacarbazine -based  chemotherapy  for metastatic 
melanoma: thirty -year experience overview. J Exp Clin Cancer Res; 19: 21 -34. 
Singer G, Oldt 3RD, Cohen Y, Wang BG, Sidransky D, Kurman RJ, Shih IM (2003) 
Mutations  in BRAF  and KRAS  characterize  the development  of low-grade  ovarian  serous 
carcinoma. J Natl Cancer Inst, 95, 484 -6. 
Smalley  KS, Flaherty  KT (2009)  Integrating  BRAF/MEK  inhibitors  into combination  therapy 
for melanoma. Br J Cancer; 100: 431 -5. 
Sosman  JA, Kim KB, Schuchter  L et al (2012)  Survival  in BRAF  V600 –Mutant  Advanced 
Melanoma Treated with Vemurafenib. N Engl J Med. 2012 Feb 23;366(8):707 -14. 
Stuart DD, Li N, Poon  D, et al. (2011) Pharmacological profile of LGX818: a potent and 
selective  RAF  kinase  inhibitor  with excellent  PK/PD,  efficacy  and toxicological  profiles  in 
preclinical models. 2011 International Melanoma Congress, Tampa, Florida.  
Tol J, Punt CJ (2010)  Monoclonal  antibodies  in the treatment  of metastatic  colorectal  cancer: 
a review. Clin Ther; 32: 437 -53. 
Wan PTC, Garnett MJ, Roe SM, et al, Cancer Genome Project (2004) Mechanism of 
activation  of the RAF -ERK  signaling  pathway  by oncogenic  mutations  of B-RAF.  Cell;  116: 
855-67. 
Weber J, Flaherty K, Infante J, et al (2012)  Updated safety and efficacy results from a phase 
I/II study  of the oral BRAF  inhibitor  dabrafenib  (GSK2118436)  combined  with the oral MEK 
1/2 inhibitor  trametinib  (GSK1120212)  in patients  with BRAFi -naive  metastatic  melanoma.  J 
Clin Oncol (Meeting Abstracts) 2012 May 30; 15suppl 8510 . 
Yoon  S, Seger  R (2006)  The extracellular  signal -regulated  kinase:  multiple  substrates  regulate 
diverse cellular functions. Growth Factors; 24: 21 -44. 
Array  BioPharma  
Amended  Protoco l Version 10 Confide ntial Page  178 
Protocol  No. CMEK162X2110  / C4221005  
PFIZER  CONFIDENTIAL   
 14 Appendices  
14.1 Appendix 1 - Response Evaluation Criteria in Solid Tumors 
(RECIST  1.1) Harmonization  of Efficacy  Analysis  of Solid  Tumor 
Studies  
This document  is based  on Novartis  implementation  guidelines  version  3. 
Glossary  
CR Complete response  
CRF Case Report Form  
CT Computed tomography  
DFS Disease -free survival  
eCRF  Electronic  Case  Report  Form  
FDG-PET Fluorodeoxyglucose Positron Emission Tomography  
FPFV  First patient first visit 
GBM  Glioblastoma multiforme  
LPLV  Last patient last visit 
MRI Magnetic resonance imaging  
OS Overall survival  
PD Progressive disease  
PFS Progression -free survival  
PR Partial response  
RAP Report Analysis Preparation  
RECIST  Response  Evaluation  Criteria  in Solid  Tumors  
SD Stable disease  
SOD  Sum of Diameter  
TTF Time to treatment failure  
TTP Time to progression  
UNK Unknown  
14.1.1  Introduction  
The purpose of this document is to provide the working definitions and rules necessary for a 
consistent  and efficient  analysis  of efficacy  for oncology  studies  in solid  tumors.  This document 
is based on the RECIST criteria for tumor  responses  (Therasse 2000 ) and the revised RECIST 
guidelines (version 1.1) ( Eisenhauer 2009 ). 
This document  will not address  the use of RECIST  1.1 for glioblastoma  multiforme  (GBM).  
The efficacy assessments described in Section 14.1.2 and the definition of best response in 
Section 14.1.17 are based on the RECIST 1.1 criteria but also give more detailed instructions 
and rules  for determination  of best response.  Section  14.1.18  is summarizing  the “time  to event” 
variables and rules which are mainly derived from internal discussions and regulatory 
consultations,  as the RECIST  criteria  do not define  these  variables  in detail.  Section  14.1.28  of 
this guideline describes data handling and programming rules. This section is to be referred to 
in the analysis plan(s) to provide further details needed for programming.  
Array  BioPharma  
Amended  Protoco l Version 10 Confide ntial Page  179 
Protocol  No. CMEK162X2110  / C4221005  
PFIZER  CONFIDENTIAL   
 14.1.2  Efficacy  assessments  
Tumor evaluations are made based on RECIST criteria for tumor responses ( Therasse 2000 ) 
and the revised RECIST guidelines (version 1.1) ( Eisenhauer 2009 ). 
The assessment schedule for tumor assessments is described in Section 7.2.1 of the protocol. 
Frequency  of tumor  re-evaluation  while  on treatment  should  be adapted  to the type and schedule 
of treatment, and the type of tumor treated.  
It is assumed that all information which is considered for assessment of the tumor is captured 
in the RECIST eCRF, i.e. not merged from several sources.  
14.1.3  Definitions  
14.1.4  Disease  measurability  
In order  to evaluate  tumors  throughout  a study  definitions  of measurability  are required  in order 
to classify lesions appropriately at baseline. In defining measurability a distinction also needs 
to be made between nodal lesions (pathological lymph nodes) and non -nodal lesions.  
• Measurable  disease  - the presence  of at least one measurable  nodal  or non-nodal  lesion. 
If the measurable disease is restricted to a solitary  lesion, its neoplastic nature should be 
confirmed by cytology/histology.  
For patients  without  measurable  disease  see Section  14.1.26 . 
Measurable  lesions  (both  nodal  and non-nodal)  
• Measurable  non-nodal  - As a rule of thumb, the minimum size of a measurable non -nodal 
target lesion at baseline should be no less than double the slice thickness or 10mm 
whichever  is greater  - e.g. the minimum  non-nodal  lesion  size for CT/MRI  with 5mm  cuts 
will be 10 mm, for 8 mm contiguous cuts the minimum size will be 16 mm.  
• Lytic  bone  lesions  or mixed  lytic-blastic  lesions  with identifiable  soft tissue  components, 
that can be evaluated by CT/MRI, can be considered as measurable lesions.  
• Measurable  nodal  lesions  (i.e. lymph  nodes)  - Lymph  nodes  15 mm in short  axis can be 
considered for selection as target lesions. Lymph nodes measuring 10mm and <15mm 
are considered non -measurable. Lymph nodes smaller than 10 mm in short axis at 
baseline, regardless of the slice thickness, are normal and not considered indicative of 
disease.  
• Non-measurable  lesions  - all other  lesions  are considered  non-measurable,  including  small 
lesions (longest diameter <10 mm with CT scan or pathological lymph nodes with  10 to  
< 15 mm short axis), e.g., blastic bone lesions, leptomeningeal disease, ascites, 
pleural/pericardial effusion, inflammatory breast disease, lymphangitis cutis/pulmonis, 
abdominal  masses  that are not confirmed  and followed  by imaging  techniques,  and cystic 
lesions.  
If any lesion should be handled differently, this must be clearly stated and justified in the 
protocol, e.g. tumor lesions that are situated in a previously  irradiated area might or might not 
be considered measurable, and the conditions under which such lesions should be considered 
must be defined in the protocol when appropriate.  
Array  BioPharma  
Amended  Protoco l Version 10 Confide ntial Page  180 
Protocol  No. CMEK162X2110  / C4221005  
PFIZER  CONFIDENTIAL   
 14.1.5  Eligibility  based on measurable disease  
If no measurable  lesions  are identified  at baseline,  the patient  may be allowed  to enter  the study 
in some  situations  (e.g. in Phase  III studies  where  PFS is the primary  endpoint).  However,  it is 
recommended that patients be excluded from trials where the main focus is on the ORR. 
Guidance on how patients with just non -measurable disease at baseline will be evaluated for 
response and also handled in the statistical analyses is given in Section 14.1.26 . 
14.1.6  Methods of tumor measurement  - general guidelines  
The following  considerations  are to be made  when  evaluating  the tumor:  
• All measurements  should  be taken  and recorded  in metric  notation  (mm),  using  a ruler  or 
calipers. All baseline evaluations should be performed as closely as possible to the 
beginning of treatment and never more than 4 weeks before the beginning of the 
treatment.  
• If different  window  for baseline  assessments  is allowed  in the protocol  this must  be 
justified in the protocol.  
• Imaging -based  evaluation  is preferred  to evaluation  by clinical  examination  when  both 
methods have been used to assess the antitumor effect of a treatment.  
• For optimal evaluation of patients the same methods of assessment and technique should 
be used to characterize each identified and reported lesion at baseline and during follow - 
up. Contrast -enhanced CT of chest, abdomen and pelvis should preferably be performed 
using a 5mm slice thickness with a contiguous reconstruction algorithm. CT/MRI scan 
slice thickness  should  not exceed  8 mm cuts using  a contiguous  reconstruction  algorithm. 
If at baseline a patient is known to be allergic to CT contrast or develops allergy during 
the trial, the following  change  in imaging  modality  will be accepted  for follow -up: a non- 
contrast CT of chest (MRI not recommended due to respiratory artifacts) plus contrast - 
enhanced MRI of abdomen and pelvis.  
• A change in methodology can be defined as either a change in contrast use (e.g. keeping 
the same  technique,  like CT, but switching  from  with to without  contrast  use or vice-versa, 
regardless of the justification for the change) or a change in technique (e.g. from CT to 
MRI,  or vice-versa),  or a change  in any other  imaging  modality.  A change  in methodology 
will result by default in a UNK overall lesion response assessment. However another 
response assessment than the calculated UNK response may be accepted from the 
Investigator or the central blinded reviewer if a definitive response assessment can be 
justified, based on the available information.  
If head and neck tumors and those of extremities are evaluated in the study, please specify  the 
methods in detail in the protocol.  
• FDG -PET : can complement CT scans in assessing progression (particularly possible for 
‘new’  disease).  New  lesions  on the basis  of FDG -PET imaging  can be identified  according 
to the following algorithm:  
• Negative  FDG -PET at baseline,  with a positive  FDG -PET at follow -up is a sign of PD 
based on a new lesion.  
• No FDG -PET at baseline  with a positive  FDG -PET at follow -up: 
Array  BioPharma  
Amended  Protoco l Version 10 Confide ntial Page  181 
Protocol  No. CMEK162X2110  / C4221005  
PFIZER  CONFIDENTIAL   
 
• If the positive  FDG -PET at follow -up coITesponds to a new site of disease  confinn ed by 
CT, this is PD. 
•  If the positive FDG -PET at follow -up is not co nfnmed as a new site of disease o n CT, 
additional  follow -up CT are needed  to dete1mine  if there is tiuly  progression  occuITin g at 
that Site (if so, the date  of PD will be the date  of the initial abnonnal CT scan).  
• If the positive  FDG-PET at follow -up coITesponds to a pre-existing  site of disease  on CT 
that is not progres sing on the basis of the anatomic images, this is not PD. 
• Chest  x-ray: Lesions on chest x-ray are acceptable  as measurab le lesions  when they are 
clearly defined and smTo unded by aerated lung. Howeve r, CT is preferable . 
• Ultrasound : When  the prirna1y  endpoint of the study is objective  response evaluation , 
ulti·asound should n ot be used to measure tmn or lesions . It is, however , a possib le 
alternative to clinical measurements of superficial palpable lymph n odes, subcutane ous 
lesions and  thyroid nodules. Ulti·asound might also  be useful to co nfinn  the complete 
disappearance of superficial lesions usually asses sed by clinical examin ation. 
•  Endoscopy and  laparoscopy : The utilizatio n of endoscopy  and laparoscopy for  objective 
tumor eval uation has not yet  been fully  and widely validated. Their uses in this specific 
context requir e sophisticated equipm ent and a high level of expe1iise that may only be 
available in  some centers. Therefore, the  utilizatio n of such technique s for objec tive tmnor 
response should be resti·icted to validatio n pmpo ses in specialized  centers. However , such 
technique s can be useful in confnmin g comple te pathological response when biopsies are 
obtained. 
If tmnor markers are  used in the study for the response assess ment, the criteria must be  clearly 
stated  in the protocol  and the presence of abno1mality in tmnor markers be entered in the eCRF 
page for RECIST evaluations (see also Section 14.1.8 ). 
•  Cytology  and histology: Cytology and histology ca n be used to differentiate between PR 
and CR in rare cases (i.e., afte r ti·eatment  to diffe rentiate between  residual benign  lesions 
and residual malignant lesions in  tmnor types  such as ge1m ce ll tmnors). Cytologic 
confnmati on of neoplastic nature of any effusion that  appea rs or worse ns during  h'eatment 
is required w hen the measurable tmnor has met the criteria for response or stable disease. 
Under such circUlllStances , the cytologic examination of the fluid  collected wi ll pennit 
differentiation  betwee n response and stable  disease  (an effusion  may be a side effect  of the 
ti·eatment) or progres sive disease (if the neoplastic origin of the fluid is confnmed ). 
When  pathological  response is being  used, the protocol must clearly state  detai ls on how 
pathological responses are documen ted. 
Array  BioPharma  
Amended  Protoco l Version 10 Confide ntial Page  182 
Protocol  No. CMEK162X2110  / C4221005  
PFIZER  CONFIDENTIAL   
 • Clinical examination : Clinical lesions will only  be considered measurable when they  are 
superficial (i.e., skin nodules and palpable lymph nodes). For the case of skin lesions, 
documentation  by color  photography,  including  a ruler  to estimate  the size of the lesion,  is 
recommended.  
If the protocol  is considering  specific  symptoms  as objective  signs  of clinical progression,  e.g. 
bone  pain or GI bleeding,  then the criteria  for clear  worsening  of these  non-measurable  ‘lesions’ 
indicative of PD should be clearly specified in the protocol. In that case, the protocol should 
clearly specify that additional criteria are used to complement RECIST criteria.  
14.1.7  Baseline  documentation  of target  and non-target lesions  
For the evaluation of lesions at baseline and throughout the study, the lesions are classified at 
baseline as either target or non -target lesions:  
• Target lesions : All measurable lesions (nodal and non -nodal) up to a maximum of five 
lesions in total (and a maximum of two lesions per organ), representative of all involved 
organs  should  be identified  as target  lesions  and recorded  and measured  at baseline.  Target 
lesions should be selected on the basis of their size (lesions with the longest diameter) and 
their suitability for accurate repeated measurements (either by imaging techniques or 
clinically). Each target lesion must be uniquely and sequentially numbered on the CRF 
(even if it resides in the same organ).  
Minimum target lesion size at baseline  
• Non-nodal target : Non -nodal target lesions identified by methods for which slice 
thickness  is not applicable  (e.g. clinical  examination)  should  be at least 10mm  in longest 
diameter. See Section 14.1.4 . 
• Nodal  target : See Section  14.1.4 . 
A sum of diameters (long axis for non -nodal lesions, short axis for nodal) for all target  lesions 
will be calculated and reported as the baseline sum of diameters (SOD). The baseline sum of 
diameters  will be used as reference  by which  to characterize  the objective  tumor  response.  Each 
target lesion identified at baseline must be followed at each subsequent evaluation and 
documented on eCRF.  
• Non-target lesions : All other lesions are considered non -target lesions, i.e. lesions not 
fulfilling the criteria for target lesions at baseline. Presence or absence or worsening of 
non-target lesions should be assessed throughout the study; measurements of these lesions 
are not required.  Multiple  non-target  lesions  involved  in the same  organ  can be assessed  as 
a group and recorded as a single item (i.e. multiple liver metastasis). Each non -target 
lesion identified at baseline must be followed at each subsequent evaluation and 
documented on eCRF.  
If the protocol  is considering  specific  symptoms  for assessment  of the tumor,  e.g. bone  pain or 
GI bleeding, then these symptoms are to be entered as non -target lesions with either presence 
or absence or as a new lesion (based on protocol specified criteria). In that case, the protocol 
should clearly specify that additional criteria are used to complement RECIST criteria.  
Array  BioPharma  
Amended  Protoco l Version 10 Confide ntial Page  183 
Protocol  No. CMEK162X2110  / C4221005  
PFIZER  CONFIDENTIAL   
 For cancers which are known to metastasize in bone, the protocol should specify if and how 
bone  lesions  should  be handled,  e.g. if they are not identified  only at baseline  and end of study 
by scintigram but also followed throughout the study by bone X -ray or CT scan.  
14.1.8  Follow -up evaluation  of target  and non-target  lesions  
To assess tumor response, the sum of diameter for all target lesions will be calculated (at 
baseline and throughout the study). At each assessment response is evaluated first separately 
for the target ( Table 14 -1) and non -target lesions ( Table 14 -2) identified at baseline. These 
evaluations  are then used to calculate  the overall  lesion  response  considering  both the target  and 
non-target lesions together ( Table 14 -3) as well as the presence or absence of new lesions.  
If tumor  markers  are used as non-target  lesions  to evaluate  response,  please  specify  criteria  for 
CR, SD and PD in the protocol,  e.g. CR=’Normalization  of tumor  marker  level’,  PD=’Elevation 
of tumor markers to certain level’, SD=’Not qualifying for CR or PD’. These criteria are 
indication and study specific. In that case, the protocol should clearly specify that additional 
criteria are used to complement RECIST criteria.  
14.1.9  Follow -up & recording of lesions  
At each visit and for each lesion  the actual  date of the scan or procedure  which  was used for the 
evaluation of each specific lesion should be recorded. This applies to target and non -target 
lesions  as well as new lesions  that are detected.  At the assessment  visit all of the separate  lesion 
evaluation data are examined by the Investigator in order to derive the overall visit response. 
Therefore all such data applicable to a particular visit should be associated with the same 
assessment number.  
14.1.10  Non-nodal  lesions  
Following treatment, lesions may  have longest diameter measurements smaller than the image 
reconstruction interval. Lesions smaller than twice the reconstruction interval are subject to 
substantial  “partial  volume”  effects  (i.e., size may be underestimated  because  of the distance  of 
the cut from  the longest  diameter;  such lesions  may appear  to have  responded  or progressed  on 
subsequent examinations, when, in fact, they remain the same size).  
If the lesion has completely  disappeared, the lesion size should be reported as 0 mm. 
When a tumor does not disappear completely and shrinks to less than the slice thickness a 
default  value  should  be assigned  depending  on the slice thickness.  With  5 mm contiguous  slice 
thickness, the default value will be 5 mm. Similarly, for a 7 mm slice thickness, the default 
value  will be 7 mm. Actual  measurement  should  be given  for all lesions  larger  than the default 
value.  
In other  cases  where  the lesion  cannot  be reliably  measured  for reasons  other  than its size (e.g., 
borders of the lesion are confounded by neighboring anatomical structures), no measurement 
should be entered and the lesion cannot be evaluated.  
14.1.11  Nodal lesions  
A nodal  lesion  less than 10 mm in size by short  axis is considered  normal.  Lymph  nodes  are not 
expected to disappear completely, so a “non -zero size” will always persist.  
Array  BioPharma  
Amended  Protoco l Version 10 Confide ntial Page  184 
Protocol  No. CMEK162X2110  / C4221005  
PFIZER  CONFIDENTIAL   
 If a nodal lesion shrinks to less than the slice thickness a default value should be assigned 
depending on the slice thickness. With 5 mm contiguous slice thickness, the default value will 
be 5 mm. Similarly, for a 7 mm slice thickness, the default value will be 7 mm. Actual 
measurement should be given for all lesions larger than the default value.  
However, once a target nodal lesion shrinks to less than 10 mm in its short axis, it will be 
considered normal for response purpose determination. The lymph node measurements will 
continue to be recorded to allow the values to be included in the sum of diameters for target 
lesions, which may be required subsequently for response determination.  
14.1.12  Determination of target lesion response  
Table  14-1    Response  criteria  for target  lesions  
Response  Criteria    Evaluation of target  lesions  
Complete  Response 
(CR):  Disappearance  of all non-nodal  target  lesions.  In addition,  any pathological  lymph  nodes 
assigned as target lesions must have a reduction in short axis to < 10 mm 1 
 
Partial  Response  (PR):  At least  a 30% decrease  in the sum of diameter  of all target  lesions,  taking  as reference 
the baseline sum of diameters.  
Progressive  Disease 
(PD):  At least a 20% increase in the sum of diameter of all measured target lesions, taking as 
reference  the smallest  sum of diameter  of all target  lesions  recorded  at or after baseline. 
In addition to the relative increase of 20%, the sum must also demonstrate an absolute 
increase of at least 5 mm2. 
 
Stable Disease (SD):  Neither  sufficient  shrinkage  to qualify  for PR or CR nor an increase  in lesions  which 
would qualify for PD.  
Unknown (UNK)  Progression  has not been  documented  and one or more  target  lesions  have  not been 
assessed or have been assessed using a different method than baseline.3 
 
1. SOD  for CR may not be zero when  nodal  lesions  are part  of target  lesions  
2. Following  an initial  CR, a PD cannot  be assigned  if all non-nodal  target  lesions  are still not present  and all nodal 
lesions are <10mm in size. In this case, the target lesion response is CR  
3. Methodology change See Section 14.1.6  
Notes on target lesion response  
Reappearance  of lesions : If the lesion appears at the same anatomical location where a target 
lesion  had previously  disappeared,  it is advised  that the time point  of lesion  disappearance  (i.e., 
the “0 mm” recording) be re -evaluated to make sure that the lesion was not actually present 
and/or not visualized for technical reasons in this previous assessment. If it is not possible to 
change the 0 value, then the Investigator/radiologist has to decide between the following three 
possibilities:  
• The lesion  is a new lesion,  in which  case the overall  tumor  assessment  will be considered 
as progressive disease  
• The lesion is clearly a reappearance of a previously disappeared lesion, in which case the 
size of the lesion  has to be entered  in the CRF  and the tumor  assessment  will remain  based 
on the sum of tumor measurements as presented in Table 14 -1 above (i.e., a PD will be 
determined if there is at least 20% increase in the sum of diameters of all measured target 
lesions, taking as reference the smallest sum of diameters of all target lesions recorded at 
or after baseline). Proper documentation should be available to support this decision.  
Array  BioPharma  
Amended  Protoco l Version 10 Confide ntial Page  185 
Protocol  No. CMEK162X2110  / C4221005  
PFIZER  CONFIDENTIAL   
 • For those  patients  who have  only one target  lesion  at baseline,  the reappearance  of the 
target lesion which disappeared previously, even if still small, is considered a PD.  
• Missing  measurements : In cases  where  measurements  are missing  for one or more  target 
lesions it is sometimes still possible to assign PD based on the measurements of the 
remaining lesions. For example, if the sum of diameters for 5 target lesions at baseline is 
100mm at baseline and the sum of diameters for 3 of those lesions at a post -baseline visit 
is 140mm  (with  data for 2 other  lesions  missing)  then a PD should  be assigned.  However, 
in other cases where a PD cannot definitely be attributed the target lesion response would 
be UNK.  
• Nodal lesion decrease to normal size : When nodal disease is included in the sum of 
target lesions and the nodes decrease to “normal” size they should still have a 
measurement recorded on scans. This measurement should be reported even when the 
nodes  are normal  in order  not to overstate  progression  should  it be based  on increase  in the 
size of nodes.  
• Lesions split : In some circumstances, disease that is measurable as a target lesion at 
baseline and appears to be one mass can split to become two or more smaller sub -lesions. 
When this occurs, the diameters (long axis - non-nodal lesion, short axis - nodal lesions) 
of the two split lesions should be added together and the sum recorded in the diameter 
field on the case report  form  under  the original  lesion  number.  This value  will be included 
in the sum of diameters when deriving target lesion response. The individual split lesions 
will not be considered  as new lesions,  and will not automatically  trigger  a PD designation.  
• Lesions coalesced : Conversely, it is also possible that two or more lesions which were 
distinctly separate at baseline become confluent at subsequent visits. When this occurs a 
plane  between  the original  lesions  may be maintained  that would  aid in obtaining  diameter 
measurements of each individual lesion. If the lesions have truly coalesced such that they 
are no longer separable, the maximal diameters (long axis - non-nodal lesion, short axis - 
nodal lesions) of the “merged lesion” should be used when calculating the sum of 
diameters for target lesions. On the case report form, the diameter of the “merged lesion” 
should  be recorded  for the size of one of the original  lesions  while  a size of “0”mm  should 
be entered for the remaining lesion numbers which have coalesced.  
• The measurements  for nodal  lesions , even  if less than 10mm  in size, will contribute  to 
the calculation of target lesion response in the usual way with slight modifications.  
• Since  lesions  less than 10mm  are considered  normal  a CR for target  lesion  response 
should be assigned when nodal target lesions shrink to less than 10mm and all non - 
nodal target lesions have disappeared.  
• Once a CR target lesion response has been assigned a CR will continue to be 
appropriate  (in the absence  of missing  data)  until progression  of target  lesions.  
• Following a CR, a PD can subsequently  only be assigned for target lesion response if 
either a non -nodal target lesion “reappears” or if the absolute sum of the remaining 
nodal target lesions increases by at least 5mm and at least one of those remaining 
lesions are at least 10mm in size. i.e. if the short axis of a remaining nodal target 
lesion  increases  from  5 mm to 10 mm or from  7 mm to 12.5 mm this is called  PD, but 
if it increases from 7 mm to 10 mm it does not qualify for PD.  
Array  BioPharma  
Amended  Protoco l Version 10 Confide ntial Page  186 
Protocol  No. CMEK162X2110  / C4221005  
PFIZER  CONFIDENTIAL   
 When  both nodal  and non-nodal  lesions  are still present  there  may be rare occasions  when  a PD 
for target lesion response is primarily due to increases in size of nodal lesions but where the 
target  lymph  nodes  are still all less than 10mm  in size. This kind of rare anomaly  is acceptable 
since otherwise the rules for determining target lesion response would become too complex.  
14.1.13  Determination  of non -target  lesion response  
Table  14-2    Response  criteria  for non-target  lesions  
Response Criteria  Evaluation  of non-target  lesions  
 
Complete  Response  (CR):  Disappearance  of all non-target  lesions.  In addition,  all lymph  nodes  assigned  a non- 
target lesions must be non -pathological in size (< 10 mm short axis)  
Progressive  Disease (PD):  Unequivocal progression of existing non -target  lesions.1 
Incomplete  Response/ 
Stable Disease (SD):  Neither CR nor PD 
 
Unknown (UNK)  Progression  has not been  documented  and one or more  non-target  lesions  have  not 
been assessed or have been assessed using a different method than baseline.  
1. Although  a clear  progression  of “non-target”  lesions  only is exceptional,  in such  circumstances,  the opinion  of 
the treating  physician  does  prevail  and the progression  status  should  be confirmed  later on by the review  panel 
(or study chair).  
 
Notes  on non -target  lesion response  
• The response for non -target lesions is CR only if all non -target non -nodal lesions which 
were evaluated at baseline are now all absent and with all non -target nodal lesions 
returned to normal size (i.e. < 10mm). If any of the non -target lesions are still present, or 
there  are any abnormal  nodal  lesions  (i.e.  10 mm)  the response  can only be ‘Incomplete 
response/Stable disease ’ unless any of the lesions was not assessed (in which case 
response is UNK ) or there is unequivocal progression of the non -target lesions (in which 
case response is PD). 
• Unequivocal progression : To achieve “unequivocal progression” on the basis of non - 
target disease there must be an overall level of substantial worsening in non -target disease 
such that, even in presence of CR, PR or SD in target disease, the overall tumor burden 
has increased sufficiently to merit discontinuation of therapy. A modest “increase” in the 
size of one or more non -target lesions is usually not sufficient to qualify for unequivocal 
progression status. The designation of overall progression solely  on the basis of change in 
non-target  disease  in the face of CR, PR or SD of target  disease  is therefore  expected  to be 
rare. Even in cases where there is no measurable disease at baseline, in order for a PD to 
be assigned  on the basis  of non-target  lesions  the increase  in the extent  of the disease  must 
be substantial. In studies where the overall non -target lesion response is not recorded but 
instead the individual status of individual lesions (Absent, Present or Worsened) is 
determined, if there is unequivocal progression of non -target lesions then at least one of 
the non -target lesions must be assigned a status of “Worsened”. Similarly, an individual 
non-target lesion should only be assigned a “Worsened” status if there is unequivocal 
progression of non -target lesions overall.  
• Where possible, similar rules to those described in Section 14.1.12 for assigning PD 
following  a CR for the non-target  lesion  response  in the presence  of non-target  lesions 
nodal lesions should be applied.  
Array  BioPharma  
Amended  Protoco l Version 10 Confide ntial Page  187 
Protocol  No. CMEK162X2110  / C4221005  
PFIZER  CONFIDENTIAL   
 14.1.14  New lesions  
The appearance  of a new lesion  is always  associated  with Progressive  Disease  (PD)  and has to 
be recorded as a new lesion in the New Lesion CRF page.  
• If a new  lesion  is equivocal , for example because of  its small size,  continued  therapy  and 
follow -up evaluation  will clarify  if it represents  truly  new disease. If  repeat  scans  confirm 
there is definitely a new lesion, then progression should be declared using the date of the 
first observation of the lesion1  
• If new disease is observed in a region which was not scanned at baseline or where the 
particular  baseline  scan is not available  for some  reason  then this should  be considered  as 
a PD. The one exception to this is when there are no baseline scans at all available for a 
patient in  which  case the response should  be UNK,  as for any of this patient's  assessment 
(see Section 14.1.15).  
• A lymph  node  is considered  as a “new  lesion”  and, therefore,  indicative  of progressive 
disease if the short axis increases in size to  10mm for the first time in the study plus 
5mm absolute increase.  
FDG -PET : can complement  CT scans  in assessing  progression  (particularly  possible  for ‘new’ 
disease). See Section 14.1.6 . 
14.1.15  Evaluation of overall lesion response  
The evaluation  of overall  lesion  response  at each assessment  is a composite  of the target  lesion 
response,  non-target  lesion  response  and presence  of new lesions  as shown  below  in Table  14-3. 
 
Table  14-3 Overall  lesion  response  at each  assessment  
 
Target lesions  Non-target lesions  New Lesions   
 
Overall  lesion 
response  
 
CR CR No CR1 
CR Incomplete response/SD3 No PR 
CR, PR, SD UNK No UNK 
PR Non-PD and not UNK No PR1 
SD Non-PD and not UNK No SD1, 2 
UNK Non-PD or UNK No UNK1 
PD Any Yes or No PD 
Any PD Yes or No PD 
Any Any Yes PD 
This overall  lesion  response  also applies  when  there  are no non-target  lesions  identified  at baseline.  
1. Once  confirmed  PR was achieved,  all these  assessments  are considered  PR. 
2. As defined in Section 14.1.8  
If there are no baseline scans taken at all at baseline then the overall lesion response at each  
assessment should be considered Unknown (UNK).  
If the evaluation of any of the target or non -target lesions identified at baseline could not be  
made during follow -up, the overall status must be ‘unknown’ unless progression was seen.  
Array  BioPharma  
Amended  Protoco l Version 10 Confide ntial Page  188 
Protocol  No. CMEK162X2110  / C4221005  
PFIZER  CONFIDENTIAL   
 In some circumstances it may be difficult to distinguish residual disease from normal tissue. 
When the evaluation of complete response depends on this determination, it is recommended 
that the residual lesion be investigated (fine needle aspirate/biopsy) to confirm the CR.  
14.1.16  Efficacy  definitions  
The following  definitions  primarily  relate  to patients  who have  measurable  disease  at baseline. 
Section 14.1.26 outlines the special considerations that need to be given to patients with no 
measurable disease at baseline in order to apply the same concepts.  
14.1.17  Best overall response  
The best overall response is the best response recorded from the start of the treatment until 
disease  progression/recurrence  (taking  as reference  for PD the smallest  measurements  recorded 
since the treatment started). In general, the patient's best response assignment will depend on 
the achievement of both measurement and confirmation criteria.  
The best overall response will usually be determined from response assessments undertaken 
while  on treatment.  However,  if any assessments  occur  after treatment  withdrawal  the protocol 
should specifically describe if these will be included in the determination of best overall 
response and/or whether these additional assessments will be required for sensitivity or 
supportive analyses. As a default, any assessments taken more than 28 days after the last dose 
of study therapy will not be included in the best overall response derivation. If any alternative 
cancer therapy is taken while on study any subsequent assessments would ordinarily be 
excluded from the best overall response determination. If response assessments taken after 
withdrawal from study treatment and/or alternative therapy are to be included in the main 
endpoint determination then this should be described and justified in the protocol.  
Where a study requires a response PR or CR, changes in tumor measurements must be 
confirmed by repeat assessments that should be performed not less than 4 weeks after the 
criteria for response are first met.  
Longer  intervals  may also be appropriate.  However,  this must  be clearly  stated  in the protocol. 
The main goal of confirmation of objective response is to avoid overestimating the response 
rate observed. In cases where confirmation of response is not feasible, it should be made clear 
when reporting the outcome of such studies that the responses are not confirmed.  
• For non-randomized  trials  where  response  is the primary  endpoint,  confirmation  is needed.  
• For trials  intended  to support  accelerated  approval,  confirmation  is needed.  
• For all other trials, confirmation of response may  be considered optional.  
The best overall response for each patient is determined from the sequence of overall (lesion) 
responses according to the following rules:  
• CR = at least two determinations of CR at least 4 weeks apart before progression where 
confirmation  required  or one determination  of CR prior  to progression  where  confirmation 
not required  
• PR = at least two determinations  of PR or better  at least 4 weeks  apart  before  progression 
(and not qualifying for a CR) where confirmation required or one determination of PR 
prior to progression where confirmation not required  
Array  BioPharma  
Amended  Protoco l Version 10 Confide ntial Page  189 
Protocol  No. CMEK162X2110  / C4221005  
PFIZER  CONFIDENTIAL   
 • SD = at least one SD assessment  (or better)  > 6 weeks  after randomization/start  of 
treatment (and not qualifying for CR or PR).  
The protocol should state if randomization or start of treatment is used as start date (baseline). 
This is then used in all definitions.  
If a different minimum follow -up period is required to classify for overall response= ’stable  
disease’, this must be specified in the protocol.  
• PD = progression   12 weeks  after randomization/  start of treatment  (and not qualifying 
for CR, PR or SD).  
If PD in a different  follow -up period  is considered  overall  response=’progressive  disease’,  this 
must be specified in the protocol.  
The protocol  should  state if discontinuation  due to ‘Disease  progression’  or death  due to study 
indication is considered PD even if this was not accompanied by documentation of PD based 
on tumor measurements. This depends on Phase of the study and the primary endpoint (e.g. 
Phase III studies in which progression -free survival is primary endpoint should consider only 
documented PD, whereas Phase I and II studies may consider all clinical deteriorations PD). 
The following sentence therefore is only applicable if this is specified in the protocol:  
• Patients  with symptoms  of rapidly  progressing  disease  without  radiologic  evidence  will be 
classified as progression only  when clear evidence of clinical deterioration is documented 
and/or patient discontinued due to ‘Disease progression’ or death due to study indication.  
• UNK  = all other  cases  (i.e. not qualifying  for confirmed  CR or PR and without  SD after 
more than 6 weeks or early progression within the first 12 weeks)  
Overall  lesion  responses  of CR must  stay the same  until progression  sets in, with the exception 
of a UNK  status.  A patient  who had a CR cannot  subsequently  have  a lower  status  other  than a 
PD, e.g. PR or SD, as this would  imply  a progression  based  on one or more  lesions  reappearing, 
in which case the status would become a PD.  
Once an overall lesion response of PR is observed (which may have to be a confirmed PR 
depending on the study) this assignment must stay the same or improve over time until 
progression sets in, with the exception of an UNK status. However, in studies where 
confirmation of response is required, if a patient has a single PR ( 30% reduction of tumor 
burden compared to baseline) at one assessment, followed by a <30% reduction from baseline 
at the next assessment  (but not 20% increase  from  previous  smallest  sum),  the objective  status 
at that assessment should be SD. Once a confirmed PR was seen, the overall lesion response 
should be considered PR (or UNK) until progression is documented or the lesions totally 
disappear in which case a CR assignment is applicable. In studies where confirmation of 
response  is not required  after a single  PR the overall  lesion  response  should  still be considered 
PR (or UNK) until progression is documented or the lesion totally disappears in which case a 
CR assignment is applicable.  
Example : In a case where confirmation of response is required the sum of lesion diameters is 
20 cm at baseline and then 14 cm - 15 cm - 14 cm - 16 cm - 16 cm at the subsequent visits. 
Assuming that non -target lesions did not progress, the overall lesion response would be PR - 
SD - PR - PR - PR. The second  assessment  with 14 cm confirms  the PR for this patient.  All 
Array  BioPharma  
Amended  Protoco l Version 10 Confide ntial Page  190 
Protocol  No. CMEK162X2110  / C4221005  
PFIZER  CONFIDENTIAL   
 subsequent assessments are considered PR even if tumor measurements decrease only  by 20% 
compared to baseline (20 cm to 16 cm) at the following assessments.  
If the patient  progressed  but continues  study  medication,  further  assessments  are not considered 
for the determination of best overall response.  
Note : these cases may be described as a separate finding in the Clinical Study Report but not 
included in the best overall response rate.  
The best overall response for a patient is always calculated, based on the sequence of overall 
lesion responses. However, the overall lesion response at a given assessment may  be provided 
from different sources:  
• Investigator  overall  lesion  response  
• Central  Blinded  Review  overall  lesion  response  
• Calculated  overall  lesion  response  (based  on measurements  from  either  Investigator  or 
Central Review)  
The primary analysis of the best overall response will be based on the sequence of 
Investigator/central blinded review/calculated (Investigator)/calculated (central) overall lesion 
responses.  
Specify which determination of best overall response will be considered primary (and delete 
the other terms in the text). If a central blinded review is used (e.g. in an open -label study in 
which response is the primary endpoint), the best overall response evaluated by the central 
blinded review will always be considered the primary response.  
Based on the patients’ best overall response during the study, the following rates are then 
calculated:  
Overall response rate (ORR) is the proportion of patients with a best overall response of CR 
or PR. This is also referred to as ‘Objective response rate’ in some protocols or publications.  
Disease  control  rate (DCR)  is the proportion  of patients  with a best overall  response  of CR or 
PR or SD.  
Another  approach  is to summarize  the progression  rate at a certain  time point  after baseline.  In 
this case, the following definition is used:  
Early  progression  rate (EPR)  is the proportion  of patients  with progressive  disease  within 
8 weeks of the start of treatment.  
The protocol should define populations for which these will be calculated. The timepoint for 
EPR is study specific. EPR is used for the multinomial designs of ( Dent and Zee 2001 ) and 
counts  all patients  who at the specified  assessment  (in this example  the assessment  would  be at 
8 weeks ± window) do not have an overall lesion response of SD, PR or CR. Patients with an 
unknown (UNK) assessment at that time point and no PD before, will not be counted as early 
progressors in the analysis but may  be included in the denominator of the EPR rate, depending 
on the analysis  population  used.  Similarly  when  examining  overall  response  and disease  control, 
patients with a best overall response assessment of unknown (UNK) will not be regarded as 
“responders”  but may be included  in the denominator  for ORR  and DCR  calculation  depending 
on the analysis population (e.g. populations based on an ITT approach).  
Array  BioPharma  
Amended  Protoco l Version 10 Confide ntial Page  191 
Protocol  No. CMEK162X2110  / C4221005  
PFIZER  CONFIDENTIAL   
 14.1.18  Time to event variables  
The protocol  should  state which  of the following  variables  is used in that study.  
14.1.19  Progression -free survival  
Usually in all Oncology studies, patients are followed for tumor progression after 
discontinuation of study medication for reasons other than progression or death. If this is not 
used, e.g. in Phase I or II studies, this should be clearly stated in the protocol. Note that 
randomized trials (preferably blinded) are recommended where PFS is to be the primary 
endpoint.  
Progression -free survival (PFS) is the time from date of randomization/start of treatment to 
the date of event defined as the first documented progression or death due to any cause. If a 
patient has not had an event, progression -free survival is censored at the date of last adequate 
tumor assessment.  
14.1.20  Overall  survival  
All patients should be followed until death or until patient has had adequate follow -up time as 
specified  in the protocol  whichever  comes  first. The follow -up data should  contain  the date the 
patient was last seen alive / last contacted, the date of death and the reason of death (“Study 
indication” or “Other”).  
Overall survival (OS) is defined as the time from date of randomization/start of treatment to 
date of death  due to any cause.  If a patient  is not known  to have  died,  survival  will be censored 
at the date of last contact.  
14.1.21  Time to progression  
Some  studies  might  consider  only death  related  to underlying  cancer  as an event  which  indicates 
progression. In this case the variable “Time to progression” might be used. TTP is defined as 
PFS except for death unrelated to underlying cancer.  
Time to progression (TTP) is the time from date of randomization/start of treatment to the 
date of event  defined  as the first documented  progression  or death  due to underlying cancer. If 
a patient  has not had an event,  time to progression  is censored  at the date of last adequate  tumor 
assessment.  
14.1.22  Time  to treatment  failure  
This endpoint  is often  appropriate  in studies  of advanced  disease  where  early  discontinuation  is 
typically related to intolerance of the study drug. In some protocols, time to treatment failure 
may be considered as a sensitivity analysis for time to progression. The list of discontinuation 
reasons  to be considered  or not as treatment  failure  may be adapted  according  to the specificities 
of the study or the disease.  
Time to treatment failure (TTF) is the time from date of randomization/start of treatment to 
the earliest  of date of progression,  date of death  due to any cause,  or date of discontinuation  due 
to reasons  other  than ‘Protocol  violation’  or ‘Administrative  problems’.  The time to treatment  
Array  BioPharma  
Amended  Protoco l Version 10 Confide ntial Page  192 
Protocol  No. CMEK162X2110  / C4221005  
PFIZER  CONFIDENTIAL   
 failure for patients who did not experience treatment failure will be censored at last adequate 
tumor assessment.  
14.1.23  Duration of response  
The analysis following variables should be performed with much caution when restricted to 
responders since treatment bias could have been introduces. There have been reports where a 
treatment with a significantly higher response rate had a significantly shorter duration of 
response but where this probably primarily reflected selection bias which is explained as 
follows:  It is postulated  that there  are two groups  of patients:  a good  risk group  and a poor risk 
group. Good risk patients tend to get into response readily  (and relatively  quickly) and tend to 
remain  in response  after they have  a response.  Poor  risk patients  tend to be difficult  to induce  a 
response,  may have  a longer  time to respond,  and tend to relapse  quickly  when  they do respond. 
Potent agents induce a response in both good risk and poor risk patients. Less potent agents 
induce  a response  mainly  in good  risk patients  only.  This is described  in more  detail  by (Morgan 
1988 ). 
It is recommended that an analysis of all patients (both responders and non -responders) be 
performed whether or not a responders only descriptive analysis is presented. An analysis of 
responders  should  only be performed  to provide  descriptive  statistics  and even  then interpreted 
with caution by evaluating the results in the context of the observed response rates... If an 
inferential comparison between treatments is required this should only be performed on all 
patients (i.e. not  restricting to  “responders” only) using appropriate statistical methods  such as 
the techniques described in ( Ellis 2008 ). It should also be stated in the protocol if duration of 
response is to be calculated in addition for unconfirmed response.  
For summary  statistics  on “responders”  only the following  definitions  are appropriate.  (Specific 
definitions for an all -patient analysis of these endpoints are not appropriate since the status of 
patients throughout the study is usually taken into account in the analysis).  
Duration of overall response (CR or PR) : For patients with a CR or PR (which may  have to 
be confirmed  the start date is the date of first documented  response  (CR or PR) and the end date 
and censoring is defined the same as that for time to progression.  
The following  two durations  might  be calculated  in addition  for a large  Phase  III study  in which 
a reasonable number of responders is seen.  
Duration of overall complete response (CR) : For patients with a CR (which may  have to be 
confirmed) the start date is the date of first documented CR and the end date and censoring is 
defined the same as that for time to progression.  
Duration  of stable  disease  (CR/PR/SD) : For patients  with a CR or PR (which  may have  to be 
confirmed) or an SD the start and end date as well as censoring is defined the same as that for 
time to progression.  
14.1.24  Time to response  
Time  to overall  response  (CR or PR) is the time between  date of randomization/start  of 
treatment  until first documented  response  (CR or PR). The response  may need  to be confirmed  
Array  BioPharma  
Amended  Protoco l Version 10 Confide ntial Page  193 
Protocol  No. CMEK162X2110  / C4221005  
PFIZER  CONFIDENTIAL   
 depending on the type of study and its importance. Where the response needs to be confirmed 
then time to response is the time to the first CR or PR observed.  
Although  an analysis  on the full population  is preferred  a descriptive  analysis may  be performed 
on the “responders”  subset  only,  in which  case the results  should  be interpreted  with caution  and 
in the context of the overall response rates, since the same kind of selection bias may be 
introduced as described for duration of response in Section 14.1.23 . It is recommended that an 
analysis of all patients (both responders and non -responders) be performed whether or not a 
responders only descriptive analysis is presented. Where an inferential statistical comparison is 
required  then all patients  should  definitely  be included  in the analysis  to ensure  the statistical  test 
is valid. For analysis including all patients, patients who did not achieve a response (which may 
have to be a confirmed response) will be censored using one of the following options.  
• at maximum follow -up (i.e. FPFV to LPLV used for the analysis) for patients who had a 
PFS event (i.e. progressed or died due to any cause). In this case the PFS is the worst 
possible  outcome  as it means  the patient  that the patient  cannot  subsequently  respond.  Since 
the statistical analysis usually makes use of the ranking of times to response it is sufficient 
to assign the worst possible censoring time which could be observed in the study which is 
equal to the maximum follow -up time (i.e. time from FPFV to LPLV)  
• at last adequate  tumor  assessment  date otherwise.  In this case patients  have  not yet 
progressed so they theoretically still have a chance of responding  
Time to overall complete response (CR) is the time between dates of randomization/start of 
treatment until first documented CR. Similar analysis considerations including (if appropriate) 
censoring rules apply for this endpoint described for the time to overall response endpoint.  
Indicate in the protocol whether a subgroup analysis of responders only will be performed in 
addition to the full population analysis (which should be included as default).  
14.1.25  Definition  of start  and end dates  for time to event  variables 
Assessment date  
For each assessment  (i.e. evaluation  number),  the assessment  date is calculated  as the latest  of 
all measurement dates (e.g. X -ray, CT -scan) if the overall lesion response at that assessment is 
CR/PR/SD/UNK. Otherwise - if overall lesion response is progression - the assessment date is 
calculated as the earliest date of all measurement dates at that evaluation number.  
Start dates  
State  in the protocol  if date of randomization  or date of start of treatment  is to be used for all 
definitions.  For randomized  studies  specify  exactly  where  the randomization  date comes  from,  
e.g. from  IVRS,  or if start of treatment  is used as randomization  date.  For non-randomized  studies 
please specify which treatment start date is taken if more than one treatment is to be given.  
For all “time  to event”  variables,  other  than the duration  of responses,  the randomization/  date of 
treatment start will be used as the start date.  
For the calculation  of duration  of responses  the following  start date should  be used:  
Array  BioPharma  
Amended  Protoco l Version 10 Confide ntial Page  194 
Protocol  No. CMEK162X2110  / C4221005  
PFIZER  CONFIDENTIAL   
 • Date  of first documented  response  is the assessment  date of the first overall  lesion  response 
of CR (for duration of overall complete response) or CR / PR (for duration of overall 
response) respectively, when this status is later confirmed.  
End dates  
The end dates  which  are used to calculate  ‘time  to event’  variables  are defined  as follows:  
• Date of death (during treatment as recorded on the treatment completion page or during 
follow -up as recorded  on the study  evaluation  completion  page  or the survival  follow -up 
page).  
• Date  of progression  is the first assessment  date at which  the overall  lesion  response  was 
recorded as progressive disease.  
If applicable, if patients who discontinued due to ‘Disease progression’ are considered to be PD 
solely based on clinical deterioration, then add the following in the protocol:  
When there is no documentation of radiologic evidence of progression, and the patient 
discontinued for ‘Disease progression’ due to documented clinical deterioration of disease, the 
date of discontinuation is used as date of progression.  
• Date of last adequate tumor assessment is the date the last tumor assessment with overall 
lesion response of CR, PR or SD which was made before an event or a censoring reason 
occurred. In this case the last tumor evaluation date at that assessment is used. If no post - 
baseline  assessments  are available  (before  an event  or a censoring  reason  occurred)  the date 
of randomization/start of treatment is used.  
• Date  of next scheduled  assessment  is the date of the last adequate  tumor  assessment  plus the 
protocol specified time interval for assessments. This date may be used if back -dating is 
considered when the event occurred beyond the acceptable time window for the next tumor 
assessment as per protocol (see Section 14.1.26 ). 
Example  (if protocol  defined  schedule  of assessments  is 3 months):  tumor  assessments  at baseline  
- 3 months - 6 months - missing - missing - PD. Date of next scheduled assessment would then 
corresponds to 9 months.  
• Date  of discontinuation is the date of the EOT visit.  
• Date of last contact is defined as the last date the patient was known to be alive. This 
corresponds  to the latest  date for either  the visit date,  lab sample  date or tumor  assessment 
date. If available, the last contact date from that survival follow -up page is used. If no 
survival follow -up is available, the date of discontinuation is used as last contact date.  
In comparative studies with long follow -up period and therefore extended visit schedule, it may 
be useful  to collect  the survival  status  at a pre-specified  cut-off within  a limited  timeframe  for all 
patients  with no documented  death.  In this case,  this requires  a contact  to be made  with the patient 
or with any reliable  source  of information  on the patient’s  status,  but not requiring  a specific  visit 
to be scheduled  
• Date  of secondary  anti-cancer  therapy  is defined  as the start date of any additional 
(secondary) antineoplastic therapy or surgery.  
Array  BioPharma  
Amended  Protoco l Version 10 Confide ntial Page  195 
Protocol  No. CMEK162X2110  / C4221005  
PFIZER  CONFIDENTIAL   
 If this is applicable for the study, it should be specified in the protocol if new cancer therapy is 
considered an event or endpoints are censored.  
14.1.26  Handling  of patients with non -measurable  disease only  at baseline  
It is possible that patients with just non -measurable disease present at baseline are entered into 
the study, either because of a protocol violation or by  design (e.g. Phase III studies with PFS as 
the primary  endpoint).  In such cases  the handling  of response  data requires  special  consideration 
with respect to inclusion in any  analysis of endpoints based on the overall response evaluations.  
The protocol should state clearly whether patients with non -measurable disease only at baseline 
will be allowed into the study. If patients with non -measurable disease only are allowed to be 
enrolled then the statistical section should describe clearly how data from these patients will be 
incorporated into the primary analysis and main analyses of the key secondary endpoints. In 
studies where presence or otherwise of measurable disease is expected to have a relatively large 
impact  on the primary  endpoint,  this factor  can even  be considered  as a stratification  factor  in the 
randomization process.  
It is recommended that any patients with only non -measurable disease at baseline should be 
included in the main (ITT) analysis of each of these endpoints.  
For studies  which  specifically  exclude patients  with non-measurable  disease  only at baseline the 
pre-specified  analysis  plan should  describe  how to handle  data from  these  types  of patients  if they 
are enrolled by error. It is recommended for these types of studies that patients with non - 
measurable disease identified through the local site evaluation be included in the list of protocol 
violations.  However,  decisions  on exclusion  from  a per protocol  analysis  should  relate  to whether 
the patient has measurable disease according to the primary data source. For example, if the 
primary data source is from a central independent review then patients with non -measurable 
disease only according to this central review should be excluded from the relevant per protocol 
analyses.  
Although  the text of the definitions  described  in the previous  sections  primarily  relates  to patients 
with measurable disease at baseline, patients without measurable disease should also be 
incorporated  in an appropriate  manner.  The overall  response  for patients  with measurable  disease 
is derived slightly differently according to Table 14 -4. 
Table 14 -4 Overall  lesion  response  at each  assessment:  patients  with non-target 
disease only  
 
Non-target lesions  New Lesions  Overall lesion response  
CR No CR 
Incomplete response/SD1 No Non-CR/non -PD 
UNK No UNK 
PD Yes or No PD 
Any Yes PD 
1 As defined in Section 14.1.8    
In general,  the non-CR/non -PD response for these patients is considered equivalent to an SD 
response  in endpoint  determination.  In summary  tables  for best overall  response  patients  with 
Array  BioPharma  
Amended  Protoco l Version 10 Confide ntial Page  196 
Protocol  No. CMEK162X2110  / C4221005  
PFIZER  CONFIDENTIAL   
 just non -measurable disease may be highlighted in an appropriate fashion e.g. in particular by 
displaying the specific numbers with the non -CR/non -PD category.  
In considering how to incorporate data from these patients into the analysis the importance to 
each endpoint of being able to identify  a PR and/or to determine the occurrence and timing of 
progression needs to be taken into account.  
For ORR  it is recommended that the main (ITT)  analysis  includes data from patients with only 
non-measurable  disease  at baseline,  handling  patients  with a best response  of CR as “responders” 
with respect to ORR and all other patients as “non -responders”. Study teams may also want to 
perform sensitivity analyses excluding patients from the analysis of ORR (e.g. possibly as part 
of a per-protocol  type analysis).  Similar  considerations  should  be given  to other  endpoints 
which rely on a clear distinction being made between a PR and an SD response.  
For PFS , it is again recommended that the main ITT analyses on these endpoints include all 
patients with just non -measurable disease at baseline, with possible sensitivity  analyses which 
exclude  these  particular  patients.  Endpoints  such as PFS which  are reliant  on the determination 
and/or timing of progression can incorporate data from patients  
14.1.27  Sensitivity analyses  
This section outlines the possible event and censoring dates for progression, as well is 
addressing the issues of missing tumor assessments during the study. For instance, if one or 
more assessment visits are missed prior to the progression event, to what date should the 
progression event be assigned? And should progression event be ignored if it occurred after a 
long period of a patient being lost to follow -up? It is important that the protocol and analysis 
plan specify  the primary  analysis  in detail  with respect  to the definition  of event  and censoring 
dates and also include a description of one or more sensitivity analyses to be performed.  
Based on definitions outlined in Section 14.1.25 , and using the draft FDA guideline on 
endpoints  (Clinical  Trial  Endpoints  for the Approval  of Cancer  Drugs  and Biologics  April  2005 ) 
as a reference, the following analyses can be considered:  
Table  14-5 Options  for event  dates  used  in PFS,  TTP,  duration  of response  
 
 
 
Situation  Options  for end-date (progression  or 
censoring?)1 
(1) = default  unless  specified  differently  in the 
protocol or analysis plan   
 
 
Outcome  
A No baseline assessment  (1) Date of randomization/start of treatment3 Censored  
B Progression  at or before  next scheduled 
assessment  (1) Date of progression  
(2) Date  of next scheduled  assessment2 Progressed 
Progressed  
C1 Progression or death after  exactly  one 
missing assessment  (1) Date of progression (or death)  
(2) Date  of next scheduled  assessment2 Progressed 
Progressed  
C2 Progression  or death  after two or more  
missing assessments  (1) Date of last adequate assessment2 
(2) Date  of next scheduled  assessment2 
(3) Date of progression (or death)  Censored 
Progressed 
Progressed  
D No progression  (1) Date of last adequate assessment  Censored  
E Treatment discontinuation due to 
‘Disease progression’ without 
documented progression, i.e. clinical 
progression  based  on Investigator  claim  (1) N/A 
(2) Date  of discontinuation  (visit date at which 
clinical progression was determined)  Ignored 
Progressed  
Array  BioPharma  
Amended  Protoco l Version 10 Confide ntial Page  197 
Protocol  No. CMEK162X2110  / C4221005  
PFIZER  CONFIDENTIAL   
  
 
 
 
Situation  Options  for end-date (progression  or 
censoring?)1 
(1) = default  unless  specified  differently  in the 
protocol or analysis plan   
 
 
Outcome  
F New anticancer therapy given  (1) Date of last adequate assessment  
(2) Date  of secondary  anti-cancer therapy  
(3) Date  of secondary  anti-cancer therapy  
(4) N/A Censored 
Censored 
Event  
Ignored  
G Deaths  due to reason  other  than 
deterioration  of ‘Study  indication’  (1) Date of last adequate assessment  Censored 
(only  TTP and 
duration of  
response)  
1=Definitions can be found in  Section 14.1.25 . 
2=After  the last adequate  tumor  assessment.  “Date  of next scheduled  assessment”  is defined  in Section  14.1.25 
3=The rare exception to this is if the patient dies no later than the time of the second scheduled assessment as 
defined in the protocol in which case this is a PFS event at the date of death.  
The primary  analysis  and the sensitivity  analyses  must  be specified  in the protocol.  Clearly 
define if and why options (1) are not used for situations C, E and (if applicable) F.  
Situations  C (C1 and C2): Progression  or death  after one or more  missing  assessments:  The 
primary analysis is usually using options (1) for situations C1 and C2, i.e.  
• (C1) taking  the actual  progression  or death  date,  in the case of only one missing 
assessment.  
• (C2) censoring  at the date of the last adequate  assessment,  in the case of two or more 
consecutive missing assessments.  
In the case of two or missing assessments (situation C2), option (3) may be considered jointly 
with option (1) in situation C1 as sensitivity analysis. A variant of this sensitivity analysis 
consists  of backdating  the date of event  to the next scheduled  assessment  as proposed  with option  
(2) in situations C1 and C2. 
Situation E: Treatment discontinuation due to ‘Disease progression’ without documented 
progression : By default, option (1) is used for situation E as patients without documented PD 
should  be followed  for progression  after discontinuation  of treatment.  However,  option  (2) may 
be used as sensitivity  analysis. If progression is claimed based on clinical deterioration instead 
of tumor assessment by e.g. CT -scan, option (2) may be used for indications with high early 
progression rate or difficulties to assess the tumor due to clinical deterioration.  
Situation F: New cancer therapy given : the handling of this situation must be specified in 
detail in the protocol. However, option (1), i.e. censoring at last adequate assessment may be 
used as a default in this case.  
Additional  suggestions  for sensitivity  analyses  
Other  suggestions  for additional  sensitivity  analyses  may include  analyses  to check  for potential 
bias in follow -up schedules  for tumor  assessments,  e.g. by assigning  the dates  for censoring  and 
events only at scheduled visit dates. The latter could be handled by  replacing in Table 14 -5 the 
“Date of last adequate assessment” by the “Date of previous scheduled assessment (from 
baseline)”, with the following definition:  
Array  BioPharma  
Amended  Protoco l Version 10 Confide ntial Page  198 
Protocol  No. CMEK162X2110  / C4221005  
PFIZER  CONFIDENTIAL   
 • Date of previous scheduled assessment (from baseline) is the date when a tumor 
assessment would have taken place, if the protocol assessment scheme was strictly 
followed  from  baseline,  immediately  before  or on the date of the last adequate  tumor 
assessment.  
In addition, analyses could be repeated using the Investigators’ assessments of response rather 
than the calculated  response.  The need  for these  types  of sensitivity  analyses  will depend  on the 
individual requirements for the specific study and disease area and have to be specified in the 
protocol or RAP documentation.  
14.1.28  Data handling and programming rules  
The following  section  should  be used as guidance  for development  of the protocol,  data handling 
procedures or programming requirements (e.g. on incomplete dates).  
14.1.29  Study/project specific decisions  
For each study (or project) various issues need to be addressed and specified in the protocol or 
RAP documentation. Any deviations from protocol must be discussed and defined at the latest 
in the RAP documentation.  
The proposed  primary  analysis  and potential  sensitivity  analyses  should  be discussed  and agreed 
with the health authorities and documented in the protocol (or at the latest in the RAP 
documentation before database lock).  
14.1.30  Treatment and study  completion CRFs  
If study drug is discontinued, the EOT Page is to be completed with a visit date reflecting the 
date the discontinuation decision was made, and with the ‘Last known date patient took study 
drug’ and one of the following reasons:  
• AE(s)  
• Abnormal laboratory  value(s)  
• Abnormal test procedure results(s)  
• Protocol violation  
• Patient  withdrew  consent  
• Lost to follow -up 
• Administrative problems  
• Death  
• Disease  progression  
• Treatment  duration  completed  as per protocol  (optional,  to be used if only a fixed  number 
of cycles is given)  
For reasons other than progression (and death) it should be checked if this was not in fact 
progression (especially  reasons AEs, Abnormal laboratory  value (s), Abnormal test procedure 
result and patient withdrew consent). Also it should be checked if patient withdrew consent 
because  of safety  issues,  in which  case reasons  AEs,  Abnormal  laboratory  value  (s), Abnormal  
Array  BioPharma  
Amended  Protoco l Version 10 Confide ntial Page  199 
Protocol  No. CMEK162X2110  / C4221005  
PFIZER  CONFIDENTIAL   
 test procedure result  should  be used.  In such cases  where  the reason  for discontinuation  is AE, 
the AE CRF page must be consistent with the EOT reason provided  
All patients  who discontinued  study  drug will be followed  for post a treatment  evaluation  until 
progression  or until a new anticancer  therapy  is initiated.  Patients  who discontinued  study  drug 
for reasons other than documented progression, death or lost  to follow -up will be followed  for 
progression thereafter (patients who withdrew consent might not be followed with regular 
tumor  assessments  at the study  site, but should  ideally  be followed  until progression  outside  the 
study site). Ideally, all patients who discontinued study drug for progression without 
documented progression will still be followed with regular tumor assessments (e.g. in case of 
central  radiology  review).If  patient  withdraws  consent,  it must  be clearly  stated  if patient  is also 
withdrawing consent from post treatment evaluations and/or post treatment follow -up 
assessments.  During  that evaluation  period,  usually  only tumor  measurements  (and/or  response 
status) and survival data are  collected. In  some protocols, the subsequent anti -cancer therapies 
may also be recorded.  
14.1.31  Study evaluation completion  
At the end of the study evaluation period, the study evaluation completion page is filled out 
with the following options:  
• Patient  withdrew  consent  
• Lost to follow -up 
• Administrative  problems  (when  follow -up for progression  has met protocol  required 
events, e.g. follow -up stopped at certain number of events or certain time)  
• Death  
• New  cancer  therapy  (optional,  to be used when  follow -up for progression  is stopped  in this 
case)  
• Disease  progression  
Thereafter, patients will be followed for survival using the survival follow -up pages. If 
information on death becomes available for patients who were lost to follow -up or withdrew 
consent, this may also be entered in the database. The reason for death must be documented 
(and will be coded  using  MedDRA);  it must  be also stated  if death  was due to ‘Study  indication’ 
or ‘Other’ reason.  
In comparative  studies  with long follow -up period  and therefore  extended  visit schedule,  it may 
be useful to collect the survival status at a pre -specified cut -off within a limited timeframe for 
all patients with no documented death. In this case, this requires a contact to be made with the 
patient or with any reliable source of information on the patient’s status, but not requiring a 
specific visit to be scheduled.  
Until  the specified  cut-off point  has been  reached,  the goal is to collect  tumor  assessments  until 
disease progression for all patients regardless of whether the patients are still receiving study 
drug.  If patients  are not followed  for progression,  e.g. in a Phase  I or II study  mainly  evaluating 
safety, the evaluation is completed when study drug is completed (in this case only the first 
completion page is used).  
Array  BioPharma  
Amended  Protoco l Version 10 Confide ntial Page  200 
Protocol  No. CMEK162X2110  / C4221005  
PFIZER  CONFIDENTIAL   
 14.1.32  Medical validation of programmed overall lesion response  
As RECIST is very strict regarding measurement methods (i.e. any assessment with more or 
less sensitive  method  than the one used to assess  the lesion  at baseline  is considered  UNK)  and 
not available evaluations (i.e. if any target or non -target lesion was not evaluated the whole 
overall lesion response is UNK unless remaining lesions qualified for PD), these UNK 
assessments  may be re-evaluated  by clinicians  at the Sponsor  or designee  or by external  experts. 
In addition, data review reports will be available to identify assessments for which the 
Investigators’ opinion does not match the programmed calculated response based on RECIST 
criteria. This may be queried for clarification. However, the Investigator response assessment 
will never be overruled.  
If the Sponsor or designee elect to invalidate an evaluation of overall lesion response upon 
internal or external review of the data, the calculated overall lesion response at that specific 
assessment is to be kept in a dataset. This must be clearly documented in the RAP 
documentation and agreed before database lock. This dataset should be created and stored as 
part of the ‘raw’ data.  
Any discontinuation due to ‘Disease progression’ without documentation of progression by 
RECIST  criteria  should  be carefully  reviewed.  Only  patients  with documented  deterioration  of 
symptoms indicative of progression of disease should have this reason for discontinuation of 
treatment or study evaluation.  
14.1.33  Programming rules  
The following should be used for programming of efficacy  results:  
14.1.34  Calculation  of ‘time  to event’ variables  
Time  to event  = end date - start date + 1 (in days)  
When no post -baseline tumor assessments are available, the date of randomization/start of 
treatment  will be used as end date (duration  = 1 day) when time is to be censored at last tumor 
assessment, i.e. time to event variables can never be negative.  
14.1.35  Incomplete  assessment  dates  
All investigation  dates  (e.g. X-ray, CT scan)  must  be completed  with day, month  and year.  
If one or more investigation dates are incomplete but other investigation dates are available, 
this/these incomplete date(s) are not considered for calculation of the assessment date (and 
assessment  date is calculated  as outlined  in Section  14.1.25 ). If all measurement  dates  have  no 
day recorded, the 1st of the month is used.  
If the month is not completed, for any of the investigations, the respective assessment will be 
considered to be at the date which is exactly  between previous and following assessment. If a 
previous and following assessment is not available, this assessment will not be used for any 
calculation.  
Array  BioPharma  
Amended  Protoco l Version 10 Confide ntial Page  201 
Protocol  No. CMEK162X2110  / C4221005  
PFIZER  CONFIDENTIAL   
 14.1.36  Incomplete dates for last contact or death  
All dates must be completed with day, month and year. If the day is missing, the 15th of the 
month will be used for incomplete death dates or dates of last contact.  
14.1.37  Non target lesion response  
If no non -target lesions are identified at baseline (and therefore not followed throughout the 
study), the non -target lesion response at each assessment will be considered ‘not applicable 
(NA)’.  
14.1.38  Study/project specific programming  
The standard  analysis  programs  need  to be adapted  for each study/project.  
14.1.39  Censoring reason  
In order to summarize the various reasons for censoring, the following categories will be 
calculated for each time to event variable based on the treatment completion page, the study 
evaluation completion page and the survival page.  
For survival  the following  censoring  reasons  are possible:  
• Alive  
• Lost to follow -up 
• For PFS and TTP (and therefore  duration  of responses)  the following  censoring  reasons 
are possible:  
• Ongoing  without  event  
• Lost to follow -up 
• Withdrew  consent  
• Adequate  assessment  no longer  available*  
• Event  documented  after two or more  missing  tumor  assessments  (optional,  see 
Table 14 -5) 
• Death  due to reason  other  than underlying  cancer  (only  used for TTP and duration  of 
response)  
• New  cancer  therapy  added  (optional;  only if the protocol  specified  that PFS/TTP  will be 
censored at that date)  
*Adequate assessment is defined in Section 14.1.25 . This reason is applicable when adequate 
evaluations are missing for a specified period prior to data cut -off (or prior to any other 
censoring reason) corresponding to the unavailability of two or more planned tumor 
assessments  prior  to the cut-off date.  The following  clarifications  concerning  this reason  should 
also be noted: - 
• This may be when there has been a definite decision to stop evaluation (e.g. 
reason=’Administrative  problems’  on study  evaluation  completion  page),  when  patients 
are not followed for progression after treatment completion or when only UNK 
assessments are available just prior to data cut -off). 
Array  BioPharma  
Amended  Protoco l Version 10 Confide ntial Page  202 
Protocol  No. CMEK162X2110  / C4221005  
PFIZER  CONFIDENTIAL   
 • The reason "Adequate assessment no longer available" also prevails in situations when 
another  censoring  reason  (e.g. withdrawal  of consent,  loss to follow -up or alternative  anti- 
cancer therapy) has occurred more than the specified period following the last adequate 
assessment.  
• This reason  will also be used for censor  in case of no baseline  assessment.  
14.1.40  References (available upon request)  
Dent  S, Zee B, Dancey  J, et al (2001)  Application  of a new multinomial  phase  II stopping  rule 
using response and early progression. J Clin Oncol; 19(3): 785 -91. 
Eisenhauer  EA, Therasse  P, Bogaerts  J, et al (2009)  New  response  evaluation  criteria  in solid 
tumors: revised RECIST guideline (version 1.1). Eur J Cancer; 45(2): 228 -47. 
Ellis S, Carroll  KJ, Pemberton  K (2008)  Analysis  of duration  of response  in oncology  trials. 
Contemp Clin Trials; 29(4): 456 -65. 
FDA  Guidelines:  2005  Clinical  Trial  Endpoints  for the Approval  of Cancer  Drugs  and 
Biologics, April 2005.  
FDA  Guidelines:  2007  Clinical  Trial  Endpoints  for the Approval  of Cancer  Drugs  and 
Biologics, May 2007.  
Morgan  TM (1988)  Analysis  of duration  of response:  a problem  of oncology  trials.  Control 
Clin Trials; 9(1): 11 -8. 
Therasse  P, Arbuck  SG, Eisenhauer  EA, et al (2000)  New  Guidelines  to Evaluate  the 
Response to Treatment in Solid Tumors. J Natl Cancer Inst; 92(3): 205 -16. 
Array  BioPharma  
Amended  Protoco l Version 10 Confide ntial Page  203 
Protocol  No. CMEK162X2110  / C4221005  
PFIZER  CONFIDENTIAL   
 14.2 Appendix  2 - The 2009  American  Joint  Committee  on Cancer 
(AJCC) staging system  
Table 14 -6 The 2009  American  Joint  Committee  on Cancer  (AJCC)  staging 
system for malignant melanoma  
 
Stage  Primary  tumour (pT) Lymph  nodes  (N) Metastases (M) 
IA < 1 mm, no ulceration,    
mitoses < 1 mm)2  
IB < 1 mm, with ulceration  or 
mitoses ‡1mm)2a 
1Æ01 -2 mm, no ulceration  
IIA 1Æ01 -2 mm, with ulceration  
2Æ01 -4 mm, no ulceration  
IIB 2Æ01 -4 mm, with ulceration  
> 4 mm, no ulceration  
IIC > 4 mm, with ulceration  
IIIA Any Breslow thickness,  Micrometastases  
no ulceration  1-3 nodes  
IIIB Any Breslow thickness,  Micrometastases  
with ulceration  1-3 nodes  
Any Breslow  1-3 palpable  
thickness, no ulceration  metastatic nodes  
Any Breslow thickness,  No nodes, but in -transit  
no ulceration  or satellite  metastasis ⁄es 
IIIC Any Breslow thickness,  Up to three palpable  
with ulceration  lymph nodes  
Any Breslow thickness,  Four or more nodes or matted  
with or without ulceration  nodes or in -transit disease  
 + lymph nodes  
Any Breslow thickness,  No nodes, but in -transit or 
with ulceration  satellite metastasis ⁄es 
IV, M1a   Skin, subcutaneous or 
distant nodal disease  
IV, M1b Lung metastases  
IV, M1c All other  sites or any other  sites 
of metastases  
with raised  lactate 
dehydrogenase  
a In the rare circumstances where mitotic count cannot be accurately determined, a Clark level of invasion of 
either  IV or V can be used  to define  T1b melanoma.  Every  patient  with melanoma  should  be accurately  staged 
using the AJCC system; this may include  performing a sentinel lymph node biopsy when this is recommended  
by the Specialist  Skin Cancer  Multidisciplinary  Team.  Staging  should  be updated  following  relapse.  
Array  BioPharma  
Amended  Protoco l Version 10 Confide ntial Page  204 
Protocol  No. CMEK162X2110  / C4221005  
PFIZER  CONFIDENTIAL   
 14.3 Appendix  3 - Guidelines  for the treatment  of study  drug 
combination induced skin toxicity  
[Any language regarding the triple combination of LGX818/MEK162/LEE011 in this 
Section is not applicable to the USA and Singapore]  
14.3.1  Rash  
Skin disorder/rash has been observed in the ongoing studies of single -agent LGX818 and 
MEK162 and thus is recognized as a potential overlapping toxicity associated with the 
concurrent use of both compounds. The majority of these events were CTCAE Grade 1 or 2, 
but also dose -limiting as Grade 3 at the 80mg BID dose for MEK162.  
The results of the STEPP study ( Mitchell 2009 ; Piperdi 2009 ) support the use of pre -emptive 
skin treatment for patients at risk of treatment induced skin toxicity. In this study, the pre - 
emptive skin treatment regimen reduced the incidence of specific CTCAE Grade ≥ 2 skin 
toxicity by more than 50% as compared to the group who received only reactive skin toxicity 
treatment.  In this study,  patients  will not initially  receive  prophylactic  treatment  for skin toxicity 
during Cycle 1. However, prophylactic treatment for skin toxicity may be introduced in 
subsequent cycles of treatment and in new patients if at least one patient has experienced 
CTCAE Grade 3 or greater skin toxicity, or if at least two patients have experienced such 
toxicities that are CTCAE Grade ≥ 2. Prophylactic supportive therapy for skin toxicity (i.e. 
initiated  24 hrs prior  to study  drug combination)  including  skin moisturizers,  sunscreen  (PABA 
free, SPF ≥ 15, UVA/UVB protection), topical steroid (1% hydrocortisone cream), and 
doxycycline (100 mg BID) may be initiated in all patients at the dose levels where these 
toxicities  have  been  observed  and may be advised  to all further  patients.  Effective  medications 
also include antihistamines, topical corticosteroids and low -dose systemic corticosteroids (the 
latter should be used with caution due to the increased risk of hyperglycemia).  
The treatment algorithm  is as follows:  
Mild Rash  (CTCAE  Grade 1) 
• Treatment  with LGX818  and MEK162  or LGX818  and MEK162  and LEE011  should  be 
maintained at the current dose.  
• Topical  hydrocortisone  (1% or 2.5%  cream)  for macular  rash and/or  topical  clindamycin 
(1%) for pustular rash is recommended.  
• The patient should be reassessed after 2 weeks.  
Moderate  Rash  (CTCAE  Grade 2) 
• Treatment  with LGX818  and MEK162  or LGX818  and MEK162  and LEE011  should  be 
maintained at the current dose, and the rash should be closely monitored for change in 
severity.  
• Doxycycline or minocycline are not recommended due to phototoxicity and should be 
replaced  with oxytetracycline  or lymecycline.  However,  if doxycycline  or minocycline  are 
used, precaution measurements should be taken (i.e., avoid direct exposure on sun, use of 
sunglasses, sunscreen, ect.). The recommendation is: topical clindamycin (1%) plus either  
Array  BioPharma  
Amended  Protoco l Version 10 Confide ntial Page  205 
Protocol  No. CMEK162X2110  / C4221005  
PFIZER  CONFIDENTIAL   
 hydrocortisone  (2.5%  cream)  or pimecrolimus  (1% cream)  plus oxytetracycline  (500 mg 
twice daily) or lymecycline (408 mg QD).  
Severe  Rash  (CTCAE  Grade  3-4) 
CTCAE Grade 3  
• The dose of LGX818 and MEK162 or LGX818 and MEK162 and LEE011 should be 
omitted  until resolved  to CTCAE  Grade  ≤ 1, in line with protocol  recommendations,  and 
the rash should be closely monitored for any change in severity.  
• In addition to the interventions recommended for moderate rash, prednisolone may be 
given  (with  caution  due to risk of hyperglycemia)  as a reducing  dose regimen  (25 mg for 7 
days, subsequently decreasing the dose by 5 mg/day every day to 0).  
• If skin toxicity  CTCAE  Grade  3 is not resolved  within  7 days,  discontinue  patient  from 
study drug treatment.  
CTCAE  Grade  4 
• If skin toxicity  CTCAE Grade 4 occurs the dose of LGX818 and MEK162 or LGX818 
and MEK162  and LEE011  should  be omitted  and patients  discontinued  from  study  drug 
treatment.  
Table  14-7 Treatment  of skin toxicity  
 
Mild Rash  (Grade  1) 
Dry Skin  
Nail changes 
Pruritus 
Desquamation  
Acneiform  Topical  hydrocortisone  1% or 2.5%  and/or  Clindamycin  1% gel 
Moderate  Rash  (Grade  2) 
Dry Skin  
Nail changes 
Pruritus 
Desquamation  
Acneiform  Topical clindamycin (1%) plus either hydrocortisone (2.5% cream) or 
pimecrolimus  (1% cream)  plus oxytetracycline  (500 mg twice  daily)  or 
lymecycline (408 mg QD).  
Severe  Rash  (Grade  3-4) 
Dry Skin  
Nail changes 
Pruritus 
Desquamation  
Acneiform  Hydrocortisone 2.5% cream or Clindamycin 1% gel or Pimecrolimus 1% 
cream  plus oxytetracycline  (500 mg twice  daily)  or lymecycline  (408 mg QD) 
plus prednisolone (with caution due to risk of hyperglycemia) (25 mg for 7 
days, decreasing the dose by 5 mg/day every day).  
Adapted from Thatcher 2009 . 
14.3.2  Hand  Foot  Skin  Reaction  
As HFSR  has been  reported  in some  patients  during  LGX818  treatment,  it is recommended  that 
patients are educated prior to starting study treatment which activities to avoid and on 
supportive measures for prevention and/or management of HFSR. Recommendations are 
summarized below in Table 14 -8. Furthermore, the patient should be treated at the first 
symptoms according the institutional standards of care. A visit at a podiatrist may also be 
recommended at the discretion of the investigator.  
Array  BioPharma  
Amended  Protoco l Version 10 Confide ntial Page  206 
Protocol  No. CMEK162X2110  / C4221005  
PFIZER  CONFIDENTIAL   
 Table  14-8 Supportive  care for the prevention  and management  of HFSR  
Stage  Recommendations  
Prior to treatment  Educate  the patient  about  the early  signs  and symptoms  of HFSR  and discuss  the 
importance of early reporting.  
Prevention of HFSR  Monitor  the patient  for signs  and symptoms  of HFSR.  Instruct the  patient to: 
- Apply emollient cream regulary to hands and feet 
- Avoid  skin irritants  (e.g. perfumes,  alcohol,  harsh  cleaning  agents)  
- Wear  cotton  socks  or gloves  to bed to enhance  the absorption  of creams  
- Avoid  tight,  irritating  or ill-fitting  clothing  and shoesa 
- Avoid  the use of band  aides  or other  types  of adhesive  bandages  or tape 
- Avoid repetitive activity or staying in one position for long periods of time 
- Keep  the skin uncovered  when  possible  to minimize  perspiration  
- Wear  rubber  gloves while  doing dishes  
- Pat (do not rub) skin dry with towels  
- Avoid extremes of temperature, pressure and friction  
- Avoid  performing  mechanically  stressful  manual  work 
- Minimise  exposure  to strong,  direct sunlight  
- Elevate affected limbs  
Treatment of HFSR  1) Ensure that patient follows treatment interruption or dosage reduction guidelines  
2) Monitor the patient for progression/resolution of HFSR  
3) Prescribe analgesics if necessary  
4) Instruct the patient to: 
- Continue  the use of prevention  strategies  
- Cushion sore skin 
- Submerge  hands  and feet in cool water  baths  or apply  cold compresses  for relief  
a Wear  loose -fitting  clothing  made  of soft, natural  fabrics  and shoes  that are wide and comfortable.  Avoid  tight 
belts, panties and bras.  
This Table  is adapted  from ( van Moos  et al 2008 ). 
14.3.3  References (available upon request)  
Mitchell EP, Lacouture M, Shearer H (2009) Final STEPP results of prophylacatic versus 
reactive  skin toxicity  (ST) treatment  (tx) for panitumumab  (pmab) -related  ST in patients  (pts) 
with metastatic colorectal cancer (mCRC). J Clin Oncol; 27:18s, (suppl; abstr CRA4027).  
Van Moos R, Thuerlimann B, Chair M , et al (2008) Pegylated liposomal doxorubicin - 
associated  hand -foot syndrome:  Recommendations  of an international  panel  of experts.  Eur J 
Cancer; 1016: 1 -10. 
Piperdi  B, Mitchell  EP, Lacouture  M, et at (2009)  STEPP,  an open -label,  randomized  study  of 
pre-emptive (P) versus reactive (R) skin toxicity (ST) treatment (tx) in metastatic colorectal 
cancer (mCRC) patients (pts) receiving panitumumab (pmab) + FOLFIRI or irinotecan -based 
(Iri) chemotherapy (CT) as second -line tx: Results by CT and KRAS status. ASCO 2009 
Gastrointestinal Cancers Symposium. Poster presentation Abstract No: 394.  
Thatcher  N, Nicolson  M, Groves  RW, et al (2009)  Expert  Consensus  on the Management  of 
Erlotinib -Associated Cutaneous Toxicity in the U.K. Oncologist; 14(8): 840 -7. 
Array  BioPharma  
Amended  Protoco l Version 10 Confide ntial Page  207 
Protocol  No. CMEK162X2110  / C4221005  
PFIZER  CONFIDENTIAL   
 14.4 Appendix  4 - List of concomitant  medications  prohibited  or to be 
used with caution for dual and triple combination  
[Any  language  regarding  the triple  combination  of LGX818/MEK162/LEE011  in this 
Section is not applicable to the USA and Singapore]  
Table 14 -9 Narrow  therapeutic  index  substrates  of CYP3A4*,  CYP2B6,  CYP2C9 
prohibited or to be administered with caution  
The information presented on sensitive and narrow TI substrates is a compilation of the 
University  of Washington  Drug -Drug Interaction  (DDI)  database  and FDA  DDI guidance. 
This list might not be exhaustive.  
 
 Sensitive Substrates  Narrow TI Substrates  
CYP1A2  Alosetron,  duloxetine,  melatonin,  ramelteon, 
tacrine, tizanidine  Theophylline, tizanidine  
CYP3A4*  budesonide,  buspirone,  eplerenone,  eletriptan, 
felodipine, fluticasone, lovastatin, midazolam, 
saquinavir, sildenafil, simvastatin, triazolam,  
vardenafil  alfentanil, astemizole(a), cisapride(a), 
cyclosporine,  diergotamine,  ergotamine, 
fentanyl, pimozide, quinidine, sirolimus,  
tacrolimus, terfenadine(a)  
CYP2B6  bupropion, efavirenz  Not Applicable  
CYP2C9  NA warfarin, phenytoin  
Reproduced from 
fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm081177.htm#4* 
prohibited for patients treated with the triple combination  
Array  BioPharma  
Amended  Protoco l Version 10 Confide ntial Page  208 
Protocol  No. CMEK162X2110  / C4221005  
PFIZER  CONFIDENTIAL   
 Table 14 -10 List of CYP inhibitors  and inducers  prohibited  or to be used  with 
caution  
The information presented on inhibitors and inducers is a compilation of the University of 
Washington  Drug -Drug  Interaction  (DDI)  database  and FDA  DDI guidance.  This list might 
not be exhaustive  
 
Strong  CYP3A4*,5,7  inhibitors  (AUC  > 5-fold increase)  
Itraconazole  Ketoconazole  Mibefradil  Nefazodone  
Nelfinavir  Posaconazole  Ritonavir  Saquinavir  
Telithromycin  Troleandomycin  Voriconazole  Boceprevir  
Clarithromycin  conivaptan  indinavir  lopinavir  
Grapefruit  juice (citrus 
paradisi fruit juice)  telaprevir  cobicistat   
Moderate  CYP3A4,5,7  inhibitors  (AUC  ≥ 2-fold increase  and < 5-fold increase)  
Amprenavir  Atazanavir  Cimetidine  Ciprofloxacin  
Diltiazem  dronedarone  Fluconazole  erythromycin  
Imatinib  Schisandra Sphenanthera  Tofisopam  Verapamil  
aprepitant  casopitant  cyclosporine  darunavir  
fosamprenavir     
Strong  & Moderate  CYP3A4  inducers**  (AUC  ≥ 2-fold increase)  
Avasimide  Bosentan  Carbamazepine  Efavirenz  
Etravirine  Modafenil  Nafcillin  Nevirapine  
Phenobarbital  Phenytoin  Rifabutin  Rifampin (Rifampicin)  
Ritonavir  St. John's wort Talviraline   
Strong  & Moderate  CYP1A2  inhibitors  (AUC  ≥ 2-fold increase)  
Clinafloxacin  Enoxacin  Etintidine  Fluvoxamine  
Idrocilamide  Methoxsalen  Mexiletine  Oltipraz  
Oral contraceptives  Phenylpropanolamine  Pipemidic acid Propranolol  
Rofecoxib  Thiabendazole  Zafirlukast  Zileuton  
CYP1A2 inducers  
Tobacco     
Strong  & Moderate  CYP2C19  inhibitors  (AUC  ≥ 2-fold increase)  
Fluconazole  Fluvoxamine  Fluoxetine  Moclobemide  
Omeprazole  Ticlopidine  Voriconazole   
CYP2C19 inducers     
Rifampin     
This database  of CYP inhibitors  and inducers  was compiled  from the Indiana  University  School  of Medicine’s 
“Clinically Relevant” Table, the University of Washington’s Drug Interaction Database, and the FDA’s 
“Guidance for Industry, Drug Interaction Studies.”* prohibited for patients treated with the dual and triple 
combination  
** prohibited for patients treated with the triple combination  
Array  BioPharma  
Amended  Protoco l Version 10 Confide ntial Page  209 
Protocol  No. CMEK162X2110  / C4221005  
PFIZER  CONFIDENTIAL   
 Table 14 -11 List of BCRP  substrates,  BSEP  inhibitors,  P-gp inhibitors/inducers,  and 
MATE1/2, P -gp, OAT1, OAT3, OCT1, OCT2, OATP1B1 and OATP1B3 substrates to be 
used with caution  
The information  presented  on transporter  substrates,  inducers  and inhibitors  is a compilation 
of the University of Washington Drug -Drug Interaction (DDI) database and FDA DDI 
guidance. This list might not be exhaustive.  
 
Category  Drug Name  
BCRP substrates  atorvastatin,  daunorubicin,  doxorubicin,  ethinyl  estradiol,  hematoporphyrin,  imatinib, 
methotrexate6, mitoxantrone, pitavastatin6, rosuvastatin6, SN-38 (irinotecan),  
simvastatin,  sulfasalazine,  sofosbuvir1, topotecan1, sulfasalazine1 
BSEP  Vinblastine  
Strong BSEP inhibitors  Alectinib,  atazanavir,  bromocriptine,  bosentan,  clofaziminie,  cerivastatin,  fusidate, 
glibenclamide, glyburide, nefazadone, paritaprevir, pioglitazone, reserpine, 
rosiglitazone, sulindac, troglitazone (TGZ -sulfate), valinomycin  
NTI substrates of P -gp1 digoxin, quinidine, paclitaxel, cyclosporine, sirolimus, tacrolimus, fentanyl, phenytoin  
Substrates  of P-gp (≥2X 
AUC change)2 aliskiren, ambrisentan, atorvastatin, atorvastatin acid, azithromycin, cerivastatin, 
colchicine,  CP-481,715,  cyclosporine,  dabigatran,  digoxin,  docetaxel,  domperidone, 
doxorubicin, fentanyl, fexofenadine, lapatinib, linezolid, loperamide, maraviroc, 
nevirapine, paclitaxel, proguanil, quinidine, ranolazine, ritonavir, saquinavir,  
simvastatin, sirolimus, sofosbuvir, tacrolimus, ticagrelor, voclosporin  
Substrates of P -gp 
mentioned  in US label3 afatinib, alfuzosin, aliskiren, alogliptin, ambrisentan, apixaban, apremilast, aprepitant, 
boceprevir, bosentan, carvedilol, carvedilol, caspofungin, ceritinib, citalopram, 
colchicine, cyclosporine, dabigatran, digoxin, doxepin, doxorubicin, eribulin, 
everolimus,  fidaxomicin,  fluvastatin,  fosamprenavir,  gatifloxacin,  idelalisib,  iloperidone, 
indacaterol, irbesartan, lacosamide, lapatinib, levetiracetam, levofloxacin, linagliptin, 
losartan, maraviroc, mirabegron, moxifloxacin, naloxegol, nateglinide, nintedanib, 
olodaterol, pantoprazole, paroxetine, pazopanib, posaconazole, pravastatin, quinine, 
ranolazine, riociguat, risperidone, rivaroxaban, saquinavir, silodosin, simeprevir, 
sirolimus, sitagliptin, sorafenib, telaprevir, tenofovir, ticagrelor, tipranavir, tolvaptan,  
topotecan,  umeclidinium, valsartan, vardenafil, vincristine, voriconazole  
P-gp inhibitors  alogliptin, amiodarone4, azithromycin4, canaglifozin, captopril4, carvedilol4, 
clarithromycin4, conivaptan4, cremophor RH40, curcumin, diltiazem4, dronedarone4, 
elacridar4, erythromycin4, felodipine4, fluvoxamine4, ginko4,5, indinavir4, 
indinavir/ritonavir4, itraconazole4, ketoconazole, lapatinib, lopinavir/ritonavir, 
mibefradil4, milk thisle4,5, mirabegron, nelfinavir4, nifedipine4, nitredipine4, paroxetine4, 
propafenone, quercetin,4, quinidine4, ranolazine4, rifampin4, ritonavir4, 
sequinavir/ritonavir4, schisandra chinesis extract4,5, simepravir, St. John’s wort 
extract4,5, talinolol4, telaprevir4, telmisartan4, ticagrelor4, tipranavir/ritonavir4, tolvaptan4, 
valspodar,  vandetanib,  verapamil4, voclosporin,  Zosuquidar  LY335979  
P-gp Inducers  avasimibe,  carbamazepine,  efavirenz,  genistein2, phenytoin,  quercetin2, rifampin,  St. 
Johns wort extract5 
OCT1/2  substrates7 , Amantadine,  , 6-beta-hydroxycortisol,  carboplatin,  cisplatin,  cephalexin,  cephradine, 
ipratropium,  lamivudine, linagliptin, metformin,  oxyplatin, oxybutynin, phenformin,  
picoplatin,  pilsicainide,  pindolol,  ranitidine,  sorafenib,  tropisetron,  trospium, 
umeclidinium, zidovudine  
MATE1/2  substrates3,8 Acyclovir,  cephalexin,  cimetidine,  fexofenadine,  ganciclovir,  glycopyrronium, 
metformin, pindolol, plisicainide, ranitidine, topotecan, varenicline  
OAT1  Adefovir,  captopril,  furosemide,  lamivudine,  methotrexate,  oseltamivir,  tenofovir, 
zalcitabine, zidovudine  
OAT3  Acyclovir, bumetanide, ciprofloxacin, famotidine, furosemide, methotrexate, 
zidovudine,  oseltamivir  acid,  (the active  metabolite  of oseltamivir),  penicillin  G, 
pravastatin, rosuvastatin, sitagliptin  
Array  BioPharma  
Amended  Protoco l Version 10 Confide ntial Page  210 
Protocol  No. CMEK162X2110  / C4221005  
PFIZER  CONFIDENTIAL   
  
Category  Drug Name  
OATP1B1 substrates  ambrisentan, anacetrapib asunaprevir, atorvastatin, atrasentan, benzylpenicillin, 
bosentan, bromociptine, caspofungin, cerivastatin, danoprevir, empangliflozin, 
enalapril, ezetimibe, fexofenadine, fimasartan, fluvastatin, maraviroc, methotrexate, 
olmesartan,  pitavastatin,  pravastatin,  repaglinide,  rifampicin,  rosuvastatin,  simvastatin 
acid, SN -38; temocapril, troglitazone, valsartan  
OATP1B3 substrates  asunaprevir, atrasentan, bosentan, danoprevir, digoxin, docetaxel, empangliflozin, 
enalapril, erythromycin, fexofenadine, fluvastatin, imatinib, methotrexate, olmesartan, 
ouabain, paclitaxel, pitavastatin, pravastatin, rifampicin, rosuvastatin, telmisartan, SN- 
38; thyroxine (T4), valsartan  
Reproduced from 
(fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm080499.htm)  
1 These  drugs  have  both a narrow  therapeutic  index  and an in vivo DDI outcome  ascribed  at least in part ascribed  to P-gp 
(inhibition or induction) that exceeds a 20% change in AUC.  
2 These  drugs  have  in vivo DDI outcomes  (inhibition)  which  are ≥2x increase  in AUC  and are at least in part ascribed  to 
P-gp. 
3 The US labels  for these  drugs  have  specific  language  on in vivo P-gp substrate  status.  
4 Dual  P-gp and CYP3A4  inhibitor  
5 Herbal  medication.  
6 Have  been  shown to  have DDI  in vivo, others  are reported as  substrates  in vitro. 
7 OCT1  and OCT2  share  considerable  substrate  specificity.  
8 MATE1  and MATE2  share  considerable  substrate  specificity.  
Array  BioPharma  
Amended  Protoco l Version 10 Confide ntial Page  211 
Protocol  No. CMEK162X2110  / C4221005  
PFIZER  CONFIDENTIAL   
 Table  14-12 List of QT prolonging  drugs  
This list might not  be exhaustive.  
 
TdP Risk  Generic  Name  
Known1 Amiodarone, anagrelide, arsenic trioxide, astemizole, azithromycin, bepridil, chloroquine, 
cocaine, chlorpromazine, cilostazol, ciprofloxacin, cisapride, citalopram, clarithromycin, 
disopyramide, dofetilide, domperidone, donepezil, dronedarone, droperidol, erythromycin, 
escitalopram,  flecainide,  fluconazole,  gatifloxacine,  grepafloxacin,  halofantrine,  haloperidol, 
ibutilide, levofloxacin, levomethadyl, mesoridazine, methadone, moxifloxacin, ondansetron 
(i.v. only), oxaliplatin, papaverine HCl, pentamidine, pimozide, probucol, procainamide, 
propofol, quinidine, roxithromycin, sevoflurane, sotalol,  sparfloxacin, sulpiride, terfenadine, 
thioridazine, vandetanib  
Possible2 Alfuzosin, apomorphine, aripiprazole, artenimol+piperaquine ,atazanavir, atomoxetine, 
asenapine, bedaquiline, bortezomib, buprenorphine, capecitabine, ceritinib, clomipramine, 
crizotinib,,clozapine, cyamemazine (cyamepromazine), dabrafenib, dasatinib, degarilix, 
delamanid, desipramine, dexmedetomidine, dolasetron, eribulin, ezogabine, famotidine, 
felbamate, fingolimod, foscarnet, gatifloxacin, gemifloxacin, granisetron, hydrocodone -ER, 
iloperidone, imipramine (melipramine), isradipine, , lapatinib, lenvatinib, leuprolide, 
loperamide, lithium, mifepristone, mirabegron, mirtazapine, moexipril,  norfloxacin, 
nortriptyline, ofloxacin, olanzapine, osimirtinib, ondansetron (p.o. only at 4 mg or 8 mg), 
oxytocin, paliperidone, panabinostat, pasireotide, pazopanib, pipamperone, promethazine, 
quetiapine,  ranolazine,  rilpivirine,  risperidone,  roxithromycin,  sertindole,  sorafenib,  sunitinib, 
telavancin, tetrabenazine, tizanidine, tolterodine, toremifene, tramadol, trimipramine, 
vardenafil, vemurafenib, venlafaxine, vorinostat, ziprasidone  
Conditional3 Amantadine, amisulpride, amitriptyline, amoxapine, chloral hydrate, diphenhydramine, 
doxepin, fluoxetine, furosemide (frusemide), galantamine, hydrochlorothiazide, 
Hydroxychloroquine  hydroxyzine,  indapamide,  itraconazole,  ivabradine  (on non US mkt), 
ketoconazole, metoclopramide, metronidazole, nelfinavir, pantoprazole, paroxetine, 
posaconazole, quinine sulfate, ritonavir, sertraline, solifenacin, telaprevir, torsemide 
(torasemide), trazodone, voriconazole  
1 Known  risk: Substantial  evidence  supports  the conclusion  that these  drugs  prolong  the QT interval  AND  are clearly 
associated with a risk of TdP, even when taken as directed in official labeling  
2 Possible risk: Substantial evidence supports the conclusion that these drugs can cause QT prolongation BUT there is 
insufficient  evidence  at this time that these  drugs,  when  used as directed  in official  labeling,  are associated  with a risk of 
causing TdP.  
3 Conditional  risk: Substantial  evidence  supports  the conclusion  that these  drugs  are associated  with a risk of TdP BUT  only 
under certain conditions (e.g. excessive dose, hypokalemia, congenital long QT or by causing a drug -drug interaction that 
results in excessive QT interval prolongation).  
Array  BioPharma  
Amended  Protoco l Version 10 Confide ntial Page  212 
Protocol  No. CMEK162X2110  / C4221005  
PFIZER  CONFIDENTIAL   
 14.5 Appendix  5 – Statistical  methodology  LGX818  and MEK162  dual 
combination  
14.5.1  Prior  Distributions  of 5 parameter  dual combo  (LGX818+MEK162) 
model  
LGX818 (cps): The initial prior parameters for the capsule of the single agent are as specified 
in study [CLGX818X2101] . Detailed derivation of this prior distribution can be found in the 
protocol of CLGX818X2101, Section 10.4.2 . 
Using a meta -analytic predictive approach, an assumption about heterogeneity between trial 
[CLGX818X2101]  and the current  combination  trial is captured  in the prior  distributions  of the 
standard  deviation  of the model  parameters  (log(α 1),log(β 1)), denoted  by τ1 and τ2. Both  τ1 and 
τ2 were  assumed  to follow  a log-normal  distribution  with mean  log(0.25)  and standard  deviation 
0.01,  assuming  moderate  between -trial heterogeneity.  This new distribution  is then used as the 
prior distribution for the model parameters (log(α 1),log(β 1)). 
MEK162: An informative bivariate normal prior for the model parameters (log(α 2),log(β 2)) is 
obtained as follows:  
As a first step, a non-informative  prior  for (log(α 2),log(β 2)) was defined  as follows:  
• The median  DLT  rate at the reference  dose (60mg)  was assumed  1/3, i.e. 
mean(log(α 2,fasted )) = log(1/2)  
• A doubling in dose  was assumed to  double the odds  of DLT, i.e.  mean(log(β 2)) = 0 
• The standard  deviations  of the two parameters  were  set to 2, such that the bivariate  normal 
distribution covers approximately 95% of the probability space.  
• The correlation  between  the two parameters  was set to 0, assuming  independence.  
Data  from  the 15 patients  eligible  for the DDS  of on-going  study  [ARRAY -162-111] was added 
into a 2 -parameter BLRM for single agent.  
The assumption about heterogeneity is captured in the prior distributions of the standard 
deviation  of (log(α 2),log(β 2)), denoted  by τ1 and τ2. Both  τ1 and τ2 are assumed  to follow  a log- 
normal distribution with mean log(0.25) and standard deviation 0.01, assuming moderate 
between -trial heterogeneity.  
The updated  model  parameters  are estimated  via simulation  from  the posterior  distribution.  This 
distribution is then used as the prior distribution for the parameters (log(α 2),log(β 2)). 
Table  14-13  Data  from  ARRAY -162-111 
 
Dose of MEK162 (mg, bid) No of DLTs / No of evaluable patients  
 
30 0/3 
45 0/3 
60 0/6 
80 2/3 
A weakly informative prior reflecting the current uncertainty about the toxicity of the 
combination  treatment  is used for η12. In order  to allow  for the potentiality  of both synergy  and 
antagonism  of the safety  profiles,  it was assumed  that η12 is normally  distributed  with median  
Array  BioPharma  
Amended  Protoco l Version 10 Confide ntial Page  213 
Protocol  No. CMEK162X2110  / C4221005  
PFIZER  CONFIDENTIAL   
 = 0 (no increase on odds of DLT, i.e. independence) and 97.5th percentile = log(20) (20 -fold 
increase on odds of DLT).  
The prior  distributions  of 5 parameter  dual combo  (LGX818+MEK162)  model  are provided  in 
Table 14 -14. 
Table  14-14   Predictive  distribution  of model  parameters  
 
Parameter  Means  Standard deviations  Correlation  
log(α 1), log(β 1) -1.415, 0.463  1.231, 1.273  0.003  
log(α 2), log(β 2) -2.326, 1.564  1.107, 1.368  -0.535  
η12 0 1.528  N/A 
For LGX818X2101, data up to dose escalation teleconference from 23/Nov/2011  
Predictive:  between -trial heterogeneity  τ1~lognormal(log(0.25),0.012), τ2~lognormal(log(0.25),0.012) for log(α 1), 
log(β 1), and τ 1~lognormal(log(0.25),0.012), τ2~lognormal(log(0.25),0.012) for log(α 2), log(β 2) 
A summary of the respective prior distribution of DLT rates for dual combo 
(LGX818+MEK162) is given in Table 14 -15. Dose combinations not satisfying the overdose 
criteria, i.e. not eligible at the start of the study, are displayed in bold.  
Note : the model was re -evaluated before the first dose escalation meeting with the available 
data from study [CLGX818X2101] . 
Array  BioPharma  
Amended  Protoco l Version 10 Confide ntial Page  214 
Protocol  No. CMEK162X2110  / C4221005  
PFIZER  CONFIDENTIAL   
 Table  14-15 Summary  of prior  probabilities  of DLT rates  
LGX818  
(mg)  Prior  probabilities  that Pr(DLT) 
is in interval:   
Mean   
SD  
Quantiles  
 [0.0, 0.16)  [0.16,  
0.35)  [0.35,1.00]    2.50%  50.00%  97.50%  
 MEK162  = 30mg  
50 0.674  0.206  0.12 0.147  0.166  0 0.086  0.616  
100 0.379  0.29 0.331  0.288  0.226  0.018  0.226  0.824  
150 0.231  0.199  0.571  0.472  0.32 0.021  0.433  0.999  
200 0.203  0.152  0.644  0.551  0.347  0.017  0.573  1 
250 0.198  0.124  0.679  0.595  0.361  0.011  0.677  1 
300 0.198  0.105  0.697  0.621  0.37 0.007  0.754  1 
 MEK162  = 45mg  
50 0.615  0.231  0.154  0.173  0.18 0.001  0.109  0.668  
100 0.365  0.254  0.381  0.319  0.256  0.014  0.249  0.891  
150 0.255  0.165  0.58 0.489  0.342  0.011  0.466  0.999  
200 0.238  0.123  0.639  0.559  0.37 0.006  0.616  1 
250 0.238  0.098  0.664  0.596  0.385  0.003  0.722  1 
300 0.242  0.083  0.675  0.616  0.395  0.001  0.798  1 
 MEK162  = 60mg  
50 0.453  0.297  0.25 0.242  0.202  0.016  0.182  0.754  
100 0.313  0.221  0.466  0.379  0.289  0.013  0.316  0.946  
150 0.255  0.137  0.608  0.521  0.36 0.006  0.532  1 
200 0.252  0.102  0.645  0.577  0.386  0.002  0.68 1 
250 0.259  0.082  0.66 0.603  0.401  0.001  0.78 1 
300 0.267  0.068  0.665  0.618  0.412  0 0.846  1 
Prior  specifications of  LGX818 New  Regimen  
If a different  regimen  (BID  and/or  every -other -day) for LGX818  is explored  in this study,  then 
two models  will be fitted  independently  for the different  dosing  regimens.  The dose escalation 
for the originally  planned  regimen  will be guided  by the model  described  previously.  The dose 
escalation for the new regimen (NR) will be guided by a model using the same mathematical 
relationship as the one for the originally  planned regimen but with different prior distributions 
based on a meta -analytic predictive approach. Details are given in Section 14.5.3.1 . 
Prior  specifications  for the MEK162  smaller  tablet  / new MEK162  tablet  variant 
if to be evaluated for MTD/RP2D in MEK162X2110 patients  
If it is decided that the MTD/RP2D of the LGX818 and MEK162 combination will need to be 
established  with one or both of the two new MEK162  tablet  variants,  then all updated  DLT  data 
from  the patients  treated  with the original  tablet  will be incorporated  into a weakly  informative 
prior distribution for MEK162 (smaller tablet /new tablet variant) using a meta -analytic 
predictive approach. Between variant variability will be assessed using the data from 
[CMEK162A2101]  and [CMEK162X2108]  and a down -weighting  factor  will be used to down - 
Array  BioPharma  
Amended  Protoco l Version 10 Confide ntial Page  215 
Protocol  No. CMEK162X2110  / C4221005  
PFIZER  CONFIDENTIAL   
 weight  the original  tablet  data.  The assumption  about  the heterogeneity  between the two tablet 
variants  will be captured  in the prior  distributions  of the standard  deviations  of (log(α),log(β)), 
denoted by τ(τ 1, τ2). A mixture prior with high or low tox components may be used to add 
robustness to the model. The equivalent dose of the MEK162 smaller tablet and/or new 
MEK162  tablet  variant  with respect  to the original  MEK162  tablet  will be calculated  based  on 
the bioavailability  ratio from  relative  bioavailability  study  or relative  PK from  first dose cohort 
prior to first DETC. More details of this process will be provided at the dose -escalation 
teleconference and will be reported in the statistical appendix, Section 16.1.9 of the CSR.  
14.5.2  Data from the ongoing study  LGX818X2101  
Table  14-16   Data  from  LGX818X2101 - as of 23/Nov/2011  
Dose of LGX818 (mg) Nr. DLTs / Nr. evaluable patients  
100 (micro -emulsion)  1/4 
14.5.3  LGX818  change  in regimen  
If a different  regimen  (BID  and/or  every -other -day) for LGX818  is explored  in this study,  then 
two models will be fitted independently  for the different dosing regimens. The dose escalation 
for the originally  planned regimen will be guided by  the model described on Section 10.4.2.1 . 
The dose escalation for the new regimen (NR) will be guided by a model using the same 
mathematical  relationship  as the one for the originally  planned  regimen  but with different  prior 
distributions based on a meta -analytic predictive approach.  
The parameters  in the model  for the new regimen  (NR)  will be denoted  by γ1, δ1 for the LGX818 
NR, by γ 2, β2 for MEK162  BID,  and by ηNR for the interaction  parameter.  The respective  total 
daily doses will be denoted by b 1 and b 2, respectively. This model can thus be expressed as:  
logit(µ 1(b1)) = log(γ  1) + δ 1log(b 1/b1*) 
logit(  µ2(b2)) = log(γ  2) + δ 2log(b 2/b2*) 
Odds(  µ12(b1,b2))) = µ12(b1,b2)/(1- µ12(b1,b2)) 
= exp(η NRb1/b1*b2/b2*)(µ1(b1)+ µ2(b2) – µ1(b1)µ2(b2))/((1 - µ1(b1))(1- µ2(b2))), 
where b 1*= 100mg (NR) and b 2*= 60mg (BID).  
14.5.3.1  Prior  specifications  for LGX818  new regimen  
At the time when a NR is introduced, the prior distribution for the parameters γ 1, δ1, γ2, δ2 and 
ηNR will be derived in the following way:  
γ1, δ1: 
The posterior means, standard deviations and correlation of log(α 1), log(β 1) incorporating all 
the data available at the time when a NR is introduced will be found via simulation.  
The assumption about heterogeneity will be captured in the prior distributions of the standard 
deviation of (log(γ 1),log(δ 1)), denoted by τ 1 and τ 2. Both τ 1 and τ 2 follow a log -normal 
distribution with mean log(0.2) and standard deviation 0.01, assuming small to moderate 
between -regimen heterogeneity.  
Array  BioPharma  
Amended  Protoco l Version 10 Confide ntial Page  216 
Protocol  No. CMEK162X2110  / C4221005  
PFIZER  CONFIDENTIAL   
 The updated  model  parameter  will be estimated  via simulation  from  the predictive  distribution. 
Means, standards deviations and correlation of this distribution will then be used as the prior 
distribution for the parameters (log(γ 1),log(δ 1)). 
γ2, δ2: 
since the  parameters  γ2, δ2 relate  to the single -agent (the marginal) dose -toxicity  relationship of 
MEK162, for which the same regimen will be used, no heterogeneity is expected. Therefore, 
the prior for γ 2, δ2 will simply be the posterior means, standard deviations and correlation of 
log(α 2), log(β 2) incorporating  all the data available  at the time when  a BID regimen  is introduced, 
found via simulation.  
ηNR: 
the posterior mean and standard deviation of η, denoted by mean(η|data), sd(η|data), 
incorporating all the data available at the time when a NR is introduced will be found via 
simulation.  Based  on the assumption  of small  to moderate  between -regimen  heterogeneity,  the 
prior distribution of η NR can be found analytically, as a normal distribution with mean = 
mean(η|data) and standard deviation = (sd(η|data)2. + 2*0.22)0.5. 
14.5.4  Operating  characteristics  of the Bayesian  Logistic  Regression  Model 
and hypothetical dose escalation scenarios  
14.5.4.1  The Bayesian  logistic  regression  model  
An adaptive Bayesian logistic regression model (BLRM) guided by the escalation with 
overdose  control  (EWOC)  principle  will guide  the dose escalation  of the combination  treatment 
to its MTD(s)/RP2D(s). The use of Bayesian response  adaptive  models  for Phase I  studies has 
been advocated by the EMEA guideline on small populations (2006) and by ( Rogatko 2007 ) 
and is one of the key elements of the FDA’s Critical Path Initiative.  
A 5-parameter  BLRM  (refer  to the protocol  Section  10.4.2  for detail)  for combination  treatment 
will be fitted on first 28 day dose limiting toxicity data (i.e. absence or presence of DLT) 
accumulated  throughout  the dose escalation  to model  the dose-toxicity  relationship  of LGX818 
and MEK162 when given in combination. To check the performance of the model, the 
document summarizes the simulation results and some hypothetical dose escalation scenarios.  
Details  regarding  dose recommendation  are described  in Section  10.4.2  of the protocol.  
14.5.5  Simulated operating characteristics  
14.5.5.1  Hypothetical  scenarios  
In order  to show  how the Bayesian  combination  model  reacts,  the following  hypothetical 
scenarios were investigated:  
• Scenario  1: no increases  in odds  of DLT,  i.e., the simulation  parameter  values  for the 
BLRM are set to the mean values of the prior.  
• Scenario  2: is scenario  1 + 50% increase  in odds  of DLT,  i.e., 50% increase  in odds  of 
DLT.  
Array  BioPharma  
Amended  Protoco l Version 10 Confide ntial Page  217 
Protocol  No. CMEK162X2110  / C4221005  
PFIZER  CONFIDENTIAL   
 • Scenario  3: is scenario  1 + 100%  increase  in odds  of DLT,  i.e., 100%  increase  in odds  of 
DLT.  
• Scenario  4: is scenario  1 but  with constant interaction  across  doses.  
• Scenario  5: is scenario  2 but  with constant interaction  across  doses.  
Scenarios 4 and 5 represent stress tests since the underlying interaction is assumed constant  
across doses and not dose -dependent (as assumed in the model).  
Array  BioPharma  
Amended  Protocol  Version  10 Confidential  Page  218 
Protocol  No. CMEK162X2110  / C4221005  
Table  14-17 True  underlying  probabilities  of DLT for Scenario  1 
PFIZER  CONFIDENTIAL   
  
 
LGX818  -QD (mg) MEK162 - BID (mg) 
 15 30 45 60 
30 0.035  0.039  0.06 0.126  
50 0.076  0.081  0.103  0.169  
100 0.203  0.213  0.239  0.304  
150 0.331  0.349  0.38 0.443  
200 0.445  0.469  0.504  0.564  
250 0.539  0.568  0.606  0.662  
300 0.615  0.648  0.686  0.737  
350 0.676  0.711  0.749  0.795  
400 0.725  0.761  0.797  0.839  
450 0.765  0.8 0.835  0.872  
Bold values  indicate dose  combinations  in the  targeted  toxicity interval  [16%, 35%)  
Table  14-18 True  underlying  probabilities  of DLT for Scenario  2 
LGX818  -QD (mg) MEK162 - BID (mg) 
 15 30 45 60 
30 0.036  0.041  0.066  0.141  
50 0.08 0.089  0.118  0.2 
100 0.22 0.249  0.298  0.396  
150 0.366  0.421  0.491  0.594  
200 0.495  0.57 0.651  0.744  
250 0.601  0.686  0.767  0.844  
300 0.684  0.772  0.845  0.904  
350 0.748  0.833  0.896  0.941  
400 0.798  0.877  0.93 0.963  
450 0.837  0.909  0.952  0.977  
Bold values  indicate dose  combinations  in the  targeted  toxicity interval  [16%, 35%)  
Table  14-19 True  underlying  probabilities  of DLT for Scenario  3 
LGX818  -QD (mg) MEK162 - BID (mg) 
 15 30 45 60 
30 0.037  0.043  0.07 0.151  
50 0.083  0.095  0.13 0.224  
100 0.232  0.277  0.345  0.466  
150 0.391  0.474  0.572  0.692  
200 0.531  0.639  0.742  0.838  
250 0.643  0.758  0.849  0.917  
300 0.729  0.839  0.912  0.957  
350 0.793  0.892  0.948  0.978  
400 0.841  0.927  0.969  0.988  
450 0.876  0.95 0.981  0.994  
Bold values  indicate dose  combinations  in the  targeted  toxicity interval  [16%, 35%)  
Array  BioPharma  
Amended  Protocol  Version  10 Confidential  Page  219 
Protocol  No. CMEK162X2110  / C4221005  
Table  14-20 True  underlying  probabilities  of DLT for Scenario  4 
PFIZER  CONFIDENTIAL   
  
 
LGX818 - QD (mg) MEK162 - BID (mg) 
 15 30 45 60 
30 0.035  0.038  0.058  0.121  
50 0.075  0.078  0.097  0.157  
100 0.196  0.198  0.215  0.267  
150 0.316  0.319  0.333  0.377  
200 0.422  0.424  0.436  0.474  
250 0.51 0.512  0.522  0.554  
300 0.582  0.583  0.592  0.619  
350 0.64 0.641  0.649  0.672  
400 0.687  0.688  0.695  0.715  
450 0.726  0.727  0.733  0.75 
Bold values  indicate  dose  combinations  in the targeted  toxicity  interval  [0.16,  0.35)  
Table  14-21 True  underlying  probabilities  of DLT for Scenario  5 
LGX818  -QD (mg) MEK162 - BID (mg) 
 15 30 45 60 
30 0.051  0.056  0.084  0.171  
50 0.108  0.113  0.139  0.218  
100 0.267  0.271  0.291  0.353  
150 0.41 0.412  0.428  0.476  
200 0.523  0.525  0.537  0.574  
250 0.61 0.611  0.621  0.651  
300 0.676  0.677  0.685  0.709  
350 0.727  0.728  0.735  0.755  
400 0.767  0.768  0.774  0.79 
450 0.799  0.8 0.804  0.819  
Bold values  indicate  dose  combinations  in the targeted  toxicity  interval  [0.16,  0.35)  
14.5.5.2  Simulation parameters  
500 trials  were  used to simulate  each scenario  and the total minimum  number  of DLT  to control 
the declaration of MTD was fixed to one.  
The maximal  dose to jump  to was orthogonal  and follows  the protocol  specifications 
(Section 10.4.2.1 of the protocol):  
Array  BioPharma  
Amended  Protocol  Version  10 Confidential  Page  220 
Protocol  No. CMEK162X2110  / C4221005  
Table  14-
220 Preference  matrix  
PFIZER  CONFIDENTIAL   
  
 
LGX818  – QD (mg) MEK162 - BID (mg) 
 15 30 45 60 
50 1 2 3 4 
100 2 3 4 5 
150 3 4 5 6 
200 4 5 6 7 
250 5 6 7 8 
300 6 7 8 9 
350 7 8 9 10 
400 8 9 10 10 
450 9 10 10 10 
The number of patients to enroll in each cohort and stopping rules used to declare MTD were 
defined as:  
• Minimum cohort size: 3 
• Minimum  number  of patients  enrolled:  18 
• Maximum  number  of patients  enrolled:  60 
• Minimum  number  of patients  enrolled  at a given  dose combination  in order  to declare 
MTD: 6  
14.5.5.3  Metrics  
Operating  characteristics  were  reviewed  for the simulations  to compare  the relative  
performance under each true scenario. The metrics reviewed were:  
I. Average  proportion  of patients  receiving a  target dose  combination on  study  (I) 
II. Average  proportion  of patients  receiving  a dose combination  with true P(DLT)  ≥ 35% on 
study (II)  
III. Average  proportion  of patients  receiving  a dose combination  with true P(DLT)  < 16% on 
study (III)  
IV. Probability  of recommending  a target  dose combination  as the MTD  (correct  final 
decision) (IV)  
V. Probability  of recommending  a dose combinations  with true P(DLT)  ≥ 35% as the MTD 
(patient risk) (V)  
VI. Probability  of recommending  dose combination  with true  P(DLT) <  16% as  the MTD (VI) 
14.5.5.4  Results  
Table  14-23 presents  the model  for the 5 different  scenarios  studied,  additionally  showing  how 
many of the trials were stopped before declaring MTD when all dose combinations were 
considered too toxic.  
Array  BioPharma  
Amended  Protocol  Version  10 Confidential  Page  221 
Protocol  No. CMEK162X2110  / C4221005  
Table  14-
221 Results  
PFIZER  CONFIDENTIAL   
  
 
Scenario  Metric  
 I II III IV V VI Stopped  
1 0.681  0.035  0.286  0.882  0.016  0.076  0.026  
2 0.532  0.147  0.32 0.716  0.126  0.122  0.036  
3 0.552  0.099  0.35 0.78 0.046  0.136  0.038  
4 0.474  0.155  0.273  0.496  0.382  0.088  0.034  
5 0.613  0.133  0.252  0.736  0.152  0.058  0.054  
In summary,  the simulated  operating  characteristics show:  
• (Metric  IV) that the identified  MTD  falls within  the targeted  interval  in more  than 72% of 
the cases, except for scenario 4.  
• (Metric  V) that on average,  less than 15% of patients  are treated  at overly  toxic  doses, 
excluding scenario 4.  
• (Metric  I) The average  proportion  of patients  receiving  a target  dose combination  on study 
is 47% to 68%.  
• Scenario 4 needs careful consideration, since the true underlying probability of DLT 
(15.7%)  for the combination  MEK162  60mg  + LGX818  50mg  is very close  to the lower 
boundary of the targeted toxicity [16%, 35%). Unsurprisingly, this combination is 
therefore  identified  relatively  often  as an MTD.  Had this combination  been  counted  as a 
correct MTD as well, then metric IV improves to 56.8%.  
14.5.6  Hypothetical  dose  escalation  scenarios  
In order to show how the Bayesian model reacts, different hypothetical dose escalation 
scenarios were investigated ( Table 14 -24). The design should make reasonable dose - 
recommendations during the clinical trial based on the observed DLTs. During the study, the 
decision to  dose escalate  after completion  of a given cohort and the actual dose chosen for the 
subsequent  cohort  will depend  on the recommendation  of the BLRM  per EWOC  principle  and 
medical review of available clinical and laboratory data.  
It is assumed for most scenarios that each cohort has exactly  3 evaluable patients. Scenario 20 
illustrates the ability for the model to handle cohorts of different size. Dose escalation follows 
the rule listed in Section 6.2.4 . 
Overall,  in the early  cohort  scenarios,  the model  is showing  appropriate  behaviors,  in agreement 
with clinical  sense  and decision -making  process:  progressive  increase  of the combination  doses 
if no DLT  is observed  (e.g.,  scenarios  1, 4, 10), staying  at the same  dose level  and opening  of a 
new cohort at the same dose combination when 1 DLT is reported (e.g., scenario 2), and 
decrease when more than 1 DLT is reported in a cohort (e.g., scenarios 5,6).  
Array  BioPharma  
Amended  Protocol Version 10 Confide ntial Page  222 
Protocol  No. CMEK162X2 110 / C422 1005 
PFIZER  CONFIDENTIAL   
 Table  14-24 Hypothetical  dose  escalation  scenarios  
 
 
Scenario   
Dose  combination 
MEK162 / LGX818   
 
Npat   
 
Ntox  Next dose 
combination  
(NDC)   
P(Target) 
NDC   
P(over) 
NDC  Median 
DLT rate 
(NDC)  
1 45/50  3 0 60/50  0.279  0.096  0.119  
2 45/50  3 1 45/50  0.398  0.232  0.211  
3 45/50  3 2 stop    
4 45/50  
45/100  3 
3 0 
0  
60/100   
0.240   
0.126   
0.107  
5 45/50  
45/100  3 
3 0 
1  
45/50   
0.224   
0.034   
0.084  
6 45/50  
45/100  3 
3 0 
2  
45/50   
0.308   
0.095   
0.123  
7 45/50  
45/100  
45/50  3 
3 
3 0 
1 
0  
45/100   
0.397   
0.243   
0.214  
8 45/50  
45/100  
45/50  3 
3 
3 0 
1 
1  
45/50   
0.407   
0.064   
0.152  
9 45/50  
45/100  
45/50  3 
3 
3 0 
1 
2  
45/50   
0.552   
0.203   
0.237  
10 45/50  
45/100  
60/100  3 
3 
3 0 
0 
0  
60/150   
0.158   
0.204   
0.084  
11 45/50  
45/100  
60/100  3 
3 
3 0 
0 
1  
60/100   
0.399   
0.185   
0.189  
12 45/50  
45/100  
60/100  3 
3 
3 0 
0 
2  
45/100   
0.480   
0.241   
0.238  
13 45/50  
45/100  
45/150  3 
3 
3 0 
0 
0  
45/200   
0.154   
0.115   
0.058  
14 45/50  
45/100  
45/150  3 
3 
3 0 
0 
1  
45/100   
0.310   
0.040   
0.121  
15 45/50  
45/100  
45/150  3 
3 
3 0 
0 
2  
45/100   
0.432   
0.135   
0.181  
16 45/50  
45/100  
45/150  
45/100  3 
3 
3 
3 0 
0 
2 
0  
60/100   
0.375   
0.177   
0.179  
17 45/50  
45/100  
45/150  
45/100  3 
3 
3 
3 0 
0 
2 
1  
45/100   
0.542   
0.169   
0.222  
18 45/50  
45/100  
45/150  
45/100  3 
3 
3 
3 0 
0 
2 
2  
45/50   
0.283   
0.042   
0.105  
Array  BioPharma  
Amended  Protocol Version 10 Confide ntial Page  223 
Protocol  No. CMEK162X2 110 / C422 1005 
PFIZER  CONFIDENTIAL   
  
 
 
Scenario   
Dose  combination 
MEK162 / LGX818   
 
Npat   
 
Ntox  Next dose 
combination 
(NDC)   
P(Target) 
NDC   
P(over) 
NDC  Median 
DLT rate 
(NDC)  
19 45/50  
45/100  
60/100  
60/150  3 
3 
3 
3 0 
0 
0 
0  
60/300   
0.076   
0.115   
0.011  
20 45/50  
45/100  
60/100  
60/150  3 
3 
3 
6 0 
0 
0 
3  
60/100   
0.467   
0.083   
0.174  
14.5.7  Power  for analysis of key  secondary  variables  
Not applicable.  
14.5.8  References (available upon request)  
Rogatko  A, Schoeneck  D, Jonas  W, et al (2007)  Translation  of innovative  designs  into phase  I 
trials. J Clin Oncol; 25(31): 4982 -6. 
Array  BioPharma  
Amended  Protocol Version 10 Confide ntial Page  224 
Protocol  No. CMEK162X2 110 / C422 1005 
PFIZER  CONFIDENTIAL   
 14.6 Appendix 6 - Operating characteristics of the combination 
Bayesian logistic regression model and hypothetical dose 
escalation  scenarios  LGX818  and MEK162  and LEE011  triple 
combination  
[This  Section is  not applicable  to the  USA  and Singapore]  
An adaptive  Bayesian  logistic  regression  model  (BLRM)  guided  by the escalation  with 
overdose  control  (EWOC)  principle  will guide  the dose-escalation  of the combination  treatment 
to its MTD(s)/RP2D(s). The use of Bayesian response adaptive models for Phase I studies has 
been  advocated  by the EMEA  guideline  on small  populations  (2006 ) and by (Rogatko  et al 2007 ) 
and is one of the key elements of the FDA’s Critical Path Initiative.  
A 10 -parameter BLRM for combination treatment will be fitted on first 28 day dose limiting 
toxicity  data (i.e. absence or presence of DLT) accumulated throughout the dose -escalation to 
model the dose -toxicity relationship of LGX818, MEK162 and LEE011 when given in 
combination. To check the performance of the model, the document summarizes some 
hypothetical dose escalation scenarios.  
14.6.1  Statistical Model  
Refer to Section 10.4.2 for the form of the model. Note that the 10 parameter model for the 
triple combination (LGX818+MEK162+LEE011) is an extension of 5 parameter model used 
for the dual combination (LGX818+MEK162). When the dose of LEE011 equals to 0, the 10 
parameter model reduces to the existing 5 parameter model.  
The Bayesian  approach  requires  the specification  of prior  distributions  for the model  parameters. 
((log(α 1),log(β 1)), (log(α 2),log(β 2)), (log(α 4),log(β 4))), η 12, η14, η24, η124 
The prior information for parameters (log(α x),log(β x)) (where x=1, 2, 4) come from prior 
available dose -DLT information of LGX818, MEK162 and LEE011.  
14.6.2  Prior Specification  
The prior  derivation  for the 5 parameter  dual combo  (LGX818+MEK162)  model  was described 
in the original protocol as shown in Appendix 5 (Section 14.5 ). 
14.6.2.1  Prior  distribution  for log(α 4),log(β 4) (LEE011  single  agent  component)  
For this trial, historical data from the ongoing study CLEE011X2101 (first -in-human LEE011 
oncology study) were used to derive an informative prior for the (log(α 4),log(β 4)) (see Table 
14-25). 
1. The informative  bivariate  normal  prior  for the model  parameters  (log(α 4),log(β 4)) was 
obtained as follows:  
• The median  DLT  rate at the LEE011  reference  dose (400 mg, 3 weeks  on 1 week  off) 
was assumed 1/10 i.e. mean(log(α 4)) = log(1/9).  
• A doubling  in dose was  assumed  to double odds  of DLT, i.e.  mean(log(β 4)) = 0. 
• The standard  deviation  of log(α 4) was set to 2 and the standard  deviation  of log(β 4) to 
1, which allows for considerably prior uncertainty for the dose -toxicity profile.  
Array  BioPharma  
Amended  Protocol Version 10 Confide ntial Page  225 
Protocol  No. CMEK162X2 110 / C422 1005 
PFIZER  CONFIDENTIAL   
 • The correlation  between  log(α 4) and log(β 4) was set to 0. 
2. Data  from  53 patients  (treated  with LEE011  3 week  on 1 week  off) eligible  for the dose 
determining set of the study [CLEE011X2101] were used to update the dose -toxicity 
profile (See Table 14 -25). 
Three percentiles (2.5, 50, 97.5) of the posterior distribution are used to find the 5 parameters 
of the bivariate -normal  distribution  that is  in best agreement  with the percentiles  for each dose 
level.  
3. Heterogeneity  between the historical and current study  was incorporated by  between -trial 
standard  deviations  and τ41 and τ42 for log(α4)  and log(β4).  Both  τ41 and τ42 were  set to 
follow a log -normal distribution. Mean log(0.25) and standard deviation 0.01 was chosen 
for τ41 and mean log(0.125) and standard deviation 0.01 was chosen for τ42 which 
correspond to moderate between -trial variability.  
Table  14-25 Data  from  CLEE11X2101  
 
Dose of LEE011 (mg, 3 weeks on, 1 week off) No of DLTs / No of evaluable patients  
50 1/4 
70 0/2 
140 0/3 
260 0/4 
280 1/4 
350 0/5 
400 1/4 
600 0/4 
750 1/7 
900 1/13 
1200  2/3 
 
 
Table  14-26 Prior,  posterior  and predictive  distribution  of (log(alpha 4),log(beta 4)) 
 
Parameter  Means  Standard deviations  Correlation  
Prior for (log(α 4),log(β 4)) (log(1/9), 0) (2, 1) 0 
Normalized  Posterior  for 
(log(α 4),log(β 4)) (-2.075, -0.744)  (0.396, 0.521)  -0.130  
Predictive for (log(α 4),log(β 4)) (-2.066, -0.749)  (0.527, 0.563)  -0.116  
Interaction  
As shown  above,  the distribution  of η12 is inherited  from  existing  LGX818  and MEK162 dual - 
combo model. A non -informative prior reflecting the current uncertainty about the toxicity of 
the combination treatment is used for η 14, η24, η124. There is no interaction expected between 
MEK162 and LEE011, we set the median of η 24 to be log (1.02) which assumes a 2% increase 
of odds. This is a conservative way to set the prior. The 97.5 percentile of η 24 is set to be log 
(2.2) which assumes a 1.2  fold increase  of odds.  LGX818  and LEE011 have  potential  positive 
interaction. Hence we set the median of η 14 to be log (1.1) which assumes a 10% increase in 
odds  of toxicity. The  97.5 percentile of η 14 is set to be  log (3), which assumes  a 2 fold increase  
Array  BioPharma  
Amended  Protocol Version 10 Confide ntial Page  226 
Protocol  No. CMEK162X2 110 / C422 1005 
PFIZER  CONFIDENTIAL   
 of odds. We also set a conservative prior for 3 way interaction. The median of η 124 is set to be 
log (1.02). The 97.5 percentile is set to be log (2.2).  
14.6.2.2  Summary  
The prior  distribution  of the parameters  is summarized  in Table  14-27. The prior  distribution  of 
the DLT rates for provisional doses is summarized in Table 14 -28. Note that the posterior 
probability of excessive toxicity of the proposed starting dose for triple combination 
(LGX818+MEK162+LEE011) is 10.2% which satisfies EWOC criteria.  
Table  14-27 Prior  distribution  of model  parameters  
 
Parameter  Means  Standard deviations  Correlation  
(log(α 1),log(β 1)) (-2.917, -1.820)  (0.986, 1.041)  0.233  
(log(α 2),log(β 2)) (-2.326, 1.564)  (1.107, 1.368)  -0.535  
(log(α 4),log(β 4)) (-2.066, -0.749)  (0.527, 0.563)  -0.116  
η12 0 1.528  NA 
η14 0.095  0.512  NA 
η24 0.020  0.392  NA 
η124 0.020  0.392  NA 
Table 14 -28 Summary of prior distribution of DLT rates for triple combo 
(LGX818+MEK162+LEE011)  including  current  DLT data (up to Apr 16, 2013)  from  dual 
combo (LGX818+MEK162)  
 
LEE011  
(mg, 3 week  
on, 1 week)   
Prior  probabilities  that Pr(DLT)  is in 
interval   
 
Mean   
 
SD  
 
Quantiles  
 [0.0, 0.16)  [0.16, 0.35)  [0.35,1.00]    2.50%  50.00%  97.50%  
 MEK162  45mg  BID, LGX818  450mg  QD 
100 0.662  0.236  0.102  0.149  0.145  0.006  0.102  0.551  
200 0.552  0.216  0.232  0.218  0.226  0.004  0.132  0.809  
400 0.468  0.14 0.392  0.337  0.341  0.001  0.194  0.986  
600 0.44 0.098  0.462  0.411  0.396  0 0.265  0.999  
800 0.428  0.075  0.498  0.455  0.424  0 0.342  1 
 MEK162  45mg  BID, LGX818  600mg  QD 
100 0.632  0.204  0.164  0.174  0.195  0.002  0.097  0.72 
200 0.543  0.169  0.288  0.253  0.281  0.001  0.129  0.926  
400 0.472  0.106  0.423  0.373  0.381  0 0.202  0.998  
600 0.447  0.073  0.481  0.439  0.423  0 0.291  1 
800 0.434  0.056  0.51 0.476  0.443  0 0.39 1 
14.6.2.3  Hypothetical  dose  escalation  scenarios  for triple  combo 
(LGX818+MEK162+LEE011)  
The BLRM model should make reasonable decisions during a study based on the observed 
toxicities  particularly  in early  cohorts.  After  completion  of a given  cohort,  the decision  to dose 
escalate and actual dose chosen for the subsequent cohort will  depend  on the recommendation 
of the BLRM  EWOC  principle  and medical  review  of all relevant  data available  up to date. 
Array  BioPharma  
Amended  Protocol Version 10 Confide ntial Page  227 
Protocol  No. CMEK162X2 110 / C422 1005 
PFIZER  CONFIDENTIAL   
 Table 14 -29 shows some scenarios of dose levels recommended by the 10 -parameter BLRM 
for the specified DLT observations.  
Note that the next dose level is selected in concordance with the provisional dose levels of 
LGX818 and LEE011 specified in the protocol, to mimic possible on -study escalation steps. 
MEK162  is maintained  at 45 mg BID.  Since  the main  goal of the dose escalation  is to escalate 
LEE011, LGX818 is fixed at 450mg in the table.  
Table  14-29  Dose  decisions  recommended  by BLRM  
 
 
 
Scenario  LEE011  
(mg, 3 week 
on, 1 week  off)  
 
Npat   
 
Ntox   
Next dose level LEE011 
(mg,  3 week  on, 1 week  off)  
 
P(Target)   
 
P(over)   
Median 
DLT rate 
1 100 3 0 200 0.193  0.109  0.079  
2 100 3 1 100 0.399  0.155  0.178  
3 100 3 2 50 0.505  0.227  0.233  
4 100 6 1 200 0.308  0.221  0.172  
5 100 3 0 400 0.131  0.130  0.042  
 200 3 0     
6 100 3 0 200 0.367  0.181  0.178  
 200 3 1     
7 100 3 0 100 0.527  0.126  0.200  
 200 3 2     
8 100 3 0 300 0.281  0.188  0.147  
 200 6 1     
10 100 3 0 400 0.221  0.225  0.131  
 200 8 1     
11 100 3 0 800 0.072  0.104  0.007  
 200 3 0     
 400 3 0     
12 100 3 0 400 0.326  0.242  0.191  
 200 3 0     
 400 3 1     
13 100 3 0 200 0.505  0.105  0.188  
 200 3 0     
 400 3 2     
14 100 3 0 600 0.233  0.229  0.139  
 200 3 0     
 400 6 1     
The BLRM model is performing reasonably for the hypothetical dose escalation scenarios. 
Within Table 14 -29, it can be seen that the model leads to decisions that are in agreement with 
clinical sense. When no DLTs are observed in a cohort, the decision is to escalate the dose. 
When  1 DLT  is observed  in one cohort,  the decision  is to stay in the current  dose level,  or dose 
escalation  depending  on the size of the cohort.  When  more  than 1 DLT  is observed  in one cohort, 
the decision is to dose de -escalation.  
14.6.3  References (available upon request)  
EMEA  (2006)  Guideline  on small  populations  (Internet)  Available from:  
<emea.europa.eu.docs/en_GB/document_library/Scientific_guidiline/2009/09/WC500003615. 
pdf>.  
Array  BioPharma  
Amended  Protocol Version 10 Confide ntial Page  228 
Protocol  No. CMEK162X2 110 / C422 1005 
PFIZER  CONFIDENTIAL   
 Ho C, Sangha R, Beckett L, et al (20 11) Escalating  week ly doses  of cetuximab and conelati on 
with skin toxicity: a phase I study. Invest New Dmgs; 29: 680-7. 
Rogatko  A, Schoeneck D, Jonas  W, et al (2007)  Translation of innovative  designs into phase  I 
trials. J Clin Oncol ; 25: 4982 -6. 
 
14.7 Appendix  7: Adverse Events:  Definitions and  Procedures for 
Recording, Evaluating, Follow -up, and Reporting  
14.7.1  Definition  of AE 
AE Definition  
• An AE is any untowar d medica l occune nce in a patient or clini cal study patient, 
temporally  associated  with the use of study intervention, whether or not considered 
related to the study interventio n. 
 
• NOTE:  An AE can therefore be any  unfavorable  and unint ended sign (includin g an 
abnonnal laborato1y  findin g), symp tom, or disease  (new or exacerbated) temporally 
assoc iated w ith the u se of study intervention . 
 
Events  Meeting  the AE Definition  
•  Any abnonnal laborato1y test results (hematology , clinical c heinistiy , or urinalysis) 
or ot her safety  assess ment s (e.g ., ECG,  radiological  scans , vital sign me asure ments), 
includin g those that worse n from  baseline , considered c linically signi ficant in the 
medical and scientific judgment of the investigator  Any abnonnal laborato1y test 
results  that meet any of the cond itions below must  be recorde d as an AE: 
• Is associated  with accompanying  symptoms ; 
• Requires  additional diagnostic  testing  or medical /surgical intervention; 
•  Leads to a c hange in study dosing (outs ide of any protocol -specified  dose 
adjustments) or discontinuation  from the study,  signi ficant additional  concomitant 
dmg ti ·eatinent , or other therapy.  
•  Exacerbation  of a chroni c or intennittent preexisting  conditi on includin g either  an 
increase in frequen cy and/or intensity of the conditio n. 
• New  cond itions detected  or diagnosed after study  ti·eatinent adininisti·ation  even 
though it may have been  present before the staii of the study . 
• Signs,  symptoms, or the clinical  sequelae of a suspected dmg-dmg interaction . 
•  Signs,  symptoms, or the clinical sequelae of a suspected ove rdose of either  study 
interve ntion or a concoini tant medication.  Overdose  per se will not be repo1ied as 
an AE /SAE unless it is an intentional  overdose taken with possib le 
suicidal/self -haiming intent. Such overdoses should be repo1ied  regardless  of 
sequelae . 
• The signs,  symptoms,  and/or  clinical sequelae  resulting  from  lack of efficacy  will be 
reoo1ied  as an AE or SAE  if they fulfill  the definition  of an AE or SAE  and meet the 
Array  BioPharma  
Amended  Protocol Version 10 Confide ntial Page  229 
Protocol  No. CMEK162X2 110 / C422 1005 
PFIZER  CONFIDENTIAL   
  
requirements as pe r Section 8.1.8.1 . Also,  "lack of  efficacy"  or "failure of expected 
phannacological ac tion" does not constitute an AE or SAE . 
 
Events Meeting  the AE Definition  
•  Any clinically signi ficant ab nonnal laborato 1y findings or other ab nonnal safety 
assess ments which are associated  with the underlying disease , unless judged by  the 
investigato r to be more severe than expected for t he patient 's condition. 
 
•  The disease /disorder be ing studied or expected  progress ion, signs, or symptoms of 
the disease /disorder be ing studied, unless more severe than expected for t he 
patie nt's co nditio n. 
 
•  Med ical or surgical procedure (e.g., endosco py, appendectomy): the condition that 
leads to the proced ure is the AE.  
•  Situat ions in which an untowar d medica l occunence did not occur (socia l and/or 
convenience admissio n to a hospital). 
 
•  Anticipated  day-to-day fluctuations of preexist ing disease(s)  or condition(s) present 
or detected at the sta1t of the study that do not worse n. 
 
•  Worse ning of signs and symp toms of t he malignancy under study  should be 
recorded as AEs in t he appropr iate section of the CRF . Disease progression 
assesse d by measure ment of malignant  lesio ns on radiograp hs or other methods 
should not be repo1ted as AEs.  
14.7.2  Definition  of an SAE  
If an event is not an AE per definition above , then it cannot be an SAE  even if serious conditions 
are met (e.g., hospitalizatio n for signs /sympto ms of the disease under study , death d ue to 
progress ion of disease).  
Array  BioPharma  
Amended  Protocol Version 10 Confide ntial Page  230 
Protocol  No. CMEK162X2 110 / C422 1005 
PFIZER  CONFIDENTIAL   
  
An SAE  is defined as  any untoward  medical  occurrence  that,  at any dose:  
a.  Results  in death  
b. Is life-threatening  
The te1m "life-threatening" in the definiti on of "serious" refers  to an event  in which the 
patient was at risk  of death at the time of the event.  It does not refer to an event that 
hypothetically might have ca used death if it were more seve re. 
c.  Requires  inpatient  hospitalization  or prolongation  of existing  hospitalization  
In general, hospitalization  signifies that the patient has been  detained  (usually  involving  at 
least an overnight  stay)  at the hospita l or emergency ward for observatio n and/or treatment 
that would not have been appropri ate in the physician's office o r outpatient setting. 
Com plications that occur during hospitalization are AEs.  If a compli cation prolongs 
hospitalization  or fulfill s any other serious criteria, the event is  serious . When  in doubt as 
to whet her "hospitalization " occmTed o r was necessaiy , the AE should be considered 
senous. 
Hospitalizat ion for elective  treatment  of a preexisting  conditio n that did  not worsen  from 
baseline is not co nsidered an AE.  
d. Results  in persistent  disability /incapacity  
• The te1m disab ility mean s a substantial dismpti on of a person 's ability to conduct 
n01mal life functions. 
•  This definition is not intend ed to include experie nces of  relatively minor medical 
significance such as uncompli cated  headache , nausea, vomi ting, diaiThea , influen za, 
and accidental trauma (e.g., sprain ed ankle) which may interfere with or prevent 
everyday life functions but do not constitute a subs tantial dismpti on. 
e.  Is a congenital  anomaly/birth  defect  
f. Other  situations:  
•  Medical or scientific judgment should be exercised in deciding w hether SAE 
repo1iing  is appropri ate in other situatio ns such as impo1iant  medi cal events that 
may not be immediately life -threatening  or result  in death  or hospitalization but may 
jeopai·d ize the patient  or may require medi cal or surgical intervention to prevent  one 
of the other outcomes listed  in the above definition . These events should usually be 
considered se rious. 
•  Examples  of such events  includ e invasive  or malignan t cance rs, intensive treatme nt 
in an emergency room or at home for allergic bronchospasm , blood  dysc rasias or 
Array  BioPharma  
Amended  Protocol Version 10 Confide ntial Page  231 
Protocol  No. CMEK162X2 110 / C422 1005 
PFIZER  CONFIDENTIAL   
  
convulsions that do not result in hospitalizat ion, or development of drng  dependency 
or dmg abu se. 
•  Progression of the malignan cy under s tudy (includin g signs and symptoms of 
progression)  should not be reported as  an SAE  unless the outcome is fatal within the 
active co llection period . Hospitalization due to signs and symptoms of disea se 
progressio n should not be repo1ied as an SAE.  If the  malignancy has a fatal 
outco me during the study  or within the active co llectio n period , then the event 
leading to death must be  recorded as an AE on the CRF, and as an SAE w ith 
CTCAE  Grade 5 (see t he Assess ment of Intensity section). 
 
 
14.7.3  Recording/Reporting  and Follow -up of AEs and/or  SAEs  
AE and SAE  Recording/Reporting  
 
The table below  summar izes the requiremen ts for recording  adve rse even ts on the CRF  and 
for repo1iing  serious adve rse even ts on the CT SAE  Repo1i  Fo1m  to Pfizer Safety . These 
requirements are delineated for  3 types  of events: (1) SAEs ; (2) nonserious adverse even ts 
(AEs) ; and (3) expos ure to the study interven tion under study d uring pregnancy  or 
breastfeeding, and occupational expos ure. 
It shou ld be noted that the CT SAE  Repo1i  Fo1m  for repo1iing of SAE infonn ation is not 
the same as the AE page  of the CRF. When  the same  data are collected, the fo1ms must be 
comple ted in a consistent manner. AEs shou ld be recorded using concise medical 
tenninology and the same AE te1m  should be used on both the CRF and the CT  SAE 
Repo1i Fo1m  for repo1iing of SAE infonn ation.  
 
Safety  Event  Recorded  on the CRF  Reported on the CT SAE 
Report Form to Pfizer 
Safety  Within 24  Hours  of 
Awareness  
SAE  All All 
Nonserious AE All None  
Exposure to the study 
interven tion under  study  All AEs/SAEs  associated 
with expos ure during All (and EDP  supplem ental 
fonn for EDP)  
during pregnancy or 
breastfeed ing, and 
occupational expos ure pregnancy  or breastfeed ing 
 
Occupational  exposure  is not 
recorded.  Note:  Includ e all SAEs 
associated  with exposure 
during pregnancy or 
breastfeeding.  Include  all 
AEs/SAEs  associated  with 
  occu pational exposure.  
Array  BioPharma  
Amended  Protocol Version 10 Confide ntial Page  232 
Protocol  No. CMEK162X2 110 / C422 1005 
PFIZER  CONFIDENTIAL   
  
•  Whe n an AE/SAE occ urs, it is the responsibility of the investigato r to review  all 
documentat ion (e.g., hospital prog ress notes, laborato 1y repo1ts, and diagnostic 
repo1ts) related to the eve nt. 
• The investigato r will then record all releva nt AE/SAE infonnation in the CRF.  
• It is not accepta ble for the investigato r to send photoco pies of the patient's medical 
records to Pfizer Safety  in lieu of completion of the CT SAE  Repo1t  Fonn/AE/SAE  
CRFpage . 
• There may be instances  when copies  of medical records fo r ce1tain cases  are 
requested  by Pfizer Safety.  In this case , all patie nt identifiers , with the exceptio n of 
the patient  number, will be redacte d on the copies of the medical  records before 
submission to Pfizer Safety.  
•  The investigato r will attempt to estab lish a diagnos is of the event based  on signs, 
symptoms, and/or other clinical infonnation. Whe never possible , the diagnosis (not 
the individual signs/sympto ms) will be documented as the AE/SAE.  
Assessment  of Inten sity 
The investigato r will make  an assess ment of intensity for each AE and SAE  repo1ted during 
the study and ass ign it to 1 of the following catego ries: 
 GRADE  Clinical  Description  of Severity   
1 MIL D adverse  event 
2 MODERATE  adverse  event 
3 SEVE RE adve rse event 
4 LIFE-THRE ATENING  consequences; urgent intervention indicated  
5 DEATH RELATE D TO adve rse event 
Assessment  of Causality  
• The investigato r is obligated  to assess  the relatio nship betwee n study  treatment  and 
each occunence of each AE/SAE . 
 
•  A "reaso nable possib ility" of a relatio nship conveys that there are  facts , evidence, 
and/o r argume nts to sugges t a causal relatio nship, rather than a relatio nship cannot  
be rnled out. 
• The investigato r will use clinical judgment to deten nine the relationship. 
Array  BioPharma  
Amended  Protocol Version 10 Confide ntial Page  233 
Protocol  No. CMEK162X2 110 / C422 1005 
PFIZER  CONFIDENTIAL   
 •  Alternative  causes, such as underlying disease(s) , concomitant therapy, and other 
risk factors, as we ll as the temporal relati onship of t he event to study treatment 
admin istration, will be considered and investigated.  
 
•  The investigator  will also consult the IB and/or product  infonn ation, for marke ted 
products , in his/her assess ment. 
• For each AE/SAE , the investigator  !!!!ll!  docume nt in the medical  notes that he/she 
has reviewed the AE/SAE  and has  prov ided an assess ment of causa lity. 
 
• There ma y be situations in which an SAE has occ uned , and the in vestigato r has 
minimal  infonnation to include  in the initial repo1t to the sponsor. Howeve r, it is 
very important that the investigator always make an  assessment of causality 
for every  event  before  the initial transmission  of the SAE  data  to the sponsor.  
 
• The investigator may  change his/her opinion of causality in light of follow -up 
infonnation and send  an SAE  follow -up repo1t with the updated ca usality 
assess ment. 
• The causality  assessme nt is one of the criteria used when detenninin g regulat o1y 
repo1ting requirements.  
•  If the investigator does  not know whet her or not the study  treatment caused the 
event, then the event  will be handled as "related to study  treatme nt" for repo1ting 
purposes, as defined by the sponsor. In addition, if the investigato r detennines that 
an SAE  is assoc iated with study procedures , the in vestigato r must record  this 
causal relationship in  the source documents and  CRF , and repo1t such an 
assess ment in the dedicated  sectio n of the CT SAE  Repo1t  Fonn and in acco rdance 
with the SAE repo1ting requir ements. 
 
 
Follow -up of AEs and SAEs  
•  The investigator is  obligated to  perfonn or anange fo r the conduct of supplemental 
measurements and/or evaluations as medically indicated or as reque sted by the 
sponsor to elucidate the nature and/or causality of t he AE or SAE as fully as 
possible.  This may includ e add itional laborato1y tests or investigatio ns, 
histopathological examinations, or consultati on with other healthcare providers.  
 
• New  or updated  info1mati on will be recorded  in the originally  completed CRF. 
 
• The investigato r will submi t any updat ed SAE  data to  the sponsor within 24 hours 
of receipt of the infonn ation. 
Array  BioPharma  
Amended  Protocol Version 10 Confide ntial Page  234 
Protocol  No. CMEK162X2 110 / C422 1005 
PFIZER  CONFIDENTIAL   
 14.7.4  Reporting of  SAEs  
 
SAE  Reporting  to Pfizer  Safety  via CT SAE  Report  Form  
• Facsimile trnnsmission of the CT SAE  Repo1i  Fo1m  is the prefened  method to 
transmit this info1mation to Pfizer Safety.  
•  In circlllllsta nces w hen the facsimile is not working, notificatio n by telephone is 
acceptable wit h a copy of t he CT SAE Report Fonn sent by  overnight mail or com .er serv.ce. -i i 
•  Initial notification via telephone does not repla ce the need for the in vestigator to 
complete and sign the CT SAE Repo1i  Fo1m  page s within the designated  repo1iing 
time fram es. 
14.8 Appendix 8:  Liver  Safety:  Suggested Actions  and Follow -up 
Assessments  
Potential  Cases  of Drug -Induced  Liver  Injur y 
 
Human s exposed to a drng who show no sign of liver injmy (as dete1mined by elevati ons in 
transaminases) are  te1med "tolerators ," while those w ho show transient liver injmy , but adapt 
are te1med "adaptor s." In some pati ents, transaminase elevatio ns are a harbinger of a more 
serious potential outco me. These patients fail to adapt and ther efore are "suscept ible" to 
progressive and serious liver injmy, commo nly refened to as DILi.  Patients who exper ience a 
transaminase elevation above 3 x ULN should be monitored more frequently to dete nnine if 
they are an "adaptor " or are "susceptible. " 
In the m ajority of DILI cases, elevation s in AST and/or ALT precede TBili elevation s (>2 x 
ULN) by severa l days or weeks. The increase in TBili typica lly occ urs while AS T/ALT is/are 
still elevated above 3 x ULN (ie, AST /ALT and TBili values will be elevated wit hin the same 
laborato 1y sample).  In rare instances , by the time TBili elevation s are detected , AST /ALT 
values might have decreased.  This occmTe nce is still regarded as a potential DILi.  Therefore , 
abnonnal elevation s in either AST OR ALT in addition to TBili that meet the criteria outlined 
below are co nsidered potentia l DILI (assessed per Hy's law criteri a) cases a nd should alway s 
be considered important medi cal event s, even before all other possible causes of liver injm y 
have been excluded.  
The threshold of laborato1y abnonnalities for a potential DILI case depends on the patient's 
individual baseline values and underlying conditions. Patients who present with the  follow ing 
laborato 1y abno1malities should be evaluated fmiher as pote ntial DILI (Hy's law) cases to 
definitively dete nnine the etiology o f the abnonnal laborato1y values: 
•  Patients  with AST/ALT  and TBili  baseline  values  within the n01mal  range who 
subsequen tly present  with AST  OR ALT  values >3 x ULN  AND a TBili  value 
>2 x ULN wit h no evide nce ofhemolysis and an alkaline phosp hatase val ue <2 x ULN 
or not available.  
Array  BioPharma  
Amended  Protocol Version 10 Confide ntial Page  235 
Protocol  No. CMEK162X2 110 / C422 1005 
PFIZER  CONFIDENTIAL   
 • For patients  with baseline  AST  OR ALT  OR TBili  values  above  the ULN,  the following 
threshold values are used in the definition mentioned above, as needed, depending on 
which values are above the ULN at baseline:  
• Preexisting AST or ALT baseline values above the normal range: AST or ALT 
values >2  times the baseline values AND >3 × ULN; or >8  × ULN (whichever 
is smaller).  
• Preexisting values of TBili above the normal range: TBili level increased from 
baseline  value  by an amount  of at least 1 × ULN  or if the value  reaches  
>3 × ULN  (whichever  is smaller).  
Rises in AST/ALT and TBili separated by more than a few weeks should be assessed 
individually based on clinical judgment; any case where uncertainty remains as to whether it 
represents a potential Hy’s law case should be reviewed with the sponsor.  
The patient  should  return  to the investigator  site and be evaluated  as soon  as possible,  preferably 
within 48  hours from awareness of the abnormal results.  This evaluation should include 
laboratory tests, detailed history, and physical assessment.  
In addition  to repeating  measurements  of AST  and ALT and TBili for suspected cases of Hy’s 
law, additional  laboratory  tests should  include  albumin,  CK, direct  and indirect  bilirubin,  GGT, 
PT/INR, total bile acids, and alkaline phosphatase.  Consideration should also be given to 
drawing  a separate  tube of clotted  blood  and an anticoagulated  tube of blood  for further  testing, 
as needed, for further contemporaneous analyses at the time of the recognized initial 
abnormalities to determine etiology.  
A detailed history, including relevant information, such as review of ethanol, 
acetaminophen/paracetamol (either by itself or as a coformulated product in prescription or 
over-the-counter medications), recreational drug, supplement (herbal) use and consumption, 
family  history,  sexual  history,  travel  history,  history  of contact  with a jaundiced  person,  surgery, 
blood transfusion, history of liver or allergic disease, and potential occupational exposure to 
chemicals, should be collected.  Further testing for acute hepatitis  A, B, C, D, and E infection 
and liver imaging (e.g., biliary tract) and collection of serum samples for 
acetaminophen/paracetamol drug and/or protein adduct levels may be warranted.  
All cases demonstrated on repeat testing as meeting the laboratory criteria of AST/ALT and 
TBili  elevation  defined  above  should  be considered  potential  DILI  (Hy’s  law) cases  if no other 
reason for the LFT abnormalities has yet been found.  Such potential DILI (Hy’s law) cases 
are to be reported as SAEs, irrespective of availability of all the results of the 
investigations performed to determine etiology of the LFT abnormalities.  
A potential  DILI  (Hy’s  law) case becomes  a confirmed  case only after all results  of reasonable 
investigations have been received and have excluded an alternative etiology.  
Array  BioPharma  
Amended  Protocol Version 10 Confide ntial Page  236 
Protocol  No. CMEK162X2 110 / C422 1005 
PFIZER  CONFIDENTIAL   
 14.9 Appendix  9: ECG Findings  of Potenti al Clinic al Concern  
 
ECG  Findings That May Qualif y as AEs 
• Marked sinus bradycardia (rate <40 bpm) lasting minut es. 
 
• New PR interval prolongation >280 msec. 
 
• New prolongation of QTcF to >480 msec (absolute) or by60 msec from baseline. 
 
• New-onset atrial flutter or fibrillation, with contrnlled ventricular response rate: ie, 
rate <120 bpm.  
 
• New-onset type I second-degree (Wenckebach) AV block of>30 seconds' duration. 
 
•  Frequent PVCs,  triplets, or short intervals (<30 seconds) o f consecutive ventricular 
complexes. 
ECG  Findin gs That May Qualif y as Serious Adverse  Events (SAEs)  
 
• QTcF prolongation >500 msec. 
 
• New ST-T changes suggestive of myocardial ischemia. 
 
• New-onset left bundle branch block (QRS >120 msec). 
 
• New-onset right bundle branch block (QRS >120 msec). 
 
• Symptomatic bradycardia. 
 
• Asysto le: 
In awake, symptom-free patients in sinus rhythm, with documented periods of 
asystole3.0 seconds or any escape rate <40 bpm, or with an escape rhythm  that 
is below the AV node; 
In awake, symptom-free patients with atrial fibrill ation and bradycardia with 1 or 
more pauses of at least 5 seco nds or longer; 
Atrial flutter or fibrillation, with rapid ventri cular response rate: rapid= rate 
>120 bpm. 
 
• Sustained supraventri cular tachycardia (rat e>120 bpm) ("sustained"= sho1i 
duration with rele vant sympt oms or lasting>1 minu te). 
Array  BioPharma  
Amended  Protocol Version 10 Confide ntial Page  237 
Protocol  No. CMEK162X2 110 / C422 1005 
PFIZER  CONFIDENTIAL   
  
• Ventricular rhythms >30 seconds' duration, inclu ding idioventricular rhythm (hea1t 
rate <40 bpm ), accelerated idioventricular rhythm (HR 40 bpm to <100 bpm), and 
monomorphic/polymorphic ventricular tachycardia (HR>100 bpm (such as 
torsades de pointes)). 
• Type II second-degree (Mob itz II) AV block. 
• Complete (third-degree) heait block. 
ECG Findin gs That  Quali fy as SAEs  
• Change in pattern suggestive of new myocardial infarction. 
• Sustained  ventricular tachyarrhythmias (>30 seconds' duration). 
• Seco nd- or third -degree AV block requirin g pacemak er placement. 
• Asys tolic pauses requiring pacemaker placement. 
• Atrial flutter or fibrillation with rapid  ventricular response requiring cardioversion. 
• Ventricular fibrillation/flutter. 
• At the discretion of the investigator, any aITh ythmia classified as an adverse 
expenence. 
The enum erated list of major events of potential clinical  conc em are recomm ended as  "ale1ts" or notifications 
from the core ECG  labora t01y to the in vestigato r and Pfizer study  team , and not to be consid ered as all 
inclusi ve of what to be reported as AE s/SAEs . 
 
14.10  Appendix  10: Alternative  Measures  During  Public  Emergencies  
 
The alternative study measures described in this section are to be followed durin g publi c 
emergencies, inclu ding the COVID -19 pandemic. This appendix applies for the duration of the 
COVID -19 global pandem ic and will become effective for other public emergencies only upon 
written notification from Pfi zer. 
Use of these alternative st udy measures are expected to cease upon the return of business as 
usual circumstances (includin g the liftin g of any quarantine s and tra vel bans/advisories). 
14.10.1  Eligibility  
Emollment for this study was closed prior to the COVID-19 pandemic. 
 
14.10.2  Telehealth  Visits  
In the e vent that in-clinic study visits cannot be conducted, eve1y effort should be made to 
follow up on the safety of study patients at scheduled  visits per the Visit Schedules and 
Array  BioPharma  
Amended  Protocol Version 10 Confide ntial Page  238 
Protocol  No. CMEK162X2 110 / C422 1005 
PFIZER  CONFIDENTIAL   
 Assessments ( Section 7, Table  7-2) or unscheduled visits. Telehealth visits may be used to 
continue to assess patient safety and collect data points. Telehealth includes the exchange of 
healthcare information and services via telecommunication technologies (e.g., audio, video, 
video -conferencing software) remotely, allowing the patient and the investigator to 
communicate on aspects of clinical care, including medical advice, reminders, education, and 
safety monitoring. The following assessments must be performed during a telehealth visit:  
• Review  and record  study  treatment(s),  including  compliance  and missed  doses.  
• Review  and record  any AEs and SAEs  since  the last contact.  Refer  to Section  8.1. 
• Review and record any new concomitant medications or changes in concomitant 
medications since the last contact.  
• Review  and record  contraceptive  method  and results  of pregnancy  testing.  Confirm  that 
the patient  is adhering  to the contraception  method(s)  required  in the protocol. Refer  to 
Section 7.2.2.5.5 and Section 14.10.3.1 of this appendix regarding pregnancy tests.  
 
Study  patients must  be reminded to  promptly  notify  site staff about  any change  in their health  
14.10.3  Alternative  Facilities  for Safety  Assessments  
14.10.3.1  Laboratory  Testing  
If a study  patient is unable to visit the site for protocol -specified safety  laboratory  evaluations, 
testing  may be conducted at a local laboratory if permitted by local regulations.  The local 
laboratory  may be a standalone  institution  or within  a hospital.  The following  safety  laboratory 
evaluations may be performed at a local laboratory:  
• Refer  to Section  7.2.2.5  for the list of safety  laboratory  evaluations,  including  pregnancy 
testing, required per protocol.  
If a local laboratory is used,  qualified study site personnel must order, receive, and review 
results. Site staff must collect  the local laboratory reference ranges and certifications/ 
accreditations for filing at the site. Laboratory  test results are to be provided to the site staff as 
soon as possible . The local laboratory reports should be  filed in the patient’s source 
documents/medical records. Relevant data from the local laboratory  report should be  recorded 
on the CRF.  
 
If a patient requiring pregnancy testing cannot visit a local laboratory for pregnancy  testing, a 
home urine pregnancy testing kit with a sensitivity of at least 25 IU/mL may be used by the 
patient to perform the test at home, if compliant with local regulatory requirements. The 
pregnancy test outcome should be documented in the patient’s source documents/medical 
records and relevant data recorded on the CRF. Confirm that the patient is adhering to the 
contraception method(s) required in the protocol.  
 
14.10.3.2  Imaging  
If the patient is unable to visit the study site for safety imaging assessments (e.g., ECHO or 
MUGA), the patient may visit an alternative facility to have the safety imaging assessments 
performed. Qualified study site personnel must order, receive, and review results.  
Array  BioPharma  
Amended  Protocol Version 10 Confide ntial Page  239 
Protocol  No. CMEK162X2 110 / C422 1005 
PFIZER  CONFIDENTIAL   
 14.10.3.3  Electrocardiograms  
If the patient  is unable  to visit the study  site for ECGs,  the patient  may visit an alternative  facility 
to have the ECGs performed. Qualified study site personnel must order, receive, and review 
results.  
 
14.10.3.4  Study  Treatment  
If the safety of a trial patient is at risk because they cannot complete required evaluations or 
adhere  to critical  mitigation  steps,  then discontinuing  that patient  from  study  treatment  must  be 
considered.  
 
Study drugs  may be shipped  by courier  to study patients if permitted by local regulations and 
in accordance  with storage  and transportation  requirements  for the study  drugs.  Pfizer  does not 
permit the shipment of  study  drugs by  mail. The tracking record of shipments and the chain of 
custody of study drugs must be kept in the patient’s source documents/medical records.  
The following is recommended for the administration of study drugs for patients who have 
active [confirmed (positive by regulatory authority -approved test) or presumed (test 
pending/clinical suspicion)] SARS -CoV2 infection:  
• For symptomatic patients with active SARS -CoV2 infection, study drugs should be 
delayed for at least 14 days from the start of symptoms. This delay is intended to allow 
the resolution of symptoms of SARS -CoV2 infection.  
• Prior  to restarting  treatment,  the patient  should  be afebrile  for 72 hours,  and SARS -CoV2 - 
related  symptoms  should  have  recovered  to ≤ Grade  1 for a minimum  of 72 hours.  Notify 
the study team when treatment is restarted.  
• Continue  to consider  potential  drug-drug interactions  as described  in protocol  Section  6.4 
for any concomitant medication administered for treatment of SARS -CoV2 infection.  
 
14.10.4  Home Health Visits  
A home health care service may  be utilized  to facilitate scheduled visits  per the Visit  schedule 
and assessments . Home health visits include a healthcare provider conducting an in -person 
study  visit at the patient’s  location,  rather  than an in-person  study  visit at the site. The following 
may be performed during a home health visit:  
• Physical  exam  including  dermatological  lesions  and vital signs  
• Review  and record  study  treatment(s),  including  compliance  and missed  doses.  
• Review  and record  any AEs and SAEs  since  the last contact.  Refer  to Section  8.1. 
• Review  and record  any new concomitant  medications  or changes  in concomitant 
medications since the last contact.  
Array  BioPharma  
Amended  Protocol Version 10 Confide ntial Page  240 
Protocol  No. CMEK162X2 110 / C422 1005 
PFIZER  CONFIDENTIAL   
 • Review  and record  contraceptive  method  and results  of pregnancy  testing.  Confirm  that 
the patient  is adhering  to the contraception  method(s)  required  in the protocol.  Refer  to 
Section 7.2.2.5.5 and Section 14.10.3.1 of this appendix regarding pregnancy tests.  
 
14.10.5  Adverse  Events  and Serious  Adverse  Events  
If a patient has COVID -19 during the study, this should be reported as an AE or SAE and 
appropriate  medical  treatment  provided.  Temporary  discontinuation  of the study  treatment  may 
be medically appropriate until the patient has recovered from COVID -19. 
 
It is recommended that the investigator discuss temporary or permanent discontinuation of 
study intervention with the study medical monitor.  
 
14.10.6  Efficacy  Assessments  
If the patient is unable to visit the study site for imaging assessments (e.g., CT, MRI, X -ray, 
FDG -PET), the patient may visit an alternative facility to have the imaging assessments 
performed. Qualified study site personnel must order, receive, and review results.  